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the thesis 
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INTRODUCTION 
 
Peripheral Arterial Disease (PAD) is a multifactorial syndrome that most commonly 
affects people over 60 years of age.1 With the aging of the population, the 
prevalence of atherosclerotic disease and its associated adverse outcomes will 
increase. It has to be noted that the process of established atherothrombosis is not 
limited to a single arterial location, giving it the character of a systemic and 
generalized disease. The Reduction of Atherothrombosis for Continued Health 
(REACH) registry demonstrated that one out of six patients with (i) PAD, (ii) 
cerebrovascular disease, or (iii) coronary artery disease had involvement of one or 
two other arterial beds.1,2 Importantly, the presence of multiple affected arterial 
territories, called polyvascular disease, has been demonstrated to be an 
independent predictor of long-term cardiovascular outcome in the general 
population.2-4    
 
In response to studies demonstrating the adverse prognosis of 
atherosclerotic disease, the need for adequate risk factor stratification and 
reduction has emerged. The importance of risk factor reduction in patients with 
PAD has resulted in universally recommended atherothrombotic risk factor 
reduction, with the objective of decreasing the high incidence of heart disease and 
cerebrovascular disease associated with PAD.5,6 In patients with PAD scheduled for 
vascular surgery, risk factor stratification is directed at the detection of 
(a)symptomatic atherosclerotic disease in other vascular beds than the primary 
symptomatic arterial location. Early detection of polyvascular atherosclerotic 
disease has important consequences for risk factor reduction strategies, including 
life-style interventions and medical therapy. 
 
 
OUTLINE OF THE THESIS 
 
Part I: Prevalence and prognosis     
 
Worldwide more than 230 million major surgeries are performed annually, and this 
number continuous to grow.7 Peri- and postoperative complications mainly have a 
cardiac origin and it is estimated that 1% of the patients (approximately 2.300.000 
patients) will have a myocardial infarction. The occurrence of cardiac complications 
during and after vascular surgery is strongly influenced by the presence of 
polyvascular disease. In chapter 2, a systematic review is performed adressing the 
prevalence of coronary artery disease in a high-risk population of patients with 
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abdominal aortic aneurysms. In addition, pathogenesis, risk factors and treatment 
possibilities are discussed. 
 
Preoperative cardiovascular risk stratification is an important tool to 
estimate the patients’ risk for peri- and postoperative complications.8 Chapter 3 
discusses the role of ankle-brachial index (ABI) measurements in addition to 
coronary heart disease risk estimation in a population-based cross-sectional study.  
 
Another important location of atherosclerotic disease is the common 
carotid artery. Cerebrovascular disease has a major impact on the patients’ quality 
of life and is associated with severe physical and mental impairment. Chapter 4 
described the use of common carotid intima-media thickness measurements for 
perioperative risk estimation and the occurrence of cardiovascular events.  
 
Several general population-based studies have described the influence of 
polyvascular disease during a follow-up period up to a maximum of 5 years. 
Chapter 5 describes the results of a large study including almost 3000 patients 
undergoing vascular surgery. At baseline the number of affected vascular beds was 
determined and long-term prognosis during a follow-up period of 10 years was 
assessed. In chapter 6 the same cohort of patients is evaluated for the presence of 
the so-called obesity paradox, in which underweight patients have an increased 
mortality risk while overweight is associated with an increased survival. 
 
Echocardiography is an important tool to determine the presence of cardiac 
involvement in the atherosclerotic process. Left ventricular function describes the 
mechanical properties of the heart and is commonly used in clinical practice for 
determining the patients’ cardiac risk. Chapter 7 describes the prevalence and 
prognostic implications of asymptomatic left ventricular dysfunction in patients 
scheduled for vascular surgery. Chapters 8 and 9 focus on the influence of 
perioperative cardiac ischemia on short- and long-term prognosis after vascular 
surgery. 
 
Part II: Diabetes mellitus     
 
Patients with PAD have a high prevalence of diabetes mellitus (DM). Diabetes 
mellitus (DM) is currently affecting over 40 million people in the European Union 
alone.9 Importantly, the prevalence of DM is strongly related to age and the 
presence of atherosclerotic disease. Atherosclerosis is associated with an increased 
risk of insulin resistance, resulting in an increasing number of pre-diabetic PAD 
patients. The presence of DM is an important risk factor for cardiovascular 
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complications during and after surgery.8 Chapter 10 systematically reviews the 
prevalence of DM in vascular surgery patients. In addition, the current available 
literature for blood sugar monitoring and control during the perioperative phase is 
discussed. 
 
The strong relation between atherosclerotic disease and DM has emerged 
the need for earlier detection of DM in vascular surgery patients. Chapter 11 
describes the role of two pre-operative testing methods for the detection of glucose 
regulation disorders (pre-diabetes) or DM.  
 
 The metabolic syndrome, also known as the insulin resistance syndrome or 
Syndrom X, is the concurrence of multiple metabolic abnormalities associated with 
cardiovascular disease. In the general population the prevalence of metabolic 
syndrome is 9 to 22%, and increases up to 50% in patients with known 
cardiovascular disease.10,11 In Chapter 12 the prevalence and prognostic 
implications of metabolic syndrome in a high-risk population of patients with 
occlusive and aneurysmatic PAD are evaluated.  
 
 Diabetes mellitus and left ventricular dysfunction have been separately 
associated with increased long-term mortality rates.12 Treatment possibilities for 
systolic left ventricular dysfunction are well defined; however, there are few data 
available for the treatment of diastolic dysfunction. Consequently, it is important to 
know if there are differences in prognosis between systolic and diastolic 
dysfunction. In Chapter 13 the influence of left ventricular dysfunction on long-
term prognosis in patients with or without diabetes is discussed. 
 
Part III: Renal disease 
 
Chronic kidney disease (CKD) is a worldwide public health problem with poor 
outcomes and high costs and patients with PAD frequently have concomitant 
CKD.13 Importantly, patients with CKD also frequently have associated 
cardiovascular disease, which is demonstrated by the fact that patients with CKD 
are more likely to die from a cardiovascular event than to develop kidney failure.14 
As the process of atherosclerotic disease is extended to the renal vasculature as 
well, we evaluated the prevalence and prognostic implications of polyvascular 
disease in a sub-cohort of  vascular surgery patients with known CKD prior to 
surgery. These results are reported in Chapter 14.  
 
 Acute kidney injury is a common and serious complication in hospitalized 
patients and is associated with a high rate of in-hospital morbidity and mortality.15 
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Although episodes of acute kidney injury seem to be reversible, there is a silent, 
ongoing inflammatory and fibrotic process, that leads to structural kidney 
damage.16 This process predisposes to a more rapid decrease in glomerular 
filtration rate, which is a well known risk factor for incident chronic kidney disease. 
In Chapter 15 the association between temporary declines in renal function after 
vascular surgery and the development of CKD during long-term follow-up is 
assessed. In Chapter 16 the influence of preoperative left ventricular dysfunction 
on the risk of postoperative acute kidney injury and long-term outcome is 
evaluated.  
 
 Phosphorus is essential for multiple and diverse biological functions, and it 
has been acknowledged as a marker of renal disease. There has been considerable 
interest in the relation between serum phosphorus levels and long-term 
cardiovascular outcome in several populations.17,18 However, no studies evaluated 
short-term postoperative outcome. Chapter 17 describes the results of a study that 
evaluated the predictive value of preoperative phosphorus levels on 30-day outcome 
after vascular surgery.          
 
Part IV: Risk reduction strategies and future perspectives 
 
Once cardiac risk has been assessed before surgery, risk reduction strategies to 
reduce perioperative and long-term complications have to be initiated. In part four 
of this thesis several possible risk reduction strategies are discussed, including (i) 
pharmacological therapy with statins, β-blockers, antiplatelet agents, and (ii) 
prophylactic coronary revascularization. In Chapter 18 a systematic review of the 
current available literature regarding the influence of statin therapy on the 
expansion rate and rupture risk of patients with an abdominal aortic aneurysm is 
performed. 
 
 The presence of extensive coronary artery disease in patients scheduled for 
vascular surgery is an important risk factor for perioperative and early 
postoperative complications. However, results from two randomized, controlled 
trials demonstrated no benefit derived from preoperative revascularization on 
immediate postoperative outcome.19,20 Chapter 19 describes the Dutch 
Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography-V 
trial, which assessed the potential long-term benefit of preoperative 
revascularization in high-risk vascular surgery patients. Chapter 20 evaluated the 
double-edged sword on the prevention of cardiac complications versus the risk of 
severe bleeding complications in patients with dual antiplatelet therapy scheduled 
for noncardiac surgery.      
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Preoperative pharmacological therapy using β-blockers is recommended by 
the recent European Society of Cardiology guidelines addressing perioperative 
care.21 Although multiple observational studies and randomized, controlled trials 
have been performed to evaluate the effect of perioperative β-blocker treatment, the 
duration of β-blocker treatment before surgery and its effect on cardiovascular 
outcome has not been evaluated yet.22,23 In Chapter 21 three different timing 
protocols for β-blocker therapy initiation are described, including the influence on 
preoperative heart rate, high-sensitive C-reactive protein levels, and postoperative 
outcome.     
 
 Future perspectives include the development of new diagnostic and 
therapeutic strategies in vascular medicine. Nowadays, screening for abdominal 
aortic aneurysms is not routinely performed. The high costs associated with 
routine conventional ultrasound and the need for well trained staff is the most 
important disadvantages. In Chapter 22 the early results of a new portable 
ultrasound scanner, developed for abdominal aortic aneurysm screening, are 
described.  
 
 Chapter 23 focusses on the use of a new treatment modality, called remote 
ischemic preconditioning. An overview is given of the current medical treatment 
possibilities for patients undergoing vascular surgery, and the additional value of 
remote ischemic preconditioning is addressed.  
 
 Patients undergoing vascular surgery are characterized by a high 
prevalence of perioperative ischemia reflected by an asymptomatic release of 
troponin T. Nowadays, asymptomatic cardiac ischemia is not treated, although late 
outcome hereafter is severely compromised. Chapter 24 describes the design of a 
new trial in which patients are randomized to either clopidogrel or placebo for the 
treatment of asymptomatic perioperative troponin T release after vascular surgery.        
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INTRODUCTION 
 
Abdominal aortic aneurysms (AAA) and coronary artery disease (CAD) have 
traditionally been regarded as two separate vessel disorders with a common 
background. Atherosclerosis has always been considered as the basic 
pathophysiologic process. However, during the last decade, evidence has emerged 
with differences between AAA and CAD. Firstly, data regarding the prevalence of 
AAA and CAD are different. Secondly, the risk profiles between AAA and CAD differ, 
mainly regarding gender, age and diabetes mellitus. Thirdly, despite the intensive 
treatment of CAD and improved outcome, the prevalence of AAA has not changed 
during the last decade. In this review we will discuss the characteristics of CAD in 
patients with AAA. In the first part we focus on epidemiological data of CAD in AAA 
patients. The pathophysiology of both AAA and CAD will be described in the second 
part. There is a common pathway between pathophysiology and risk profiles that is 
discussed in the third chapter. Based on the presence of risk factors and their 
influence on cardiovascular events, the preoperative work-up and testing for CAD 
in AAA has gained an important role. The role of (non)-invasive testing will be 
described in the fourth chapter. The treatment of AAA traditionally consisted solely 
of surgery. However, due to the influence of CAD on adverse outcomes, medical 
intervention is potentially useful. Surgical approaches for the treatment of both 
AAA and CAD, and most importantly, their influence on long-term outcome will be 
discussed in the fifth chapter.  
       
 
EPIDEMIOLOGY  
 
Prevalence of diseases in the general population is investigated by population-
based screening studies. However, the prevalence of AAA and concomitant 
cardiovascular disease is difficult to determine, as there is a lack of objective data. 
Current data suggest that many individuals with AAA suffer from co-existing 
atherotrombotic risks such as coronary heart and cerebrovascular disease. (Figures 
1 to 3) 
 
Subjective data 
The REACH registry included 68.236 patients with established CAD, CVD, PAD or 
at least three atherotrombotic risk factors.1,2 At baseline 1.722 (2.52%) patients 
had known AAA as well, and no screening for AAA was performed in the remaining 
patients. This large registry provides subjective data about the concomitant 
presence of CAD and AAA. Data on the incidence of AAA in the general population 
is limited. Due to increased life expectancy, the incidence is increasing.3 However; 
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two other aspects have influenced the incidence as well. Firstly, during and about a 
decade after the Second World War, the risk profile changed because of changes in 
smoking habits. Secondly, the easy availability of ultrasound diagnostic tools 
nowadays, has increased the identification of asymptomatic AAA. 
 
Figure 1. Prevalence of AAA in patients with   Figure 2. Prevalence of CAD in patients with  
established CAD      established AAA 
   
  
Objective data 
Screening studies provide objective data regarding the prevalence of AAA. A 
Norwegian population-based study of 6.386 civilians, showed a prevalence of AAA 
in 263 (8,9%) men and 74 (2,2%) women, respectively.4 The prevalence of AAA 
varies with gender and is roughly three times higher in men then that it is in 
women. Age is the most influential factor on prevalence. About 6% of men have an 
aortic diameter of more than 2.9 cm by the age of 65 years, with an estimated 
increase in prevalence of 6% per decade.5 A meta-analysis of 14 population-based 
screening studies, including 110.000 patients, showed a prevalence ranging from 
4.1% to 14.2% in men and 0,35% to 6,2% in women.6 The prevalence of CAD in 
patients with AAA is analyzed more accurately by cardiovascular testing. In 1984, 
Hertzer was the first to describe the strong relationship between abdominal aortic 
aneurysms and CAD.7 Coronary angiography (CAG) was performed in 1.000 
patients with a primary peripheral vascular diagnosis. In 263 patients the primary 
diagnosis was AAA. Severe, correctable CAD was present in 81 patients (31%). Only 
16 patients (6%) were classified as having normal coronary arteries. Several other 
studies analyzed the prevalence of CAD in AAA by performing CAG as well. As 
shown in Table 1, the average prevalence of CAD in patients with established AAA 
varies between 31 to 90%.  
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ETIOLOGY 
 
Aortic aneurysms can be occlusive, aneurysmatic or a combination. Most AAA are 
called non-specific, as no direct pathogenic mechanism can be identified. 
Traditionally, AAA has been regarded as a consequence of atherosclerosis, mainly 
because it is invariably associated with atherosclerotic wall damage, supported by 
the presence of risk factors such as age, male gender, smoking, 
hypercholesterolemia, hypertension and a positive family history.8 Recently, the 
REACH trial investigators analyzed these risk factors and found distinctions 
between CAD and AAA in cardiac risk profiles that were already proposed in the 
last decade.1  
 
Figure 3. The presence of concomitant vascular disease. Data are based on analysis of our own vascular 
surgical population 
 
 
Abbreviations: AAA; Abdominal Aortic Aneurysm, CAD; Coronary Artery Disease, Carotid; Carotid surgery or 
a history of cerebrovascular disease, LEAD: Lower Extremity Arterial Disease 
 
In 1992, Tilson was the first to propose different pathogenic mechanisms, 
compared to athero-occlusive disease.9 In 2003, Lederle et al. summarized the 
following aetiologic differences between AAA and CAD: (i) patients with severe 
systemic or aortic occlusive disease do not primarily have aortic aneurysms, (ii) 
aortic aneurysm has greater male predominance, (iii) aortic aneurysm is often 
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familial and occurs in genetic diseases unrelated to occlusive disease, and (iv) 
aortic aneurysm is uncommon in patients with diabetes mellitus.10-13 This supports 
the hypothesis that AAA may represent arterial disease with an inherent 
pathophysiology. Specific causes of aneurismal dilatation include infection, mycotic 
aneurysms, trauma and connective tissue disorders (Ehlers-Danlos type IV, Marfan 
Syndrome).14  
 
Table 1 Prevalence of CAD in populations with established AAA 
 AAA* CAG** CAD prevalence Defined stenosis*** 
Hertzer [7] 263 263 (100%) Mild 58% (144pt) >50% 
   Moderate 31% (81pt)  
   Severe 5% (12pt)  
Bayazit[15] 125 125 (100%) Mild 25% (31pt) >70% 
   Moderate 22% (28pt)  
   Severe 6% (7pt)  
Kishi[2] 102 102 (100%)  65% (66pt) >75% 
Islamoglu[8] 81 43 (53%)  84% (36pt) Unknown 
Kioka[9] 94 94 (100%)  46% (43pt) >75% 
Kieffer[10] 133 84 (63%)  43% (36pt) >70% 
Sukhija[11] 110 78 (71%)  90% (70pt) >50% 
Takahashi[16] 159 145 (91%)  27% (43pt) >75% 
      
Total 908 789  45% (total CAG) Variable 
    47.5% (total pt)  
* Number of patients with established AAA. ** Number of patients in whom a CAG was performed. 
***Definition of percentage of coronary artery stenosis. 
 
 
PHYSIOLOGY 
 
Mechanical properties of the aortic wall are provided by elastic fibers and fibrillar 
collagen. The viscoelastic properties of the aortic wall are created by the formation 
of a network of elastic fibres, together with associated proteins. The network is 
stabilized by cross-links, which can be degraded by specific proteases. Together 
with smooth muscle cells (SMC), elastic fibers are most abundant in the medial 
layer of the aortic wall. Another significant component of the media and the 
surrounding fibrious adventitia is collagen. Structural integrity of the vascular wall 
is provided by two types of fibrillar collagen, namely type I and III. A third 
component, which is involved in the organisation of the aortic wall, are 
proteoglycans.14  
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PATHOPHYSIOLOGY 
 
AAA development is clearly associated with connective tissue alterations in the 
aortic wall. The pathophysiologic process of both CAD and AAA contain several 
shared factors, of which the process of atherosclerosis is regarded as the most 
important. The process of atherosclerosis leads to either aortic occlusive, 
aneurysmatic or a combined disease (Figure 4). The generally accepted starting 
point for the process of atherogenesis is an injury of the vascular endothelium.15 
Contributing factors are infection, shear stress forces, angiotensin II, increased 
oxidative stress and cytokine release. This combination leads to endothelial 
activation and dysfunction.16 
 
Figure 4. Schematic representation of the inflammatory processes leading to aortic wall dilatation 
 
Abbreviations: ROS; reactive oxygen species, MMP; matrix metalloproteinases, IL-6; Interleukin 6, SMC; 
smooth muscle cells    
 
Inflammation 
The major process mediating accelerated progression of atherosclerosis and its 
complications is inflammation.15 Supporting evidence for this association includes 
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an increase in CRP levels and a local influx of inflammatory cells into the aortic 
wall.17 Atherosclerotic plaques are characterized by an accumulation of 
intracellular lipid droplets and formation of foam cells.15 AAA have a 
lymphomonocytic infiltrate in the arterial wall as well. This infiltrate consists of 
inflammatory cells in the media and adventitia, derived from aortic blood and from 
medial neovascularisation.17 Histological features of aneurismal tissue are: (i) 
fragmentation of the elastic fibers, and (ii) decreased concentration of elastin. The 
loss of elastic fibres seems to be an early step in the pathophysiological process of 
developing an AAA. Mycotic aneurysms develop through localized inflammation of 
the aortic wall. This process of inflammation is different from that in 
atherosclerosis, although both can lead to aneurysmatic dilatation.  
 
Matrix metalloproteinases 
Matrix Metalloproteinases (MMP) are the most potent proteolytic enzymes that 
degrade elastic and collagen fibres. Infiltrating leukocytes are important sources of 
MMP and serine proteases. These degrade elastin and collagen, thereby weakening 
the aortic wall.18 As a defence mechanism, tissue inhibitors of MMP are increased 
in the aneurysm wall as well.19 Unfortunately, as the process progresses, the 
balance between proteases and antiproteases favors the proteolysis.20  
 
Smooth muscle cells 
The infiltration of immune cells into the aortic wall exacerbates tissue injury 
through release of cytokines, such as Interleukin-6 (IL-6). This will lead to 
recruitment of immune cells and the induction of smooth muscle cell apoptosis. 
Reduction of SMC density in the elastic media is a key event in aneurysmatic 
dilatation. Physiologically, SMC have a protective influence on inflammation and 
proteolysis.21 However, proteinases released from dying SMC, contribute to further 
matrix degeneration.22 
 
Thrombus formation 
In CAD patients, thrombus formation is an important step in plaque instability. In 
AAA, most patients have an associated mural thrombus as well. As blood flow is 
maintained there is persistent remodelling of the thrombus components. On one 
hand, the thrombus can reduce aneurismal wall stress. On the other, its increasing 
thickness leads to local hypoxia at the inner layer of the media. This results in 
increased medial neovascularisation and inflammation.23 Fontaine et al. showed 
that plasminogen and its activator (uPA) are present in the thrombus of the 
aneurismal wall, which might result in local generation of plasmin, an activator of 
MMP.24  
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Oxidative stress 
Oxidative stress can be defined as tissue damage occurring secondary to increased 
production and/or decreased destruction of Reactive Oxygen Species (ROS). ROS 
play causal roles in many chronic (inflammatory) disease states, including 
atherosclerosis and hypertension.25 Localized inflammatory responses enhance the 
production of ROS, leading to progressive cell and tissue damage. Increasing 
evidence points to these factors in the pathogenesis of AAA.17 The influence of ROS 
is widespread in the process of inflammation, including the activation of MMP and 
the plasminogen-plasmin system. In the case of MMP activation, ROS acts as a 
promoter of further wall degeneration. However by activating the plasminogen-
plasmin system, oxidative stress can activate Plasminogen Activator Inhibitor type 
1 (PAI-1). This is an endogenous inhibitor of plasminogen, which is decreased in 
human aneurismal aortic wall tissue. The activation of PAI-1 by oxidative stress 
may serve to oppose vascular remodelling, thereby limiting AAA progression.26 
 
In conclusion, the pathogenesis of CAD and AAA share several aspects, in which 
atherosclerosis plays a pivotal role. Insights regarding the differences in 
pathophysiological backgrounds between AAA and CAD are changing.  Processes 
involved in further development of either occlusive or aneurysmatic diseases 
consist at least of an imbalance between: i) destruction and regeneration of the 
aortic wall by enhanced matrix proteolysis, ii) increased SMC apoptosis, iii) altered 
mechanical forces, and iv) most importantly the process of inflammation. All these 
processes are strongly influenced by oxidative stress (Figures 4 and 5). 
 
Figure 5. Schematic representation of the factors influencing the imbalance between aneurysmatic and 
occlusive aortic disease. SMC: smooth muscle cells   
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RISK FACTOR PROFILES  
 
The cardiovascular risk profile is well established. Not all patients with 
atherosclerosis develop an AAA, therefore it is conceivable that the pathophysiology 
and risk profile of AAA are different. Supporting evidence for a distinct 
cardiovascular risk profile between AAA and established atherotrombotic disease 
like CAD and PAD has been provided.10,11,13  
 
Gender and age 
The prevalence of AAA increases with age. Epidemiological screening studies have 
identified age and male gender as non-modifiable risk factors for AAA. The REACH 
trial found that patients with AAA were significantly more often male and older, 
compared to patients without.1 The ADAM Program included 126.196 veterans, 
mean age 66 years, without a history of AAA.10,11 An AAA of 3,0 cm or larger was 
detected in 5.283 participants (4.2%). Again, risk factor analysis identified male 
gender and age to be strongly associated with the development of AAA. On the 
contrary, female gender had a negative association with AAA. Coronary artery 
disease and AAA share the same relationship regarding age, but not gender.  
 
Genetics 
Familial clustering of abdominal aortic aneurysms has drawn attention to a 
possible genetic background of the disorder. Monogenic disorders associated with 
an increased risk of aortic aneurysm, like Marfan´s Syndrome and Ehlers-Danlos, 
are rare. In 1977, Clifton suggested AAA as one of the most common familial 
diseases.27 In first degree relatives, the frequency of the disorder was 15-19% 
compared to only 1-3% in unrelated patients.28 Three important aspects create a 
high suspicion of familial AAA. When the proband is: (i) female, (ii) young, and (iii) 
AAA rupture is present. Kuivaniemie et al. provided a multinational study with 233 
families including 653 affected members.28 The inheritance mode was autosomal 
recessive in 72% of the families and autosomal dominant in 25%.28 Having a first-
degree relative with an AAA was associated with an odds ratio of 1.9 to 2.4 for 
developing an AAA.29 Several candidate genes on chromosome 19 have been 
proposed, such as LDL related protein 3 (LPR3).30 However, no concluding genetic 
profile can be established at this moment. To study the genetic associations, very 
large numbers (up to 12000 for alleles present in 5% of the population) of patients 
are required.31 Currently, ongoing multi-center studies are generating data. These 
will possibly identify candidate genes, which play a crucial role in the development 
of AAA. 
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Hyperlipidaemia 
High levels of serum cholesterol and other lipids have an established role in the 
pathogenesis of atherosclerosis. In the ADAM trial, an odds ratio of 1.44 (95% CI: 
1.27 to 1.63) was found for the association of high cholesterol levels and AAA.10 A 
positive correlation between a history of, or treatment for, high serum total 
cholesterol and LDL-cholesterol concentrations and the presence of AAA was shown 
in screening studies.32-34 However, in 1995, the Rotterdam study showed a negative 
correlation.35 A very strong relation between low HDL cholesterol levels and a high 
risk for AAA in both genders was shown by Singh.4 The risk of having an AAA was 
70 percent lower in subjects with HDL cholesterol levels ≤1.20 mmol/L. A weak 
relation was found between high serum total cholesterol and AAA, and no relation 
was found between serum triglyceride (TGC) levels and risk for AAA.4  
 
Diabetes mellitus 
The ADAM program found that diabetes, together with female gender and black 
race, had a negative association with the development of AAA. As diabetes is a 
clinical risk factor for atherosclerosis, this finding surprised the investigators.10 
However as described above, the pathophysiology of AAA is only partly associated 
with the process of atherosclerosis. The effect of diabetes on the vessel wall mainly 
includes an increasing stiffness. Mainly, this effect is present in the medial layers 
of the peripheral arteries. It has been proposed that increasing stiffness could 
stabilize the aorta and resist aneurysmatic dilatation. However, in AAA patients, 
aortic stiffness was found to be increased as well.36,37 This relatively surprising 
negative association was, however, confirmed by several leading studies.1,6,29 In our 
own analysis we found a negative association of DM with AAA as well. The 
investigators of the REACH trial suggested a difference in abdominal aortic wall 
constitution between diabetic and non-diabetic individuals.1 However, to our 
knowledge no clear pathophysiological explanation for the negative relationship 
between diabetes and AAA has been provided. 
 
Hypertension 
The main pathophysiological effect of hypertension is directed by increased shear 
stress on the arterial wall. The increased mechanical stretch induces production of 
ROS by the SMC. Reactive oxygen species induce mobilization of pressure 
normalizing chemokines and inflammatory parameters. However, as described 
above, ROS has detrimental effects on blood pressure by a multitude of possible 
mechanisms.25 These mechanisms play a leading role in the process of 
atherosclerosis and are suspected to play a role in the pathogenesis of AAA as well. 
Studies regarding the role of hypertension as a risk factor for AAA have varying 
results. On the one hand, because the definition of hypertension is often based on 
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whether the patient is receiving treatment for this condition or not. On the other 
hand, because the understanding of the pathophysiological processes have 
changed. Previously, it was assumed that hypertension was an established risk 
factor for AAA, both in the pathogenesis and risk of rupture.38 Vardulaki found a 
strong role of hypertension in the development, growth rate and risk of rupture of 
AAA.39 Current or former use of antihypertensive medication was associated with 
an increased risk of AAA in both genders in a study by Singh et al.4 They found 
odds ratios in men and women of 1.61 (95% CI: 1.16 to 2.24) and 2.02 (95% CI 
1.14 to 3.57), respectively. In the ADAM screening program, an odds ratio of 1.23 
(95% CI 1.14 to 1.32) was detected.10 However, current prospective studies have 
shown a relatively weak association of hypertension with AAA prevalence.10,33,39,40 
Recently, the REACH trial showed an increased mortality in patients with AAA and 
current high blood pressure.1 Nowadays, the possible explanation is that 
hypertension is a poor predictor for the development of AAA in the general 
population, but an important risk factor for expansion and rupture.41  
 
Tobacco smoking 
Smoking is the most important and well established risk factor for AAA. However, 
the mechanisms between smoking and AAA formation remain, at least in part, 
unknown. Smoking leads to endothelial damage of the arterial wall, with a 
subsequent inflammatory process and plaque formation. Aortic wall elasticity 
decreases as smoking stimulates elastase and MMP production by 
macrophages.36,42 However, smoking also promotes coronary and cerebral vascular 
disease through a variety of other mechanisms. These include: i) adverse effects on 
lipids, ii) hemodynamic stress, iii) oxidant injury, iv) enhanced thrombosis, and v) 
increased blood velocity. In several large studies, smoking was the most important 
variable associated with an increased risk of AAA development.2,4,6,11,41,42 Additional 
studies compared a history or current smoking to non-smoking in AAA 
development. Odds ratios for this risk between current smokers and non-smokers 
varied between 2.89 and 8.0 (95% CI 2.63 to 12.6).4,6 In a systematic review the 
relative risk of smoking for aortic aneurysms was compared to that for CAD, 
cerebrovascular disease and PAD.43 Relative risk for aortic aneurysms in current 
smokers was generally 3 to 6, compared with 1-2 for CAD and cerebrovascular 
disease. These differences in risks have negative implications for the theory of a 
common cause of vascular disease and aortic aneurysms. This relation was 
confirmed in the ADAM trial. After adjusting for smoking habits, both trials showed 
a modest independent association between atherosclerosis and aortic aneurysms. 
The duration of smoking habits reveals a stronger odds ratio for AAA than the 
number of cigarettes smoked daily.39 Wilmink et al. found a clear dose-response 
relationship with the duration of smoking.42 Each year smoked, increased the 
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relative risk by 4% (95% CI 2 to 5%). Ex-smokers are 3 times more likely to develop 
an AAA compared with non-smokers. The effect of smoking cessation has been 
investigated as well, and showed a slow decrease in risk for AAA of 4% per year. 
Singh et al. stated that the risk of AAA after 20 years of smoking cessation was not 
statistically significant different from the risk of current smokers.4 This relative 
slow decline in risk after cessation of smoking differs strongly between AAA and 
CAD. Patients with CAD, who stop smoking, reduce their risk of myocardial 
infarction by up to 50% in 1 year. Their remaining risk approaches that of those 
who never smoked after 10 years. However, although there is a relative slow 
decrease in the risk of AAA development, more and more attention is given to the 
importance of smoking cessation. This has important consequences for AAA 
prevention, decreasing the growth rate and declining the risk of rupture.  
 
 
SURGICAL TREATMENT AND RISK STRATIFICATION 
 
Surveillance interval 
Rupture of an AAA leads to death in 65-85% of the patients.38,42,44-46 Elective 
surgical treatment of AAA consists of open surgical repair or endovascular stenting 
of the aneurysm. Timing of the procedure depends on: (i) aortic diameter, (ii) 
expansion rate, (iii) symptomacity, (iv) concomitant disease leading to perioperative 
mortality, and v) general health status. The American Society of Cardiology (ACC) / 
American Heart Association (AHA) guidelines and the Trans-Atlantic Inter-Society 
Consensus (TASC) provided a Class I recommendation (level of evidence: B) for the 
repair of infrarenal or juxtarenal AAA measuring 5.5 cm or larger. Intervention is 
not recommended if they measure a diameter of less than 5.0 cm in men and 4.5 
cm in women, respectively (Level of Evidence: A).47,48 The expansion rate differs 
between patients and is influenced by high blood pressure, smoking and 
inflammatory processes.25,39,46 Evidence from two studies suggests that one-time 
ultrasound screening of men, at the age of 65 years, is sufficiently to identify nearly 
all those who are at risk.49 Surveillance intervals differ between studies, mainly 
based on the use of varying criteria. The ACC/AHA recommends ultrasound or 
computed tomography (CT) scans every 6 to 12 months for AAAs measuring 4.0 to 
5.4 cm in diameter.47 However, other studies suggested an interval of 12-24 
months for asymptomatic aneurysms smaller than 5.0 cm.8,50,51  
 
Risk stratification 
Pre-operative risk stratification and screening is performed in the presence of 
concomitant disease. The high frequency of perioperative cardiac complications 
reflects the high prevalence of underlying coronary artery disease [CAD].7 Autopsy 
 31 
studies demonstrated that in more than 50% of perioperative MI cases, a coronary 
plaque rupture could be identified at the site of MI.52,53 It is now generally accepted 
that coronary plaque rupture leading to thrombus formation and subsequent vessel 
occlusion is an important cause of perioperative MI. Patients undergoing major 
vascular surgery (MVS), such as open or endovascular abdominal aneurysm repair, 
are at high-risk of developing postoperative myocardial complications.54 During 
surgery there is an increased cardiac oxygen demand. In combination with 
perioperative tachycardia and increased myocardial contractility, this can result in 
an oxygen supply–demand mismatch in patients with coronary artery stenosis. 
Currently, the predominant theory holds that postoperative MI is triggered by 
surgical stress, caused by high catecholamine production associated with the 
following factors: (i) haemodynamic stress, (ii) vasospasm (iii) reduced fibrinolytic 
activity, (iv) platelet activation and (v) consequent hypercoagulability.54 
Postoperative cardiovascular outcome in patients undergoing MVS is influenced by 
cardiovascular risk factors, including: age >70, diabetes, MI, coronary 
revascularization, congestive heart failure, type of surgery and renal insufficiency.55 
The great majority of cardiac events in patients undergoing MVS are asymptomatic. 
Biagini et al. noted that in at least 69% of patients who experienced coronary artery 
disease by dobutamine echocardiography, silent ischemia was present.56 In the 
growing elderly population, many major surgical interventions are performed in 
patients with increasing age, leading to an increased incidence of cardiovascular 
risk factors. In future times, a progressive influence of the patient’s risk profile 
towards cardiovascular disease is to be expected with great impact on postoperative 
survival, especially in patients undergoing MVS such as open or endovascular 
abdominal aneurysm repair.  
 
 
PREOPERATIVE SCREENING 
 
In addition to risk stratification by obtaining the patients history and physical 
examination, preoperative screening and treatment is performed. Laboratory 
investigation includes assessment of the biomarkers N-terminal pro-B-type 
natriuretic peptide (NT-proBNP), High sensitive CRP (HsCRP) and cardiac troponin 
T. Recent studies showed that an increased plasma level of NT-proBNP is 
associated with adverse postoperative outcome, as it is a marker of left ventricular 
dilatation caused by fluid overload (e.g. CHF and renal dysfunction), pressure 
overload (e.g. aortic valve stenosis), cardiac arrhythmias and myocardial 
ischemia.57 HsCRP is an inflammation marker for determining heart disease risk in 
those with undetected heart disease and risk of complications for those who have 
already had a cardiac event. Cardiac troponin T is a very sensitive and specific 
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indicator of myocardial damage. It is an important marker of all heart muscle 
damage, not only myocardial infarction.  
 
Non-invasive cardiac testing 
The REACH trial found an increased risk of 1.4 - 14.1% for adverse cerebro-
cardiovascular events in AAA patients. Therefore, non-invasive cardiac testing is 
performed to assess: (i) the presence of ischemia, (ii) valve abnormalities, and (iii) 
left ventricular function. Tests can be performed in rest or during exercise, either 
by physiological stress or pharmacological induced stress.  
   
Resting / Ambulatory ECG 
A resting electrocardiogram (ECG) is performed to assess a baseline for the 
detection of ECG changes during the peri- and postoperative period. However, as 
this is a one-moment measurement, ambulatory (Holter) ECG monitoring can also 
be performed. The advantages of this test are that it is cheap and widely available. 
However, the presence of resting ECG changes (bundle branch block, left 
ventricular hypertrophy) may influence reliable ST segment analysis.  
 
Exercise ECG 
Exercise ECG’s are performed either during treadmill walking or bicycle ergometry. 
Conventional exercise ECG is considered the most physiological form of stress. 
Compared to other non-invasive tests, exercise ECG has shown reasonable 
sensitivity and specificity for the prediction of perioperative cardiac complications. 
 
Resting echocardiography 
Without directly visualizing (most of) the coronary arteries, echocardiography has 
proven to be an excellent diagnostic tool in the detection and quantification of CAD. 
With two-dimensional transthoracic echocardiography ischemic segment l wall 
motion abnormalities can be detected. Visual assessment categorises wall motion 
as being normal or abnormal, in which wall motion abnormalities can be further 
characterized as hypokinetic, akinetic, or dyskinetic (Table 2). Although there is 
tremendous variability in the coronary artery blood supply to the myocardium, a 
model with 17 myocardial segments is recommended by the American Society of 
Echocardiography for visual interpretation of regional left ventricular wall motion 
abnormalities.58 Therefore individual myocardial segments can be assigned to one 
of the 3 major coronary arteries with recognition that there is anatomic variability. 
Wall motion abnormalities at rest represent scarred myocardium caused by 
transmural infarction in which the epicardium is involved (STEMI). However, 
myocardial segments can have a normal function at rest and develop wall motion 
abnormalities during exercise or stress. 
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Stress echocardiography 
During exercise or stress the myocardial oxygen demand is increased and ischemia 
occurs in patients with coronary artery stenosis. When cardiac myocytes are 
damaged, but still viable, they become dysfunctional. This dysfunctionality is a 
reversible process, characterized by an oxygen demand-supply mismatch. With the 
use of stress echocardiography this mismatch can be observed by: (i) detecting 
reversible ischemia, (ii) distinguishing ischemia from fixed wall motion 
abnormalities, and (iii) identifying regions supplied by a specific coronary vessel. 
When stress testing induces ischemia, it permits wall motion analysis during stress 
with the use of exercise or pharmacologically induced stress. As most patients with 
vascular disease are not able to reach sufficient exercise, stress echocardiography 
with the use of a pharmacological stressor is often used. During stress testing, 
either dobutamine or dipyridamole is administered. Prior to infusion of the 
stressor, images are recorded which serve as a baseline for comparison with stress 
images. Many reports have demonstrated that Dobutamine and Dipyridamole 
Stress Echocardiography (DSE) can predict perioperative events in patients 
undergoing vascular surgery.59 Both tests have a high negative predictive value, 
however the positive predictive value is much lower. Kertai et al. reported a 
weighted sensitivity of 85% (95% CI: 74 to 97%) and a specificity of 70% (95% CI: 
62 to 69%) for dobutamine stress echo in 850 patients from 8 studies.60 
Dipyridamole stress echo showed a similar high sensitivity, but a significantly 
lower specificity. For this reason, dobutamine stress echocardiography is preferred 
in clinical practice, unless patients have serious arrhythmias, severe hypertension 
or hypotension. 
 
Table 2 Regional wall function at rest 
Normal Normal inward systolic motion 4-10 mm systolic thickening 
Hypokinesia Reduced inward systolic motion Reduced systolic thickening 
Akinesia Absent inward systolic motion Absent systolic thickening 
Dyskinesia Abnormal outward systolic motion Systolic thinning 
Classification of wall function at rest in echocardiography 
 
Radionuclide Ventriculography 
Radionuclide ventriculography is used to assess the left ventricular ejection 
fraction. It is useful for measuring resting and exercise ejection fraction in CAD and 
valvular heart disease. A preoperatively assessed low ejection fraction (<35%) has a 
proven value for the prediction of perioperative cardiac complications. Compared to 
other tests, radionuclide ventriculography did not have a better predictive 
performance. Radionuclide ventriculography has been largely replaced by 
echocardiography, which is less expensive, does not require radiation exposure, 
and theoretically can measure ejection fractions as accurately. 
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Myocardial perfusion scintigraphy  
Myocardial perfusion scintigraphy (MPS) has been widely used for the evaluation of 
patients undergoing vascular surgery and serves as a valuable diagnostic tool in 
preoperative risk stratification. The major goal of noninvasive risk stratification 
with MPS is to identify patients at high-risk for developing unrecognized myocardial 
infarction or myocardial ischemia during surgery. Nuclear imaging differs from 
other imaging techniques by focusing on physiologic processes in the left ventricle 
myocardium instead of anatomy. Both Positron Emission Tomography (PET) and 
Single Photon Emission Computed Tomography (SPECT) scanners globally assess 
left ventricle function by detecting gamma radiation emitted by radiotracers, which 
are administrated intravenously in a small quantity. The detection of coronary 
artery disease is based on a difference in blood-flow distribution through the left 
ventricle myocardium. These perfusion abnormalities can be explained by 
insufficient coronary blood-flow based on coronary artery stenosis. In patients with 
significant CAD and transmural MI, a reduced radiopharmaceutical signal is 
observed after maximal vasodilatation due to a decrease or loss in regional 
perfusion. Myocardial perfusion scintigraphy is a diagnostic tool with low 
specificity, however the negative predictive value derived from a normal scan is 
high in predicting future myocardial infarction and cardiac death. A meta-analysis 
conducted by Kertai et al. reported a sensitivity of 83% (95% CI, 77% to 89%) and a 
much lower specificity of 47% (95% CI, 41% to 57%) for thalium-201 MPS to 
predict perioperative cardiac events.60  
 
Table 3 Non-invasive testing 
Type of test Sensitivity (%) Specificity (%) 
Resting ECG 50 (32-69) 91 (87-96) 
Exercise ECG 52 (21-84) 70 (57-83) 
Rest Echocardiography 74 (60-88) 69 (60-78) 
Stress Echocardiography 74 (53-94) 86 (80-93) 
Radionuclide Ventriculography 73 (77-89) 49 (41-57) 
Myocardial perfusion scintigraphy 85 (74-97) 70 (62-79) 
Summary of sensitivity and specificity of non-invasive tests. Adjusted from Kertai et al.67 
 
Invasive cardiac testing 
 
Coronary Angiography 
Coronary angiography is used for directly visualizing the coronary arteries. With 
the use of contrast agents, X-ray can directly visualize wall irregularities and 
occlusive disease. Invasive cardiac testing by CAG is the golden standard for 
investigating the presence of CAD, and the positive and negative predictive value 
are high. However, because an arterial access route is needed the risk of 
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complications is higher as well. Therefore screening has to be performed primarily 
by non-invasive testing.    
 
Summary 
Resting ECG and ambulatory ECG have a relatively low sensitivity and specificity; 
therefore these tests have a low value in perioperative risk assessment. The 
ACC/AHA guidelines recommend an exercise ECG in the preoperative phase. 
However, vascular surgical patients frequently have abnormalities on their resting 
ECG, and are very often not able to perform adequate exercise. In those patients, 
stress echocardiography or MPS should be considered. Kertai et al. reported a 
similar sensitivity for dobutamine stress echocardiography compared to MPS, but a 
higher specificity and a better overall predictive performance. Stress 
echocardiography has an additional advantage in visualizing valvular or left 
ventricular dysfunction. Coronary angiography should be performed if indicated by 
non-invasive testing. 
 
 
MANAGEMENT OF ABDOMINAL AORTIC ANEURYSMS AND CORONARY 
ARTERY DISEASE 
 
In patients with an accurately assessed cardiac risk, two risk reduction strategies 
can be performed to reduce the incidence of peri –and postoperative cardiovascular 
events: prophylactic pharmacological treatment and/or preoperative coronary 
revascularization. 
 
Pharmacological management 
β-blocking agents 
β-blockers have beneficial effects in congestive heart failure (CHF) by increasing the 
ejection fraction and reducing functional deterioration of the left ventricle in which 
heart rate reduction plays a pivotal role. After myocardial infarction, β-blocker use 
has a class I recommendation by the ACC/AHA.61 During the perioperative phase 
mixed results for the use of β-blockers are available. However, in all studies 
outcome was improved in patients with known or suspected CAD.  Poldermans et 
al. randomized 112 patients with more than 1 cardiac risk factor. Before surgery, a 
dobutamine stress echocardiography was performed. β-blocker therapy showed to 
improve peri-operative cardiac morbidity and mortality a 10-fold following major 
cardiovascular surgery.62 However, during the past years, evidence is suggesting β-
blockers to be ineffective in reducing cardiovascular events. The recent 
PeriOperative Ischemic Evaluation (POISE) study suggested a net harm of β-
blockers in surgical patients.63 Hereafter, use of β-blocking agents is recommended 
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to be used only in those patients who are on them already. The role of β-blockers 
(i.e. propanolol) for the prevention of aneurysm expansion has been investigated in 
only one randomized controlled trial, which showed no reduction in AAA growth 
rate. On the contrary, propanolol use significantly impaired quality of life.64 The 
ACC/AHA guidelines on perioperative care strongly recommend the achievement 
and maintenance of a heart rate between 65-70 beats per minute.61   
 
Statins 
Irrespectively of their lipid lowering effects, statins seem to improve postoperative 
cardiac outcome by stabilizing coronary artery plaques and preventing 
atherosclerotic plaque rupture during surgery. Pleiotropic effects play a pivotal role 
and include: (i) increased expression of endothelial nitric-oxide-synthase, (ii) 
reduced production of endothelin-1, (iii) generation of reactive oxygen species, (iv) 
improvement of the trombogenic profile, and (v) reduction of inflammation.65 Use of 
statins after AAA repair, has been associated with a 3-fold reduction in the risk of 
cardiovascular death.29,66,67 Based on the Heart Protection study, it could be 
suggested that all patients should receive statin-therapy, irrespective of their 
cholesterol pattern.68  
 
ACE-inhibitors 
The influence of hypertension as a risk factor for the development of AAA is 
moderate. However, the influence of hypertension on the expansion of aneurysms 
is significant. According to the British Hypertension Society guidelines, an 
angiotensin converting enzyme (ACE) inhibitor should be preferred for the 
treatment of hypertension in patients with CAD and AAA.66,69  
 
Anti-platelets 
The presence of intraluminal thrombi creates possibilities for antiplatelet therapy in 
patients with AAA. Treatment with aspirin or clopidogrel is recommended in 
patients with stable CAD to prevent cardiovascular events.70 Aspirin reduces 
platelet activation and vasoconstriction, thereby limiting the risk of non-fatal MI by 
34%. In the setting of secondary prevention, aspirin reduces cardiovascular events 
by 27 and cardiovascular deaths by 18%.71 In MVS aspirin is routinely used 
preoperatively and associated with improved peripheral bypass patency.61 Addition 
of clopidogrel next to low-dose aspirin might be beneficial towards postoperative 
cardiac outcome, however the effect on the incidence of postoperative bleeding 
complications might be a potential problem that should be sorted out in future 
studies.  
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Future perspectives 
Some studies suggested the use of MMP inhibitors. However, only a handful of 
small trials have been performed.72 These showed some beneficial effects in 
decreasing the expansion of aneurysms. Much larger randomized trials will be 
necessary before these treatments can be evaluated properly. The role of non-
steroidal inflammatory drugs (NSAIDs) in the treatment of AAA has not been 
established. A positive effect on the decrease of prostaglandin E2 and Interleukin 1 
and 6 in the aneurysmatic tissue was shown.22 With respect to the role of 
inflammation in the development of AAA, the role of NSAIDs in AAA prevention and 
treatment has to be investigated more thoroughly.  
 
Revascularization 
Patients with CAD detected by preoperative screening might benefit from 
prophylactic revascularization by coronary artery bypass grafting or percutaneous 
coronary intervention (PCI). However, the value of prophylactic revascularization is 
controversial and debated. The Coronary Artery Revascularization Prophylaxis 
(CARP) trial was the first that randomized trial that investigated the benefit of 
coronary revascularization before elective MVS. During short- and long-term follow-
up, no reduction in the number of cardiovascular events was observed.73 The 
optimal preoperative management of patients with (i) left main disease, (ii) severe 
left ventricle dysfunction, (iii) unstable angina pectoris and (iv) aortic stenosis has 
not been determined yet. Recent findings by Landesberg et al. suggest that 
intermediate-risk patients are most likely to benefit from preoperative coronary 
revascularization, in contrast to low-risk patients and high-risk patients.74 In the 
current ACC/AHA guidelines routine prophylactic coronary revascularization is not 
recommended before non-cardiac surgery in patients with stable CAD.61  
 
  
PERIOPERATIVE SURVEILLANCE AND POSTOPERATIVE SURVIVAL 
 
Perioperative surveillance 
The general assessment of postoperative patients with CAD should be focused on 
evaluating asymptomatic and unstable myocardial ischemia. The diagnosis of 
postoperative myocardial infarction is frequently difficult to make since it often 
presents atypically and may have a different etiology compared with non-operative 
myocardial infarction. The evaluation of postoperative myocardial infarction should 
include cardiac monitoring, electrocardiography, and serial cardiac enzyme 
measurements. Special attention should be given to perioperative volume infusion 
since excessive fluid administration is a common cause of decompensated heart 
failure in patients with CAD. 
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Postoperative survival 
Postoperative survival is strongly influenced by the presence of associated 
cardiovascular disease. Crawford et al. showed that cardiac risk factors counted for 
the postoperative deaths in 95%.75 Another study of 167 patients with in 45% CAG-
established CAD showed a cardiovascular perioperative mortality of 13.8% after 
AAA repair.76 Back et al. reviewed the amount of cardiac deaths during the follow-
up of infrarenal AAA repair and found an average of 40%.77 During the last two 
decades, reducing cardiac mortality associated with AAA repair has been an 
important goal. Correction of severe or unstable CAD before or coincident with AAA 
repair was performed in several studies, showing a decline in operative mortality.78-
80 The combined open repair has mortality rates similar to a consecutive 
approach.79-81 However, a proposed combined approach with endovascular stenting 
seems to be associated with lower morbidity and mortality rates.82  
 
 
CONCLUSION 
 
The incidence and prevalence of AAA are rising. Risk factor analysis identified age 
and gender as the most influencing factors. With the rising population of the 
elderly, the influence of cardiovascular disease will increase as well. Risk 
stratification and subsequent life style intervention and preventive pharmacological 
interventions deserve more attention. Postoperative outcome is strongly influenced 
by the presence of concomitant CAD. Therefore, screening for cardiovascular 
disease in the preoperative phase will decrease the risk of cardiovascular events 
during the peri- and postoperative period. Treatment possibilities are traditionally 
directed at surgical aneurysm repair. However, as a consequence of the presence of 
concomitant cardiovascular disease, preoperative pharmacological treatment of 
both CAD and AAA has become an important topic. The present ACC / AHA 
guidelines recommend continuation of life style changes and pharmacological 
treatment after surgery, to reduce cardiovascular events in the postoperative 
period.  
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PREVALENCE OF PERIPHERAL ARTERIAL DISEASE 
 
The prevalence of peripheral arterial disease (PAD) in the general population varies 
between 7 and 21%.1,2 This is strongly related to age, gender and the definition of 
PAD, defined by the ankle-brachial index (ABI) cut-off and/or the presence of 
intermittent claudication (IC). PAD is typically asymptomatic before progressing to 
clinical stages such as IC or even critical limb ischemia.3 The ABI, as a screening 
tool, has emerged as an accurate and reliable marker of (a)symptomatic PAD and 
as a measure of systemic atherosclerotic burden. The getABI study detected a PAD 
prevalence of 18% in the primary-care setting, while only 2.8% of the patients were 
symptomatic.2  
 
In this issue of the Journal, Ramos et al. identified the prevalence of 
symptomatic and asymptomatic PAD in a population-based cross-sectional study 
including 6.262 participants aged 35-79 years.4 Furthermore, they evaluated the 
value of ABI measurement in addition to coronary heart disease (CHD) risk 
estimation. PAD, defined as an ABI <0.9, was present in 4.5% of the study 
population, of which only 0.62% presented with IC assessed by the Edinburgh 
questionnaire. Prevalence increased up to 14% in patients aged 75 to 79 years. 
These findings are in line with several previous population-based studies, 
demonstrating a relation between age and prevalence of PAD. Importantly; the vast 
majority of the patients were asymptomatic, addressing the importance of PAD 
detection in an early phase.1,2 
 
 
CARDIOVASCULAR RISK STRATIFICATION AND TREATMENT  
 
The present study evaluated the CHD risk for all participants of 35 to 74 years old 
free of cardiovascular disease, using the Framingham function adapted to Spain 
and validated in this population. The mean 10-year CHD risk in the subgroup of 
patients with ABI <0.9 was 9.2 in men and 3.0% in women. In 16.8% of the 
patients with ABI <0.9, 10-year CHD risk was moderate-to-high (≥10%). There was 
an inverse association between ABI and the 10-year CHD risk. Combining CHD 
risk estimation with ABI measurement changed the proportion of participants aged 
35 to 74 years with CHD risk ≥10% from 6.1 to 8.7%. Over the last years, PAD has 
become an indicator disease for generalized atherosclerosis. Study results reported 
a high prevalence of coronary artery disease (CAD) and cerebrovascular disease 
(CVD) in PAD patients.5,6 The Framingham CHD risk function was developed to 
provide a 10-year risk estimate for the development of CHD in patients free of 
cardiovascular history.5 Ramos et al. demonstrated that including ABI <0.9 in the 
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screening process resulted in a considerable increased proportion of moderate-to-
high risk population when combined with 10-year risk ≥10% by risk functions 
using χ2 tests.  
 
High prevalence of multiple affected vascular beds (polyvascular disease) in 
patients with symptomatic PAD, but also in asymptomatic patients was reported by 
several studies.2 The REACH registry indicated that in patients with symptomatic 
PAD, 1 out of 6 (17%) patients have concomitant CAD and/or CVD.6 As patients 
with (a)symptomatic PAD have a high prevalence of polyvascular disease, the 
impact of polyvascular disease in asymptomatic PAD patients may have huge 
consequences as well for (i) the need for screening, (ii) preventive life-style 
modification, and (iii) medical treatment. The REACH registry demonstrated that 
PAD patients are generally ignored with respect to lifestyle changes and risk factor 
management.6 Treatment goals according the current guidelines include aspirin 
and statins (low-intermediate risk (Lee-cardiac index <2) patients: target LDL level 
<100 mg/dL, high-risk (Lee Cardiac index ≥2) patients <70 mg/dL) for patients 
with PAD, and if necessary combined with antihypertensive drugs to achieve a 
target blood pressure below 140/90 mmHg.7 In patients with ischemic heart 
disease additional recommended therapy consists of β-blockers. Furthermore, in 
case of diabetes mellitus and/or heart failure (left ventricular ejection fraction 
<40%), treatment should be extended with ACE-inhibitors or Angiontensin receptor 
blockers in case of intolerance.8 Importantly, a recent study showed that there is a 
care-gap in medical treatment between guideline recommendations and clinical 
practice in PAD patients.9 Therefore, especially for patients with polyvascular 
disease, medical treatment adherence according the current guidelines needs to be 
emphasized. 
 
In conclusion, the current study demonstrated a prevalence of 
symptomatic and asymptomatic PAD that is in line with previous studies in the 
primary care setting.2 The low prevalence of symptomatic PAD in these patients 
indicates that PAD can only be comprehensively diagnosed by systematic 
screening, including ABI measurement. The additional value of ABI measurement 
to CHD risk estimation outlines the impact of PAD as an indicator of 
atherosclerotic disease, which is often not limited to one arterial location. 
Therefore, screening for asymptomatic PAD in high-risk patients needs to be part of 
systematic screening for atherosclerotic disease. Development of less time-
consuming ABI measurement techniques should be supported to enlarge the 
applicability of ABI measurement in the primary care setting. Furthermore, the 
high prevalence of asymptomatic PAD creates the need for optimal life-style 
modification and medical treatment, as stated by the current guidelines on PAD. 
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ABSTRACT 
 
Background: Cardiovascular (CV) complications are the leading cause of morbidity 
and mortality in vascular surgery patients. The Revised Cardiac Risk (RCR) index, 
identifying cardiac risk factors, is commonly used for preoperative risk 
stratification. However, a more direct marker of the underlying atherosclerotic 
disease, such as the common carotid artery intima-media thickness (CCA-IMT) may 
be of predictive value as well. The current study evaluated the prognostic value of 
the CCA-IMT for postoperative CV outcome.  
 
Methods: In 508 vascular surgery patients, the CCA-IMT was measured using 
high-resolution B-mode ultrasonography. We recorded the RCR factors: ischemic 
heart disease, heart failure, cerebrovascular disease, diabetes mellitus and renal 
dysfunction. Repeated Troponin T measurements and electrocardiograms were 
performed postoperatively. The study end point was the composite of 30-day CV 
events and long-term CV mortality. Multivariate regression analyses were used to 
assess the additional value of CCA-IMT for the prediction of cardiac events.  
 
Results: In total, 30-day events and long-term CV mortality were noted in 122 
(24%) and 81 (16%) patients, respectively. The optimal predictive value of CCA-IMT, 
using receiver-operating characteristic curve analysis, for the prediction of CV 
events was calculated to be 1.25 mm (sensitivity 70%, specificity 80%). An 
increased CCA-IMT was independently associated with 30-day CV events (OR 2.20, 
95% CI: 1.38 to 3.52) and long-term CV mortality (HR 6.88, 95% CI: 4.11 to 11.50), 
respectively.  
 
Conclusions: This study shows that an increased CCA-IMT has prognostic value in 
vascular surgery patients to predict 30-day CV events and long-term CV mortality, 
incremental to the RCR index. 
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INTRODUCTION 
 
Cardiovascular (CV) complications are the leading cause of morbidity and mortality 
in vascular surgery patients.1 Adequate preoperative evaluation is inevitable to: (i) 
identify patients at increased risk, (ii) initiate risk reduction therapy, and (iii) select 
optimal surgical and anaesthesia techniques. Heart failure, ischemic heart disease, 
cerebrovascular disease, renal dysfunction, diabetes mellitus and high-risk 
surgery, as summarised in the Revised Cardiac Risk (RCR) index, have been 
identified as independent predictors of perioperative CV events.2,3 However, a more 
direct marker of the underlying atherosclerotic disease, such as the common 
carotid artery intima-media thickness (CCA-IMT),4 may be of predictive value as 
well. Although an increased CCA-IMT is associated with an increased risk for 
myocardial infarction and stroke,5,6 limited information is available concerning the 
predictive value of an increased CCA-IMT for postoperative CV events in vascular 
surgery patients. This study evaluated the predictive value of the CCA-IMT for CV 
events in vascular surgery patients, incremental to the predictive value of the RCR 
index. 
 
 
METHODS 
 
Study population 
The study population was derived from a cohort of 1.005 consecutive vascular 
surgery patients undergoing lower extremity artery, abdominal aortic aneurysm, 
abdominal aortic stenosis or carotid artery repair from 2002 to 2008. From 2004 to 
2008, standard CCA-IMT measurements were performed, and 508 consecutive 
patients with CCA-IMT measurements were included during this time period, with 
exclusion of patients undergoing carotid artery repair. Both open and endovascular 
procedures were included. The study was approved by the hospital’s ethics 
committee and performed with informed consent of all patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Risk factors 
according to the RCR index were recorded such as: heart failure (defined as the 
presence of heart failure symptoms according the New York Heart Association 
classification or previous hospital admission for decompensated heart failure), 
ischemic heart disease (defined as history of angina pectoris, coronary 
revascularization or myocardial infarction), cerebrovascular disease (defined as a 
history of ischemic or hemorrhagic stroke), renal dysfunction (defined as serum 
creatinin >2 mg/dL) and diabetes mellitus (defined as fasting blood glucose ≥7.0 
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mmol/L or requirement for insulin and/or anti-diabetic medication). Cardiac risk 
score was determined for each patient according the RCR index with one point 
assigned to each characteristic. Furthermore; age, sex, body mass index, 
hypertension (blood pressure was measured during preoperative evaluation at the 
outpatient clinic and hypertension was defined as systolic blood pressure ≥140 
mmHg, diastolic blood pressure ≥90 mmHg in nondiabetic patients, systolic blood 
pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg in diabetics, or the use 
of antihypertensive medication), hypercholesterolemia (low-density lipoprotein 
cholesterol >3.50 mmol/L), chronic obstructive pulmonary disease (according to 
the Global Initiative on Obstructive Lung Diseases classification) and smoking 
status were recorded. Finally, use of the following medication was recorded: β-
blockers, statins, aspirin, oral anticoagulants, angiotensin-converting enzyme 
inhibitors, calcium antagonists, and diuretics. Medication use was ascertained if 
medication was documented at least one month before surgery. 
 
Measurement of the intima-media thickness 
The CCA-IMT was measured according to the ‘Mannheim Carotid Intima-Media 
Thickness Consensus’ scanning and reading protocol recommendations.7-9 
Measurements were taken at 10 mm proximal to the carotid bifurcation in the near 
and far wall of the left and right common carotid artery. Repeated measurements 
were performed along a minimum of 10 mm length. Four measurements were taken 
from both the left and right common carotid artery, two of which in the near and 
two in the far wall. The maximal measurement, of these eight measurements, was 
used. Plaques (defined as a focal structure encroaching into the arterial lumen of at 
least 0.5 mm)7 when present, were not used in the CCA-IMT measurements. 
Measurements were electrocardiogram-gated at the peak of the QRS complex to 
control for changes in CCA-IMT during the cardiac cycle. Two sonographers, 
unaware of the clinical information for each patient, performed the measurements 
with an interobserver correlation of 96.2%. 
 
Clinical cardiac outcome and follow-up 
Serial electrocardiograms and troponin T measurements were obtained from all 
patients before surgery, postoperatively on day 1, 3, 7 and before discharge. Main 
study endpoints were (i) 30-day CV events defined as myocardial infarction, 
myocardial ischemia, and CV mortality, and (ii) long-term CV mortality. Myocardial 
ischemia was present when cardiac enzyme levels were elevated >0.03 ng/mL.10 
Myocardial infarction was present when cardiac enzyme levels were elevated >0.03 
ng/mL in combination with electrocardiographic changes such as new-onset ST-T 
changes, new onset left bundle branch block or development of pathological Q 
waves.11 Thirty-day follow-up was completed during regular follow-up visits at the 
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outpatient clinic and, if needed, by reviewing hospital records or the electronic 
patient file. Long-term mortality was assessed by approaching the municipal civil 
registries. All surviving patients received a mailed questionnaire and, if needed, 
survival status was completed by approaching the referring physician. Mortality 
was considered CV unless explicit proof of a noncardiac cause could be delivered. 
Mean follow-up was 1.8 ± 1.1 years.  
 
Statistical analysis 
Dichotomous data are described as numbers and percentages. The continuous 
variables age and body mass index are described as means ± SD. Differences in 
baseline characteristics between CCA-IMT groups were evaluated using χ2 tests for 
categorical data. Continuous data were compared using one-way ANOVA. Receiver 
operating characteristic curve analysis was used to assess the optimal cutoff value 
of CCA-IMT for predicting 30-day CV events and long-term CV mortality. The 
optimal value of CCA-IMT for predicting 30-day CV events and long-term CV 
mortality was defined as the concentration with the largest sum of sensitivity plus 
specificity. Uni- and multivariate logistic regression analysis were performed to 
evaluate the prognostic value of an increased CCA-IMT towards 30-day CV events 
and Cox regression analysis towards long-term CV mortality. Multivariate 
regression analyses were adjusted for age, sex, hypertension, hypercholesterolemia, 
chronic obstructive pulmonary disease, current smoking, β-blocker use, statin use, 
and aspirin use. We report crude and adjusted ORs and HRs with their 95%-CI. 
For all tests, a p < 0.05 (two-sided) was considered significant. Cumulative long-
term survival was determined by the Kaplan-Meier method. All analyses were 
performed using SPSS version 15.0 statistical software (SPSS, Chicago, IL). No 
extramural funding was used to support this work. The authors are solely 
responsible for the design and conduct of this study; all study analyses, the 
drafting and editing of the article, and its final contents. 
 
 
RESULTS 
 
A total of 508 patients undergoing lower extremity artery repair (N=245) and 
abdominal aortic aneurysm or abdominal aortic stenosis repair (N=263) were 
included in the study. Endovascular procedures comprised 38% of the studied 
surgical procedures. Mean age was 68 ± 11 years and 78% were men. Mean CCA-
IMT (i.e. mean of the maximum CCA-IMT measurements) was 1.07 ± 0.35. In total, 
30-day CV events were observed in 122 patients (24%) and long-term CV mortality 
in 81 patients (16%). The optimal predictive value of CCA-IMT for the prediction of 
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30-day CV events and long-term CV mortality was calculated to be 1.25 mm 
(sensitivity 70%, specificity 80%) (Figure 1).  
 
Figure 1: Receiver operating characteristics curve analysis of common carotid artery intima-media thickness 
to predict postoperative cardiovascular events. Sensitivity and specificity are plotted for various levels  
 
 
In total, 145 patients (29%) had an increased CCA-IMT defined as a CCA-
IMT ≥1.25 mm. Patients with an increased CCA-IMT were older (71 vs 67 years, p = 
0.01) and more likely to be male (85 vs 75%, p = 0.013) compared to patients with a 
CCA-IMT <1.25 mm. Other factors associated with an increased CCA-IMT were a 
history of heart failure, cerebrovascular disease, chronic obstructive pulmonary 
disease, β-blocker use, calcium-antagonist use and diuretic use. Baseline 
characteristics according the CCA-IMT groups are listed in Table 1. 
 
30-day outcome 
The study end point 30-day CV events was reached in 122 (24%) patients, of which 
66 (18%) occurred in patients with a CCA-IMT <1.25 and 56 (39%) in patients with 
an increased CCA-IMT (p < 0.01) as shown in Table 2. During 30-day follow-up, 
117 (23%) had a nonfatal myocardial event, of which 30 patients (26%) had a 
myocardial infarction and 87 patients (74%) had myocardial ischemia. In total, 61 
(17%) patients with a CCA-IMT <1.25 and 56 (39%) patients with an increased 
CCA-IMT had a nonfatal myocardial event (p < 0.01).  
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Table 1 Baseline characteristics according to CCA-IMT groups 
 
All 
[N=508] 
CCA-IMT <1.25 
[N=363] 
CCA-IMT ≥1.25 
[N=145] 
p-value 
 
Demographics     
  Age (± SD) 68 (11) 67 (11) 71 (10)  0.01 
  Male (%) 394 (78) 271 (75) 123 (85) 0.01 
  Body mass index (± SD) 26 (4) 26 (4) 26 (3) 0.70 
Medical history (%)     
  Heart failure  56 (11) 32 (9) 24 (17) 0.01 
  Ischemic heart disease  221 (44) 157 (43) 64 (44) 0.86 
  Cerebrovascular disease  83 (16) 45 (12) 38 (26) <0.01 
  Renal dysfunction  103 (20) 63 (17) 40 (28) 0.01 
  Diabetes mellitus  124 (24) 83 (23) 41 ()28 0.20 
  Hypertension  340 (67) 235 (65) 105 (72) 0.10 
  Hypercholesterolemia  249 (49) 174 (48) 75 (52) 0.44 
  COPD 126 (25) 81 (22) 45 (31) 0.04 
  Smoker, current  221 (44) 156 (43) 65 (45) 0.70 
RCR index (%)     
 0-1 risk factors  250 (49) 196 (54) 54 (37) <0.01 
 2 risk factors  145 (29) 101 (28) 44 (30) <0.01 
 >3 risk factors 111 (22) 64 (18) 47 (32) <0.01 
Surgery type (%)     
  Open  314 (62) 220 (61) 94 (65) 0.376 
Medication (%)     
  β-blocker   397 (78) 274 (76) 123 (85) 0.02 
  Statin  343 (68) 241 (66) 102 (70) 0.39 
  Aspirin  287 (57) 211 (58) 76 (52) 0.24 
  Oral anticoagulant  87 (17) 57 (16) 30 (21) 0.18 
  ACE-inhibitor   153 (30) 111 (31) 42 (29) 0.72 
Calcium-antagonist  92 (18) 56 (15) 36 (25) 0.01 
Diuretic 121 (24) 77 (21) 44 (30) 0.03 
Common carotid artery intima-media thickness (CCA-IMT), revised cardiac risk (RCR), standard deviation 
(SD), Chronic obstructive pulmonary disease (COPD) 
 
Table 2 CCA-IMT and postoperative outcome 
 
CCA-IMT <1.25 
[N=363] 
CCA-IMT ≥1.25 
 [N=145] 
Univariate 
 
30-day (%)   OR [95%-CI] 
Cardiovascular events  [N=122] 66 (18) 56 (39) 2.93 1.85-4.34 
All-cause mortality  [N=25] 10 (3) 15 (10) 4.07 1.79-9.30 
Long-term (%)   HR [95%-CI] 
Cardiovascular mortality  [N=81] 24 (7) 57 (39) 6.90 4.23-11.13 
All-cause mortality  [N=113] 53 (15) 60 (41) 3.28 2.26-4.77 
Confidence interval (CI), common carotid artery intima-media thickness (CCA-IMT), hazard ratio (HR), odds 
ratio (OR). 
 
The study end point CV mortality was reached in 21 (4%) patients, of which 
6 (2%) occurred in patients with a CCA-IMT <1.25 and 15 (10%) in patients with an 
increased CCA-IMT (p < 0.01). Multivariate analysis showed that the RCR index 
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was predictive for 30-day CV events (2 risk factors: OR 1.96, 95% CI: 1.12 to 3.43; 
≥3 risk factors: OR 6.43, 95% CI: 3.66 to 11.28), as shown in Table 3 (Model 1). 
When adding CCA-IMT to this model, an increased CCA-IMT was independently 
associated with 30-day CV events (OR 2.20, 95% CI: 1.38 to 3.52), as shown in 
Table 3 (Model 2).  
 
Table 3 Multivariate association between CCA-IMT and 30-day follow-up 
 Model 1 * Model 2 ** 
 
[N=508] OR [95% CI] OR [95% CI] 
Cardiovascular events  
RCR index *** 
 1 risk factor 34/250 1.00  1.00  
 2 risk factors 35/146 1.96 1.12-3.43 1.86 1.06-3.28 
 ≥3 risk factors 53/112 6.43 3.66-11.28 5.70 3.21-10.11 
CCA-IMT 
 <1.25 66/363 - - 1.00  
 ≥1.25  56/145 - - 2.20 1.38-3.52 
All-cause mortality 
RCR index *** 
 1 risk factor 6/250 1.00  1.00  
 2 risk factors 9/146 2.73 1.32-12.21 2.42 0.80-7.37 
 ≥3 risk factors 10/112 4.02 0.90-8.22 2.92 0.93-9.15 
CCA-IMT 
 <1.25 10/363 - - 1.00  
 ≥1.25  15/145 - - 3.76 1.44-8.93 
* Model 1: predictive value of RCR index for adverse outcome. Multivariate analyses were adjusted for age, 
gender, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, current 
smoking, β-blocker use, statin use and aspirin use.  
** Model 2: additional value of CCA-IMT for prediction of adverse outcome additionally to clinical risk factors. 
Multivariate analysis adjusted for RCR risk factors and risk factors described in model 1. *** RCR 
risk factors: heart failure, ischemic heart disease, cerebrovascular disease, diabetes mellitus and 
renal dysfunction. Confidence interval (CI), common carotid artery intima-media thickness (CCA-
IMT), odds ratio (OR), revised cardiac risk (RCR). 
 
Long-term outcome 
During long-term follow up, 81 (16%) patients died due to a CV cause. Of these 
patients, 24 (7%) had a CCA-IMT <1.25 mm and 57 (39%) had an increased CCA-
IMT (Table 2). Cumulative 5-year survival (log rank p < 0.01) is shown in Figure 2. 
Multivariate analysis showed that the RCR index was predictive for CV mortality for 
patients with 2 and ≥3 risk factors with HRs of 2.02 (95% CI: 1.05 to 3.88) and 
3.81 (95% CI: 1.95 to 7.45), respectively (Table 4, Model 1). When including CCA-
IMT in the model (Table 4, Model 2), an increased CCA-IMT was independently 
associated with CV mortality with an HR of 6.57 (95% CI: 3.93 to 10.96). The 
incremental value of CCA-IMT in the prediction of CV events is further illustrated 
in Figure 3.  
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Table 4 Multivariate association between CCA-IMT and long-term mortality 
 Model 1 * Model 2 ** 
 
[N=508] HR [95% CI] HR [95% CI] 
Cardiovascular events  
RCR index *** 
 1 risk factor 27/250 1.00  1.00  
 2 risk factors 24/146 1.84 1.02-3.35 1.74 0.95-3.19 
 ≥3 risk factors 35/112 3.66 2.08-6.43 2.97 1.67-5.29 
CCA-IMT 
 <1.25 24/363 - - 1.00  
 ≥1.25  57/145 - - 6.88 4.11-11.5 
All-cause mortality 
RCR index *** 
 1 risk factor 48/250 1.00  1.00  
 2 risk factors 37/146 1.53 0.94-2.50 1.50 0.92-2.44 
 ≥3 risk factors 40/112 2.49 1.53-4.04 2.14 1.31-3.49 
CCA-IMT 
 <1.25 53/363 - - 1.00  
 ≥1.25  69/145 - - 2.88 1.94-4.27 
* Model 1: predictive value of RCR index for adverse outcome. Multivariate analyses were adjusted for age, 
gender, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, current 
smoking, β-blocker use, statin use and aspirin use.  
** Model 2: additional value of CCA-IMT for prediction of adverse outcome additionally to clinical risk factors. 
Multivariate analysis adjusted for RCR risk factors and risk factors described in model 1. *** RCR 
risk factors: heart failure, ischemic heart disease, cerebrovascular disease, diabetes mellitus and 
renal dysfunction. Confidence interval (CI), common carotid artery intima-media thickness (CCA-
IMT), hazard ratio (HR), revised cardiac risk (RCR). 
 
Figure 2. Cumulative long-term survival (Carotid artery intima-media thickness (CCA-IMT) 
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Figure 3: Incremental value of CCA-IMT in the prediction of postoperative cardiovascular mortality 
 
 
Risk factors: age, gender, current smoking, hypercholesterolemia, chronic obstructive pulmonary disease. 
Common carotid intima-media thickness (CCA-IMT), revised cardiac risk (RCR). 
 
 
DISCUSSION 
 
To our knowledge, our study is the first to describe the prognostic value of an 
increased CCA-IMT in patients undergoing vascular surgery. We have found a 
cutoff value (maximum CCA-IMT) of 1.25 mm, using receiver operating 
characteristic curve analysis, to be most indicative for the prediction of 30-day CV 
events and long-term CV mortality. In patients with an increased CCA-IMT, the 
occurrence of 30-day CV events was more than twice as high compared to patients 
with a CCA-IMT <1.25 mm. The occurrence of long-term CV mortality was more 
than five times higher in patients with an increased CCA-IMT compared to patients 
with a CCA-IMT <1.25 mm. 
 
Atherosclerosis, a systemic inflammatory disease, is known to affect 
multiple sections of the arterial tree simultaneously. Previous studies have 
demonstrated a correlation between an increased CCA-IMT with cardiac risk 
factors and coronary atherosclerosis.12-14 However, the extent of the atherosclerotic 
process is thought to differ between the vascular beds. In the general population, 
the median carotid IMT ranges from 0.5-1.0 mm,15 and the CCA-IMT is considered 
increased being >1.0 mm.16  In the prediction of myocardial infarction and stroke, 
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the Rotterdam Study found the average maximum CCA-IMT to be 1.03 ± 0.22 and 
divided the carotid IMT into quartiles based on the population distribution. Using 
maximal CCA-IMT cutoff values of 0.88, 0.99, and 1.12 mm, they have defined 
mild, moderate, and severe thickening of the carotid wall, irrespectively.12,17 The 
Multi-Ethnic Study of Atherosclerosis study divided the maximal common carotid 
IMT in quartiles as well and found cutoff values of 0.74, 0.84, 0.97 and 2.45 mm, 
respectively.18 Our study population consisted of major vascular surgery patients, 
which are prone to have atherosclerosis. In comparison, the Rotterdam study and 
Multi-Ethnic Study of Atherosclerosis study were population-based studies. As 
patients with operable vascular disease may have more diffuse and more severe 
vascular disease, this might explain our relatively high cutoff value for CCA-IMT to 
predict future CV events.  
 
The carotid IMT is increasingly used as a surrogate marker of early 
atherosclerosis, which is associated with CV diseases such as myocardial 
infarction, stroke and peripheral arterial disease. Several studies have 
demonstrated that carotid IMT is associated with risk of CV events.5,19 This study 
was performed to evaluate the predictive value of the CCA-IMT for preclinical stages 
of atherosclerosis. Therefore, focal thickened regions in the carotid arteries were 
excluded, as they reflect later stages of atherosclerosis. A meta-analysis performed 
by Lorenz et al,12 in which 37.197 patients were included, provided data on the use 
of carotid IMT to predict myocardial infarction and stroke in the general population. 
In this study an absolute carotid IMT difference of 0.1 mm, was associated with an 
increased risk for myocardial infarction of 10 to 15% and an increased risk for 
stroke of 13 to 18%. However, as reported in the Mannheim Carotid IMT 
Consensus statement, the Food and Drug Administration does not yet approve 
carotid IMT as a surrogate marker of vascular events. Although, it is stated that 
carotid IMT is the most important candidate to be studied, as an independent 
marker for CV events.7 To our knowledge, the prognostic value of an increased 
CCA-IMT has not been previously described in patients undergoing vascular 
surgery. Only limited information is available regarding the prognostic value of 
CCA-IMT in patients undergoing cardiac interventions. Lacroix et al.20 evaluated 
whether CCA-IMT thickening was related to an increased risk of CV events after 
percutaneous transluminal coronary angioplasty. Univariatee analysis 
demonstrated that a CCA-IMT >0.7 mm was associated with increased CV events 
after percutaneous transluminal coronary angioplasty (p = 0.03). They concluded 
CCA-IMT could be useful to identify high-risk patients. Aboyans et al.21 enrolled 
609 patients undergoing coronary artery bypass grafting and hypothesized CCA-
IMT could be used for perioperative and long-term risk stratification. However, in 
multivariate analysis, CCA-IMT failed to be an independent predictor for secondary 
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CV events after coronary artery bypass grafting. Both studies mentioned above 
included patients with known coronary artery disease and long-term follow-up 
included non-fatal CV events as well. This might explain our relatively high cutoff 
value for CCA-IMT to predict future CV events.  
 
The “American Society of Echocardiography Carotid IMT task force” have 
stated that carotid IMT imaging should not be performed in patients with 
established atherosclerotic vascular disease or if the results would not be expected 
to alter therapy. They recommend prospective studies to investigate the 
effectiveness of carotid ultrasound imaging, in support to improve CV outcome.5 It 
is suspected that 95% of the episodes of perioperative myocardial infarction and 
ischemia are asymptomatic,1,22-25 and subsequently, these patients do not receive 
adequate treatment. We have shown that an increased CCA-IMT is an independent 
predictor of perioperative myocardial infarction and ischemia and could therefore 
contribute to optimize medical treatment as well. With current ultrasound 
scanners, CCA-IMT can be easily used in clinical routine for objective and 
reproducible cardiac risk assessment. Importantly, CCA-IMT has an additional 
value, incremental to subjective cardiac risk assessment using the RCR index. 
Validation of our results in future studies is needed to justify the recommendation 
of standard CCA-IMT measurements in preoperative risk stratification of vascular 
surgery patients. 
 
Potential limitations of these data merit consideration. First, the study 
population consisted of patients referred to a tertiary referral center and may not 
fully represent a general population scheduled for elective major vascular surgery. 
Second, although two experienced investigators performed offline assessments of 
the obtained ultrasound images, we cannot rule out interobserver variability to 
have had minor influence on our results.26 Third, we did not validate the CCA-IMT 
cutoff point in a prospective group of patients undergoing vascular surgery.  
 
In conclusion, the present study shows that an increased CCA-IMT of 
≥1.25 mm has a prognostic value in vascular surgery patients to predict 30-day CV 
events and long-term, incremental to the widely used RCR index. 
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ABSTRACT 
 
Aims: Patients with peripheral atherosclerotic disease often have multiple affected 
vascular beds (AVB); however, data on long-term follow-up and medical therapy are 
scarce. We assessed the prevalence and prognostic implications of polyvascular 
disease on long-term outcome in symptomatic peripheral arterial disease (PAD) 
patients. 
 
Methods: Two thousand nine hundred and thirty-three consecutive patients were 
screened prior to surgery for concomitant documented cerebrovascular disease and 
coronary artery disease. The number of AVB was determined. Cardiovascular 
medication as recommended by guidelines was noted at discharge.  
 
Results: Single, two and three AVB were detected in 1.369 (46%), 1.249 (43%) and 
315 (11%) patients, respectively. During a median follow-up of 6 years, 1.398 (48%) 
patients died, of which 54% secondary to cardiovascular cause. After adjustment 
for baseline cardiac risk factors and discharge-medication, the presence of 2-AVB 
or 3-AVB was associated with all-cause mortality (HR 1.3, 95% CI: 1.2 to 1.5; HR 
1.8, 95% CI: 1.5 to 2.2) and cardiovascular mortality (HR 1.5, 95% CI: 1.2 to 1.7; 
HR 2.0, 95% CI: 1.6 to 2.5) during long-term follow-up, respectively. Patients with 
2- and 3-AVB received extended medical treatment compared with 1-AVB at time of 
discharge. 
 
Conclusions: Polyvascular atherosclerotic disease in PAD patients is independently 
associated with an increased risk for all-cause and cardiovascular mortality during 
long-term follow-up.  
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INTRODUCTION 
 
Peripheral arterial disease (PAD) is a multifactorial syndrome that most commonly 
affects people over 60 years of age.1 As population age increases, the prevalence of 
atherosclerotic disease and its associated adverse outcomes will increase. 
Cardiovascular risk profiles have been established in several large studies, showing 
an equal risk factor distribution among all populations and across age groups and 
gender.2,3 It has to be noted that the process of established atherothrombosis is not 
limited to a single arterial location. The Reduction of Atherothrombosis for 
Continued Health (REACH) registry showed that one out of 6 patients with PAD, 
cerebrovascular disease (CVD) or coronary artery disease (CAD) had involvement of 
1 or 2 other arterial beds.1,4 The REACH registry also demonstrated a substantial 
gap between recommended clinical guidelines and actual clinical practices in the 
care of patients with or at risk for atherothrombosis. A pattern of underutilization 
of established medical therapies and lifestyle interventions was shown throughout 
all geographic regions studies and vascular disease subtypes.1 Consequently, 
patients with PAD have a three to six-fold increased risk for the occurrence of 
cardiovascular mortality compared with patients without PAD.5,6 Therefore, the 
importance of risk factor reduction in patients with PAD has resulted in universally 
recommended atherothrombotic risk factor reduction, with the objective of 
decreasing the high incidence of heart disease and cerebrovascular disease 
associated with PAD.7,8 However, although these large studies have identified the 
risk factor profiles and treatment protocols of atherosclerotic patients, most data 
are based on the screening of polyvascular disease, especially in the primary care 
setting. Therefore, the aim of the current study was to assess (i) the prevalence and 
number of affected vascular beds, and (ii) the prognostic implications of 
polyvascular disease on short- and long-term mortality in high-risk vascular 
surgery patients with symptomatic PAD.   
 
 
METHODS 
 
Study design and population 
This retrospective single-centre study comprised a population of 2.933 consecutive 
patients with PAD, referred for elective major vascular surgery. All patients 
underwent a major vascular surgery procedure during the time period 1990 to 
2008, and included lower extremity revascularization, abdominal aortic surgery 
(dilatating or stenotic) or carotid surgery. From 1990 until 2001, standard pre-
operative screening included a detailed cardiac history, physical examination, 
electrocardiogram (ECG), standard laboratory measurements and additional 
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(stress)-testing if indicated. After 2002, standard pre-operative echocardiography 
was added to the screening program. The study complies the Declaration of 
Helsinki. Patient enrolment was performed after approval of the hospital’s ethics 
committee and after informed consent of all patients (or their guardians) at time of 
inclusion. 
 
Patient data 
At baseline all medical records were reviewed to determine the presence of 
documented CAD and CVD. Patients undergoing lower extremity revascularization 
or abdominal aortic surgery were screened for the concomitant presence of 
documented CAD and CVD. Patients undergoing carotid surgery were screened for 
CAD and PAD. Coronary artery disease was defined as a documented history of 
ischemic heart disease [composite of angina pectoris, myocardial infarction (MI), 
percutaneous coronary intervention or coronary artery bypass grafting], using 
myocardial stress-testing (ergometry, stress-echocardiography, or CT-scan) or 
coronary angiogram. Patients with stable or unstable angina pectoris were 
classified as having documented CAD according the ESC guidelines.9 The presence 
of coronary ischemia was established by one of the following techniques: exercise 
ECG [horizontal or down-sloping ST-segment depression or elevation (≥1mm 
(0.1mV) for ≥60-80ms after the end of the QRS complex)], or exercise testing with 
echocardiography, CT-scan (≥50% stenosis in one or more of the coronary 
arteries).10 The presence of documented CVD was defined as a history of 
cerebrovascular accident or transient ischemic attack (TIA). Cerebrovascular 
accidents had to be confirmed by a CT-scanning report. The diagnosis of TIA had to 
be confirmed by a neurologist report. Lower extremity arterial disease was defined 
as current intermittent claudication with ankle-brachial-index <0.9, or a history of 
intermittent claudication with a previous intervention, such as angioplasty, 
stenting, atherectomy, peripheral arterial bypass graft, or other vascular 
intervention including amputation. Polyvascular disease was defined as the 
presence of 2 or 3-AVB. One-AVB included: PAD, 2-AVB: PAD and CAD or CVD, 3-
AVB: PAD and CAD and CVD.  
 
 Finally, the use of the following medication was recorded at discharge: 
aspirin, statins, ß-blockers, diuretics, angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers, oral anticoagulants, and ticlopidines. 
Treatment goals were defined according the current guidelines and included low-
dose aspirin (75-325mg daily) and statins (low-intermediate risk patients: target 
LDL level <100 mg/dL, high-risk patients <70 mg/dL) for patients with PAD, and if 
necessary combined with antihypertensive drugs to receive a target blood pressure 
below 140/90 mmHg.7 Additionally, PAD patients with diabetes should receive 
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ACE-inhibitors to a target blood pressure less than 130/80 mmHg.7 Patients with 
CAD should be treated with aspirin, statins (target LDL <100 mg/dL) and ß-
blockers, and additionally with ACE-inhibitors or Angiontensin receptor blockers in 
case of diabetes mellitus and/or heart failure.11    
 
Risk factors 
All cardiac risk factors were determined at baseline, including age, gender, body 
mass index, smoking status, hypertension (defined as systolic blood pressure ≥140 
mmHg, diastolic blood pressure ≥90 mmHg in non-diabetics, systolic blood 
pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg in diabetics or the use of 
antihypertensive medication), diabetes mellitus (fasting blood glucose ≥7.0 mmol/l 
or requirement for insulin and/or oral anti-diabetic medication), 
hypercholesterolemia (LDL cholesterol > 135 mg/dL and/or the requirement of 
lipid-lowering medication), chronic obstructive pulmonary disease (according to the 
Global Initiative on Obstructive Lung Diseaseas (GOLD)-classification12) and 
chronic renal insufficiency (serum creatinine >2,0 mg/dL). The cardiac risk score 
was calculated according the adapted Lee cardiac index which assigns 1 point for 
each of the following characteristics: high-risk surgery, ischemic heart disease, 
heart failure, cerebrovascular disease, chronic renal insufficiency, and diabetes 
mellitus.13 
 
Follow-up and endpoints 
The median follow-up of all patients was 6 years (interquartile range 2 to 9). 
Primary study endpoint was the occurrence of all-cause mortality. Survival status 
was assessed by reviewing the municipal civil registries. Cause of death was 
ascertained by examining death certificates, and otherwise by reviewing medical 
records. Cause of death was further classified as either cardiovascular or 
noncardiovascular death. Cardiovascular death was defined as any death with a 
cerebro-cardiovascular complication as the primary or secondary cause and 
includes death following MI, serious cardiac arrhythmias (defined as the presence 
of a sustained cardiac rhythm disturbance that required urgent medical 
intervention), congestive heart failure, stroke (cerebrovascular event or transient 
ischemic attack), and surgery related bleeding complications (only a post-operative 
cause of death). Sudden unexpected death was classified as a cardiovascular 
death. 
 
Statistics  
Continuous data were compared using analysis of variance, and are expressed as 
mean ± SD. Categorical data are presented as percentage frequencies and 
compared using χ2 tests. Analyses for trends in all baseline characteristics 
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(including age) between the number AVB were performed with linear-by-linear 
association. Logistic regression analysis was used to determine the association 
between polyvascular disease (2 and 3-AVB compared with 1-AVB) and short-term 
mortality (30 days). Cumulative survival of patients with 1, 2, or 3-AVB was 
determined by the Kaplan-Meier method and compared using the log-rank test. 
Univariate and multivariate Cox regression models were used to investigate the 
association between AVB (patients with 1-AVB as reference group) and mortality 
during long-term follow-up. All multivariate analyses were primarily adjusted for 
demographics (age and gender) and cardiovascular risk factors (smoking, 
hypertension, diabetes mellitus, hypercholesterolemia, renal dysfunction, heart 
failure and COPD). Secondary adjustments were made for medications usage 
recommended by the ESC/ACC guidelines in patients with PAD, including aspirin, 
statins, ß-blockers in case of prior myocardial infarction and angiotensin-
converting enzyme (ACE) inhibitors in case of heart failure.7 Finally, adjustment 
was made for preoperative hemoglobin levels. To evaluate the effect of medication 
use (aspirin, statins, ß-blockers and ACE-inhibitors) on long-term outcome, 
multivariate Cox regression analyses were performed with propensity score 
adjustment for each medication. Separate propensity scores were developed with 
logistic regression analyses for each type of medication. Variables included in the 
propensity score model were demographics (age and gender), cardiovascular risk 
factors (smoking, hypertension, diabetes mellitus, hypercholesterolemia, renal 
dysfunction, heart failure and COPD), medication use and hemoglobin. Statistical 
analyses were performed using SPSS software (SPSS version 15.0; SPSS, Inc., 
Chicago, Illinois). Hazard ratios (HR) were calculated from these models along with 
their 95% confidence intervals (C.I.).  A p value <0.05 (2-sided) was considered 
statistically significant.   
 
 
RESULTS 
 
Description of the study population 
The study population consisted of 2.933 consecutive patients with PAD referred for 
elective major vascular surgery. Lower extremity revascularization was performed 
in 1.031 (35%) patients, abdominal aortic surgery in 1.170 (40%) patients, and 
carotid surgery in 732 (25%) patients, respectively. Coronary artery and 
cerebrovascular disease were detected in 1.248 (43%) and 1.037 (35%) patients, 
respectively. In patients referred for lower extremity revascularization, 454 (44%) 
and 144 (14%) patients had concomitant documented CAD and CVD, respectively. 
Coronary artery disease and CVD were present in 575 (49%) and 166 (14%) of the 
patients referred for abdominal aortic surgery. Patients referred for carotid surgery, 
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219 (30%) and 79 (11%) patients had concomitant CAD and PAD. The number of 
affected vascular beds was determined at baseline, and one-vessel disease (1-AVB), 
two-vessel disease (2-AVB) and three-vessel disease (3-AVB) was detected in 1.369 
(46%), 1.249 (43%) and 315 (11%) patients, respectively (Figure 1). 
 
Figure 1. Number of affected vascular beds in the total study population and subdivided for type of surgery   
 
Abbreviations: PAD; peripheral arterial disease, AAA; abdominal aortic aneurysm, LEAD; lower extremity 
arterial disease, CVD; cerebrovascular disease, AVB; affected vascular beds 
 
Lee cardiac index and number of affected vessels 
Baseline characteristics of the study population were compared between the groups 
with different number of affected vascular beds and included demographic 
parameters and cardiovascular risk factors. A significant trend for an increased 
number of cardiovascular risk factors was present in patients with 2- or 3-AVB, 
compared with 1-AVB. Additionally, risk factor patterns were calculated following 
the Lee cardiac index and showed a relationship with the number of affected 
vessels. A Lee risk score of ≥3 was only present in 5% of patients with 1-AVB while 
252 (80%) patients had a Lee risk score of ≥3 in patients with 3-AVB (p < 0.001, 
Figure 2).  
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Figure 2. Distribution of the Lee cardiac index according to the number of affected vascular beds 
 
 
Medication use and number of affected vessels 
Medication use at time of hospital discharge was registered and compared between 
the different patient groups (Table 1). Aspirin, statins, ß-blockers and ACE-
inhibitors were used by 1.502 (51%), 1.131 (39%), 1.293 (44%) and 740 (25%) 
patients, respectively. There was a clear relationship between the year of surgery 
and medical treatment intensity after surgery (Figure 3). Importantly, aspirin was 
used in ≥50% of the patients from 1996, whereas statins and ß-blockers were 
prescribed in ≥50% of the patients from 2002. The number of AVB (1- vs. 2- vs. 3-
AVB) showed a relationship with the use of statins (34 vs. 41 vs. 51%, p < 0.001), 
ß-blockers (37 vs. 48 vs. 60%, p < 0.001) and ACE-inhibitors (19 vs. 28 vs. 40%, p 
< 0.001). In contrast, there was no significant relationship between the number of 
AVB and aspirin use (53 vs. 49 vs. 53%, p = 0.25).  
 
Short-term outcome 
During the first 30 postoperative days, 112 (3.8%) patients died, of which 90 (80%) 
patients died secondary to a cardiovascular cause. Using univariate analysis, 
patients with 2- or 3-AVB had a significant increased mortality risk compared with 
patients with 1-AVB (2-AVB: OR 1.9, 95% CI: 1.22 to 2.88, 3-AVB: OR 2.5, 95% CI: 
1.42 to 4.50), respectively (Table 2). This increased risk was present for the 
occurrence of cardiovascular death as well (2-AVB: OR 1.9, 95% CI: 1.16 to 3.00, 3-
AVB: OR 2.2, 95% CI: 1.16 to 4.30). In multivariate analysis 2- and 3-AVB were 
independently associated with all-cause mortality (2-AVB: OR 1.7, 95% CI 1.03 to 
2.63, 3-AVB: OR 2.5, 95% CI: 1.29 to 4.71). However, cardiovascular mortality was 
not longer significantly associated with polyvascular disease during short-term 
follow-up. 
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Table 1 Baseline characteristics of the study population 
 
Total 
[N=2.933] 
1-AVB 
[N=1.369] 
2-AVB 
[N=1.249] 
3-AVB 
[N=315] 
P- 
value 
Demographics   
Age (year), mean ± SD 66 (11) 66 (12) 67 (11) 68 (10) <0.001 
Male (%) 2.189 (75) 958 (70) 984 (78) 257 (82) <0.001 
Year of surgery  0.001 
 < 1992 429 (15) 187 (14) 205 (16) 37 (12)  
 1993-1995 653 (22) 323 (24) 270 (22) 60 (19)  
 1996-1998 586 (20) 303 (22) 228 (18) 55 (18)  
 1999-2001 353 (12) 177 (13) 150 (12) 26 (8)  
 2002-2004 249 (9) 96 (7) 112 (9) 41 (13)  
 2005-2008 663 (23) 283 (21) 285 (23) 314 (11)  
Cardiovascular risk factors   
Smoking     <0.001 
 No 1.139 (39) 585 (43) 456 (37) 98 (31)  
 Current 1.092 (37) 490 (36) 471 (38) 131 (42)  
 History 702 (24) 294 (22) 322 (26) 86 (27)  
Hypertension 1.514 (52) 594 (43) 706 (57) 214 (68) <0.001 
Hypercholesterolaemia 798 (27) 289 (21) 392 (31) 117 (37) <0.001 
Renal dysfunction 297 (10) 95 (7) 146 (10) 56 (18) <0.001 
Chronic heart failure 206 (7) 24 (2) 126 (10) 56 (18) <0.001 
COPD 557 (19) 201 (15) 271 (22) 85 (27) <0.001 
Medication at discharge   
Aspirin 1.502 (51) 726 (53) 610 (49) 166 (53) 0.25 
Statin 1.131 (39) 463 (34) 506 (41) 162 (51) <0.001 
Β-blocking agents 1.293 (44) 506 (37) 599 (48) 188 (60) <0.001 
Diuretics 696 (24) 244 (18) 340 (27) 112 (36) <0.001 
ACE inhibitors 740 (25) 260 (19) 335 (28) 125 (40) <0.001 
Calcium Antagonists 711 (24) 265 (19) 360 (29) 86 (27) <0.001 
AT-II antagonists 157 (5) 61 (5) 71 (6) 25 (8) 0.01 
Oral anticoagulants 1.108 (38) 463 (34) 505 (40) 140 (44) <0.001 
Ticlopidines 132 (5) 45 (3) 60 (5) 27 (9) <0.001 
Abbreviations: AVB: affected vascular beds, COPD: chronic obstructive pulmonary disease, ACE-inhibitors: 
angiotensin converting enzyme-inhibitors, AT-II antagonists: angiotensin II antagonists. 
 
Long-term outcome 
After one-year follow-up, 308 (11%) patients died, of which 227 (74%) and 71 (26%) 
secondary to a cardiovascular or non-cardiovascular cause, respectively. Patients 
with 2- or 3-AVB had an increased risk for the occurrence of 1-year all-cause 
mortality (2-AVB: HR 1.3, 95% CI: 1.03 to 1.7; 3-AVB: 1.6, 95% CI: 1.1 to 2.3) and 
cardiovascular mortality (2-AVB: HR 1.7, 95% CI: 1.2 to 2.2; 3-AVB: 1.7, 95% CI: 
1.1 to 2.6), compared with patients with 1-AVB, respectively. During long-term 
follow-up, 1.389 (47%) patients reached the primary endpoint of all-cause 
mortality. A cardiovascular or non-cardiovascular cause of death was detected in 
849 (61%) and 434 (31%) patients, respectively. 
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Figure 3. Post-operative prescription of aspirin, statins, ß-blockers, and ACE-inhibitors stratified according to 
the year of surgery 
 
Multivariate (1): adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, 
renal dysfunction, heart failure, chronic obstructive pulmonary disease, haemoglobin. Multivariate (2): 
adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal 
dysfunction, heart failure, chronic obstructive pulmonary disease, haemoglobin + medication use, including: 
aspirin, statins, ß-blockers, and ACE-inhibitors.  
 
 
 
 
Table 2 Short-term (30 days) survival 
Events Univariate Multivariate (1) Multivariate (2) 
 
N (%) OR 95% CI OR 95% CI OR 95% CI 
All cause mortality 
 1-AVB(N=1.369) 36 (3) Ref.  Ref.  Ref.  
 2-AVB (N=1.249) 57 (5) 1.87 1.22-2.88 1.59 1.01-2.50 1.65 1.03-2.63 
 3-AVB (N=315) 19 (6) 2.53 1.42-4.50 1.76 0.95-3.27 2.46 1.29-4.71 
Cardiovascular mortality 
 1-AVB(N=1.369) 29 (3) Ref.  Ref.  Ref.  
 2-AVB (N=1.249) 47 (5) 1.87 1.16-3.00 1.52 0.93-2.50 1.56 0.94-2.60 
 3-AVB (N=315) 14 (7) 2.23 1.16-4.30 1.44 0.72-2.89 1.94 0.94-4.02 
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Figure 4. Kaplan-Meier estimates for long-term all-cause mortality, stratified according to the number of 
affected vascular beds 
 
 
In the remaining 106 (8%) patients, no specific cause of death could be determined. 
The occurrence of all-cause mortality showed a significant relationship with the 
number of affected vascular beds (1-AVB 43, 2-AVB 50, 3-AVB 54%, p < 0.001). 
Kaplan-Meier estimates for long-term mortality stratified according the number of 
AVB showed that patients with 2- or 3-AVB had lower survival compared with 
patients with 1-AVB (Figure 4).  
 
 At 1-year follow-up, survival rates in patients with 1-, 2-, and 3-AVB were 
91.4, 87.9 and 83.6, respectively. Furthermore, at 10-year follow-up, survival rates 
in 1-, 2- and 3-AVB were 48.0, 40.6, 29.2, respectively. Log rank rest compared 
cumulative survival between 1- and 2-AVB and 2- and 3-AVB and showed a 
significant difference in survival between both comparisons (p < 0.001). After 
multivariate regression analysis, adjusted for baseline demographic and risk 
factors, a strong relationship between the number of AVB and the risk of all-cause 
and cardiovascular mortality was detected at both 1 and 10 years of follow-up 
(Table 3). During long-term follow-up, patients with 2 or 3-AVB had an increased 
risk for the occurrence of all-cause mortality (2-AVB: HR 1.3, 95% CI: 1.15 to 1.45; 
3-AVB: HR 1.8, 95% CI: 1.50 to 2.15), and also for the occurrence of cardiovascular 
mortality (2-AVB: HR 1.5, 95% CI: 1.24 to 1.68; 3-AVB: HR 2.0, 95% CI 1.60 to 
2.51), compared with patients with 1-AVB, respectively. 
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  Optimal medical therapy according the ESC/ACC guidelines was 57% in 
the patient group that underwent surgery between 2002 and 2008. During this 
period, aspirin (HR 0.52, 95% CI: 0.37 to 0.72), statins (HR 0.38, 95% CI 0.27 to 
0.53) and ACE-inhibitors (HR 0.32, 95% CI 0.11 to 0.94) were significantly 
associated with lower mortality rates in propensity adjusted analysis. Of note, over 
90% of the patients who underwent surgery after 2002 were on perioperative ß-
blocker therapy.   
 
Table 3 Long-term survival 
Events Univariate Multivariate (1) Multivariate (2) 
 
N (%) OR 95% CI OR 95% CI OR 95% CI 
All cause mortality 
 1-AVB(N=1.369) 558 (43) Ref.  Ref.  Ref.  
 2-AVB (N=1.249) 630 (50) 1.32 1.18-1.48 1.27 1.13-1.43 1.29 1.15-1.45 
 3-AVB (N=315) 171 (54) 1.87 1.57-2.22 1.62 1.36-1.94 1.79 1.50-2.15 
Cardiovascular mortality 
 1-AVB(N=1.369) 334 (24) Ref.  Ref.  Ref.  
 2-AVB (N=1.249) 401 (32) 1.50 1.29-1.73 1.42 1.22-1.65 1.45 1.24-1.68 
 3-AVB (N=315) 114 (36) 2.14 1.73-2.65 1.81 1.45-2.27 2.00 1.60-2.51 
Multivariate (1): adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, 
renal dysfunction, heart failure, chronic obstructive pulmonary disease, haemoglobin. Multivariate (2): 
adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal 
dysfunction, heart failure, chronic obstructive pulmonary disease, haemoglobin + medication use, including: 
aspirin, statins, ß-blockers, and ACE-inhibitors.  
 
 
DISCUSSION 
 
To our knowledge, the current study is the first to show a strong relationship 
between the number of affected vessel beds and long-term prognosis in patients 
with known symptomatic PAD. Compared with 1-AVB, patients with 2- or 3-AVB 
had significantly higher rates of all-cause and cardiovascular mortality during long-
term follow-up after major vascular surgery. The process of atherosclerotic vascular 
disease is a diffuse progressive condition that usually affects multiple vascular 
territories concomitantly. All manifestations of arterial diseases are preceded by 
atherosclerotic plaques formation in the arterial wall. The presence of risk factors 
like hypertension, diabetes mellitus, smoking and hypercholesterolemia make 
patients prone for the development of atherosclerotic plaques. Therefore, lifestyle 
modification and medical treatment are strongly recommended for patients with 
atherosclerotic disease.7,8 
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Until now, most data regarding the prevalence and long-term prognosis of 
patients with polyvascular disease included determination of polyvascular disease 
in the primary care setting, while follow-up was generally limited to 1-year.4,14 In 
most studies and registries, data on the prevalence of polyvascular disease were 
mainly on the presence of risk factors, symptoms and medical treatment. Hirsch et 
al. found a prevalence of polyvascular disease (PAD and CVD) of 16% in the 
primary care setting, which was observed by the REACH registry as well.1,15 Recent 
data from the CRUSCADE investigators in patients presenting with non-ST-
segment elevation acute coronary syndrome, reported a prevalence of 12% 
established PAD, 10% documented CVD, and 43% prior CAD.16 Objective 
determination of polyvascular disease by screening and/or additional testing was 
performed primary by Hertzer et al. who observed a prevalence of CAD in 44, 30 
and 33% of the PAD patients, respectively.17 Analysis of the REACH registry 
showed that 2- or 3-AVB is present in 48 or 14% of PAD patients, respectively.4 We 
demonstrated in the current study of patients with known PAD, a documented 
prevalence of 2- and 3-AVB of 43 and 11%, respectively. The slightly higher 
prevalence of polyvascular disease in the PAD subset of REACH patients is likely 
due to the inclusion of patients with ≥3 atherothrombotic risk factors without 
symptomatic vascular disease, in the REACH registry. 
 
 The current study showed a significant association between the presence of 
multiple risk factors and the presence of polyvascular disease, which was in line 
with previous studies that focused on the prevalence of risk factors in several 
atherosclerotic populations.14,15,18 Atherothrombotic risk factor reduction is 
universally recommended for patients with PAD to reduce their high incidence of 
heart disease and stroke.7,8,19-21 Although we found that patients with 2- or 3-AVB 
received better medical treatment compared with patients with lone PAD, there was 
still a underutilization of medication. In this study, aspirin use was observed in 
more than 50% of the patients included after 1996 and was associated with 
increased survival rates, which is in line with a recent meta-analyses.22 The 
underutilization of optimal medical therapy is strongly related to the 
implementation of the guidelines on PAD after 2003, as before the implementation 
of guidelines only a minority of patients received a combination of aspirin, statins, 
ACE-inhibitors and in cases of ischemic heart disease additional ß-blockers was 
used.7 Thereafter, the use of statins and ß-blockers has strongly increased, and 
57% of the patients included in this cohort received optimal medical therapy. As 
reported by others, aspirin, statins and ACE-inhibitor use were all significantly 
associated with increased survival rates.22 The gap between guideline 
recommendations and clinical practice in PAD patients remains a concerning and 
significant problem. Potential reasons for this under treatment could be related to 
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(i) low perception of the risk associated with PAD compared with CAD and CVD, 
and (ii) the absence of healthcare campaigns directed at providing information to 
individuals with PAD, especially during the previous decade. 
 
 Data regarding the perioperative outcome in the polyvascular patient 
population are scarce, as most studies are directed at one-year mortality rates. Our 
study showed that patients with 2- or 3-AVB had higher perioperative mortality 
rates compared with patients with 1-AVB (5 and 6 vs. 3% p < 0.001, respectively). 
Cardiovascular mortality was present in 75% of the patients that died within the 
first 30-days after major vascular surgery. In multivariate analyses polyvascular 
disease was significantly associated with increased all-cause mortality rates. Our 
data are in keeping with others reporting 30-day mortality rates up to 6%, of which 
76% are due to cardiovascular cause in major vascular surgery patients.18 Bhatt et 
al. reported a 30-day all-cause mortality rate of 7.3% in patients presenting with 
non-ST-elevation acute coronary syndrome and concomitant 3-AVB. In this study, 
only 3-AVB was significantly associated with increased all-cause mortality (OR 
1.25, 95% CI: 1.02 to 1.54) in multivariate analysis.16 
 
 After one year follow-up, 11% of the patients died of which 74% secondary 
to a cardiovascular cause. A significant association between the number of AVB 
and the occurrence of all-cause and cardiovascular mortality was observed. 
Mortality rates increased from 8 in 1-AVB to 16% in 3-AVB. These findings are in 
keeping with others, as in the REACH registry one-year all-cause and 
cardiovascular mortality rates were approximately doubled in patients with 
polyvascular disease, compared with single arterial disease.14 Furthermore, the 
Polyvascular Atherothrombosis Observational Survey (PATHOS) found that patients 
with acute myocardial infarction or stroke and concomitant PAD had an increased 
mortality risk (OR 2.05, 95% CI: 1.31 to 3.22) compared with patients without 
PAD.23 These findings support the need for increased awareness of the cross-risk 
that is related to the overlap between the various arterial locations of 
atherothrombosis. 
 
 No prior large studies investigated the long-term prognosis of patients with 
polyvascular atherosclerotic disease up to 10 years. The current study found that 
after a follow-up period of 5 years, 50% of the patients with 3-AVB had already 
died, pointing at the grave prognosis of polyvascular disease. Criqui et al. 
performed the first long-term outcome study in 565 patients with large-vessel PAD 
and detected an increased relative risk for cardiovascular mortality (RR 5.9, 95% 
CI: 3.0 to 11.4) after 10-years follow-up, compared with patients without PAD.5 
Eagle et al. and Sutton et al. observed that during 10-year follow-up, CAD patients 
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with concomitant PAD had a 25% greater likelihood of mortality compared with 
CAD patients without PAD at any point in time.24,25 Recently, Welten et al. 
performed a propensity-matched study in PAD and CAD patients, showing that 
during a mean follow-up of 6 ± 4 years, patients with PAD had a significantly worse 
long-term prognosis compared with patients with CAD (unadjusted HR 2.4, 95% CI: 
2.18 to 2.65).18 Hence, patients with combined PAD, CAD and/or CVD have the 
worst prognosis. Therefore, early objective detection and treatment of asymptomatic 
concomitant cardiovascular risk factors in patients with PAD is recommended and 
strongly emphasized by the current guidelines.7,8 
 
Limitations  
Potential limitations of the current study merit consideration. First, this study has 
the disadvantage of a retrospective design. Second, the standardized protocol for 
preoperative screening did not include echocardiography before 2002; therefore 
there could be an underestimation of subclinical atherosclerosis in patients 
undergoing surgery before this date. In addition, diagnostic methods and accuracy 
have changed over time, which could have influenced the criteria for the presence 
of documented CAD or CVD. Third, a specific cause of death could not be 
established in 3.6% of the patients that died during the follow-up period. One year 
after the last patient had been included, mortality rates were verified according the 
civil registries; however, reviewing the death certificates or contacting the treating 
general practioner could not establish cause of death. Therefore, we performed two 
additional analyses in which patients for whom cause of death was unknown were 
regarded either as cardiovascular or noncardiovascular deaths. These analyses 
found similar results with no influence on the significance of the outcome 
parameters. Finally, although this study detected significant associations between 
medical treatment and increased survival rates, these results need to be 
interpreted with some caution as this study only included medical treatment at 
discharge and no evaluation of treatment adherence during follow-up was 
available. 
 
Conclusion 
Polyvascular atherosclerotic disease in PAD patients scheduled for elective major 
vascular surgery is independently associated with an increased risk for all-cause 
and cardiovascular mortality during long-term follow-up. Peripheral arterial disease 
patients with polyvascular disease have more atherosclerotic risk factors and 
receive extended medical treatment, mainly as a result of the implementation of 
guidelines. However, as PAD patients with polyvascular disease still receive sub-
optimal cardioprotective medication; more attention should be given to optimization 
of life style modification and treatment. 
 78 
REFERENCES 
 
1. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of 
cardiovascular risk factors in outpatients with atherothrombosis. Jama. 2006;295(2):180-189. 
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with 
myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 
2004;364(9438):937-952. 
3. Wilson PW. Framingham and European risk algorithms: implications for African Americans. Rev 
Cardiovasc Med. 2004;5 Suppl 3:S34-41. 
4. Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in 
peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health 
(REACH) Registry. Atherosclerosis. 2008. 
5. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with 
peripheral arterial disease. N Engl J Med. 1992;326(6):381-386. 
6. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an 
 independent predictor of mortality. Atherosclerosis. 1991;87(2-3):119-128. 
7. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the 
 management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and 
 abdominal aortic): a collaborative report from the American Association for Vascular 
 Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and 
 Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, 
 and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines 
for the Management of Patients With Peripheral Arterial Disease): endorsed by the American 
Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood 
Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and 
 Vascular Disease Foundation. Circulation. 2006;113(11):e463-654. 
8. Smith SC, Jr., Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC 
 guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular 
disease: 2001 update: A statement for healthcare professionals from the American Heart 
Association and the American College of Cardiology. Circulation. 2001;104(13):1577-1579. 
9. Fox K, Garcia MA, Ardissino D, et al. [Guidelines on the management of stable angina pectoris; 
the experts of the European Society of Cardiology on the management of stable angina pectoris]. 
Kardiol Pol. 2006;64(8):823-880. 
10. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart 
Association Expert Consensus Document on electron-beam computed tomography for the 
diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol. 2000;36(1):326-340. 
11. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management 
of patients with chronic stable angina--summary article: a report of the American College of 
Cardiology/American Heart Association Task Force on practice guidelines (Committee on the 
Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159-168. 
12. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit 
Care Med. 2007;176(6):532-555. 
13. Boersma E, Kertai MD, Schouten O, et al. Perioperative cardiovascular mortality in noncardiac 
surgery: validation of the Lee cardiac risk index. Am J Med. 2005;118(10):1134-1141. 
14. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with 
atherothrombosis. Jama. 2007;297(11):1197-1206. 
15. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, 
and treatment in primary care. Jama. 2001;286(11):1317-1324. 
16. Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse 
ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10):1195-1202. 
 79 
17. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. 
A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 
1984;199(2):223-233. 
18. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral 
arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 
2008;51(16):1588-1596. 
19. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events 
(CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-1339. 
20. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk 
individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22. 
21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, 
ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention 
Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153. 
22. Hackam DG, Sultan NM, Criqui MH. Vascular protection in peripheral artery disease: systematic 
review and modelling study. Heart. 2009;95(13):1098-1102. 
23. Agnelli G, Cimminiello C, Meneghetti G, et al. Low ankle-brachial index predicts an adverse 1-
year outcome after acute coronary and cerebrovascular events. J Thromb Haemost. 
2006;4(12):2599-2606. 
24. Eagle KA, Rihal CS, Foster ED, et al. Long-term survival in patients with coronary artery disease: 
importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) 
Investigators. J Am Coll Cardiol. 1994;23(5):1091-1095. 
25. Sutton-Tyrrell K, Rihal C, Sellers MA, et al. Long-term prognostic value of clinically evident 
noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass 
Angioplasty Revascularization Investigation (BARI). Am J Cardiol. 1998;81(4):375-381. 
 
 
 80 
 81 
Chapter 6 
 
 
 
 
 
 
The influence of polyvascular disease 
on the obesity paradox in vascular 
surgery patients 
 
 
Jan-Peter van Kuijk 
Willem-Jan Flu 
Wael Galal 
Michel Chonchol  
Hence J.M.Verhagen 
Jeroen J. Bax 
Don Poldermans 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Vascular Surgery 2010; in press 
 98 
 
 99 
Chapter 7 
 
 
 
 
 
 
Prognostic implications of 
asymptomatic left-ventricular 
dysfunction in patients undergoing 
vascular surgery  
 
 
Willem-Jan Flu 
Jan-Peter van Kuijk 
Sanne E Hoeks 
Ruud J. Kuiper 
Olaf Schouten 
Dustin Goei 
Abdou Elhendy 
Hence J.M. Verhagen 
Ian R Thomson 
Jeroen J. Bax 
Lee A Fleisher 
Don Poldermans  
 
 
 
 
 
Anesthesiology, 2010;112(6):1316-1324 
 100 
ABSTRACT 
 
Background: The prognostic value of heart failure symptoms on postoperative 
outcome is well acknowledged in the American College of Cardiology/American 
Heart Association and European Society of Cardiology perioperative guidelines. 
However, the prognostic value of asymptomatic left ventricular (LV) dysfunction 
remains unknown. This study evaluated the prognostic implications of 
asymptomatic LV dysfunction, assessed with routine preoperative 
echocardiography, in high-risk vascular surgery patients.  
 
Methods: Echocardiography was performed preoperatively in 1.005 consecutive 
vascular surgery patients. Systolic LV dysfunction was defined as LV ejection 
fraction <50%. Isolated diastolic LV dysfunction was diagnosed based on the ratio 
of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A), 
pulmonary vein flow and deceleration time. Troponin-T measurements and 
electrocardiograms were performed routinely before and after surgery. Study 
endpoints were 30-day cardiovascular events and long-term cardiovascular 
mortality. Multivariate regression analyses evaluated the relation between LV 
function and cardiovascular outcome.  
 
Results: Left ventricular dysfunction was diagnosed in 506 (50%) patients, of 
which 80% were asymptomatic. In open vascular surgery (N=649), both 
asymptomatic systolic and isolated diastolic LV dysfunction were associated with 
30-day cardiovascular events (OR 2.3, 95% CI: 1.4 to 3.6 and OR 1.8, 95% CI: 1.1 
to 2.9) and long-term cardiovascular mortality (HR 4.6, 95% CI: 2.4 to 8.5 and HR 
3.0, 95% CI: 1.5 to 6.0). In endovascular surgery (N=356), only symptomatic heart 
failure was associated with 30-day cardiovascular events (OR 1.8, 95% CI: 1.1 to 
2.9) and long-term cardiovascular mortality (HR 10.3, 95% CI: 5.4 to 19.3).  
 
Conclusions: This study demonstrated that asymptomatic LV dysfunction is 
predictive for 30-day and long-term cardiovascular outcome in open vascular 
surgery patients. These data suggest that preoperative risk stratification should not 
solely include heart failure symptoms, but routine preoperative echocardiography 
might be considered for risk stratification of patients undergoing open vascular 
surgery. 
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INTRODUCTION 
 
Worldwide, about 100 million adults undergo noncardiac surgery every year,1 and 
by the year 2020 this number will increase by 25%.2 The risk of adverse 
perioperative cardiovascular events after vascular surgery is particularly high as 
compared with other noncardiac surgeries.3 Although ischemic heart disease is 
acknowledged to be the most important risk factor for cardiovascular events after 
noncardiac surgery, several studies indicate that symptomatic heart failure is 
equally important.4-6  In the general population the prevalence of symptomatic 
heart failure is estimated to be around 2 to 3% and increases with age, with a 
prevalence estimated between 10 to 20% in septo- and octogenarians.7 Whereas the 
term heart failure describes a clinical syndrome, LV dysfunction describes the 
impaired mechanical properties of the left-ventricle. Asymptomatic LV dysfunction 
is considered a precursor of symptomatic heart failure, associated with high 
mortality.7 The prevalence of patients with asymptomatic LV dysfunction and 
symptomatic heart failure is assumed to be similar.8 
 
In the most recent American College of Cardiology/American Heart 
Association (AHA) and European Society of Cardiology (ESC) perioperative 
guidelines,3,9 the prognostic value of symptomatic heart failure on postoperative 
outcome is well acknowledged. However, the prognostic implications of 
asymptomatic LV dysfunction remains unknown. Routine perioperative evaluation 
of LV function is not recommended in ACC/AHA perioperative guidelines (Class III, 
Level of Evidence: C).9 Additionally, LV assessment with rest echocardiography is 
not recommended in ESC perioperative guidelines (Class III, Level of Evidence: C) 
for asymptomatic patients.3 We conducted the present study to evaluate the impact 
of asymptomatic isolated diastolic and asymptomatic systolic LV dysfunction, 
evaluated with routine preoperative echocardiography, on postoperative outcome of 
patients undergoing open or endovascular surgery.  
 
 
MATERIAL AND METHODS 
 
Study population 
The study population has been previously described and consisted of 1.005 
consecutive vascular surgery patients undergoing elective (open or endovascular) 
lower extremity artery, carotid artery or abdominal aorta repair.10 This prospective 
cohort study was performed at the Erasmus Medical Center in Rotterdam, the 
Netherlands, during the period of 2002 to 2008. The study was approved by the 
hospital’s ethics committee and performed with informed consent of all patients.  
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Baseline characteristics 
Prior to surgery, a detailed history was obtained from every patient. Cardiac history 
was assessed and ischemic heart disease was defined as a history of angina 
pectoris, coronary revascularization or myocardial infarction. Additional clinical 
data included age, gender, blood pressure, heart rate, cerebrovascular disease 
(history of ischemic or hemorrhagic stroke), renal dysfunction (serum creatinine >2 
mg/dL), diabetes mellitus (fasting blood glucose ≥126 mg/dL or requirement of 
anti-diabetic medication), hypertension (blood pressure ≥140/90 mmHg in non-
diabetics and ≥130/80 mmHg in diabetics,11 or requirement of antihypertensive 
medication), hypercholesterolemia (low density lipoprotein cholesterol ≥135 mg/dL 
or requirement of lipid-lowering medication), chronic obstructive pulmonary 
disease (according to the Global Initiative on Obstructive Lung Diseases 
classification) and smoking status. Finally, the use of β-blockers, statins, aspirin, 
oral anticoagulants, angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers, diuretics and nitrates was recorded.  
 
Echocardiography 
Preoperatively, transthoracic echocardiography was performed in all patients using 
a portable Acuson Cypress Ultrasound System (Acuson, A Siemens Company, 
Mountain View, CA) with a 3V2C transducer (3.0/3.5/2.5/2.0 MHz) for adult 
cardiac evaluation. Standard parasternal and apical 2- and 4-chamber views were 
obtained during rest with the patient in the left lateral decubitus position as 
recommended.12 Left-ventricular end-systolic and end-diastolic volumes were 
determined and LV ejection fraction was calculated using the biplane Simpson’s 
technique,13 with an inter- and intra-observer variability of 9 to 12 and 6%, 
respectively.14 Systolic (S) and diastolic (D) pulmonary vein flow, deceleration time 
and ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late 
filling (A) were determined in apical 4-chamber. Echocardiographic data were for 
research purposes and were not used for clinical management.  
 
Definition of LV dysfunction  
Left-ventricular ejection fraction <50%, both with and without accompanying 
diastolic dysfunction, defined systolic LV dysfunction.7 Diastolic LV dysfunction 
was confirmed in patients with E/A-ratio <0.8 (impaired relaxation) or >2 
(restrictive relaxation).15 Abnormal pulmonary vein flow (S/D <1) was used to 
distinguish normal and pseudo-normal diastolic LV function in patients with E/A-
ratio between 0.8 to 2.16 Deceleration time >220 ms (impaired relaxation) or <140 
ms (restrictive relaxation) defined diastolic LV dysfunction in patients with atrial 
fibrillation.16 Diastolic LV dysfunction, in the presence of a LV ejection fraction 
≥50%, defined asymptomatic isolated diastolic dysfunction. The presence of LV 
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dysfunction in combination with heart failure symptoms (shortness of breath, 
fatigue, exercise intolerance, signs of fluid retention) defined symptomatic heart 
failure.7 Two experienced investigators performed off-line assessments of the 
obtained ultrasound images. When there was disagreement between the two 
assessors, a third investigator viewed the images without knowledge of the previous 
assessment and a majority decision was reached.  
 
Study outcomes 
Serial electrocardiograms and troponin-T measurements were obtained from all 
patients prior to surgery, postoperatively on day 1, 3, 7 and before discharge. Study 
endpoints were 30-day cardiovascular events (CV), defined as myocardial ischemia, 
myocardial infarction and CV mortality, and long-term CV mortality. Myocardial 
ischemia was present in patients with normal preoperative and  elevated (>0.03 
ng/mL) troponin-T levels postoperatively.17 Elevated troponin-T levels in 
combination with electrocardiographic changes (new onset ST-T changes and 
pathological Q waves) defined myocardial infarction.18 Troponin T level was 
measured using a whole blood rapid test (TropT version 2, Roche Diagnostics, 
Mannheim, Germany). Patients with elevated troponin-T levels before surgery were 
not included in the study. Patients were subjected to a follow up visit with one of 
the study investigators 30-day post surgery and for those patients who did not 
attend, we approached the referring physicians. In patients still admitted or re-
admitted at the Erasmus MC, 30-day follow up was completed using the Erasmus 
MC medical records. Long-term mortality was assessed by approaching the 
municipal civil registries. Cause of death was ascertained by examining death 
certificates, and otherwise by reviewing medical records. Cause of death was 
classified as either cardiovascular or noncardiovascular death. Cardiovascular 
death was defined as any death with a cerebro-cardiovascular complication as the 
primary or secondary cause and includes death following myocardial infarction, 
serious cardiac arrhythmias (defined as the presence of a sustained cardiac rhythm 
disturbance that required urgent medical intervention), congestive heart failure, 
stroke (cerebrovascular event or transient ischemic attack), and surgery related 
bleeding complications (only a postoperative cause of death). Sudden unexpected 
death was classified as a cardiovascular death. Cause of death was separately 
assessed by two authors. In the absence of consensus, a third investigator 
assessed the cause of death and a majority decision was reached. Follow-up was 
completed in all patients.  
 
Statistical analysis 
Continuous variables are described as means ± standard deviation (SD) and 
dichotomous data as numbers and percentages. Continuous data were compared 
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using ANOVA for trend and categorical data using the linear by linear association. 
The prognostic value of LV dysfunction towards 30-day and long-term follow up 
was evaluated with logistic and Cox regression analysis, respectively. Multivariate 
analysis were primarily adjusted for covariates (age and sex, ischemic heart 
disease, cerebrovascular disease, renal dysfunction, diabetes mellitus, 
hypertension, hypercholesterolemia, chronic obstructive pulmonary disease and 
smoking status) prospectively locked into the model based on the clinical 
knowledge and belief that these factors might (i) contribute to the study outcomes 
and (ii) confound the association between the primary echo predictors and the 
study outcomes. Secondary adjustments were done in a step-wise fashion and 
these analyses were adjusted for medication use (β-blockers, statins, aspirin, oral 
anticoagulants, angiotensin-converting enzyme inhibitors, angiotensin-receptor 
blockers, diuretics and nitrates) on top of the covariates used in the primary 
regression model We report (crude and adjusted) odds and hazard ratios with their 
95% confidence interval (95%-CI). For all tests, a p-value <0.05 (two-sided) was 
considered significant. Cumulative long-term survival was determined by the 
Kaplan-Meier method. All analyses were performed using SPSS version 15.0 
statistical software (SPSS, Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
Patient population 
A total of 1.005 patients undergoing open vascular (N=649 or 65%) or endovascular 
(N=356 or 35%) surgery were included in the study. Of the open vascular surgery 
patients; 148 patients (23%) underwent carotid artery repair, 249 patients (38%) 
underwent abdominal aorta repair, and 252 patients (39%) underwent lower 
extremity artery repair. In comparison, of the endovascular patients; 90 patients 
(25%) underwent carotid artery repair, 162 patients (46%) underwent abdominal 
aorta repair, and 104 patients (29%) underwent lower extremity artery repair. All 
patients undergoing open vascular surgery had general anesthesia and 56 (35%) of 
the patients undergoing endovascular aortic repair had general anesthesia. General 
anesthesia was not provided for the percutaneous procedures.  
 
The majority of patients were men (77%) and the mean age was 67 ± 10 
years. Mean follow-up was 2.2 ± 1.8 years (range 3 to 79 months). Left-ventricular 
dysfunction was diagnosed in 506 (50%) patients. Of the patients with LV 
dysfunction, 403 (80%) patients had asymptomatic LV dysfunction and 103 (20%) 
had symptomatic heart failure. Of the patients with asymptomatic LV dysfunction, 
209 (52%) had asymptomatic isolated diastolic LV dysfunction and 194 (48%) had 
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asymptomatic systolic LV dysfunction. Of the 103 patients with symptomatic heart 
failure, 72/70% patients had New York Heart Association Class II, 28/27% patients 
had New York Heart Association Class III (12 patients had signs of fluid retention 
objectified as peripheral oedema) and 3/3% patients had New York Heart 
Association Class IV, with signs of pulmonary oedema objectified with physical 
examination. 
 
Table 1 Baseline characteristics according to left-ventricular function 
 
Normal 
LV 
function 
[N=499] 
Asymptomatic 
diastolic LV 
dysfunction 
[N=209] 
Asymptomatic 
systolic LV 
dysfunction 
[N=194] 
Symptomatic 
heart 
failure 
[N=103] 
P 
for 
trend 
Demographics (mean ± SD) 
Age  65 (11) 70 (10) 70 (8) 70 (10) <0.001 
Male (%)   363 (73) 154 (74) 168 (87) 84 (82) 0.001 
Systolic blood pressure  141 (24) 142 (24) 141 (26) 135 (23) 0.111 
Diastolic blood pressure  79 (12) 80 (12) 79 (12) 77 (12) 0.199 
Heart rate  70 (13) 73 (13) 73 (15) 72 (15) 0.012 
Medical history (%)      
Ischemic heart disease  165 (33) 83 (40) 102 (53) 80 (78) <0.001 
Cerebrovascular disease  169 (34) 83 (40) 76 (39) 25 (24) ()0.603 
Renal dysfunction  62 (12) 34 (16) 41 (21) 42 (41) <0.001 
Diabetes mellitus   141 (28) 62 (30) 64 (33) 30 (29) 0.698 
Hypertension   294 (59) 153 (73) 135 (70) 76 (74) <0.001 
Hypercholesterolemia  303 (65) 131 (65) 114 (60) 61 (63) 0.729 
COPD  100 (20) 49 (23) 50 (26) 32 (31) <0.001 
Smoker, current  225 (45) 85 (41) 69 (36) 41 (40) 0.046 
Surgery type (%)      
Open 320 (64) 129 (62) 118 (61) 82 (80) 0.102 
  LEAD  131 (26) 42 (21) 43 (22) 36 (35) 0.926 
  Abdominal aorta repair  110 (22) 51 (24) 48 (25) 40 (39) 0.100 
  Carotid artery repair 79 (16) 36 (17) 27 (14) 6 (6) 0.062 
Endovascular 179 (36) 80 (38) 76 (39) 21 (20) 0.102 
  LEAD  61 (12) 22 (10) 16 (8) 5 (5) 0.179 
  Abdominal aorta repair  71 (14) 40 (19) 37 (19) 14 (14) 0.065 
  Carotid artery repair 47 (10) 18 (9) 23 (12) 2 (1) 0.633 
Medication (%)      
β-blockers  368 (74) 161 (77) 162 (84) 87 (84) 0.001 
Statins  352 (71) 145 (70) 149 (77) 72 (70) 0.433 
Aspirin  303 (61) 110 (53) 114 (60) 61 (59) 0.578 
Oral anticoagulants   61 (12) 35 (17) 41 (21) 27 (26) <0.001 
ACE inhibitors   129 (26) 65 (31) 63 (33) 53 (52) <0.001 
ARB  49 (13) 29 (14) 36 (19) 23 (22) 0.011 
Diuretics 95 (19) 54 (26) 56 (29) 49 (48) <0.001 
Nitrates   32 (6) 19 (9) 20 (10) 30 (29) <0.001 
Angiotensin-converting enzyme (ACE), chronic obstructive pulmonary disease (COPD), left-ventricular (LV), 
standard deviation (SD), lower extremity arterial disease (LEAD), angiotensin receptor blocker (ARB) 
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Baseline characteristics 
Clinical parameters are shown in Table 1. Patients with LV dysfunction were older 
and had higher incidence of ischemic heart disease, renal dysfunction, 
hypertension, chronic obstructive pulmonary disease and had higher resting heart 
rate compared to patients with normal LV function. In addition, patients with LV 
dysfunction more often received β-blockers, oral anticoagulants, angiotensin-
converting enzyme inhibitors, angiotensin-receptor blockers, diuretics and nitrates. 
Patients with asymptomatic systolic LV dysfunction or symptomatic heart failure 
were more often male. A higher number of patients with symptomatic heart failure 
underwent open surgery compared to the other groups. 
 
Table 2 Left-ventricular function and postoperative outcome 
 
Normal 
LV 
function 
[N=499] 
Asymptomatic 
diastolic LV 
dysfunction 
[N=209] 
Asymptomatic 
Systolic LV 
dysfunction 
[N=194] 
Symptomatic 
heart 
failure 
[N=103] 
P- 
value 
30-day (%)         
  Cardiovascular 5 (10) 38 (18) 44 (23) 50 (49) <0.001 
  Myocardial 5 (10) 36 (17) 41 (21) 45 (44) <0.001 
  Cardiovascular 2 (0) 4 (2) 7 (4) 11 (11) <0.001 
  All cause mortality   6 (1) 5 (2) 7 (4) 11 (11) <0.001 
Long-term (%)         
  Cardiovascular 1 (3) 21 (10) 31 (16) 40 (39) <0.001 
  All cause mortality  5 (11) 31 (15) 38 (20) 41 (40) <0.001 
Left-ventricular (LV) 
 
Thirty-day outcome 
During 30-day follow-up 172 (17%) patients had a non-fatal myocardial event of 
which 131 (76%) patients had myocardial ischemia and 41 (24%) patients had 
myocardial infarction. In total, 51 (10%) patients with normal LV function had a 
30-day CV event, compared to 38 (18%) patients with asymptomatic isolated 
diastolic LV dysfunction, 44 (23%) patients with asymptomatic systolic LV 
dysfunction and 50 (49%) patients with symptomatic heart failure (p < 0.001, Table 
2). Multivariate analyses, in patients undergoing open surgery, demonstrated that 
asymptomatic isolated diastolic LV dysfunction, asymptomatic systolic LV 
dysfunction and symptomatic heart failure were all associated with 30-day CV 
events with odds ratio’s of 1.8 (95% CI: 1.1 to 2.9), 2.3 (95% CI: 1.4 to 3.6) and 6.8 
(95% CI: 4.0 to 11.6), respectively (Table 3). Other risk factors associated with 30-
day CV events were age, ischemic heart disease, renal dysfunction and chronic 
obstructive pulmonary disease with odds ratios of 1.8 (95% CI: 1.0 to 1.1), 1.7 (95% 
CI: 1.1 to 2.6), 3.9 (95% CI: 2.2 to 7.1) and 1.8 (95% CI: 1.2 to 2.6), respectively. 
Multivariate analyses, in patients undergoing endovascular surgery, demonstrated 
that symptomatic heart failure was associated with 30-day CV events with an odds 
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ratio of 9.3 (95% CI: 2.3 to 37.7) (Table 4). For both types of surgical procedures, 
additional adjustment for medication use (β-blockers, statins, angiotensin-
converting enzyme inhibitors, angiotensin-receptor blockers and diuretics) did not 
change the prognostic value of LV dysfunction towards 30-day outcome. 
 
Long-term outcome 
During long-term follow-up 164 (16%) patients died. The study endpoint long-term 
CV mortality was reached in 107 (11%) patients. In total, 15 (3%) patients with 
normal LV function died due to CV causes, compared to 21 (10%) patients with 
asymptomatic isolated diastolic LV dysfunction, 31 (16%) patients with 
asymptomatic systolic LV dysfunction and 40 (39%) patients with symptomatic 
heart failure (p < 0.001, Table 2).  
 
Figure 1. Left-ventricular (LV) function and long-term survival after vascular surgery  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cumulative survival for all patients is shown in Figure 1 (log rank p < 0.001). Of the 
patients with LV dysfunction who reached the study endpoint long-term CV 
mortality, 48 patients (52%) demonstrated myocardial ischemia or infarction during 
30-day follow-up.  
 
Multivariate analyses, in patients undergoing open surgery, demonstrated 
that asymptomatic isolated diastolic LV dysfunction, asymptomatic systolic LV 
dysfunction and symptomatic heart failure were all associated with long-term CV 
mortality with hazard ratio’s of 3.0 (95% CI: 1.5 to 6.0), 4.6 (95% CI: 2.4 to 8.5) and 
10.3 (95% CI: 5.4 to 19.3), respectively (Table 3).  
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Table 3 
Association between left-ventricular function and postoperative 
outcome: Open vascular surgery 
 N (%) Univariate Multivariate 
30-day CV events   OR [95% CI] OR [95% CI] 
  Normal LV function  44/320 (14) 1.0  1.0  
  Isolated diastolic LV dysfunction  30/129 (23) 2.0 1.2-3.1 1.8 1.1-2.9 
  Systolic LV dysfunction  36/118 (31) 2.6 1.7-4.0 2.3 1.4-3.6 
  Symptomatic heart failure 44/82 (54) 8.3 5.1-13.4 6.8 4.0-11.6 
Long-term CV mortality   HR [95% CI] HR [95% CI] 
  Normal LV function  8/320 (3) 1.0  1.0  
  Isolated diastolic LV dysfunction  14/129 (11) 3.5 1.8-6.8 3.0 1.5-6.0 
  Systolic LV dysfunction  23/118 (20) 5.2 2.8-9.7 4.6 2.4-8.5 
  Symptomatic heart failure 31/82 (38) 13.6 7.5-24.6 10.3 5.4-19.3 
Long-term all cause mortality   HR [95% CI] HR [95% CI] 
  Normal LV function  37/320 (12) 1.0  1.0  
  Isolated diastolic LV dysfunction  20/129 (16) 1.5 0.9-2.3 1.4 0.9-2.1 
  Systolic LV dysfunction  28/118 (24) 1.8 1.2-2.7 1.7 1.1-2.5 
  Symptomatic heart failure 32/82 (39) 3.9 2.6-5.8 3.1 2.0-4.8 
Multivariate analysis adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal 
dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease 
and smoking. Cardiovascular (CV), confidence interval (CI), hazard ratio (HR), left-ventricular (LV) 
 
Table 4 
Association between left-ventricular function and postoperative 
outcome: Endovascular surgery 
 N (%) Univariate Multivariate 
30-day CV events   OR [95% CI] OR [95% CI] 
  Normal LV function  7/179 (4) 1.0  1.0  
  Isolated diastolic LV dysfunction  8/80 (10) 2.7 0.9-7.8 2.2 0.7-6.9 
  Systolic LV dysfunction  8/76 (11) 2.9 1.0-8.6 2.5 0.8-7.8 
  Symptomatic heart failure 6/21 (29) 9.8 2.9-33.0 9.3 2.3-37.7 
Long-term CV mortality   HR [95% CI] HR [95% CI] 
  Normal LV function  7/179 (4) 1.0  1.0  
  Isolated diastolic LV dysfunction  7/80 (9) 2.2 0.8-6.4 1.7 0.5-5.3 
  Systolic LV dysfunction  8/76 (11) 2.4 0.8-6.5 2.2 0.8-6.6 
  Symptomatic heart failure 9/21 (43) 14.5 5.4-39.1 11.4 3.7-35.6 
Long-term all cause mortality   HR [95% CI] HR [95% CI] 
  Normal LV function  17/179 (10) 1.0  1.0  
  Isolated diastolic LV dysfunction  11/80 (14) 1.5 0.7-3.2 1.2 0.5-2.7 
  Systolic LV dysfunction  10/76 (13) 1.3 0.6-2.9 1.2 0.5-2.9 
  Symptomatic heart failure 9/21 (43) 6.1 2.7-13.8 5.1 1.9-13.3 
Multivariate analysis adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal 
dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease 
and smoking. Cardiovascular (CV), confidence interval (CI), hazard ratio (HR), left-ventricular (LV) 
 
Other risk factors associated with long-term CV mortality were age, 
ischemic heart disease, renal dysfunction and smoking with hazard ratios of 1.1 
(95% CI: 1.1 to 1.2), 1.6 (95% CI: 1.1 to 2.8), 2.5 (95% CI: 1.3 to 5.1) and 2.0 (95% 
CI: 1.2 to 3.1), respectively. Multivariate analyses, in patients undergoing 
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endovascular surgery, demonstrated that symptomatic heart failure was associated 
with long-term CV mortality with a hazard ratio of 11.4 (95% CI: 3.7 to 35.6) (Table 
4). For both types of surgical procedures, additional adjustment for medication use 
did not change the prognostic value of LV dysfunction towards long-term outcome.   
 
 
DISCUSSION 
 
The present study demonstrated that open vascular surgery patients with 
asymptomatic isolated diastolic- or systolic LV dysfunction, were at increased risk 
for 30-day CV events and long-term CV mortality. In endovascular surgery 
patients, only symptomatic heart failure was associated with an increased risk for 
30-day CV events and long-term CV mortality. In ACC/AHA and ESC guidelines, 
symptoms of heart failure are acknowledged to be an important predictor of 
postoperative outcome.  However, our data suggest asymptomatic LV dysfunction 
should be imbedded in preoperative risk stratification of vascular surgery patients, 
as well.   
 
Left-ventricular dysfunction is caused by neuro-hormonal responses 
activated by cardiac injury or an increased hemodynamic load. These responses are 
known to induce (i) sympathetic stimulation, (ii) salt and water retention, and (iii) 
vasoconstriction.19,20 Although these responses are initially adaptive, they become 
maladaptive over time, due to a process called LV remodelling. This process leads 
to (i) LV hypertrophy (concentric remodelling) associated with diastolic LV 
dysfunction, or (ii) LV dilatation (eccentric remodelling) associated with systolic LV 
dysfunction.21 During surgery, high catecholamine production is responsible for 
vasoconstriction and hemodynamic stress.2 Surgical stress and perioperative fluid 
administration increases ventricular pre- and afterload, making patients with 
systolic LV dysfunction susceptible for perioperative myocardial damage.22 During 
surgery there is an increased oxygen demand and patients with coronary artery 
stenosis are at increased risk for perioperative myocardial damage, due to an 
oxygen supply–demand mismatch.3,23 Patients with diastolic LV dysfunction have a 
reduced coronary flow reserve making them susceptible to perioperative myocardial 
damage as well.21 In addition, concentric remodelling causes a reduction of LV 
compliance, making LV filling dependent upon blood volume contributed by 
ventricular preload. Perioperative LV preload reductions can result in tachycardia 
with concomitant reduction of coronary perfusion, leading to myocardial damage.24  
 
Episodes of perioperative myocardial damage are most often silent and 
therefore patients often remain untreated, which might contribute to an increased 
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risk of long-term CV mortality.25,26 We have found that approximately three out of 
four patients with perioperative damage, had LV dysfunction. In line with previous 
studies, we have found that endovascular surgery was associated with a reduced 
incidence of perioperative myocardial damage, compared with open surgery, 
possibly explained by reduced myocardial stress and the need for lower fluid 
administration during endovascular procedures.27,28 In addition, one should keep 
in mind that carotid surgery is associated with lower cardiac risk compared with 
abdominal aneurysm repair and lower extremity revascularization.  
 
Myocardial perfusion scintigraphy and pharmacological stress 
echocardiography are known to accurately stratify patients at risk for perioperative 
myocardial damage.29-31 In addition, the presence of wall motion abnormalities at 
rest has predictive value for the development of perioperative cardiac events as 
well.31 Until now, studies addressing the impact of heart failure in surgical 
patients, mainly focused on symptomatic patients with a reduced LV ejection 
fraction.5,23,32,33 A retrospective study conducted by Xu-Cai et al. evaluated the 
impact of symptomatic heart failure with a preserved LV ejection fraction, 
demonstrating an increased risk for long-term mortality. However no increased risk 
for perioperative mortality was observed.34 Recently, Maytal et al. studied 313 
vascular surgery patients and found diastolic LV dysfunction to be a predictor of 
adverse CV outcome, however systolic LV dysfunction was not.35 Several differences 
between the study conducted by Maytal et al. and the present study that might 
explain the different outcome regarding the impact of systolic LV dysfunction on CV 
outcome, such as: (i) subanalysing open vs. endovascular surgery, (ii) troponin T 
measurements obtained routinely or when clinically indicated, (iii) definition of the 
LV function groups, and (iv) follow-up duration. To our knowledge, the present 
study is first to demonstrate that asymptomatic LV dysfunction (diastolic and 
systolic) is associated with an increased risk for in open vascular surgery patients.  
 
In the most recent ACC/AHA and ESC perioperative guidelines,3,9 the 
prognostic value of symptoms of heart failure on postoperative outcome is well 
acknowledged and incorporated into the decision process with regard to proceeding 
directly to surgery. In addition, preoperative cardiac risk indices incorporate 
symptomatic heart failure as an important risk factor.4,6,36 To define surgical 
patients at ‘high risk’ for developing adverse CV events, one point should be 
assigned to patients with (a medical history of) current symptoms of heart failure, 
next to other risk factors such as ischemic heart disease, cerebrovascular disease, 
renal dysfunction, diabetes mellitus or high-risk surgery. To prevent an 
underestimation of the ‘cardiac risk burden’ of vascular surgery patients, our data 
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suggest that asymptomatic LV dysfunction should be imbedded in these risk 
indices as well. 
 
Our results indicate that asymptomatic LV dysfunction is not associated 
with increased risk for 30-day CV events and long-term CV mortality in 
endovascular surgery patients. An explanation of this finding could lie in the fact 
that endovascular surgery is associated with reduced myocardial stress compared 
to open vascular surgery.27,28 The detection of asymptomatic LV dysfunction with 
routine preoperative echocardiography could, therefore, add valuable information 
in the decision making between open and endovascular surgery.    
 
Biochemical markers, such as N-terminal pro-B-type natriuretic peptide, 
are increasingly used in the detection and exclusion of heart failure,37 and have 
proven to predict poor outcome after vascular surgery.38 Standard measurements 
of this biochemical marker may play an important role to detect asymptomatic LV 
dysfunction in vascular surgery patients, regardless of the presence of heart failure 
symptoms. However, the diagnostic value of natriuretic peptides in asymptomatic 
patients at risk for diastolic or systolic LV dysfunction is controversial. In  a recent 
study conducted by Luers et al., plasma levels of natriuretic peptides significantly 
increased with a decreasing ejection fraction and with a severe degree of diastolic 
dysfunction.39 Therefore, the authors suggest that high-risk individuals may be 
screened most efficiently by using a score system, incorporating clinical data and 
N-terminal pro-B-type natriuretic peptide. In vascular surgery patients, future 
studies are needed to evaluate the value of B-type natriuretic peptides vs. 
echocardiography to detect LV dysfunction in patients with or without heart failure 
symptoms. In 2003 Grayburn et al. proposed to shift the paradigm from 
preoperative noninvasive risk stratification to therapy.40 Routine preoperative 
evaluation of LV function could reveal patients with asymptomatic LV dysfunction 
eligible for pharmacological treatment. Before surgery, low-dose β-blockade could 
be considered, titrated to obtain a heart rate between 60-70 beats per minute.41 In 
addition, initiation of angiotensin blockers could be considered after surgery.42 
 
Potential limitations of these data merit consideration. First, the study 
population consisted of patients referred to a tertiary referral center and may not 
fully represent the general vascular surgery population scheduled. Second, 
although two experienced investigators performed an off-line assessment of 
ultrasound images, we cannot rule out inter-observer variability to have had a 
minor influence on our results. Third, the evaluation of diastolic LV function with 
conventional Doppler, ratio of mitral peak velocity of early filling (E) to mitral peak 
velocity of late filling (A) and pulmonary vein filling patterns was limited due to 
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preload dependency and not including Valsalva maneuver, ratio of mitral peak 
velocity of early filling (E) to early diastolic mitral annular velocity (E'), isovolumetric 
relaxation time or Tissue Doppler Imaging. 
 
In conclusion, this study demonstrated that asymptomatic LV dysfunction 
is a predictor of CV outcome in open vascular surgery patients. These data suggest 
that preoperative risk stratification should not solely include symptomatic heart 
failure, already acknowledged in ACC/AHA and ESC perioperative guidelines; 
however asymptomatic LV dysfunction should be imbedded as well. Standard 
preoperative evaluation of LV function could be argued based on our results, 
suggesting a move towards more routine use of cardiac echo in open vascular 
surgery patients. 
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To the editor: Dr Lederle and colleagues conducted a randomized trial to compare 
endovascular (EVAR) vs open repair of abdominal aortic aneurysm (AAA), showing 
lower perioperative mortality for endovascular than open repair.1 Importantly, the 
early advantage of endovascular repair was not offset by increased mortality in the 
first 2 years after repair.  
 
The atherosclerotic process is often not limited to a single arterial location, 
giving it a character of a systemic and generalized disease. More than 25 years ago, 
Hertzer and colleagues already demonstrated that only 6% of the patients with an 
AAA have a healthy coronary tree.2 Feringa and colleagues studied a group of 
vascular surgery patients who underwent preoperative cardiac testing, and 
observed an asymptomatic ejection fraction <40% or silent ischemia (new wall 
motion abnormalities) was present in 14% and 41% of the patients, respectively.3    
   
In the vast majority of the patients, the atherosclerotic process remains 
asymptomatic. However, surgical stress elucidates a rapid progression of the 
atherosclerotic disease. This progression is reflected by asymptomatic perioperative 
troponin T release, an important marker of underlying coronary artery disease. 
Studies have demonstrated prevalence’s of 10% and 30% of troponin T release after 
endovascular and open repair, respectively.4 Importantly, up to 90% of the troponin 
T elevations were asymptomatic. The occurrence of asymptomatic perioperative 
myocardial damage, assessed with troponin T measurements and continuous 
electrocardiographic monitoring for 72 hours, was associated with a 2.3 fold 
increased risk for long-term mortality in vascular surgery patients.4, 5          
 
In conclusion, EVAR has a reduced perioperative stress response compared 
to open repair, which is very likely to explain the reduced short-term mortality 
rates. The disappearance of the early advantage of endovascular repair after 2 
years could be explained by the high incidence of asymptomatic coronary artery 
disease, with an accelerated subclinical progression due to surgical stress. This 
results in asymptomatic perioperative cardiac damage and reduced survival rates 
during long-term follow-up. Routine perioperative troponin T evaluation should be 
recommended to detect early postoperative cardiac damage and identify patients 
who will benefit from aggressive follow-up and medical treatment after AAA repair.   
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PERIOPERATIVE CARDIAC DAMAGE 
 
Worldwide more than 230 million major surgeries are performed annually, and this 
number continues to grow.1 The estimated post-operative myocardial infarction (MI) 
rate is 1% (approximately 2.300.000 patients) and the cardiovascular mortality rate 
is approximately 0.3% (690.000 patients).1 The incidence of asymptomatic 
perioperative cardiac damage is not well known but can be as high as 20% in 
patients undergoing high-risk surgery, such as vascular surgery.2,3 
 
Despite improved medical treatment strategies, perioperative cardiac 
complications remain a significant problem. With aging of the population, more 
high-risk cardiac patients will undergo surgery, possibly resulting in an increased 
incidence of perioperative MI. According to current guidelines, MI is characterized 
by ECG criteria and cardiac enzymes including creatine kinase (MB) and cardiac 
troponins.4 However, in the perioperative period symptoms of cardiac complications 
might be masked by residual anesthetic effects and postoperative conditions such 
as incisional pain. Consequently, as most cardiac events are asymptomatic or 
concealed by other postoperative symptoms, while ECG changes are often 
transient, cardiac damage might not be detected until it develops into complete MI. 
In fact, it is estimated that up to 75% of postoperative cardiac complications 
remains unnoticed.  
 
The pathophysiology of perioperative cardiac events is described by two 
distinct mechanisms that have been described as type 1 and type 2 by the 
universal definition of MI.4 Type 1 MI was defined as an acute coronary syndrome 
(ACS) that occurs when a coronary plaque ruptures, leading to thrombus formation 
and subsequent acute coronary thrombosis, ischemia and infarction. This type of 
MI is elucidated by the perioperative surgical stress response that includes a 
catecholamine surge with associated hemodynamic stress, vasospasm, reduced 
fibrinolytic activity, platelet activation and consequent hypercoagulability.5 In 
patients with significant coronary artery disease, MI may also be caused by a 
sustained myocardial supply-demand imbalance (type 2 MI) due to tachycardia and 
increased myocardial contractility.5 The presence of silent, heart rate-related ST-
segment depression in high-cardiac-risk patients undergoing major surgery have 
been described in up to 41% of the patients during the post-operative period and 
has been demonstrated to be associated with short- and long-term morbidity and 
mortality.6 In addition, several studies have correlated continuous 12-lead ST-
segment analysis with serial cardiac troponin measurements after major vascular 
surgery.7 Troponin elevations occurred after prolonged, transient, postoperative ST-
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segment depression, and peak troponin elevations correlated with the duration of 
ST depression.8  
  
Detection of asymptomatic perioperative cardiac damage 
The detection of asymptomatic cardiac damage in surgical patients is challenging 
and requires standard assessment of cardiac troponin levels in the perioperative 
period with short time intervals, for example, on day 1, 2, and 3 after surgery. 
Importantly, recent studies using highly sensitive troponin essays have 
demonstrated that low-level  troponin elevations (>0.03 ng/mL) are common in 
high-cardiac-risk patients postoperatively, even with little but most often with no 
evidence of ECG ischemia.9 In this respect, it has to be recognized that the majority 
of perioperative cardiac events occur within the first 3 days after surgery.10 
Preferably, continuous ECG monitoring is applied for the first days after surgery in 
studies reporting on the incidence and consequences of perioperative cardiac 
events. This time consuming approach might explain why there are only few 
studies published so far exploring the effects of asymptomatic perioperative cardiac 
damage. The prognostic implication of asymptomatic perioperative cardiac damage, 
in particular low-level troponin elevations, is ill defined.  
 
Prognostic implications of asymptomatic perioperative cardiac damage 
Perioperative ST-segment depression and postoperative troponin elevations have 
both been related to adverse short-, mid- and long-term cardiac morbidity and 
mortality.11-13 Early mortality after perioperative MI ranges between 3.5 to 25% and 
is higher in patients with major troponin elevation compared to patients with minor 
troponin elevation.8,13,14 Lopez-Jimenez et al. and Kim et al. demonstrated that 
asymptomatic abnormal levels of troponin T in patients scheduled for noncardiac 
surgery were associated with a more than four to six-fold increased risk of cardiac 
events during a six months follow-up period.11 The long-term prognostic value of 
postoperative troponin release has especially been studied in major vascular 
surgery patients. Landesberg et al. and Kertai et al. studied the prognostic value of 
low-level and conventional troponin elevations on long-term mortality after major 
vascular surgery, and observed that postoperative troponin elevations even at low 
cut-off levels are independent and complementary predictors of long-term 
mortality.8,12  
 
Recently Winkel et al. demonstrated that asymptomatic perioperative 
cardiac damage, defined as cardiac troponin T elevations without ischemic 
symptoms or ECG abnormalities, was associated with an increase for mortality 
during a follow-up of 2.9 years in 220 patients who underwent endovascular 
abdominal aortic aneurysm repair.15 Patients with asymptomatic cardiac damage 
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had a mortality rate of 49 versus 15% for patients without perioperative cardiac 
damage (p < 0.001). Also after adjustment for clinical risk factors and medication 
use applying multivariate Cox regression analysis, asymptomatic cardiac damage 
was associated with a 2.3-fold increased risk for death (hazard ratio 2.30, 95% 
confidence interval 1.1 to 5.1).    
 
Management of patients with asymptomatic cardiac damage 
The strong association between high-risk patients, perioperative ischemia 
characterized by troponin release, and its influence on short- and long-term 
outcome has emerged the need for prevention and treatment. The unpredictable 
progression of an instable coronary plaque during surgical stress is the most 
important target for systemic therapy. Medical treatment aimed at plaque 
stabilization has shown promising results for perioperative as well as long-term 
risk reduction. Prophylactic ß-blockade is advised for patients already on ß-blocker 
therapy, those with preoperative stress-inducible myocardial ischemia and to treat 
angina, symptomatic arrhythmias, heart failure or hypertension.16 In our center all 
patients scheduled for major vascular surgery are prescribed a low dose ß-blocker 
(e.g. bisoprolol 2.5 mg) started as early as possible, preferably 30 days prior to 
surgery. This allows safe dose titration to achieve a target heart rate of 
approximately 65 beats per minute. Furthermore, we promote the idea of prolonged 
treatment after surgery. In addition to ß-blocker therapy, high-risk patients should 
also receive statins in the perioperative period. Several recent retrospective studies 
have shown a beneficial effect of statins on perioperative cardiac outcome with 
adjusted Hazard ratio’s ranging from 0.20 to 0.62.17 Importantly, Kertai et al. also 
found the effect of statins to be independent of β-blocker use. Recently, the results 
of the randomized, double-blind, placebo controlled Dutch Echographic Cardiac 
Risk Evaluation Applying Stress Echo (DECREASE) III trial became available 
confirming the efficacy and safety of perioperative statin therapy for the prevention 
of perioperative cardiovascular events. 
 
 
FUTURE PERSPECTIVES 
The perioperative surgical stress results in a hypercoagulable state, which is in 
combination with atherosclerotic plaques the perfect substrate for the development 
of perioperative cardiac damage. Although aspirin reduces the risk of plaque 
rupture and subsequent cardiovascular events, there remains a substantial risk for 
such events during follow-up. The thienopyridine derivate clopidogrel is an 
antiplatelet agent that inhibits the platelet aggregation induced by adenosine 
diphosphate. The efficacy and safety of combining clopidogrel and aspirin (dual 
antiplatelet therapy) compared to aspirin alone, has recently been proven in a 
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meta-anlyses of studies including patients with acute coronary syndromes (34% 
risk reduction of nonfatal MI).18 Nowadays, asymptomatic perioperative cardiac 
damage is not treated with clopidogrel, although late outcome hereafter is severely 
compromised. Randomized controlled studies are needed to investigate the role of 
clopidogrel as a preventive treatment in patients with asymptomatic cardiac 
damage. 
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ABSTRACT 
 
Diabetes Mellitus (DM) is an independent predictor for morbidity and mortality in 
the general population, which is even more apparent in patients with concomitant 
cardiovascular risk factors. As the prevalence of DM is increasing, with an ageing 
general population, it is expected that the number of diabetic patients requiring 
surgical interventions will increase. Perioperative hyperglycaemia, without known 
DM, has been identified as a predictor for morbidity and mortality in patients 
undergoing surgery. Moreover, early studies showed that intensive blood-glucose-
lowering therapy reduced both morbidity and mortality among patients admitted to 
the postoperative intensive care unit (ICU). However, later studies have doubted the 
benefit of intensive glucose control in medical-surgical ICU patients. This article 
aims to comprehensively review the evidence on the use of perioperative intensive 
glucose control, and to provide recommendations for current clinical practice. A 
systematic review was performed of the literature on perioperative intensive glucose 
control. Based on this literature review, we observed that intensive glucose control 
in the perioperative period has no clear benefit on short-term mortality. Intensive 
glucose control may even have a net harmful effect in selected patients. In addition, 
concerns on the external validity of some studies are important barriers for 
widespread recommendation of intensive glucose control in the perioperative 
setting. We propose that guidelines recommending intensive glucose control should 
be re-evaluated. In addition, moderate tight glucose control should currently be 
regarded as the safest and most efficient approach to patients undergoing major 
vascular surgery.     
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INTRODUCTION 
 
Diabetes Mellitus (DM) is currently affecting over 40 million people in the European 
Union alone. Importantly, the prevalence of DM is strongly related to age; over 20% 
of the population aged above 60 years is diabetic.1 With an ageing Western 
population, the impact of diabetes is a major health burden and will increase 
dramatically within the next 20 years.2  
 
Simultaneously, aging of the population will also cause an increase of 
patients with peripheral arterial disease (PAD). The combination of an increasing 
incidence of diabetes and PAD will result in an increasing number of pre-diabetic 
patients requiring vascular surgical procedures. Patients with diabetes or an 
impaired glucose tolerance (IGT) are more prone to dysregulation of glucose 
haemostasis, especially during surgical stress or critical illness.  This condition 
develops independently of previous diagnosed diabetes and is also called stress 
diabetes or diabetes of injury.3,4 These hyperglycaemic conditions have been 
identified as an important risk factor (Relative Risk 3.9) for morbidity and mortality 
in patients undergoing surgery.5 
 
Since glucose dysregulation has such an impact on postoperative and long-
term outcome in these patients, adequate preoperative screening as well as 
perioperative and postoperative glucose management are of critical importance. 
Therefore, the aim of the current systematic review is to (i) provide an overview of 
recent evidence on preoperative screening of vascular surgery patients with respect 
to diabetes and glucose tolerance, and (ii) to provide an overview of recent evidence 
on monitoring and treatment strategies for adequate glucose regulation in the 
perioperative period during vascular surgical procedures. 
  
 
PATHOPHYSIOLOGY OF GLUCOSE REGULATION DISORDERS 
 
In patients with pre-diabetes, many factors are involved in determining the 
glycemic response, both during a stable homeostatic phase and during stressing 
moments like surgery or critical illness. During normal daily activities, there is a 
relative balance between glucose metabolism and insulin secretion, resulting in 
slightly elevated blood glucose levels. These elevated glucose levels do not result in 
classical diabetic symptoms. However, the abundance of glucose molecules in the 
blood result in microvascular damage of the kidneys, retina and peripheral nerves.6 
The glucose balance can be easily disturbed by stress and fasting associated with 
surgery. During the time between the preoperative period and the postoperative 
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recovery the following factors may change radically: (i) insulin secretory capability, 
(ii) insulin sensitivity, (iii) overall metabolism, and (iv) nutritional intake.7 There is 
an imbalance in blood glucose lowering and stimulating agents, leading to 
hyperglycaemia and excess circulating free fatty acids.7 These free fatty acids 
require aerobic metabolism, and result in increased oxygen consumption with 
major consequences, especially in the presence of concomitant myocardial 
ischemia. Free fatty acids also inhibit myocardial glucose use, decrease 
contractility, predispose to develop arrhythmias, and increase accumulation of free 
radicals.8 In addition to this, hyperglycaemia also causes fluid shifts (glycosuria 
and dehydration), promotes the inflammatory response leading to endothelial 
dysfunction, enhances platelet aggregation, and reduces immune function by 
impaired complement activity.4 In summary, hypoglycaemia results from 
predominance of the glycemic effects of a decrease in carbohydrate intake and an 
increase in circulating insulin. Hyperglycaemia is characterized by a predominance 
of the glycemic effects of an increase in stress hormones and a decrease of 
circulating insulin levels (Figure 1). 
 
Figure 1. Schematic representation for the balance of perioperative blood glucose status 
 
 
 
PREOPERATIVE TESTING FOR DIABETES 
 
In pre-diabetic patients, elevated glucose levels are usually present for 7 to 10 
years before the diagnosis of DM is made.9 Screening for glucose regulation 
disorders can be performed by either fasting plasma glucose (FPG) measurement or 
oral glucose tolerance testing (OGTT). Fasting plasma glucose measurement 
includes a blood glucose measurement in the morning after overnight fasting. Oral 
glucose tolerance testing included a fasting glucose measurement and an 
additional blood glucose sample 2 hours after the ingestion of 75-gram oral glucose 
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load. Impaired fasting glucose is defined as plasma glucose of 100 to 125 mg/dl 
(5.6 to 6.9 mmol/l), and IGT as plasma glucose of 140 to 199 mg/dl (7.8 to 11.1 
mmol/l). According to the American Diabetes Association guidelines, DM was 
defined as FPG ≥126 mg/dl (7.0 mmol/l) and/or plasma glucose ≥200 mg/dl (11.1 
mmol/l).2 Several prospective studies in nondiabetic adults demonstrated a 
significant additional value of OGTT to FPG, with respect to the relationship 
between hyperglycemia and risk of cardiovascular disease. The “Diabetes 
Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe”(DECODE) 
Study group showed that the addition of OGTT to FPG significantly improved the 
prediction of all-cause mortality (HR 1.73, 95% CI: 1.5 to 2.1), cardiovascular 
disease (HR 1.42, 95% CI: 1.02 to 1.9) and coronary heart disease (HR 1.56, 95% 
CI: 1.03 to 2.4).9 These results were confirmed by The Cardiovascular Health Study 
that showed an association between FPG levels >6.3 mmol/L and increased 
cardiovascular risk (HR 1.66, 95% CI: 1.4 to 2.0).10 Furthermore, this population-
based study showed the additional value of the OGTT to fasting plasma glucose 
measurement, as two-hour glucose loading level was associated with a linear 
increased cardiovascular risk (HR 1.02, 95% CI: 1.00 to 1.04) per 0.6 mmol/L 
increase in blood glucose level 2 hours after glucose loading.  
 
Figure 2. Additional value of Oral Glucose Tolerance Testing over Fasting Plasma Glucose measurement. 
Figure reproduced from reference 11, with permission of the publisher 
 
 
In a recent study, van Kuijk et al. (Figure 2) studied the additional effect of 
OGTT to FPG for the detection of IGT and DM in patients scheduled for major 
vascular surgery as well.11 A strong additional effect on diagnosing IGT and DM by 
oral glucose tolerance testing was shown. Seventy-five percent of the patients with 
IGT and 72% of the patients with DM would have been missed, if only the fasting 
glucose levels were measured. Importantly, as DM is one of the cardiovascular risk 
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factors of the adapted Lee Risk index, detection of new DM in patients scheduled 
for major vascular surgery, results in an increased risk score.12 In patients with 
other concomitant cardiovascular risk factors, addition of DM will result in a need 
for more extended pre-operative testing and subsequent treatment. However, 
preoperative testing for glucose regulation disorders is not routinely performed in 
vascular surgery patients.  
 
Currently, the use of pre-operative FPG or OGTT is only recommended by 
the European Society of Cardiology / European Association for the Study of 
Diabetes in patients undergoing surgery with ≥2 clinical cardiovascular risk 
factors.13 The American College of Cardiology / American Heart Association 
(ACC/AHA) guidelines for preoperative management in patients with PAD 
undergoing non-cardiac surgery, recommend a fasting plasma glucose 
measurement, but not a pre-operative glucose-loading test.6  
 
 
OUTCOME AFTER VASCULAR SURGERY IN PRE-DIABETIC PATIENTS 
 
In vascular surgery patients, pre-operative elevated glycated hemoglobin  and pre-
operative impaired fasting glucose have been related to an increase in 
cardiovascular events and/or all cause mortality during follow-up.14,15 O’Sullivan et 
al. showed that patients scheduled for vascular surgery without DM but with 
suboptimal glycated hemoglobin levels (6 to 7%) had a significantly higher 
incidence of overall 30-day mortality compared to patients with glycated 
hemoglobin  levels <6% (56.5 vs 15.7% p < 0.001).14 This was confirmed by Feringa 
et al. in vascular surgery patients with IGT and/or DM detected by OGTT, which 
had an 2.2-fold increased risk for ischemia, 3.8-fold for troponin T release, 4.3-fold 
for 30-day cardiac events, and 2.7-fold for long-term cardiovascular events.15  
  
The presence of DM is an established and risk factor for atherosclerotic 
coronary disease and PAD, independent of other atherogenic risk factors, with a 
relative risk averaging two fold for men and three fold for women.16 Patients with 
DM can have two types of vascular disease: (i) a non-occlusive microcirculatory 
dysfunction involving the kidneys, retina and peripheral nerves, and (ii) a 
macroangiopathy characterized by atherosclerotic lesions of the coronary and 
peripheral arterial circulation.17 Based on these pathogenic mechanisms it could be 
assumed that patients scheduled for vascular surgery and concomitant DM would 
have an increased risk of morbidity and mortality due to atherosclerotic disease. 
However, several studies have shown conflicting results regarding the association 
between DM and the risk of cardiovascular morbidity and mortality in vascular 
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surgery patients. Malmstedt et al. studied a group of diabetic patients who 
underwent infrainguinal bypass surgery.18 They observed an increased risk of renal 
insufficiency and infected foot ulcer in patients with perioperative hyperglycemia. 
This was confirmed by Ramos et al. who demonstrated an increased risk of 
postoperative infections after vascular surgery in patients with perioperative 
hyperglycemia.19 Importantly, this was independent of diabetic status. Van Kuijk et 
al. recently showed that patients with IGT or DM detected by OGTT have an 
increased risk for the development of cardiovascular events during follow-up 
(Figure 3).11 However, other studies demonstrated that patients with DM do not 
appear to be at increased risk of death after intermediate20 or high risk surgery.21 
Some of these studies suffered from a small number of adverse outcomes and 
incomplete documentation of important comorbidities. In response to this 
controversy, Axelrod et al. performed a large study in patients undergoing elective 
major vascular surgery. They demonstrated that in univariate analysis, patients 
with DM had a higher incidence rate of perioperative death (3.9 vs 2.6%, p = 0.001) 
and cardiovascular complications (3.3 vs 2.6%, p = 0.01) compared to patients 
without diabetes. After controlling for comorbid conditions, procedure type, and 
diabetic complications, only insulin-dependent diabetes was an independent risk 
factor for death or cardiovascular complications.22 However, this study mainly 
included lower risk patients with known DM, while the risk of diabetes is most 
clear in intermediate and high-risk patients.  
 
Figure 3. Cardiovascular event free survival during long-term follow-up after glucose-loading test in patients 
undergoing major vascular surgery. Figure reproduced from reference 11 with permission from the publisher 
 
 
Recently, Protack et al. investigated the influence of DM as part of the 
metabolic syndrome in patients who underwent carotid revascularization.23 
Vascular surgery patients with metabolic syndrome and/or DM had an increased 
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risk of perioperative morbidity as well as stroke, myocardial infarction and major 
adverse events during long-term follow-up, compared to those without metabolic 
syndrome. Overall, vascular surgical patients with concomitant diabetes are more 
likely to experience perioperative and long-term cardiac events.     
 
 
PERIOPERATIVE MONITORING AND TREATMENT OF BLOOD GLUCOSE LEVEL 
DISORDERS 
 
Aims of perioperative management  
In 2001, Van den Berghe et al. published the first Leuven study, a randomized 
controlled trial of critically ill patients, which showed that tight glucose control 
significantly reduced hospital morbidity and mortality.24 Other studies have shown 
that tight glycemic control is associated with decreased infection rates and 
improved survival during cardiac surgery 25, in the setting of acute neurologic 
injury 26 and acute myocardial infarction.27 Based on these studies, several 
professional societies, including the American Diabetes Association and the 
American Association of Clinical Endocrinologists, now recommend tight glucose 
control in all surgical or medical critically ill adults.2,24,28 Based on the 
pathophysiologic mechanisms of symptomatic DM and the study by Van den 
Berghe et al., prevention of hyperglycaemic periods has been suggested to decrease 
the risk of dehydration, electrolyte abnormalities, diabetic ketoacidosis but also 
improved wound healing.24 Therefore, the following treatment aims are provided for 
known diabetic patients: (i) avoid hypoglycaemia, (ii) avoid excessive 
hyperglycaemia (main aim <11 mmol/L), (iii) avoid loss of electrolytes (potassium, 
magnesium and phosphate), and (iv) prevent lipolysis and proteolysis. 29,30  
 
However, patients with unknown DM or IGT are not sufficiently controlled 
during the perioperative period.  This status of relative insulin deficiency is 
associated with an increased secretion of catabolic hormones during surgery, but 
also in critical illness and trauma. As patients undergoing surgery are routinely not 
extensively tested for IGT or unknown DM, hyperglycaemic episodes may have their 
first occurrence during surgery or critical illness.31 Especially older patients 
without known DM are prone for the development of critical illness-induced or 
surgery-induced hyperglycaemia (blood glucose of ≥ 11 mmol/L). Treatment aims in 
these patients are mainly directed at avoidance of hyperglycaemia and loss of 
electrolytes. Hyperglycaemic periods are most often treated with short-acting 
insulin therapy. However, the risk of hypoglycaemia may not be underestimated 
and can have serious adverse effect, including seizure, coma or even death. 
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INFLUENCE OF PERIOPERATIVE HYPERGLYCEMIA AND TREATMENT ON 
OUTCOME 
 
Post-operative outcome in patients with and without known DM has extensively 
been studied in intensive care unit (ICU) patients. However, data regarding the 
influence of glucose regulation disorders on the outcome after major vascular 
surgery are relatively scarce. Therefore, treatment recommendations for vascular 
surgery patients are based on the current knowledge in ICU patients. For the 
current systematic review, all studies in surgical and combined surgical-medical 
ICU patients were selected and reviewed to provide an overview of mortality rates 
and other outcome parameters (Table 1).  
 
Table 1 Study characteristics of the selected studies 
Author 
 
Patients 
(N) 
DM 
(%) 
Type of 
surgery 
Glucose target 
(mmol/L) 
Mortality RR 
(95%CI) 
Surgical ICU patients 
He [31] 188 18 Abdominal 4.4-6.1 Not reported 
Stecher [32] 117 13 Abdominal 4.4-6.1 1.05 (0.45-2.46) 
Grey [33] 61 12 General 4.4-6.6 0.53 (0.17-1.69) 
Kia [34] 265 26 Abdominal 4.1-6.3 1.74 (0.86-3.51) 
Total 635 20  4.1-6.6 1.12 (0.60-2.10) 
Surgical-Medical ICU patients 
Mitchell [35] 70 14 Surgical 62% 4.4-6.1 3.00 (0.89-10.16) 
Wang [36] 116 11 Surgical 15% 4.4-6.1 0.27 (0.13-0.57) 
Brunkhorst [37] 537 30 Surgical 53% 4.4-6.1 0.95 (0.71-1.27) 
Iapichino [38] 72 17 Surgical 32% 4.4-6.1 Not reported 
Mackenzie [39] 240 83 Surgical 46% 4.0-5.9 0.82 (0.58-1.15) 
Arabi [40] 523 40 Surgical 17% 4.4-6.1 0.84 (0.64-1.09) 
Devos [41] 1101 19 Surgical 58% 4.4-6.1 1.20 (0.93-1.55) 
Azevedo [#] 337 31 Surgical 40% 4.4-6.6 0.91 (0.62-1.34) 
NICE-SUGAR 6104 20 Surgical 34% 4.5-6.0 1.14 (1.02-1.28) 
Overall 3631 23  4.0-6.6 0.96 (0.80-1.15) 
Abbreviations: DM; diabetes mellitus, RR; relative risk, ICU; intensive care unit 
 
Intensive care unit patients 
Known diabetes mellitus is present in up to 26% of the critically ill patients 
requiring intensive care treatment.24,32 If a critically ill patient requires more than 
five days intensive care treatment, there is a 20% risk of death and substantial 
morbidity.33 Intensive care patients with DM are known to have higher risk of 
severe infections and failure of vital organs, thereby amplifying the risk of an 
adverse outcome. However, not only patients with known DM have higher risk of 
adverse outcome after ICU treatment. New onset DM, presenting with perioperative 
hyperglycaemia common in critically ill patients. The occurrence of hyperglycaemia 
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in non-diabetics has been suggested to be associated with an increased morbidity 
and mortality in those patients.34  
 
Randomized controlled trials 
Van den Berghe et al. performed the first single-center randomized (but unblinded) 
controlled trial (RCT) to study the influence of intensive insulin therapy compared 
to conventional treatment in 1548 surgical ICU patients.24 They hypothesized that 
hyperglycaemia or relative insulin deficiency during critical illness may confer to 
morbidity and mortality. Target blood glucose levels were 9.9 to 11.0 mmol/L and 
4.4 to 6.1 mmol/L in the conventional and intensive group, respectively. The study 
showed a 34% relative risk reduction in overall in-hospital mortality in the 
intensive treatment group. However, this reduction was observed only in patients 
requiring more than 5 days of intensive care treatment. Regression analysis of 
these results indicated that the lowered blood glucose rather than the insulin dose 
was related to the reduction in mortality and morbidity.35 Since the first study by 
vd Berghe et al. additional studies have been performed, to determine if the benefits 
and risks of tight glucose control are generalizable to surgical ICU patients, medical 
ICU patients and operating rooms.32,36 Several studies have shown inconsistent 
results as some showed a positive result on mortality and other neutral or even 
negative results. In 2006, Van den Berghe et al. performed a second RCT to 
compare intensive insulin treatment and conventional therapy in 1200 medical ICU 
patients.37 Intensive insulin treatment decreased ICU and hospital length of stay, 
ventilator days, and incidence of kidney injury. However, it did not reduce overall 
mortality in the total study population. Again in patients with longer ICU stay (≥3 
days) intensive insulin treatment was associated with a decrease in mortality from 
53 to 43%. In contrast, there was a trend towards higher mortality rates in the 
subgroup of patients with ICU stays shorter than 3 days. Additionally, the 
increased occurrence of hypoglycemia in the intensive treatment group (19 vs 3%) 
was an independent predictor of death in multivariate analysis. Recently, the 
European GLUCONTROL trial (mixed medical-surgical ICU patients) and the VISEP 
trial (medical ICU patients) were stopped early due to safety concerns given a high 
incidence of severe hypoglycemia and serious adverse events.38,39  
 
The recent Normoglycemia in Intensive Care Evaluation – Survival Using 
Glucose Algorithm Regulation (NICE-SUGAR) trial was designed to test the 
hypothesis that intensive glucose control reduces mortality at 90 days in medical-
surgical ICU patients. Recent published results showed that patients with intensive 
insulin treatment had an increased risk for overall mortality within the first 90 
days from ICU stay (OR 1.14, 95% CI: 1.02 to 1.28, p = 0.02).40 In addition, severe 
hypoglycaemia was significantly more often noted in patients with tight glucose 
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control (6.8 vs 0.5%). Subgroup analysis of surgical vs nonsurgical ICU patients 
showed no significant difference for the treatment effect. These results suggest that 
achieving normoglycaemia in medical-surgical ICU patients does not necessarily 
benefit ICU patients, but may be even harmful. 
 
Meta-analysis 
Wiener et al. recently summarized all intensive insulin treatment studies in a meta-
analysis.41 They included 29 randomized controlled trials regarding tight glucose 
control in critically ill adults, totalling 8.432 patients. The included studies were 
subdivided according to the ICU setting (surgical, medical or combined) and to 
glucose goal (tight vs moderate glucose control). No significant differences in 
hospital mortality rates were detected, even not when mortality rates were 
subdivided for type of ICU setting and/or glucose target. Tight glucose control 
significantly reduced the risk of septicaemia in surgical ICU patients, when 
compared to usual glucose control. However, this was at the cost of an over fivefold 
increased in the risk of hypoglycaemia when the tight glucose control regimen was 
used (RR 5.13, 95% CI: 4.09 to 6.43). The meta-analysis had the usual limitations 
of pooled data and the fact that some of the included studies were relatively small. 
In addition to this, the analyses on hospital mortality were underpowered to detect 
the 1.7% difference in mortality rate that was identified. As the study by Van Den 
Berghe is regarded as the main basis for the present guidelines on tight glucose 
control in critically ill patients, it is remarkable that this study was identified as 
having outlying results by tests of heterogeneity in the meta-analysis by Wiener. 
Three important reasons for these different results are: (i) bias by an un-blinded 
trial design, (ii) the unusual high mortality in the conventional group may be the 
result of chance, and (iii) several atypical clinical practices were performed (use of 
early glucose infusion and high levels of parenteral nutrition, both possible 
inducing hyperglycaemia). This meta-analysis is a large effectiveness study. In 
general there is lack of agreement for standard glycemic control levels and 
incomplete reporting in most included trials. However, as this meta-analysis 
presents the effect of targeting tight glycemic control in several ICU settings with 
different treatment regimens, the results are more generalizable.  
 
Conclusion intensive care unit patients  
Although several RCTs, systematic reviews and a meta-analysis have led to 
differing conclusions, many professional organizations recommend tight glucose 
control for patients treated at the ICU. However, barriers to widespread adoption of 
tight glucose control include the risk of hypoglycaemia, concerns about the 
external validity of some studies, and the difficulty of achieving normoglycemia in 
ICU patients.  
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MONITORING AND TREATMENT RECOMMENDATIONS IN MAJOR VASCULAR 
SURGERY  
 
Patients undergoing major vascular surgery most often die from cardiovascular co-
morbidities.42 With the growing age of the population, patients scheduled for 
vascular surgery more often have additional cardiovascular risk factors at time of 
surgery. Screening for glucose regulation disorders should be performed in all 
patients with ≥2 clinical risk factors. The current guidelines for patients undergoing 
surgery recommend strict glucose regulation during the perioperative phase and 
intensive care treatment.2,28,43 These recommendations are based largely based on 
1 clinical trial that showed decreased mortality in a surgical intensive care unit.24 
Several large RCT’s have been provided since then, however, all of them failed to 
show the same mortality benefit. We performed a critical review of the available ICU 
studies and concluded that overall mortality in patients randomized to tight 
glucose regulation is not decreased compared to moderate tight glucose control.  
The recent NICE-SUGAR trial also observed an increased mortality risk for all types 
of ICU patients at 90 days from ICU stay, independent of diabetic status.  
 
No randomized controlled trials specifically addressing the monitoring and 
treatment of hyperglycaemia during major vascular surgery have been performed. 
Therefore results of studies in comparable patient groups have to be translated for 
this patient population. The current guidelines for perioperative care in PAD 
patients recommend a target glucose level of <11 mmol/L during the perioperative 
phase. Based on the current available studies, moderate tight glucose control with 
a target blood glucose level between 6.0 and 8.3 mmol/L could be more beneficial. 
Additionally, there is an increased risk for hypoglycaemia in patients with tight 
glucose control. Therefore moderate tight glucose control could have the advantage 
of decreasing the risk of both hyperglycaemia and the prevention of hypoglycaemia 
during major vascular surgery. 
 
 
CONCLUSION 
 
A few studies regarding the influence of perioperative blood sugar monitoring and 
treatment in patients undergoing vascular surgery have been performed. Based on 
these studies and a diversity of studies in the intensive care setting, patients 
scheduled for vascular surgery with known DM should be treated with insulin 
infusion during the perioperative phase with a moderate tight glucose control 
regimen. Unknown diabetics should be tested pre-operatively for glucose regulation 
disorders if ≥2 clinical risk factors are present.  Further prospective randomized 
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studies needs to be undertaken to establish the absolute benefits of moderate 
versus tight glucose control in vascular surgical patients in the perioperative 
period.  
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ABSTRACT 
 
Background: Diabetes Mellitus (DM) is an important risk factor in vascular surgery 
patients, influencing late outcome. Screening for diabetes is recommended by 
fasting glucose measurement. Oral glucose tolerance testing (OGTT) could enhance 
the detection of patients with impaired glucose tolerance (IGT) and DM. The study 
aim was to asses the additional value of OGTT on top of fasting glucose levels in 
vascular surgery patients to predict long-term cardiovascular outcome. 
 
Methods: A total of 404 patients without signs or histories of IGT (plasma glucose 
7.8 to 11.1 mmol/l) or DM (glucose ≥11.1 mmol/l) were prospectively included and 
subjected to OGTT. Cardiac risk factors were noted. Primary outcome was the 
occurrence of late cardiovascular events (composite of cardiovascular death, angina 
pectoris, myocardial infarction, percutaneous coronary intervention / coronary 
artery bypass grafting or cerebrovascular accidents / trainsient ischemic attack), 
and secondary outcome included all-cause and cardiovascular mortality rates, in 
survivors of vascular surgery. Median follow-up was 3.0 [interquartile range 2.4 to 
3.8] years.  
 
Results: Impaired glucose tolerance (N=104) and DM (N=43) were detected by 
fasting glucose levels in 26 (25%) and 12 (28%) patients, and by OGTT in 78 (75%) 
and 31 (72%) patients, respectively. During follow-up, 131 patients experienced a 
cardiovascular event. Using multivariate analysis, patients with IGT showed a 
significant increased risk for cardiovascular events (HR 2.77, 95% CI: 1.83 to 4.20) 
and mortality (HR 2.06, 95% CI: 1.03 to 4.12). Patients with DM showed a non-
significant increased risk for cardiovascular events.  
 
Conclusion: Vascular surgery patients with IGT or DM detected by pre-operative 
OGTT, have an increased risk of developing cardiovascular events and mortality 
during long-term follow-up. It is recommended that non-diabetic vascular surgery 
patients should be tested for glucose regulation disorders prior to surgery. 
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INTRODUCTION 
 
Patients with known diabetes are at increased risk for developing peri-operative 
complications.1 Dysregulation of glucose hemostasis, especially during (surgical) 
stress, is an important characteristic of the prediabetes phase. Impaired fasting 
glucose (IFG) has been shown to be associated with adverse cardiovascular 
outcome.1,2 Therefore, the American Diabetes Association recommends pre-
operative assessment of fasting glucose levels.3 However, during the last decade, 
other studies showed an increased value of oral glucose tolerance testing (OGTT) 
compared to IFG for the prediction of cardiovascular events in various nonsurgical 
populations.4-7 The DECODE (Diabetes Epidemiology: Collaborative analysis Of 
Diagnostic criteria in Europa) study demonstrated substantial discrepancies 
between the predictive values of IFG compared to OGTT.8 In this study of non-
surgical patients, the risk of death from all-cause, cardiovascular and coronary 
artery disease was significantly increased in subjects with impaired glucose 
tolerance (IGT) and newly diagnosed DM. Furthermore, the predictive value of IFG 
depended strongly on the OGTT.  Currently, the European Society of Cardiology 
(ESC) / European Association for the Study of Diabetes (EASD) guidelines provide a 
class I recommendation for primary screening in patients with clinical 
cardiovascular risk factors.9 The American College of Cardiology (ACC) / American 
Heart Association (AHA) guidelines for preoperative management in patients with 
peripheral arterial disease (PAD) undergoing non-cardiac surgery, do not 
recommend a pre-operative glucose-loading test.10 Prior results of the current 
study showed an increase in postoperative ischemia in patients with IGT and DM 
during short-term follow-up. To our knowledge, no prior studies investigated the 
association between OGTT and long-term cardiovascular outcome after vascular 
surgery. As we know that glucose intolerance leads to impaired outcome in 
nonsurgical patients, we hypothesize that this association could be present in 
patients scheduled for vascular surgery as well.  
 
 
METHODS 
 
Study design and population 
This prospective study consisted of 404 consecutive non-diabetic patients 
scheduled for elective vascular surgery in the Erasmus medical centre during the 
time period from November 2004 till May 2007. All patients gave informed consent. 
The exclusion criterion was the presence of DM, defined as a known history of DM, 
with or without the use of insulin or oral glucose-lowering agents. 
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Study protocol 
Preoperatively, all patients underwent an OGTT, carried out as stated by the 
American Diabetes Association (ADA).3 First blood sample was taken in the 
morning after overnight fasting and the second sample was obtained 2 hours after 
the ingestion of 75-g oral glucose load. Glucose status was scored using fasting 
plasma glucose (FPG) and the OGTT. Impaired fasting glucose was defined as 
plasma glucose of 100 to 125 mg/dl (5.6 to 6.9 mmol/l), and IGT as plasma 
glucose of 140 to 199 mg/dl (7.8 to 11.1 mmol/l). According to the ADA guidelines, 
DM was defined as FPG ≥ 126 mg/dl (7.0 mmol/l) and/or plasma glucose ≥ 200 
mg/dl (11.1 mmol/l). Consequently, all patients were classified as having normal 
test results, IGT or DM.  
 
Patient data 
Previous medical history, clinical characteristics and medication use were obtained 
from the outpatient clinic visits and the patients’ medical record. During hospital 
stay, type of surgery was recorded and classified into the following categories: 
carotid surgery, abdominal and thoracic aortic surgery (dilatating or occlusive), and 
lower extremity (dilatating or occlusive). The cardiac risk score was calculated 
according the adapted Lee cardiac index.11 Ischemic heart disease was defined as a 
history of angina and/or myocardial infarction. Renal impairment was defined as a 
serum creatinine concentration of ≥2.0 mg/dl and hypertension was defined as 
blood pressure ≥140/90 mmHg or the use of blood pressure lowering agents. 
Congestive heart failure was defined according the American Heart Association 
(AHA) and the American College of Cardiology (ACC) guidelines.10 Stroke was 
defined as a history of either a cerebral vascular accident (CVA; either ischemic or 
hemorrhagic) or a transient ischemic attack (TIA). Smoking status was defined as 
current smoking or a history of smoking. 
 
Follow-up 
The median follow-up of all patients was 3.0 years [interquartile range 2.4 - 3.8]. 
One year after inclusion of the last patient, mortality rates were verified according 
the Civil Registry. Cause of death was ascertained by examining the death 
certificates, and otherwise by reviewing the medical records. Secondly, for 
ascertainment of the occurrence of the other composites of the primary endpoint, 
the authors (J.P.K. and M.D.) reviewed primarily all medical records of all patients. 
In addition to this the survivors were sent the questionnaire. A response rate of 
82% was achieved within the group of survivors. There was a close agreement 
between the medical record review data and the data collected from the 
questionnaires. The survivors were sent a questionnaire for the registration of 
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major adverse cardiovascular events during the post-operative period. 
Furthermore, current medication use was assessed with the questionnaire as well.  
 
Endpoints 
The primary endpoint was the occurrence of cardiovascular events during long-
term follow-up, with a minimum of at least one year. Cardiovascular events were 
defined as the composite of cardiovascular death, angina pectoris, myocardial 
infarction, percutaneous coronary intervention / Coronary Artery bypass grafting 
or CVA/TIA. Secondary endpoints included all-cause and cardiovascular mortality. 
All-cause mortality was defined as death due to any cause. Cardiovascular death 
was defined as any death with a cerebro-cardiovascular complication as the 
primary or secondary cause and includes death following MI, serious cardiac 
arrhythmias (defined as the presence of a sustained cardiac rhythm disturbance 
that required urgent medical intervention), congestive heart failure, stroke 
(cerebrovascular event or transient ischemic attack), surgery related bleeding 
complications (only a post-operative cause of death), and others. Sudden 
unexpected death was classified as a CV death. 
 
Statistics 
Continuous data were compared using analysis of variance, and are expressed as 
mean ± SD. Categorical data are presented as percentage frequencies, and 
differences between proportions were compared using χ2 test. Logistic regression 
analysis was used to determine the association between IGT, DM and short-term 
cardiac ischemia. Cumulative survival between patients with normal test results, 
IGT and DM was determined by the Kaplan-Meier method and compared using the 
log-rank test. Univariate and multivariate Cox regression models (using SPSS 
version 15.0; SPSS, Inc., Chicago, Illinois) were used to investigate the association 
between IGT, DM (patients with normal test results as reference group) and 
postoperative cardiovascular events and mortality. In addition, Cox regression 
analysis was used to assess the relationship between Lee risk index and both 
endpoints. Adjustments were made for age, gender, history of myocardial 
infarction, angina pectoris, percutaneous coronary intervention / coronary artery 
bypass grafting, congestive heart failure, CVA/TIA, renal insufficiency, smoking, 
COPD, hypertension, hypercholesterolemia and type of surgery. Hazard ratios (HR) 
were calculated from these models along with their 95% confidence intervals (CI).  
A p-value < 0.05 was considered statistically significant. The authors are solely 
responsible for the design and conduct of this study; all study analysis, the 
drafting and editing of the paper and its final contents. 
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RESULTS 
 
Description of the study population 
Elective vascular surgery was performed in 404 patients, who underwent a 
preoperative FPG and OGTT measurement. Baseline characteristics of the patients 
with normal test results, IGT and DM are listed in Table 1. Mean age of the study 
population was 66 ± 13 years, and 74% of the patients were male. At baseline, no 
significant differences between the groups were detected in previous history. 
However, patients with DM had more often hypertension and hypercholesterolemia. 
Renal function, estimated by serum creatinine and Modification of Diet in Renal 
Disease formula, in patients with IGT and DM was significantly worse than in 
patients with a normal test. In patients with IGT, there was less use of statins and 
β-blocking agents during the follow-up period, compared to patients with DM. 
Normal glucose levels were observed in 257 (63%) patients after both tests. 
Impaired glucose tolerance was detected in 104 (26%) patients, of which 26 (25%) 
patients presented with impaired fasting glucose (IFG). In the remaining 78 (75%) 
patients, IGT was only detected after the OGTT. Forty-three (11%) patients were 
diagnosed as having DM, of which 12 (28%) patients presented with diabetic fasting 
glucose levels. In the remaining 31 (72%) patients, diabetic fasting glucose levels 
were only detected after glucose loading (Figure 1).    
 
Figure 1. Additional value of the oral glucose loading test compared to fasting plasma glucose measurement 
for the detection of diabetes mellitus 
 
 
Cardiovascular events and mortality 
During a median follow-up period of 3.0 years [interquartile range 2.4 - 3.8], 131 
patients experienced a cardiovascular event (Figure 2 and Table 2). Patients with 
IGT showed a significant increased risk in cardiovascular events during long-term 
follow-up in both univariate (HR 2.41, 95% CI: 1.65 to 3.53) and multivariate 
analysis (HR 2.68, 95% CI: 1.80 to 3.98) (Table 2). In patients with DM, a 
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borderline unadjusted increased risk in cardiovascular events was seen (HR 1.68, 
95% CI: 0.96 to 2.95). After adjustment for baseline characteristics a slight trend 
was observed as well, though it did not achieve statistical significance (HR 1.59, 
95% CI: 0.89 to 2.82).  
 
Table 1 Baseline characteristics 
 
Total 
[N=550] 
Normal 
[N=257] 
IGT 
[N=104] 
DM 
[N=43] 
P- 
value 
Demograhics   
Age (yrs), mean ± SD 66±13 65 ±14 66±12 77±11 0.68 
Male  74 72 76 81  
Medical history   
Myocardial infarction (%) 25 22.8 30.0 28.6 0.33 
Angina Pectoris (%) 26 26 24 29 0.84 
PCI/CABG (%) 16 14 22 13 0.15 
Ischemic heart disease (%) 26 26 28 22 0.78 
Chronic heart failure (%) 3 3 1 8 0.13 
CVA/TIA (%) 28 27 32 26 0.59 
Cardiovascular risk factors   
Smoking     0.17 
 No 19 4 5 28  
 Current 33 37 27 26  
 History 56 52 69 57  
Hypertension 56 53 58 70 0.12 
Hypercholesterolemia 55 50 60 69 0.09 
Renal failure 11 10 13 12 0.75 
COPD 27 30 22 23 0.30 
Medication use   
Preoperative   
 Statin 71 67 79 77 0.06 
 Β-blocking agents 83 82 85 84 0.78 
 Diuretics 26 22 33 33 0.07 
 ACE inhibitors 32 31 35 30 0.75 
 Calcium Antagonists 20 21 18 21 0.90 
 Angiotensin II antagonists 11 10 10 19 0.25 
 Nitrates 10 10 12 9 0.78 
 Aspirin  62 63 57 67 0.42 
Follow-up 
 Statin 72 68 76 87 0.12 
 Β-blocking agents 69 65 73 87 0.09 
 Diuretics 28 28 28 32 0.92 
 ACE inhibitors 32 29 38 30 0.47 
 Calcium Antagonists 20 20 24 13 0.57 
 Angiotensin II antagonists 13 12 15 17 0.68 
 Nitrates 10 8 13 17 0.29 
 Aspirin  64 65 58 71 0.52 
IGT, Impaired glucose tolerance; DM, diabetes mellitus; PCI/CABG, percutaneous coronary 
intervention/coronary artery bypass grafting; CVA/TIA, cerebrovascular accident/trainsient ischemic attack; 
COPD, chronic obstructive pulmonary disease; ACE, angiotensin converting enzyme 
 150 
During follow-up, 87 (22%) patients died, of which 40 (46%) were classified 
as cardiovascular. All cause mortality was not significantly increased in patients 
with IGT and DM compared to patients with normal test results. However, 
multivariate analysis showed a significant increase in cardiovascular death in 
patients with IGT (HR 2.06, 95% CI: 1.03 to 4.12). This association was not found 
in patients with DM (Table 2 and Figure 3).  
 
Table 2 Cardiovascular events and mortality 
Events Univariate Multivariate 
 
N (%) HR [95%-CI] HR [95%-CI] 
Cardiovascular events 
Normal (N=257) 67 (25) Ref.  Ref.  
IGT (N=104) 49 (46) 2.41 1.65-3.53 2.68 1.80-3.98 
DM (N=43) 15 (35) 1.68 0.96-2.95 1.59 0.89-2.82 
All-cause mortality 
Normal (N=257) 49 (18) Ref.  Ref.  
IGT (N=104) 27 (26) 1.35 0.83-2.20 1.54 0.93-2.55 
DM (N=43) 11 (26) 1.43 0.72-2.83 1.49 0.73-3.01 
Cardiovascular mortality 
Normal (N=257) 20 (8) Ref.  Ref.  
IGT (N=104) 17 (16) 2.10 1.10-4.01 2.06 1.03-4.12 
DM (N=43) 3 (7) 0.97 0.29-3.25 0.88 0.25-3.13 
The following variables were entered into the multivariate Cox proportional hazards model: age, gender, 
history of myocardial infarction, angina pectors, PCI/CABG, congestive heart failure, CVA/TIA, smoking, 
COPD, hypertension, hypercholesterolemia, renal insufficiency, and type of surgery 
 
Table 3 Prognostic value of Lee cardiac risk index 
Events Univariate Multivariate 
 
N (%) HR [95%-CI] HR [95%-CI] 
Cardiovascular events 
Lee risk factors 
No  54 (26) Ref.  Ref.  
1 49 (33) 1.37 0.93-2.02 1.22 0.81-1.83 
≥ 2 28 (62) 3.14 1.98-4.96 2.69 1.66-4.34 
All-cause mortality 
No  37 (18) Ref.  Ref.  
1 35 (23) 1.43 0.90-2.28 1.57 0.96-2.57 
≥ 2 15 (33) 2.50 1.37-4.56 2.41 1.27-4.56 
Cardiovascular mortality 
No  13 (6) Ref.  Ref.  
1 16 (11) 1.86 0.89-3.86 1.60 0.74-3.46 
≥ 2 11 (24) 5.03 2.25-11.25 3.96 1.70-9.19 
The following variables were entered into the multivariate Cox proportional hazards model: age, gender, 
history of myocardial infarction, angina pectors, PCI/CABG, congestive heart failure, CVA/TIA, smoking, 
COPD, hypertension, hypercholesterolemia, renal insufficiency, and type of surgery 
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Figure 2. Cardiovascular event free survival during long-term follow-up after glucose loading test  
 
 
Figure 3. Cardiovascular survival in patients undergoing preoperative oral glucose loading test  
 
 
Lee risk index 
At baseline, 208 (51%) patients had no cardiac risk factors and 151 (37%) patients 
had one risk factor. In the remaining 45 patients, 2 or 3 clinical risk factors were 
present in 42 (10%) patients and 3 (1%) patients, respectively. Fasting plasma 
glucose measurement detected DM in 12 patients, thereby increasing the risk score 
from 0 to 1 or 1 to ≥2 in 7 and 5 patients, respectively. Glucose loading testing 
detected an additional 31 patients with DM. A total of 19 patients reached an 
increased cardiac risk score of ≥2 after testing. A Lee index of ≥2 risk factors prior 
to surgery was significantly and independently associated with increased long-term 
cardiovascular events (HR 2.69, 95% CI: 1.66 to 4.34, p < 0.001), all cause 
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mortality (HR 2.41, 95% CI: 1.27 to 4.56) and cardiovascular mortality (HR 3.96, 
95% CI: 1.70 to 9.19), respectively (Table 3). These associations remained after 
performing glucose loading tests. 
 
 
DISCUSSION 
 
To our knowledge, this study is the first to describe long-term cardiovascular 
outcome in vascular surgery patients who underwent a pre-operative glucose-
loading test. The present data show a significant increase in cardiovascular events 
and mortality during the follow-up in patients with IGT. Patients scheduled for 
vascular surgery diagnosed with IGT by OGTT seem to have an adverse prognosis. 
Until now, only in nonsurgical patients, IGT was shown as an important 
cardiovascular risk factor with a strong influence on cardiovascular outcome.1,4-7,12 
We showed that especially patients with IGT had adverse prognosis, even worse 
than patients with DM. A possible explanation for this difference in outcome could 
be undertreatment of vascular surgery patients with IGT.13 We found a 
nonsignificant trend for less use of statins and β-blocking agents in patients with 
IGT compared to DM. Nowadays, vascular surgery patients with IGT are not 
recognized as being at increased risk of diminished cardiovascular outcome. As a 
result, they may receive less pharmacological preventive treatment. In our center, 
in addition to medical therapy all diabetics are followed at a special outpatient 
clinic with dedicated nursing staff. During visits life-style changes are 
recommended and followed, such as smoking cessation, weight control and 
exercise. This care was not provided for the patients with IGT, and might have 
further influenced outcome. 
 
As patients with IGT have an increased risk for the development of 
cardiovascular events, this has especially long-term prognostic implications. 
Therefore, establishing the diagnosis of IGT or DM in the pre-operative phase 
should lead to more aggressive management of risk factors such as hypertension 
and hypercholesterolemia. Long-term glucose control may prevent micro –and 
macrovascular complications, at least in patients with newly diagnosed type 2 
DM.14 In contrast to patients with IGT, most patients with PAD and concomitant 
DM will receive standard care and treatment according the ACC/AHA guidelines, 
including ACE-inhibition, aspirin and statins.15 The reduction of cardiovascular 
events in diabetic patients by pharmacological treatment is an important topic, as 
the elderly population is growing and the incidence of type 2 DM is increasing as 
well.16 
 
 153 
During follow-up, a significant increase in cardiovascular mortality in 
patients with IGT was shown. In patients with DM, no relationship with 
cardiovascular death was shown; however this is possibly to be due to a power 
problem. All-cause mortality showed a nonsignificant association for higher rates in 
patients with IGT and DM. There seems to be a discrepancy in IGT patients as 
there is a significant increase in cardiovascular mortality but not in all-cause 
mortality. A reasonable explanation for this could be the suggested undertreatment 
of patients with IGT resulting in higher rates of cardiovascular mortality. However, 
the lack of study power to reach a significant increase in all-cause mortality could 
have influenced the results as well. The DECODE study showed an increased risk 
of cardiovascular death in patients with OGTT compared to patients with only 
fasting plasma glucose measured as well.4 These findings were confirmed in several 
other trials, all showing a superiority of 2-hour glucose loading to fasting glucose in 
assessing the risk of future cardiac events.1,6 
 
In this study we used the cutoff values for IFG according the 2003 
guidelines of the ADA. The ADA lowered, in 2003, the cutoff value of plasma 
glucose for IFG from 6.1 to 5.6 mmol/l.17,18 There has been debate about the 
influence of this lower cutoff for the prediction of cardiovascular events. Nowadays, 
the new cutoff is used in most studies comparing IFG and 2-hr glucose loading.2 In 
the present study, use of OGTT showed a clear additional effect on diagnosing IGT 
and DM. Seventy-five percent of the patients with IGT and 72% of patients with DM 
would have been missed, if only the fasting glucose levels were measured.  
Compared to the use of IFG, the current study shows that OGTT adds significantly 
in the diagnosis of IGT and DM. As patients with IGT have an adverse prognosis, 
detection of this glucose regulation disorder has major implications for the 
management of risk factors, but also for the prevention of complications.  
 
The ACC/AHA identified DM as an atherosclerotic risk factor for 
perioperative cardiac complications in patients with PAD scheduled for vascular 
surgery.10,19 Pre-operative risk stratification according to the Lee cardiac index has 
a proven association with perioperative outcome.11 The detection of IGT and DM 
has a significant clinical relevance, both in pre-operative cardiovascular risk 
stratification and treatment. In the present study, DM was detected in 43 (11%) 
patients. Addition of this clinical risk factor to the pre-operative cardiac risk score 
resulted in a Lee risk index of ≥ 2 in 19 patients. Use of the OGTT provides the 
physician to make more accurate risk stratification and the possibility to perform 
additional pre-operative (non-) invasive testing and subsequent treatment. These 
patients with newly found DM need additional treatment, compared to PAD 
patients without DM. Target blood pressure should be lowered to 130/80 mmHg in 
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stead of 140/90 mmHg, using ACE-inhibitors and β-blocking agents. The presence 
of DM deserves attention during the perioperative and postoperative phase as well. 
Plasma glucose levels need to be close monitoring during surgery.10 In a recent 
study by Hoeks et al. the pre-operative Lee Risk Index was shown to be an 
important prognostic factor for late mortality and impaired health status in 
patients with PAD.20 The present study confirmed these results by showing a 
significant increase in cardiovascular events and mortality during long-term follow-
up if ≥2 clinical risk factors are present at baseline in patients with IGT. Currently, 
the use of pre-operative OGTT is only recommended in patients undergoing cardiac 
surgery with ≥2 clinical risk factors.10 The ACC/AHA guidelines for pre-operative 
management in patients with peripheral arterial disease (PAD) undergoing 
noncardiac surgery do not recommend a pre-operative glucose-loading test. This 
study showed that patients with IGT and DM have a worse prognosis following 
vascular surgery during long-term follow-up. Therefore, pre-operative glucose 
loading testing and subsequent expanded medical treatment should be 
recommended in patients with ≥2 clinical risk factors. However, cost-effectiveness 
analysis regarding the use of OGTT in this specific setting needs to be evaluated, 
before applying the test in all high-risk vascular surgery patients. There are several 
arguments why OGTT should be used in the pre-operative phase: (i) patients with 
newly detected DM have an increased risk of peri-operative ischemia21, (ii) the 
relative simple OGTT can easily be performed within the first 2 in-hospital days 
prior to surgery, and (iii) the known risk of perioperative hyperglycemia could 
influence the OGTT if performed post-operatively.   
 
The first limitation of this study was the single measurement of fasting 
glucose levels. The World Health Organization recommends a repeated 
measurement for diagnostic purposes. This could have influenced the prevalence of 
the detected glucose regulation disorders. Cardiovascular events were not 
significantly increased in patients with DM, however a trend was shown. The lack 
of significance in the DM group is possibly due to a study power problem as this 
group consisted only of 43 patients. Although all medical records were reviewed by 
two authors (JPK and MD) and there was a close agreement between these data, 
the potential limitation of recall bias cannot be ruled out completely. 
 
 
CONCLUSION 
 
Pre-operative OGTT should be part of a routine assessment in patients with PAD, 
as OGTT adds significantly to fasting glucose in the diagnosis of IGT and DM. 
Furthermore, patients with IGT detected by pre-operative glucose loading test, have 
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an increased risk in cardiovascular events and mortality during long-term follow-
up.  Therefore, it is recommended that non-diabetic vascular surgery patients 
should be tested for glucose regulation disorders prior to surgery and receive more 
aggressive risk factor management and adequate pharmacological treatment for the 
prevention of micro- and macrovascular complications during long-term follow-up. 
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ABSTRACT 
 
Objective: Metabolic syndrome (MetSyn) is a well-known risk factor for 
cardiovascular (CV) disease in the general population; however, the additional 
predictive value for CV events in high-risk patients with peripheral arterial disease 
(PAD) is unknown. The aims of the current study were to assess and compare the 
(i) prevalence of MetSyn, and (ii) predictive value of MetSyn for CV events, in 
patients with either occlusive or aneurysmatic PAD.  
 
Methods: We screened 2.069 patients scheduled for lower occlusive arterial 
revascularization (N=1.031) or abdominal aortic aneurysm repair (N=1.038) for the 
presence of MetSyn. Adult Treatment Panel III report (ATP III) was used for defining 
MetSyn. Central obesity was defined as body-mass-index >30 kg/m2. Main 
outcomes were the occurrence of CV events and CV mortality during a median 
follow-up of 6 years (IQR 2-9 yrs). 
 
Results: Metabolic syndrome was diagnosed in 421 (41%) and 432 (42%) patients 
with occlusive and aneurysmatic PAD, respectively (p = 0.72). Patients with 
occlusive or aneurysmatic PAD and MetSyn had an increased risk for the 
development of CV events, when compared to patients without MetSyn (27 vs 18% 
and 27 vs 19%, p < 0.001, respectively). In occlusive and aneurysmatic PAD, 
MetSyn was independently associated with an increased risk of CV events (HR 1.6, 
95% CI: 1.2 to 2.1 and HR 1.4, 95% CI: 1.1 to 1.8). No significant association 
between the presence of MetSyn and CV mortality was observed. 
 
Conclusions: Metabolic syndrome is highly prevalent in high-risk PAD patients. In 
occlusive and aneurysmatic PAD patients, MetSyn is an independent predictor of 
long-term CV events. 
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INTRODUCTION 
 
The metabolic syndrome (MetSyn), also known as the insulin resistance syndrome 
or Syndrome X, is the concurrence of multiple metabolic abnormalities associated 
with cardiovascular (CV) disease. The prevalence of MetSyn in the general healthy 
population is 9 to 22%, and increases up to 50% in patients with known 
cerebrocardiovascular disease.1-3 Importantly, the prevalence depends on the 
definition of MetSyn.4 In 1988, Raeven was the first who defined MetSyn, based on 
the fundamental pathogenic process of insulin resistance.5 In 1999, the World 
Health Organization (WHO) defined specific metabolic components and laboratory 
thresholds for the definition of MetSyn, primarily based on the presence of insulin 
resistance.6 The U.S. National Cholesterol Education Program (NCEP) redefined the 
MetSyn in 2003, in an attempt to simplify the clinical application of its criteria.7 Of 
note, the fundamental pathogenic mechanism was not longer insulin resistance, 
but the presence of abdominal obesity.8 
  
Metabolic syndrome was primarily developed as a predictor of CV disease 
in healthy populations, however, only recently studies have indeed demonstrated 
the association between MetSyn and increased risk of CV events.1,9-11 Important to 
notice is that these studies had different definitions of MetSyn and varying study 
populations. In patients with known cerebrocardiovascular disease it has been 
demonstrated that MetSyn was associated with increased risk for CV events and 
CV mortality.9 However, the prevalence and predictive value of MetSyn in patients 
with occlusive peripheral arterial disease (PAD) or abdominal aortic aneurysms 
(AAA) has been examined only in low to intermediate risk patients or small groups 
of AAA patients.1,12-15 Therefore, the primary aim of the current study was to assess 
the prevalence of MetSyn in these two high-risk populations. In addition, as data 
about the predictive value of MetSyn in these high-risk patients is scarce,3,11 the 
secondary aim of the current study was to assess the long-term predictive value of 
MetSyn in patients with either established occlusive or aneurysmatic PAD which 
has not been previously examined.  
 
 
METHODS 
 
Study design and population 
This retrospective study included a total of 2.933 patients with PAD, scheduled for 
elective lower extremity revascularization (N=1.031), abdominal aortic aneurysm 
surgery (N=1.038) and carotid endarterectomy (N=864) during the time period 1990 
to 2008. The focus of the current study was to examine the prevalence and 
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predictive value of MetSyn in patients with occlusive lower extremity arterial 
disease (symptomatic PAD requiring surgical intervention) or aneurysmatic PAD 
(N=2.069). Patients undergoing surgery for occlusive disease with a history of 
aneurysmatic PAD were regarded as occlusive disease (3%), while patients 
undergoing surgery for aneurysmatic PAD and a history of occlusive disease were 
regarded as aneurysmatic PAD (10%). Patient enrolment was performed after 
approval of the hospital’s ethics committee. 
 
Patient data 
At baseline all medical records were reviewed to determine the presence of 
documented ischemic heart disease and cerebrovascular disease. Ischemic heart 
disease was defined as a composite of previous angina pectoris, myocardial 
infarction, percutaneous coronary intervention or coronary artery bypass grafting. 
In addition, all (cardiac) risk factors were determined at baseline, including age, 
gender, body-mass-index (BMI), smoking status, chronic obstructive pulmonary 
disease (according to the Global Initiative on Obstructive Lung Diseaseas-
classification16) and chronic renal insufficiency (serum creatinine >2,0 mg/dL). 
During pre-operative evaluation fasting glucose and lipid-profiles (total cholesterol, 
HDL, LDL, triglycerides) were measured. Finally, the use of the following 
medication was recorded: aspirin, statins, β-blockers, diuretics, angiotensin-
converting enzyme (ACE) inhibitor, oral anticoagulants and ticlopidines. 
 
Metabolic syndrome 
The presence of MetSyn was defined according the National Cholesterol Education 
Program’s (NCEP) Adult Treatment Panel III report (ATP III), which identified the 
MetSyn as a multiplex risk factor for CV disease.17 According the ATP III report, 
diagnosis of MetSyn can be made when 3 out of 5 of the following characteristics 
are present: (i) abdominal obesity (waist circumference men >102cm, women 
>88cm), (ii) triglycerides ≥150 mg/dL (>1.695 mmol/L), (iii) HDL cholesterol in men 
<40mg/dL (<0.9 mmol/L) or in women <50mg/dL (<1.0 mmol/L), (iv) systolic blood 
pressure ≥130mmHg or diastolic blood pressure ≥85mmHg, and (v) fasting glucose 
≥110mg/dL (>6.1 mmol/L). For the current study we defined abdominal obesity as 
BMI >30 kg/m2.18  
 
Follow-up and endpoints 
The median follow-up of all patients was 6 years (interquartile (IQR) range 2 – 9). 
Primary study endpoint was the occurrence of CV events, defined as a composite of 
myocardial infarction, percutaneous coronary intervention / coronary artery 
bypass grafting or cerebrovascular accident / transient ischemic attack. Follow-up 
data were recorded by reviewing the medical records. Secondary endpoint included 
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CV mortality. Survival status was completed by reviewing the municipal civil 
registries. Cause of death was ascertained by examining the death certificates, and 
otherwise by reviewing the medical records. Cardiovascular death was defined as 
any death with a cerebro-cardiovascular complication as the primary or secondary 
cause and included death following myocardial infarction, serious cardiac 
arrhythmias (defined as the presence of a sustained cardiac rhythm disturbance 
that required urgent medical intervention), congestive heart failure, stroke 
(cerebrovascular event or transient ischemic attack), surgery related bleeding 
complications (only a post-operative cause of death), and others. Sudden 
unexpected death was classified as a CV death as well. 
 
Statistics 
Continuous data were compared using analyses of variance, and are expressed as 
mean ± Standard Deviation (SD). Categorical data are presented as percentage 
frequencies and compared using χ2 tests. Cumulative estimated event rates of 
patients with or without MetSyn were determined by the Kaplan-Meier method and 
compared using the log-rank test. Univariate and multivariate Cox regression 
models were used to investigate the association between MetSyn (patients without 
MetSyn as reference group) and prespecified endpoints. Multivariate analyses were 
adjusted for potential confounders (age, gender, smoking, heart failure, chronic 
renal insufficiency, and history of cerebrocardiovascular disease). We used 
interaction terms to study a possible interaction between these potential 
confounders and the primary endpoint for both groups of patients. Statistical 
analyses were performed using SPSS software (SPSS version 15.0; SPSS, Inc., 
Chicago, Illinois). Hazard ratios (HR) were calculated from these models along with 
their 95% confidence intervals (C.I.).  A two-sided p-value < 0.05 was considered 
statistically significant. 
 
 
RESULTS 
 
Baseline characteristics of the study population 
A total of 2.069 eligible patients, referred for lower extremity revascularization 
(N=1.031) or abdominal aortic aneurysm repair (N=1.038) comprised the study 
population (Table 1). Diagnosis of MetSyn was established in 421 (41%) and 432 
(42%) patients with occlusive and aneurysmatic PAD, respectively (p = 0.72). The 
distribution of the number of MetSyn components among occlusive and 
aneurysmatic PAD patients with or without MetSyn is shown in Figure 1. In 
addition, baseline characteristics of patients with occlusive and aneurysmatic PAD 
and MetSyn are shown in Table 1. 
 162 
Table 1 Baseline characteristics of the study population 
 Metabolic Syndrome 
 
Group 1  
occlusive disease 
Group 2  
Aneurysmatic disease 
MetSyn in group 1 
vs. MetSyn in 
group 2 (N=853) 
 
Yes  
[N=421] 
No 
[N=610] 
Yes 
[N=432] 
No 
[N=606] 
P- 
value 
Demographics 
Age >70 years (%) 142 (34) 254 (42) 207 (48) 355 (39) <0.001 
Male (%) 372 (65) 442 (73) 365 (85) 505 (83) <0.001 
Medical history 
Ischemic heart disease 215 (51) 239 (39) 239 (55) 277 (46) 0.19 
CVA/TIA 80 (19) 64 (11) 81 (19) 71 (12) 0.90 
Metabolic syndrome components 
Abdominal obesity 89 (21) 32 (5) 388 (68) 141 (30) 0.21 
Triglycerides ≥150mg/dl 394 (94) 123 (20) 433 (76) 50 (11) 0.05 
HDL Cholesterol      
 Men <40 mg/dl 255 (94) 81 (18) 369 (75) 39 (10) 0.09 
 Women <50 mg/dl 140 (94) 27 (16) 67 (81) 10 (12) 0.25 
Blood pressure ≥130/85  409 (94) 433 (71) 537 (94) 334 (72) 0.22 
Fasting glucose 6.1 mmol/l 112 (27) 55 (9) 324 (57) 131 (28) <0.001 
Additional risk factors 
Smoking     0.08 
 No 120 (29) 260 (43) 148 (34) 249 (41)  
 Current 185 (44) 233 (38) 158 (37) 220 (36)  
 History 116 (27) 117 (19) 126 (29) 137 (23)  
Renal insufficiency 69 (16) 51 (8) 60 (14) 67 (11) 0.29 
Chronic heart failure 54 (11) 37 (7) 36 (8) 45 (7) 0.10 
COPD 69 (16) 101 (17) 124 (29) 171 (28) <0.001 
Medication at discharge 
Aspirin 223 (53) 192 (32) 215 (50) 219 (36) 0.31 
Statin 255 (61) 121 (20) 223 (52) 159 (26) 0.01 
Β-blocking agents 237 (56) 167 (27) 260 (60) 261 (43) 0.25 
ACE-inhibitors 142 (34) 136 (22) 143 (33) 132 (22) 0.87 
Diuretics 138 (33) 124 (20) 131 (30) 129 (21) 0.46 
Oral anticoagulants 201 (48) 382 (63) 115 (27) 191 (32) <0.001 
Ticlopidines 30 (7) 15 (3) 14 (3) 19 (3) 0.01 
Abbreviations: PAD; peripheral arterial disease, MetSyn; Metabolic syndrome, CVA/TIA; Cerebrovascular 
accident / transient ischemic attack, COPD; Chronic obstructive pulmonary disease 
 
Occlusive peripheral arterial disease 
Patients with occlusive PAD and MetSyn were more likely to have a history of 
cerebrocardiovascular disease (ischemic heart disease/cerebrovascular disease), 
smoking habits (current or history), chronic renal insufficiency and chronic heart 
failure (p < 0.001), compared to patients without MetSyn. Lipid spectrum disorders 
and hypertension were the most often present components in patients with 
MetSyn. Medical treatment with aspirin, statins and β-blockade was higher in 
patients with MetSyn (p < 0.001). In addition, patients with MetSyn were more 
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often treated with antihypertensive drugs (p < 0.001). During a median follow-up of 
6 years (IQR 2 – 9), 228 (22%) occlusive disease patients developed CV events. 
Patients with MetSyn had an increased risk for the occurrence of CV events, 
compared to patients without MetSyn (27 vs 19%, p = 0.001). Kaplan-Meier 
estimates for long-term CV event rates showed that patients with MetSyn had 
higher event rates compared to patients without MetSyn (Figure 2a). 
 
Figure 1. Distribution of the metabolic syndrome components among patients with occlusive or aneurysmatic 
peripheral arterial disease 
 
 
Moreover, the presence of MetSyn proved to be an independent prognostic factor for 
long-term cardiovascular events (HR 1.61, 95% CI: 1.2 to 2.1). For the occurrence 
of late cardiovascular events, diabetes mellitus, and BMI >30 kg/m2 were the 
independent prognostic factors contributing to the MetSyn (Table 2). 
 
Table 2 Long-term cardiovascular events 
 Hazard Ratio 95% CI 
Occlusive peripheral arterial disease 
 Metabolic syndrome 1.61 1.23-2.11 
 Abdominal obesity 1.79 1.25-2.58 
 Triglycerides ≥ 150 mg/dL 1.10 0.80-1.52 
 HDL Cholesterol 1.31 0.88-1.96 
 Blood pressure ≥ 130/85   1.15 0.77-1.71 
 Fasting glucose ≥ 6.1 mmol/L 2.07 1.49-2.86 
Aneurysmatic peripheral arterial disease 
 Metabolic syndrome 1.36 1.05-1.76 
 Abdominal obesity 0.95 0.57-1.60 
 Triglycerides ≥ 150 mg/dL 1.50 1.09-2.07 
 HDL Cholesterol 0.98 0.71-1.35 
 Blood pressure ≥ 130/85   0.88 0.61-1.25 
 Fasting glucose ≥ 6.1 mmol/L 1.10 0.84-1.44 
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Furthermore, age (HR 1.02, 95% CI: 1.0 to 1.1), ischemic heart disease (HR 
2.16, 95% CI: 1.6 to 2.9) and chronic renal insufficiency (HR 2.93, 95% CI: 2.1 to 
4.2) were independent predictors for long-term cardiovascular events. No 
interaction between age, gender, smoking, heart failure, chronic renal insufficiency, 
and history of cerebrocardiovascular disease and the occurrence of cardiovascular 
events in patients with MetSyn was observed. The secondary endpoint CV mortality 
occurred in 337 (33%) patients. Regression analyses demonstrated no association 
between the presence of MetSyn and the occurrence of all cause or CV mortality. 
 
Figure 2a. Kaplan-Meier estimates of cardiovascular event rates during long-term follow-up in patients with 
occlusive arterial disease. MetSyn; metabolic syndrome, CV: Cardiovascular 
 
Aneurysmatic peripheral arterial disease 
Aneurysmatic PAD patients with MetSyn were significantly younger and had more 
often a history of cerebrocardiovascular disease (p < 0.05). At discharge, patients 
with MetSyn were more often treated with aspirin, statins and β-blocking agents, 
compared to aneursymatic patients without MetSyn (p < 0.001). Hypertension was 
the most frequent component of MetSyn and medical treatment was in line with 
this finding as the majority of the MetSyn patients were treated with diuretics or 
ACE-inhibitors (p < 0.001). Cardiovascular events occurred in 153 (27%) 
aneurysmatic PAD patients with MetSyn, compared to 88 (19%) of the patients 
without MetSyn (p = 0.001). Estimates for long-term CV event rates according the 
Kaplan-Meier curves, demonstrated that patients with MetSyn had significantly 
higher event rates compared to patients without MetSyn (Log-rank test, p = 0.006) 
(Figure 2b). Using multivariate analyses, the presence of MetSyn in patients with 
aneurysmatic PAD was an independent predictor for long-term CV events (HR 1.36, 
95% CI: 1.1 to 1.8). Of the components contributing to the MetSyn, only elevated 
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triglycerides were significantly associated with an increased risk of long-term CV 
events. In line with occlusive disease patients, age (HR 1.03, 95% CI: 1.0 to 1.1), 
ischemic heart disease (HR 1.45, 95% CI: 1.1 to 1.9) and chronic renal insufficiency 
(HR 3.60, 95% CI: 2.6 to 4.9) were independent predictors for long-term 
cardiovascular events. Using interaction terms, no significant interaction for age, 
gender, smoking, heart failure, chronic renal insufficiency, and history of 
cerebrocardiovascular disease were demonstrated. Of note, during long-term follow-
up 324 (31%) patients died due to a CV cause. 
 
Figure 2b. Kaplan-Meier estimates of cardiovascular event rates during long-term follow-up in patients with 
aneurysmatic peripheral arterial disease. MetSyn: Metabolic Syndrome, CV: cardiovascular 
 
However, no association between the presence of MetSyn and CV mortality was 
observed in patients with aneurysmatic PAD. Additional analyses were performed 
to study the predictive usefulness of MetSyn in patients without diabetes. After 
excluding the patients with known DM (N=362, 17%), and those with a fasting 
glucose >7.0 mmol/L (N=142), there was a remaining population of 1.564 patients 
(76%). Using multivariate Cox regression analysis, MetSyn remained to be an 
independent predictor of adverse cardiovascular events with a HR of 1.4 (95% CI: 
1.09 to 1.81). Furthermore, we evaluated the predictive value of MetSyn using three 
(N=563, 27%), four (N=256, 12%) or five (N=34, 1,6%) criteria for the diagnosis of 
MetSyn. In multivariate analyses, MetSyn defined with the three, four and five 
criteria were all independently associated with a 1.3 (95% CI: 1.1 to 1.6), 1.8 (95% 
CI: 1.3 to 2.3) and 2.2-fold (95% CI: 1.2 to 4.1) increased risk of cardiovascular 
events.  
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DISCUSSION 
 
To our knowledge, this is the first study demonstrating the predictive value of 
MetSyn on the occurrence of CV events in patients with symptomatic occlusive and 
aneurysmatic PAD. We found a high prevalence of MetSyn in both groups of 
patients. In addition, in both occlusive and aneurysmatic PAD patients, MetSyn 
was an independent predictor for the occurrence of CV events during long-term 
follow-up, compared to PAD patients without MetSyn. No association between the 
presence of MetSyn and the occurrence of CV mortality was observed. 
 
Metabolic syndrome has two potential pathophysiological processes, 
including (i) insulin resistance, and (ii) obesity and disorders of adipose tissue. In 
line with Raeven5 who proposed the first definition of MetSyn, the WHO identified 
insulin resistance as the fundamental mechanism. Insulin resistance and 
hyperinsulinemia directly causes other metabolic risk factors, including an 
increased body fat content.6 The emphasis of insulin resistance as the basic 
pathophysiological mechanism is based on the presence of reduced insulin 
sensitivities throughout several degrees of obesity.10 In contrast, by the NCEP 
expert panel7,17 the rising prevalence of MetSyn was considered to be a direct 
consequence of the “obesity epidemic”, as obesity directly or indirectly contributes 
to hypertension, high serum cholesterol, low HDL cholesterol and hyperglycemia. 
Although there is no definite consensus about the leading pathophysiological 
mechanism of MetSyn, a combined process of increased obesity and insulin 
resistance with a strong interaction seems most appropriate mechanism.  
 
A direct consequence of the lack of consensus about the pathogenic 
mechanisms of MetSyn, are the differences in clinical criteria for the diagnosis 
recommended by at least 3 organizations, including the ATP III17, the WHO6 and 
the American Association of Clinical Endocrinologists (AACE).19 Although their 
criteria are similar in several aspects, they reveal fundamental differences in 
positioning of the predominant causes of the syndrome. In the ATP III criteria, 
priority is given to abdominal obesity as a contributor of MetSyn, recognized by 
increased waist circumference.17 In contrast, the WHO regarded insulin resistance 
as a required component for diagnosis, while this was not explicitly required in the 
ATP III definition.6 Furthermore, abdominal obesity was defined as a BMI >30 
kg/m2. The AACE criteria appear to be a hybrid of the ATP III and WHO criteria. In 
this set of criteria, abdominal obesity is a major criteria and is defined as BMI >30 
kg/m2.19 These different abdominal obesity parameters could influence the 
prevalence of MetSyn and its predictive value for CV events. However, a meta-
analysis by Gami et al. demonstrated that the heterogenity between the predictive 
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values of the WHO and ATP III criteria was not explained by the use of different 
obesity metrics. Currently, ATP III criteria are most commonly used as they provide 
a practical tool to identify patients at increased risk for CV disease.20 Furthermore, 
WHO and AACE criteria require additional oral glucose tolerance testing if impaired 
fasting glucose and diabetes are absent.  
 
The prevalence of MetSyn is strongly related to the definition of MetSyn, 
but to the target population as well. The impact of MetSyn as a growing and 
pressing problem for the general population is reflected by the high prevalence of 
the condition in healthy subjects (9 to 22%).1,2 The current study showed a 
prevalence of 41 and 42% of MetSyn in patients with symptomatic occlusive and 
aneurysmatic PAD, respectively. Previous studies reported that the prevalence of 
MetSyn in PAD patients can be up to 58%, which is even higher than in patients 
with coronary heart disease (41%) or cerebrovascular disease (43%).3,11 These 
findings have important clinical implications, considering that PAD is highly 
prevalent in the adult population and is associated with an increased risk of CV 
events.21,22 The current study observed no difference in prevalence of MetSyn in 
patients with aneurysmatic compared to patients with occlusive PAD. These 
findings have not been examined by previous studies, however, the difference in 
prevalence might be a result of the small sample size of previous studies compared 
to the present study.3,23 In addition, the use of different criteria for defining MetSyn 
could have influenced the observed prevalence. In the present study we used ATP 
III criteria as these provide a practical tool to identify patients at increased risk for 
CV events and have been acknowledged as a reliable prognostic indicator of 
adverse cardiac outcome.20 
 
In this study the presence of MetSyn in patients with established occlusive 
or aneurysmatic PAD was independently associated with an increased risk for the 
occurrence of CV events during long-term follow-up. Although patients undergoing 
vascular surgery are classified as being a high-risk population for perioperative and 
long-term adverse cardiac outcome, the present study demonstrated that 
diagnosing MetSyn has an additional value for long-term prognosis. Therefore, 
based on our results we support the clinical use of MetSyn as a prognostic factor 
for long-term cardiac outcome in both patients with occlusive and aneurysmatic 
PAD. Despite the high prevalence of MetSyn in patients with aneurysmatic PAD, 
the correlation between MetSyn and CV events seemed to be less strong compared 
to patients with occlusive disease. The most reasonable explanation for this low 
correlation could be the difference in risk factors and the pathophysiological 
processes. Occlusive arterial disease is a direct consequence of atherosclerotic wall 
damage, while aneurysmatic PAD is an inflammatory process of the arterial wall 
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with subsequent weakening of the aortic wall as a result of connective tissue 
degradation.24 In the present study these differences were underlined by different 
risk factor patterns, especially lower age at presentation in patients with occlusive 
disease and high prevalence of COPD (a connective tissue disease as well) in 
patients with aneurysmatic PAD.  
 
Some studies have demonstrated no additional effect of MetSyn above its 
individual components for the prediction of cardiovascular events.20 In the present 
study of patients with occlusive PAD, obesity and elevated fasting glucose levels 
were independent predictors. In aneurysmatic PAD patients, only 
hypertriglyceridemia was an independent predictor of adverse outcome. MetSyn is a 
unique and uniform entity, requiring at least three out of five diagnostic 
components; therefore, it is reasonable that the combination of components 
(MetSyn) has an additional value in the current study. In addition, using only the 
significant individual components for predicting future cardiovascular events, the 
importance of the nonsignificant components would be under-estimated. To study 
the specific influence of diabetes as an individual component on the predictive 
value of MetSyn, we performed additional analyses in which we excluded patients 
with known DM and/or fasting glucose levels >7.0 mmol/L. Importantly, MetSyn 
remained to be an independent predictor of cardiovascular events during long-term 
follow-up. The kind, magnitude and number of the diagnostic components are 
likely to influence the prognostic information of MetSyn; therefore, future studies 
should be performed using MetSyn as a weighted-risk model in which each 
component has its own predictive value. 
 
Previous studies in patients with PAD have been performed and observed a 
predictive value of MetSyn for future vascular events.12-15 However, most of these 
studies included patients out of the general population12,13 (low-risk) or patients 
with symptomatic PAD (intermediate-risk).14,15 Of note, one study included a small 
number of patients with AAA, but no association between the presence of MetSyn 
and future vascular events or all-cause mortality was detected.15 In contrast, the 
current study included high-risk patients and a large cohort of AAA patients.  
 
No relation between the presence of MetSyn and CV mortality was observed 
in patients with either occlusive or aneurysmatic PAD. According to the WHO and 
ATP III definition, the primary clinical outcome of MetSyn as a multiplex risk factor 
is the development of CV disease in patients free of cardiac history.6, 17 A meta-
analysis addressing MetSyn and CV risk showed an increased risk for the 
development of CV events (RR 2.18, 95% CI 1.6 to 2.9) and CV death (RR 1.91, 95% 
CI 1.5 to 2.5).25 However, this meta-analysis included a diversity of study 
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populations evaluating studies with and without previous histories of CV disease. 
In addition, definitions of MetSyn were different between the included studies. We 
performed additional analyses using a diagnosis of MetSyn based on three, four or 
even five diagnostic criteria for MetSyn to explore whether the risk estimates 
changed with the number of criteria. These analyses demonstrated that with an 
increased number of diagnostic criteria the risk of cardiovascular events increased 
as well, however; the accuracy of the risk estimates diminished. Importantly, the 
current study included high-risk PAD patients of which almost 50% had a history 
of CV disease. This could be a possible explanation for the absence of a relation 
between the presence of MetSyn and the risk of CV mortality as well. Patients with 
PAD are known to be at increased risk of CV mortality, and based on the present 
study the presence of MetSyn had no incremental risk for CV mortality in these 
patients. Therefore, the presence of MetSyn only has an additional value as a 
predictor for CV events in high-risk PAD patients. Finally, patients with MetSyn 
received more optimal medical treatment. Although this did not influence the risk 
of developing CV events, medical treatment could possibly be related to a 
stabilization of the risk for CV mortality.   
 
Potential limitations of the current study merit consideration. First, we 
used the ATP III criteria for the definition of MetSyn; however, abdominal obesity 
was defined as BMI >30 kg/m2 instead of increased waist circumference. Although 
this abdominal obesity parameter could have influenced the outcome parameters, 
the meta-analysis discussed above demonstrated that obesity metrics did not 
influence the predictive value of MetSyn.25 Second, for the current study we used 
ATP III criteria for defining MetSyn. As there are other definitions using different 
combinations of diagnostic criteria, this could have influenced the prognostic 
information in this study. Third, this study has the inherent limitations of a 
retrospective study design. Although the present study found no association 
between MetSyn and increased CV mortality risk, other studies did show this 
relation. This might be related to the associations between target population, 
cardiovascular disease history, and the prevalence of MetSyn. Finally, although 
medication at discharge was recorded, no data on medication during the follow-up 
period were available.  
 
 
CONCLUSION 
 
Patients with occlusive or aneurysmatic PAD have a high prevalence of metabolic 
syndrome. In both patients with occlusive or aneurysmatic PAD, the presence of 
metabolic syndrome was independently associated with an increased risk for the 
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occurrence of CV events during long-term follow-up. Concomitant presence of 
metabolic syndrome in patients with occlusive or aneurysmatic PAD was not 
associated with an increased long-term risk of CV mortality. 
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ABSTRACT 
 
Background: Atherosclerotic disease is often extended to multiple affected vascular 
beds (AVB). Polyvascular disease (PVD) and chronic kidney disease (CKD) have 
both separately been associated with an adverse cardiovascular outcome. We 
assessed the prevalence of PVD in vascular surgery patients with preoperative CKD 
and studied the influence on long-term cardiovascular survival. 
 
Methods: Consecutive patients (2.933) were preoperatively screened for PVD, 
defined as 1-, 2-, or 3-AVB. Preoperative glomerular filtration rate (GFR in 
ml/min/1.73m2 body-surface area) was estimated by the Modification of Diet in 
Renal Disease (MDRD) prediction equation, and patients were categorized 
according their estimated GFR. Primary endpoint was (cardiovascular) mortality 
during a median follow of 6.0 years (IQR 2-9). 
 
Results: Preoperative MDRD-GFR was classified as normal kidney function (GFR 
≥90), or mild (GFR 60-89), moderate (GFR 30-59) and severe (GFR <30) kidney 
disease in 779 (27%), 1423 (48%), 605 (21%) and 124 (4%) patients, respectively. 
One-vessel disease was present in 54% of the patients with normal kidney function, 
while 62% of the patients with CKD (GFR <60) had PVD. In patients with moderate 
or severe kidney disease, the presence of PVD was independently associated with 
even higher cardiovascular mortality rates (2-AVB: HR 1.65, 95% CI: 1.09 to 2.48; 
3-AVB: 2.07, 95% CI: 1.08 to 3.99), compared to 1-AVB. 
 
Conclusion: Patients with CKD had a high prevalence of PVD, which was 
independently associated with increased all-cause and cardiovascular mortality. 
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INTRODUCTION 
 
With aging of the population, the prevalence of atherosclerotic disease and its 
associated adverse outcomes is increasing. It has to be noted that the process of 
established atherothrombosis is not limited to a single arterial location. The 
Reduction of Atherothrombosis for Continued Health (REACH) registry showed that 
one out of 6 patients with peripheral arterial disease (PAD), cerebrovascular disease 
(CVD) or coronary artery disease (CAD) had involvement of 1 or 2 other arterial 
beds.1 The presence of polyvascular disease has been demonstrated to be an 
independent predictor of long-term cardiovascular outcome in the general 
population.2-4  
 
 Chronic kidney disease (CKD), defined as an estimated GFR of less than 60 
ml/min/1.73m2, is a worldwide public health problem with poor outcomes and 
high costs5, and kidney failure requiring treatment with chronic dialysis or kidney 
transplantation is the most visible outcome of this patient population. However, 
patients with CKD also frequently have associated cardiovascular disease, as 
individuals with CKD are more likely to die of a cardiovascular event than to 
develop kidney failure.6 
 
 The studies mentioned above have shown a worse prognosis of patients in 
the general population with polyvascular disease, and other studies have 
demonstrated a graded relationship between a reduced estimated glomerular 
filtration rate (GFR) and the risk of death and cardiovascular events.2,3,7,8 However, 
no prior studies have examined the influence of preoperative reduced estimated 
GFR and polyvascular disease on long-term outcome in PAD patients undergoing 
elective vascular surgery. Therefore, the aim of the current study was to assess (i) 
the prevalence of polyvascular disease in PAD patients with preoperative CKD, and 
(ii) the influence of polyvascular disease in CKD patients on long-term outcome.   
 
 
MATERIALS AND METHODS 
 
Study design and population 
This retrospective study comprised a population of 2.933 consecutive patients with 
PAD, referred for elective major vascular surgery. All patients underwent a major 
vascular surgery procedure during the time period 1990 to 2008, and included 
lower extremity revascularization, aneurysmatic abdominal aortic surgery or 
carotid surgery. From 1990 until 2001, standard pre-operative screening included 
a detailed cardiac history, physical examination, electrocardiogram (ECG), standard 
 190 
laboratory measurements and additional (stress)-testing if indicated. After 2002, 
standard pre-operative echocardiography was added to the screening program. The 
study complies with the Declaration of Helsinki. Patient enrolment was performed 
after approval of the hospital’s ethics committee and after informed consent of all 
patients (or their guardians) at time of inclusion. 
 
Renal function measurement 
Prior to surgery (1-3 days), serum creatinine was measured in all patients. 
Glomerular filtration rate (GFR) was estimated using the Modification of Diet in 
Renal Disease (MDRD) prediction equation. Patients were categorized using the 
MDRD-GFR in the following categories according the National Kidney foundation 
criteria5: (i) normal kidney function (GFR ≥90 ml/min/1.73m2), (ii) mild kidney 
disease (GFR 60-89 ml/min/1.73m2), (iii) moderate kidney disease (GFR 30-59 
ml/min/1.73m2) and (iv) severe kidney disease (GFR<30 ml/min/1.73m2). 
 
Patient data 
At baseline, all medical records were reviewed to determine the presence of 
documented CAD and CVD. Patients undergoing lower extremity revascularization 
or abdominal aortic surgery were screened for the concomitant presence of 
documented CAD and CVD. Patients undergoing carotid surgery were screened for 
CAD and PAD. Coronary artery disease was defined as a documented history of 
ischemic heart disease (composite of angina pectoris, myocardial infarction, 
percutaneous coronary intervention or coronary artery bypass grafting) using 
myocardial stress testing [ergometry, stress-echocardiography or computed 
tomography] or coronary angiogram. Patients with stable or unstable angina 
pectoris were classified as having documented CAD according the European Society 
of Cardiology (ESC) guidelines.9 The presence of coronary ischemia was established 
by one of the following techniques: exercise ECG (horizontal or down-sloping ST-
segment depression or elevation [≥1 mm (0.1 mV) for ≥60-80 ms after the end of the 
QRS complex]) or exercise testing with echocardiography or CT-scan (≥50% stenosis 
in one or more of the coronary arteries).10 The presence of documented CVD was 
defined as a history of Cerebrovascular Accident (confirmed by a CT-scanning 
report) or Transient Ischemic Attack (confirmed by a neurologist report). Lower 
extremity arterial disease was defined as current intermittent claudication with 
Ankle-Brachial-Index (ABI) <0.9, or a history of intermittent claudication with a 
previous intervention. Polyvascular disease was defined as the presence of 2 or 3 
affected vascular beds (AVB). One-AVB included: PAD, 2-AVB included: PAD and 
CAD or CVD, 3-AVB included: PAD and CAD and CVD. Finally, the use of the 
following medication was recorded at discharge: angiotensin-converting enzyme 
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(ACE) inhibitors, angiotensin receptor blockers, diuretics, β-blockers, calcium 
antagonists, statins, aspirin, oral anticoagulants, and ticlopidines.  
 
Risk factors 
All cardiac risk factors were determined at baseline, including age, gender, body 
mass index, smoking status, hypertension (blood pressure ≥140/90 mmHg in 
nondiabetics and ≥130/80 mmHg diabetics or requirement of antihypertensive 
medication), diabetes mellitus (fasting blood glucose ≥7.0 mmol/l or requirement 
for insulin and/or oral anti-diabetic medication), hypercholesterolemia (LDL 
cholesterol > 135 mg/dL and/or the requirement of lipid-lowering medication), 
chronic obstructive pulmonary disease (according to the Global Initiative on 
Obstructive Lung Diseases-classification).11 
 
Follow-up and endpoints 
The median follow-up of all patients was 6 years (interquartile range 2-9). Primary 
study endpoint was the occurrence of all-cause mortality. Survival status was 
assessed by reviewing the municipal civil registries. Cause of death, classified as 
either cardiovascular or noncardiovascular death, was ascertained by examining 
death certificates, or by reviewing medical records. Cardiovascular death was 
defined as any death with a cerebro-cardiovascular complication as the primary or 
secondary cause and includes death following myocardial infarction, serious 
cardiac arrhythmias (defined as the presence of a sustained cardiac rhythm 
disturbance that required urgent medical intervention), congestive heart failure, 
stroke (cerebrovascular event or transient ischemic attack). Surgery related 
bleeding complications were classified as a cardiovascular cause of death only 
when patients died within 30 days after surgery. During long-term follow-up, 
surgery related bleeding complications were not classified as a cardiovascular 
cause of death. Sudden unexpected death was classified as a cardiovascular death. 
 
Statistics 
Continuous data were compared using analyses of variance, and are expressed as 
mean ± SD. Categorical data are presented as percentage frequencies and 
compared using χ2 tests. For all baseline characteristics (including age), analyses 
for trends between the kidney function groups were performed with linear-by-linear 
association. Logistic regression analyses were used to determine the association 
between kidney function (mild, moderate or severe kidney disease compared to 
normal kidney function) and short-term mortality (30 days). Cumulative survival of 
patients with kidney disease was determined by the Kaplan-Meier method and 
compared using the log-rank test. Cox regression models were used to investigate 
the association between kidney disease (patients with normal kidney function as 
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reference group) and mortality during long-term follow-up. All multivariate analyses 
were primarily adjusted for demographics (age and gender) and cardiovascular risk 
factors (smoking, hypertension, diabetes mellitus, hypercholesterolemia, heart 
failure, pre-operative Hemoglobin levels and COPD). Secondary adjustments were 
made for medications usage recommended in PAD patients, including aspirin, 
statins, and β-blockers in case of prior myocardial infarction and angiotensin-
converting enzyme (ACE) inhibitors in patients with heart failure.1 Statistical 
analyses were performed using SPSS software (SPSS version 15.0; SPSS, Inc., 
Chicago, Illinois). Odds and Hazard ratios (OR/HR) were calculated from these 
models along with their 95% confidence intervals (C.I.).  A p-value < 0.05 (two-
sided) was considered statistically significant. 
 
 
RESULTS 
 
Description of the study population 
The study population consisted of 2.933 consecutive patients with PAD referred for 
elective major vascular surgery. Lower extremity revascularization was performed 
in 1.031 (35%) patients, abdominal aortic surgery in 1.170 (40%) patients, and 
carotid surgery in 732 (25%) patients, respectively. At baseline, MDRD-GFR 
categorized all patients into their pre-operative kidney function, and included 
normal kidney function, mild, moderate and severe kidney disease in 779 (27%), 
1423 (48%), 605 (21%) and 124 (4%) patients, respectively (Table 1). Coronary 
artery and CVD were detected in 1248 (43%) and 1037 (35%) patients, respectively.  
 
The number of affected vascular beds at baseline was calculated for all 
kidney function groups and presented in Figure 1. The majority of the patients with 
normal kidney function had 1-AVB (54%), while only 8% had 3-AVB. In contrast 
patients with moderate and severe kidney disease had 1-AVB in 38 and 39% 
respectively, while the majority had 2 or 3-AVB (62 and 61%, respectively). These 
differences in the number of affected vascular beds were also reflected in the 
distribution of cardiovascular risk factors.  
 
Patients with severe kidney disease most frequently had concomitant 
hypertension (73%), diabetes mellitus (27%) and chronic heart failure (22%) (p < 
0.001). Remarkably, patients with normal kidney function were most frequent 
current smokers (41%), while patients with severe kidney disease were more often 
non- or previous smokers (52%) (p = 0.03). 
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Figure 1. Distribution of the number of affected vascular beds among the four categories of baseline kidney 
function;  AVB: Affected vascular beds 
 
 
 
Table 1 Baseline characteristics of the study population 
 
Normal 
[N=779] 
Mild 
[N=1.423] 
Moderate 
[N=605] 
Severe 
[N=124] 
P-value for 
trend 
Demographics   
Age (year), mean ± SD 61.4 ± 12 67.4 ± 10 71.2 ± 9 64.1 ± 12 <0.001 
Male (%) 608 (78) 1059 (74) 438 (72) 83 (67) 0.02 
Previous history      
CVA/TIA 255 (33) 528 (37) 227 (38) 27 (22) 0.99 
Lower-extremity arterial 
disease 
228 (29) 348 (25) 159 (26) 30 (24) 0.14 
Aortic aneurysmatic disease 10 (1) 29 (2) 25 (4) 3 (2) <0.001 
Ischemic heart disease 288 (37) 581 (41) 315 (52) 63 (51) <0.001 
Cardiovascular risk factors   
Smoking      
 No 282 (36) 548 (39) 245 (41) 64 (52) 0.03 
 Current 320 (41) 524 (37) 212 (35) 36 (29) 0.02 
 History 177 (23) 351 (25) 148 (25) 24 (19) 0.94 
Hypertension 322 (41) 735 (52) 365 (60) 91 (73) <0.001 
Diabetes mellitus 116 (15) 218 (15) 123 (20) 34 (27) <0.001 
Dyslipidemia 223 (29) 374 (26) 164 (27) 36 (29) 0.71 
Chronic heart failure 37 (5) 67 (5) 75 (12) 27 (22) <0.001 
COPD 134 (17) 286 (20) 124 (21) 13 (11) 0.91 
Medication at discharge   
Aspirin 406 (52) 766 (54) 282 (47) 47 (38) 0.002 
Statin 311 (40) 573 (40) 211 (35) 35 (28) 0.006 
ß-blocking agents 318 (41) 628 (44) 280 (46) 65 (52) 0.006 
Diuretics 121 (16) 335 (24) 193 (32) 47 (38) <0.001 
ACE inhibitors 154 (20) 344 (24) 201 (33) 41 (33) <0.001 
Calcium Antagonists 146 (19) 342 (24) 170 (28) 52 (42) <0.001 
Angiotensin receptor blockers 34 (4) 79 (6) 37 (6) 7 (6) 0.18 
Oral anticoagulants 301 (39) 513 (36) 249 (41) 45 (36) 0.63 
Ticlopidines 26 (3) 61 (4) 38 (6) 7 (6) 0.01 
Abbreviations: CVA/TIA: Cerebrovascular accident/transient ischemic attack; COPD: chronic obstructive 
pulmonary disease; ACE -inhibitors: angiotensin converting enzyme-inhibitors. 
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Medication use and kidney disease 
Medication use at time of hospital discharge was registered and compared between 
the different patient groups (Table 1). Aspirin and statin use was lower in patients 
with moderate or severe kidney disease, compared to patients with normal kidney 
function (p < 0.01). Blood pressure lowering agents were significantly more often 
prescribed in patients with moderate and severe kidney disease. ß-blocking agents 
and diuretics were used in 52 and 38% of the patients with severe kidney disease, 
compared to 41 and 16% of the patients with normal kidney function (p < 0.01). 
The same association was detected between these patient groups regarding the use 
of ACE-inhibitors, calcium antagonists, and angiotensin receptor blockers (p < 
0.001)  
 
Short-term outcome 
During the first 30 postoperative days, 112 (3.8%) patients died, of which 90 (80%) 
patients died secondary to a cardiovascular cause. Using univariate regression 
analyses, patients with moderate or severe kidney disease had an increased risk for 
all-cause mortality compared to patients with normal kidney function (moderate: 
OR 3.0, 95% CI: 1.73 to 5.35, severe: OR 4.9, 95% CI: 2.33 to 10.26). This 
increased risk was present for the occurrence of cardiovascular mortality as well 
(moderate: OR 2.8, 95% CI: 1.51 to 5.25, severe: OR 4.9, 95% CI: 2.20 to 10.90). In 
multivariate analyses these associations were not longer present for both all-cause 
and cardiovascular mortality.  
 
Long-term outcome 
During long-term follow-up, 1.389 (47%) patients reached the primary endpoint of 
all-cause mortality. A cardiovascular or non-cardiovascular cause of death was 
detected in 849 (61%) and 434 (31%) patients, respectively. In the remaining 106 
(3.6%) patients, no specific cause of death could be determined. The occurrence of 
all-cause mortality showed a significant association with the decrease in kidney 
function (normal 39%, mild 44%, moderate 61%, severe 75%, p < 0.001). Kaplan-
Meier estimates for long-term mortality stratified according to kidney disease 
severity demonstrated that patients with mild, moderate or severe kidney disease 
had lower survival rates compared to patients with normal kidney function (Figure 
2). Log-rank test was used to compare cumulative survival between normal vs mild 
(p = 0.006), mild vs moderate, and moderate vs severe kidney disease and 
demonstrated a significant difference in survival between the three compared 
groups (p < 0.001). In multivariate regression analyses, adjusted for baseline 
demographics, vascular disease at baseline, risk factors and medication, an evident 
relationship between the degree of kidney disease and the risk of all-cause and 
cardiovascular mortality was detected (Table 2). Patients with moderate or severe 
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kidney disease had an increased risk for the occurrence of all-cause mortality 
(moderate: HR 1.3, 95% CI: 1.09 to 1.50; severe: HR 2.9, 95% CI 2.25 to 3.72), and 
also for the occurrence of cardiovascular mortality (moderate: HR 1.5, 95% CI 1.23 
to 1.87; severe: HR 3.8, 95% CI 2.80 to 5.11), compared to patients with normal 
kidney function, respectively.  
 
Figure 2. Kaplan-Meier estimates for long-term all-cause mortality, stratified according the four categories of 
baseline kidney function  
 
 
Table 2 Long-term survival of all patients 
Events Univariate Multivariate 
 
N (%) HR 95% CI HR 95% CI 
All cause mortality 
 Normal [N=770] 302 (39) Ref.  Ref.  
 Mild [N=1408] 625 (44) 1.2 1.05-1.40 1.0 0.85-1.13 
 Moderate [N=604] 369 (61) 2.0 1.75-2.37 1.3 1.09-1.51 
 Severe [N=124] 93 (75) 3.7 2.94-4.69 2.9 2.24-3.71 
Cardiovascular mortality 
 Normal [N=770] 167 (22) Ref.  Ref.  
 Mild [N=1408] 364 (27) 1.3 1.06-1.52 1.0 0.85-1.23 
 Moderate [N=604] 245 (43) 2.5 2.03-3.02 1.6 1.25-1.91 
 Severe [N=124] 73 (60) 5.0 3.82-6.64 3.8 2.81-5.15 
Multivariate: adjustment for age, gender, history of vascular disease (cerebrovascular disease, peripheral 
arterial disease, ischemic heart disease), smoking, hypertension, diabetes mellitus, dyslipidemia, heart 
failure, chronic obstructive pulmonary disease, haemoglobin, aspirin, statins, ß-blockers and ACE-inhibitors 
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Additional analyses on the influence of the number of affected vascular beds in 
those patients with moderate and severe kidney disease demonstrated an 
independent association between polyvascular disease (2 or 3-AVB) and the 
occurrence of all-cause and cardiovascular mortality (Figure 3).  
 
Figure 3. Kaplan-Meier estimates for long-term cardiovascular mortality in patients with moderate or severe 
kidney disease (N=729) prior to surgery and concomitant presence of polyvascular disease, compared to 
monovascular disease 
 
 
Using multivariate regression analyses in patients with moderate or severe kidney 
disease, the presence of 2- or 3-AVB was associated with an increased risk for the 
occurrence of all-cause mortality (2-AVB: HR 1.20, 95% CI 1.01 to 1.49; 3-AVB: HR 
1.66, 95% CI: 1.24 to 2.23) and for the occurrence of cardiovascular mortality (2-
AVB: HR 1.46, 95% CI: 1.12 to 1.90; 3-AVB: HR 1.78, 95% CI: 1.24 to 2.55) as well, 
compared to patients with 1-AVB (Table 3).  
 
Table 3 Long-term survival in patients with renal dysfunction [N=729] 
Events Univariate Multivariate 
 
N (%) HR 95% CI HR 95% CI 
All cause mortality 
 1-AVB [N=251] 150 (60) Ref.  Ref.  
 2-AVB [N=355] 233 (66) 1.22 1.04-1.50 1.20 1.01-1.49 
 3-AVB [N=123] 79 (64) 1.53 1.16-2.01 1.66 1.01-2.87 
Cardiovascular mortality 
 1-AVB [N=251] 92 (40) Ref.  Ref.  
 2-AVB [N=355] 173 (51) 1.49 1.15-1.91 1.65 1.09-2.48 
 3-AVB [N=123] 53 (44) 1.63 1.16-2.29 2.07 1.08-3.99 
Multivariate: adjustment for age, gender, history of vascular disease (cerebrovascular disease, peripheral 
arterial disease, ischemic heart disease), smoking, hypertension, diabetes mellitus, dyslipidemia, heart 
failure, chronic obstructive pulmonary disease, haemoglobin, aspirin, statins, ß-blockers and ACE-inhibitors 
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DISCUSSION 
 
To our knowledge, the current study is the first to demonstrate an independent 
graded association between a preoperative reduced estimated GFR and the number 
of affected vascular beds in a population of almost 3.000 atherosclerotic PAD 
patients. Preoperative moderate or severe kidney disease had an increased risk for 
long-term cardiovascular mortality. Of note, in patients with preoperative CKD, the 
presence of polyvascular disease was associated with higher mortality rates 
compared to patients with a single affected vascular bed.    
 
 In CKD, 2 subtypes of arterial vascular disease can be considered, namely, 
atherosclerosis and large-vessel remodelling arteriosclerosis.12 Atherosclerosis is a 
highly prevalent intimal disease in CKD and is characterized by the presence of 
plaques and occlusive lesions.13 Clinical presentations of atherosclerosis include 
ischemic heart disease, cerebrovascular disease and PAD, which are all common in 
CKD. Arteriosclerosis is characterized by diffuse non-occlusive arterial remodelling 
and arterial stiffening due to haemodynamic alterations.12 The main adverse effects 
of arterial stiffening are (i) left ventricular hypertrophy due to an elevated left 
ventricular afterload, and (ii) altered coronary perfusion and blood flow distribution 
with relative subendocardial ischemia.12 These factors have been identified as 
independent predictors of overall and cardiac mortality in patients with advanced 
CKD.13 In addition, the frequent association between CVD and CKD is important, 
because individuals with CKD are more likely to die of CVD than to require renal 
replacement therapy.14,15 
 
 We observed in our population of PAD patients that 54% of the patients 
with normal kidney function had monovascular disease, while the majority of 
patients with moderate and severe kidney disease had polyvascular disease (62 and 
61%, respectively). Data on the prevalence of polyvascular disease most often come 
from the general population in the primary care setting or from registries.1,4,16 The 
REACH registry found a prevalence of polyvascular disease (PAD and CVD) of 16% 
in the primary care setting.1 More recent data from the Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA guidelines (CRUSCADE) investigators in patients 
presenting with non-ST-segment elevation acute coronary syndrome, reported a 
prevalence of 12, 10 and 43% for established PAD, documented CVD, and prior 
CAD, respectively.3 Objective determination of polyvascular disease by screening 
and/or additional testing was performed primary by Hertzer et al. who observed a 
prevalence of CAD in 44, 30 and 33% of the PAD patients, respectively.17 Analyses 
of the REACH registry showed that 2 or 3-AVB is present in 48 or 14% of PAD 
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patients, respectively.2 Of note, the presence of polyvascular disease in patients 
with PAD has been shown to be independently related to an increased risk of long-
term cardiovascular mortality in several studies.2-4 Eagle et al. and Sutton et al. 
observed that during a 10-year follow-up, CAD patients with concomitant PAD had 
a 25% greater likely-hood of mortality compared to CAD patients without PAD at 
any point in time. Hence, patients with combined PAD, CAD and/or CVD had the 
worst prognosis. However, data on the prevalence of polyvascular disease in 
patients with CKD are scarce. There have been several reports detailing the co-
morbid prevalence of PAD and their relationship to atherosclerotic renovascular 
disease, but these included only small groups of PAD patients.18-21 For example, 
Missouris et al. reported a prevalence of 45% renal artery stenosis in patients 
referred for angiography for PAD.19 Other studies have reported a prevalence of 
renal artery stenosis in patients with PAD between 28 and 45%.20,21 Nonetheless, 
the prevalence of atherosclerosis in other vascular beds has not been thoroughly 
examined.  
       
 In 2004, Go et al. demonstrated an independent, graded association 
between a reduced estimated GFR and the risk of death, cardiovascular events, and 
hospitalization in a large community-based cohort of 1.120.295 adults.8 These 
findings highlighted the clinical and public health importance of CKD. Glynn et al. 
confirmed these results in a cohort of 1.609 patients with established CVD as they 
observed that patients with CKD had an increased mortality risk compared to 
patients with normal kidney function.22 In the present study, patients with 
moderate or several kidney disease had an increased risk of all-cause and 
cardiovascular mortality during long-term follow-up.  
 
 No previous studies investigated the influence of the number of affected 
vascular beds in patients with CKD on the long-term survival. In the current study 
we found that the presence of polyvascular disease was independently associated 
with an increased risk of all-cause and cardiovascular mortality in PAD patients 
with CKD. Although PAD patients with CKD already have an increased mortality 
risk compared to patients with normal kidney function, the additional presence of 
multiple affected vascular territories was associated with an even higher mortality 
risk. Shurrab et al. studied a cohort of 95 patients with atherosclerotic 
renovascular disease during 50 months follow-up, and observed that patients with 
both coronary heart disease and PAD had the highest mortality rates (64%).23 
Furthermore, those patients with solely coronary heart disease had significantly 
higher mortality than patients with isolated renovascular disease (55 vs 22%).       
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 Potential limitations of the current study merit consideration. First, this 
study has the disadvantage of a retrospective design. Second, the standardized 
protocol for pre-operative screening did not include echocardiography before 2002; 
therefore there could be an underestimation of subclinical atherosclerosis in 
patients undergoing surgery before this date. Third, in the present study the 
presence of CAD and CVD was based on reviewing the medical history and 
screening reports. Consequently, not all patients underwent additional testing for 
the detection of nonclinical atherosclerosis. Screening with stress testing for 
polyvascular disease was not systematic but dictated by the risk of clinical 
findings. Although there is a possible underestimation of significant atherosclerotic 
lesions, the association between CKD and polyvascular disease would become even 
stronger if all patients should be screened more extensively. In addition, no data 
were available about the presence of renal artery stenosis. Finally, diagnostic 
methods and accuracy have changed over time, which could have influenced the 
criteria for the presence of documented CAD or CVD. 
 
 
CONCLUSION 
 
In conclusion, in this large cohort of PAD patients, a high prevalence of 
preoperative reduced kidney function was observed. Reduced preoperative 
estimated GFR appeared to be a graded and independent risk factor for all-cause 
and cardiovascular mortality during long-term follow-up. In addition, patients with 
CKD had a high incidence of polyvascular disease, which was independently 
associated with increased mortality rates.   
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ABSTRACT 
 
Background and objectives: Acute kidney injury is an independent predictor of 
short- and long-term survival; however, data on the relationship between reversible 
transitory decline in kidney function and chronic kidney disease (CKD) are lacking. 
We assessed the prognostic value of temporary renal function decline on the 
development of long-term CKD.  
 
Design, setting, participants, & measurements: The study included 1.308 
patients undergoing major vascular surgery (aortic aneurysm repair, lower 
extremity revascularization or carotid surgery), divided into three groups on the 
basis of changes in Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
estimated GFR on days 1, 2, and 3 after surgery, compared with baseline: Group 1, 
improved or unchanged (change in CKD-EPI-eGFR ±10%); group 2, temporary 
decline (decline>10% at day 1 or 2, followed by complete recovery within 10% to 
baseline at day 3); and group 3, persistent decline (>10% decrease). Primary 
endpoint was the development of incident CKD during a median follow-up of 5.0 
years (IQR 2.6-8.5).  
 
Results: Perioperative renal function was classified as unchanged, temporary and 
persistent decline in 739 (57%), 294 (22%) and 275 (21%) patients, respectively. 
During follow-up, 272 (21%) patients developed CKD. In multivariate logistic 
regression analyses, temporary and persistent declines in renal function both were 
independent predictors of long-term CKD, compared to unchanged renal function.  
 
Conclusion: Vascular surgery patients have a high incidence of temporary or 
persistent perioperative renal function declines, both of which were independent 
predictors for development of long-term incident CKD. 
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INTRODUCTION 
 
Acute kidney injury (AKI) is a common and serious complication in hospitalized 
patients and is associated with a high rate of in-hospital morbidity and mortality 
and prolonged length of stay.1 The incidence of AKI ranges between 2 and 45% and 
depends on the type of population, underlying comorbidities, and the definition 
used to define AKI.2-4 During the last decade, the incidence of AKI has increased to 
approximately 500 events per 100.000 in the general population.1  
 
 Although episodes of AKI seem to be reversible, there is a silent, ongoing 
inflammatory and fibrotic process, that leads to progressive structural kidney 
damage.5,6 This process predisposes to worsening blood pressure (BP) control, 
proteinuria, and more rapid decreases in glomerular filtration rate (GFR), which are 
well known risk factors for incident chronic kidney disease (CKD) and 
cardiovascular disease.7 Meta-analyses have demonstrated an increased risk for 
short- and long-term mortality after an episode of AKI.6,8 In these analyses, several 
definitions of AKI were used, including small temporary kidney function decline. In 
fact, a meta-analyses by Coca et al.8 demonstrated that even patients with a 10 to 
24% increase in serum creatinine (Scr) levels was strongly associated with an in 
increased mortality risk; therefore, small changes in Scr levels seem to provide a 
sensitive definition of AKI and could promote early prevention or treatment 
strategies.  
 
 Although numerous studies4,6,9,10 have investigated the predictive value of 
AKI for long-term cardiovascular disease and mortality, data regarding the 
relationship between a temporary decline in renal function during the perioperative 
period with incident CKD are lacking; therefore, we performed this study to assess 
the relationship between temporary decline of renal function and the development 
of CKD during long-term follow-up.   
 
 
METHODS 
 
Study design and population 
This single-center retrospective study comprised a source population of 2.933 
consecutive patients who had peripheral arterial disease (PAD) and were referred 
for elective major vascular surgery. All patients underwent a major vascular 
surgery procedure during the time period 1990 to 2008, and included lower 
extremity revascularization (N=1.031 [35%]), aneurysmatic abdominal aortic 
surgery (N=1.170 [40%]) or carotid surgery (N=732 [25%]). Patients with known 
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CKD at baseline or unavailable Scr levels prior to surgery were excluded (N=481 
[16%]). Scr levels during the perioperative period were available for all patients 
(N=2.452). Patients with an estimated GFR (eGFR) <60 mL/min/1.73m2 at day 3 
after surgery were excluded for the analyses that examined the primary endpoint 
(N=234). Of the remaining 2.218 patients, 1.308 (59%) had a Scr measurement at 
least 1 year after surgery. These 1.308 patients composed the final analyzed study 
population. Baseline characteristics between the source population and the final 
study population were compared to rule out the possibility of selection bias. No 
significant differences with respect to all baseline characteristics, cardiac risk 
factors and medication use at discharge between the two populations were 
observed. The study complies with the Declaration of Helsinki, and enrolment was 
performed after approval of the hospital’s ethics committee and after informed 
consent of all patients (or their guardians). 
 
Renal function assessment 
Scr was assessed by means of a nonkinetic alkaline picrate (Jaffé) method.11 
Estimated GFR was calculated by using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula: eGFR = 141 x min (Scr/к, 1)ª x max (Scr/к, 1)-
1.209 x 0.993age x 1.018 [if female] x 1.159 [if black].12 Scr is micromoles per liter, к 
is 0.7 for females and 0.9 for males, a is -0.329 for females and -0.411 for males, 
min indicates the minimum of Scr/к or 1, and max indicates the maximum of 
Scr/к or 1.  
 
Renal function groups      
Before surgery (1 to 3 days) Scr level was measured at baseline in all patients. Scr 
level was measured at day 1 or 2, and 3 after surgery. Patients were divided into 3 
groups on the basis of changes in CKD-EPI eGFR from baseline to day 1 or 2 and 
from day 1 or 2 to day 3: Group 1, unchanged or improved renal function (change 
in CKD-EPI GFR function –10% to +10% compared to baseline); group 2, temporary 
decline of renal function (temporary decline >10% at day 1 or 2, then complete 
recovery within 10% of baseline value at day 3); and group 3, persistent decline of 
renal function (>10% decrease compared with baseline). Baseline CKD-EPI eGFR 
was defined as the value recorded within 3 days before surgery. The purpose of this 
study was to investigate the prognostic value for the risk of developing CKD after 
small decrements in renal function. On the basis of our previous studies, we used a 
cut-off value of ±10% in eGFR.8,10 To confirm the validity of our initial definition we 
performed additional sensitivity analyses  by repeating all analyses using the Risk, 
Injury, Failure, Loss, and ESRD (RIFLE) classification for AKI.13 
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Follow-up and endpoints 
During the follow-up period, long-term Scr level was used to determine the primary 
endpoint of the development of incident CKD. Long-term creatinine measurements 
had to be obtained at least 1 year after surgery. The median follow-up period 
between date of surgery and last Scr recorded was 5.0 years (Interquartile range 
[IQR] 2.6–8.5). The primary outcome of interest, incident CKD, was defined using 
the National Kidney Foundation Disease Outcome Quality Initiative (NKF/DOQI) 
definition of eGFR <60 mL/min/1.73m2, calculated using CKD-EPI equation.11 In 
addition, for prevention of the occurrence of information bias as a result of 
misclassification of CKD, patients were classified as having CKD only when the 
CKD-EPI eGFR was decreased by at least 25% from the baseline GFR. In 916 (70%) 
patients, more than one Scr measurement was used to define the presence of CKD. 
 
Statistical analyses 
Continuous data were described as mean with standard deviation (SD) or median 
(IQR). Categorical data were presented as percentage frequencies and compared 
using χ2 tests. Differences in baseline characteristics between the perioperative 
renal function groups were analyzed with χ2 test for trend and ANOVA for trend, 
when appropriate. We performed multivariate logistic regression analyses to 
investigate the independent value of perioperative temporary or persistent decline 
in renal function and the development of CKD. Adjustments were made for 
demographics (age, gender), cerebrocardiovascular history, cardiovascular risk 
factors (body mass index, smoking status, hypertension (BP ≥140/90mmHg in 
patients who did not have diabetes and ≥130/90mmHg in patients who had 
diabetes or need for antihypertensive medication), diabetes mellitus (fasting blood 
glucose ≥6.1 mmol/l or need for insulin and/or oral anti-diabetic medication), 
hypercholesterolemia (low density lipoprotein cholesterol >135 mg/dL and/or the 
need for lipid-lowering medication), chronic obstructive pulmonary disease14), 
baseline CKD-EPI eGFR, and BP lowering drugs (diuretics, angiotensin converting 
enzyme (ACE)-inhibitors, calcium antagonists and angiotensin receptor blockers). 
Furthermore, because the Scr levels were not measured at a prespecified time point 
after surgery but at least 1 year after surgery, we also adjusted for time between 
surgery and last Scr recorded and used for prediction of CKD-EPI eGFR. To 
evaluate further the strength of the 10% change in CKD-EPI eGFR, we performed 
additional sensitivity analyses using a 20, 30, 40 and 50% cut-off value for renal 
function decline. Because the incidence of the outcome of interest (CKD) in the 
study population was >10%, we calculated relative risks (RR) along with their 95% 
confidence intervals (C.I.) from the adjusted Odds ratios (OR). Zhang et al. 
proposed the following formula to calculate RR from OR, because this better 
represents the true relative risk: RR = OR / ((1-Po) + (P0 x OR). P0 indicates the 
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incidence of the outcome of interest in the nonexposed group. Statistical analyses 
were performed using SPSS 15.0 (SPSS, Inc., Chicago, Illinois). P < 0.05 (two-sided) 
was considered statistically significant. 
 
 
RESULTS 
 
Description of the study population 
The study population consisted of 1.308 patients who had peripheral arterial 
disease and were referred for elective major vascular surgery. Lower extremity 
revascularization was performed in 527 (40%) patients, abdominal aortic surgery in 
514 (39%) patients, and carotid surgery in 267 (21%) patients. In the source 
population (N=2.452), 1.569 (64%) patients were classified as normal or improved 
renal function, whereas 441 (18%) and 436 (18%) had temporary or persistent 
declines in renal function, respectively. Of the patients in the final study 
population, 815 (62%) patients had no change or improved in CKD-EPI eGFR 
compared with baseline during the first 3 postoperative days. Temporary and 
persistent declines of renal function was observed in 261 (20%) and 232 (18%) 
patients, respectively. At baseline, patients with temporary renal function decline 
had a significant lower CKD-EPI eGFR compared to patients with normal renal 
function (p = 0.01). Mean changes in CKD-EPI eGFR on day 1 or 2 and day 3 for 
the groups are described in Figure 1. Patients with temporary or persistent renal 
function decline more often had vascular disease, resulting in a higher incidence of 
polyvascular disease (p = 0.03; Table 1). Risk factors for CKD, including 
hypertension and chronic heart failure, were more often present in patients with 
temporary or persistent renal function decline (p = 0.05). There was a significant 
trend for increased use of statins, diuretics and angiotensin-converting enzyme 
inhibitors in patients with temporary or persistent renal function decline (p < 0.05).    
 
Figure 1. Subdivision of renal function groups on the basis of CKD-EPI eGFR, with changes in CKD-EPI eGFR 
(mean ± SD). 
 
(Left) Improved or unchanged renal function; ∆CKD-EPI -10 to 10% function compared with baseline. (Middle) 
Temporary decline of renal function; temporary decline >10% at day 1 or 2, then complete recovery within 
10% of baseline at day 3. (Right) Persistent decline of renal function of >10% compared with baseline 
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 Table 1 Baseline characteristics of the study population 
 
No change 
/ Improved 
[N=815] 
Temporary  
Decline 
[N=261] 
Persistent 
Decline 
[N=232] 
P-value for trend 
 
 
Demographics  
Age (year), mean ± SD 64 ± 11 67 ± 10 64 ± 11 0.01 
Male (%) 605 (74) 201 (77) 167 (72) 0.73 
Baseline eGFR (mean ± SD) 77 ± 20 74 ± 19 76 ± 22 0.01 
Cardiac history (N [%])     
Ischemic heart disease 358 (44) 148 (57) 125 (54) 0.01 
CVA/TIA 276 (34) 71 (27) 54 (23) 0.01 
Lower-extremity arterial disease 197 (24) 70 (27) 59 (25) 0.55 
Aortic aneurysmatic disease 20 (3) 8 (3) 6 (3) 0.80 
Polyvascular disease 440 (54) 168 (64) 145 (63) 0.03 
Cardiovascular risk factors (N [%])  
Smoking    0.87 
 No 304 (37) 92 (35) 83 (36)  
 Current 321 (39) 101 (39) 89 (38)  
 History 190 (23) 68 (26) 60 (26)  
Hypertension 377 (46) 142 (54) 124 (53) 0.02 
Diabetes  115 (14) 51 (20) 36 (16) 0.28 
Hypercholesterolemia 223 (27) 64 (25) 69 (30) 0.71 
Chronic heart failure 40 (5) 20 (8) 18 (8) 0.05 
COPD 140 (17) 52 (20) 47 (20) 0.21 
Medication at discharge (N [%])  
Aspirin 382 (47) 121 (46) 109 (47) 0.91 
Statin 278 (34) 92 (35) 99 (43) 0.03 
ß-blocking agents 306 (38) 108 (41) 91 (41) 0.29 
Diuretics 158 (19) 65 (25) 56 (24) 0.05 
ACE inhibitors 181 (22) 72 (28) 69 (30) 0.01 
Calcium Antagonists 196 (24) 77 (30) 59 (25) 0.37 
Angiotensin receptor blockers 36 (4) 13 (5) 12 (5) 0.59 
Abbreviations: CVA/TIA: Cerebrovascular accident/transient ischemic attack; COPD: chronic obstructive 
pulmonary disease; ACE -inhibitors: angiotensin converting enzyme-inhibitors. 
 
Long-term incident chronic kidney disease 
Median follow-up between surgery and the last Scr recorded was 5.0 years (IQR 
2.6–8.5). Median CKD-EPI eGFR during long-term follow-up in patients with 
normal or improved renal function, temporary decline of renal function, and 
persistent decline of renal function was 81 mL/min/1.73m2 (IQR 63-95 
mL/min/1.73m2), 61 mL/min/1.73m2 (IQR 40-82 mL/min/1.73m2) and 59 
mL/min/1.73m2 (IQR 36-76 mL/min/1.73m2). During the observation period 272 
(21%) patients developed CKD. Of the patients without a change or an improvement 
in perioperative renal function, 87 (11%) developed CKD. In contrast, 94 (32%) and 
84 (36%) patients with temporary and persistent renal function declines, 
respectively, developed CKD. There was a significant association between the 
presence of perioperative renal function decline and the development of CKD in 
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unadjusted analyses (p < 0.001). In multivariate regression analyses, adjusted for 
demographics, cerebrovascular history, cardiovascular risk factors, BP-lowering 
agents, and time of Scr measurement the presence of temporary renal function 
decline was independently associated with an increased risk for CKD (RR 3.4, 95% 
CI: 2.7 to 4.1) compared with no change or improvement in renal function. 
Persistent renal function decline in the perioperative period was associated with a 
3.6 fold increased risk of CKD (RR 3.6, 95% CI: 2.8 to 4.4). Other covariates that 
were significantly associated with the outcome of interest were age (RR 1.04, 95% 
CI: 1.02 to 1.06), diabetes (RR 1.9, 95% CI: 1.4 to 2.5) and smoking (RR 1.2, 95% 
CI: 1.0 to 1.4).  
 
Sensitivity analyses 
To evaluate the strength of the 10% cut-off value for temporary changes in CKD-
EPI eGFR, we performed additional analyses using 20, 30, 40 and 50% cut-off 
values, respectively (Table 2). Using a 20% change in CKD-EPI eGFR compared 
with baseline, temporary renal function decline was independently associated with 
a 3.5 fold increased risk (RR 3.5, 95% CI: 2.8 to 4.2). Furthermore, for a 50% 
change in CKD-EPI eGFR compared with baseline, a comparable independent 
association was observed (RR 3.8, 95% CI: 2.9 to 4.3). Importantly, as the change 
in CKD-EPI eGFR cut-off values increased, the independent risk remained stable 
for patients with a temporary decline of renal function. In contrast, performing the 
same analyses in patients with a persistent decline of perioperative renal function, 
there was a graded relation between the cutoff value and the estimated risk of CKD 
up to a cutoff value of 30%. Using a 30% change in CKD-EPI eGFR, there was a 4.3 
fold increased risk (RR 4.3, 95% CI: 3.3 to 5.4); however, when a cutoff value of 40 
or 50% was used, the risk estimates stabilized at a fourfold increased risk (RR 3.9, 
95% CI: 2.8 to 5.1).    
 
 We performed additional sensitivity analyses to test more specific 
definitions of CKD, using eGFR<45 and <30 ml/min, respectively. In total, 252 
(19%) patients had an eGFR<45 ml/min and 124 (9%) patients had eGFR <30 
ml/min. For both definitions, temporary renal function decline remained an 
independent predictor of long-term CKD (eGFR <45: RR 2.2, 95% CI: 1.7 to 2.8, 
eGFR <30: RR 3.1, 95% CI: 2.1 to 4.5).   
 
 To confirm the validity of the results, we repeated all analyses using the 
RIFLE classification for AKI. Logistic regression analyses demonstrated that Risk 
(RR 3.6, 95% CI: 2.6 to 4.8), Injury (RR 3.3, 95% CI: 1.8 to 5.1), and Failure (RR 
4.6, 95% CI: 2.6 to 6.6) were independent predictors of CKD. Finally, to address the 
fact that death is a competing endpoint of CKD, we studied the combined endpoint 
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of death and CKD. Using the combined endpoint, temporary and persistent decline 
remained independent predictors of the primary endpoint incident CKD and death 
(temporary; RR 2.1, 95% CI: 1.6 to 3.0, persistent; RR 2.2, 95% CI: 1.6 to 3.1); 
however the magnitude of the odds ratio’s decreased.  
 
Table 2 
Predictive value of temporary renal dysfunction on long-term CKD, 
using various (small) changes in CKD-EPI eGFR 
Cutoff Values No change Temporary Decline Persistent Decline 
10% 
 Patients (n [%]) 815 (62) 261 (20) 232 (18) 
 RR (95% CI) Ref. 3.4 (2.7 to 4.1 3.6 (2.8 to 4.4) 
20% 
 Patients (n [%]) 856 (65) 313 (24) 139 (11) 
 RR (95% CI) Ref. 3.5 (2.8 to 4.2) 4.2 (3.2 to 5.2) 
30% 
 Patients (n [%]) 863 (66) 337 (26) 108 (8) 
 RR (95% CI) Ref. 3.5 (2.8 to 4.2) 4.3 (3.3 to 5.4) 
40% 
 Patients (n [%]) 866 (66) 355 (27) 87 (7) 
 RR (95% CI) Ref. 3.6 (2.9 to 4.3) 3.9 (2.8 to 5.1) 
50% 
 Patients (n [%]) 866 (66) 365 (28) 77 (6) 
 RR (95% CI) Ref. 3.8 (2.9 to 4.3) 3.9 (2.8 to 5.1) 
Adjustment for demographics (age, gender), cerebrovascular history, cardiovascular risk factors (polyvascular 
disease, smoking, hypertension, diabetes, hypercholesterolemia, heart failure, chronic obstructive pulmonary 
disease), baseline CKD-EPI eGFR, and BP-lowering drugs (diuretics, angiotensin-converting enzyme inhibitors, 
calcium antagonists, and angiotensin receptor blockers)  
 
 
DISCUSSION 
 
To our knowledge, this study is the first to show that temporary perioperative renal 
function decline is an independent predictor for the development of incident CKD 
during long-term follow-up. During the perioperative period, >40% of the patients 
developed temporary or persistent renal function decline, which was invariably 
associated with the development of CKD independent of other important 
confounders that are known to be associated with kidney disease progression.  
 
 Ischemia-reperfusion injury due to hypotension or sepsis is one of the 
major causes of AKI.15 Ischemia and/or reperfusion initiate changes in vascular 
endothelial cells, tubular epithelial cells, and leukocytes that result in the loss of 
immune system homeostasis in the kidney with a consequent inflammatory 
response.16 Animal studies have demonstrated that AKI causes permanent damage 
to the microvasculature with subsequent abnormalities in kidney structure and 
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function.17 Basile et al. demonstrated that recovery from ischemia-reperfusion 
injury in rats is not complete, and that it compromises sodium hemostasis and 
predisposes to hypertension and secondary renal disease.18 In addition, this same 
group of investigators have reported that in rats that were recovering from acute 
renal failure, genes with known inflammatory, remodeling, and vasoactive activities 
were identified, some of which may play a role in altering long-term renal 
function.19-21 In human studies it has been demonstrated that after an episode of 
AKI, residual kidney injury promotes the release of inflammatory markers such as 
C-reactive protein, Interleukin-6, and D-dimer.22 In combination with fibrotic 
signaling pathways, these inflammatory pathways can lead to progressive 
structural kidney damage.6 This silent, ongoing process predisposes to worsening 
hypertension, proteinuria, and more rapid decreases in renal function, all of which 
are widely known risk factors for kidney disease progression and establishment of 
cardiovascular disease.5,7   
 
 The incidence of AKI varies between 2 and 45%, depending on the study 
population and the definition used for AKI.2-4 Especially, patients who undergo 
surgical procedures and have a high risk for ischemia-reperfusion injury as a 
consequence of hemodynamic instabilities are at increased risk for AKI.2,4 The 
association between the development of AKI and increased rates of in-hospital 
mortality has been widely known for decades and has been reported in several 
studies4,23,24; however, the association of AKI and long-term outcome, especially 
incident CKD, has been less studied. This could be a result of the apparent 
reversibility of the clinical episode as observed by improvements in Scr levels. 
Better understanding of the impact of AKI on long-term outcomes may identify a 
segment of patients who may need extended follow-up after discharge. A meta-
analysis by Coca et al. demonstrated that in hospitalized patients, AKI is common 
and an independent predictor of long-term myocardial infarction and all-cause 
mortality (RRs 1.6 to 2.6 and 1.6 to 3.9, respectively)6; however, in this analysis, 
the relative risk for incident CKD after AKI was unattainable because of lack of 
follow-up studies with appropriate controls who did not have AKI. In this study, 
11% of the patients with a normal or improved renal function during the 
perioperative period developed CKD during long-term follow-up. These findings are 
in line with several (general) population studies in which the incidence of CKD 
ranged between 10 to 17%.7,25 Chronic kidney disease was defined according the 
NKF/DOQI-definition, using a cut-off value of eGFR <60 mL/min/1.73m2. Stevens 
et al. have demonstrated that GFR estimates near 60 mL/min/1.73m2 should be 
interpreted with caution26,27; therefore, we performed additional sensitivity analyses 
using more specific definitions of CKD (eGFR <45 mL/min/1.73m2 and <30 
mL/min/1.73m2), which demonstrated a change in the strength of the predictive 
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value. Both temporary and persistent renal function decline remained independent 
predictors of long-term CKD, however. Importantly, because the number of patients 
with more advance CKD decreased significantly, the results for these cutoffs need 
to be interpreted with some caution.     
 
 In this study we are the first to describe the value of a small, temporary 
impairment in renal function as an independent predictor of long-term CKD. The 
prognostic importance of small, acute decrements in renal function has been 
studied in several surgical and intensive care unit populations. Coca et al. 
summarized these results in a meta-analysis and demonstrated that patients with 
a 10 to 24% increase in Scr levels had a RR for death of 1.8 (95% CI 1.3 to 2.5).8 A 
graded relation between the increase in Scr levels and adverse outcome in a variety 
of clinical settings and patient types was observed. Welten et al. demonstrated that 
although renal function may recover completely after aortic surgery, temporary 
decline of renal function was still associated with increased mortality during long-
term follow-up.10 It has been noted by other investigators that the use of smaller 
changes in Scr levels to define AKI are more likely to be only a reflection of 
hemodynamic changes than real kidney injury28 and that small or very temporary 
increases in Scr are simply markers for comorbid conditions. In this study we used 
a cutoff value of 10% change in CKD-EPI GFR compared with baseline preoperative 
CKD-EPI eGFR. To evaluate the predictive strength of this small, temporary change 
in CKD-EPI eGFR, we performed additional sensitivity analyses using a stepwise 
increased cutoff value of 20, 30, 40 and 50% change in CKD-EPI GFR compared 
with baseline. It is interesting that there seemed to be a dosage-dependent 
relationship between the magnitude of exposure and the risk for outcome in 
patients with a temporary decline in renal function. In patients with a persistent 
decline of renal function after the perioperative period, the dosage-dependent 
relationship was observed up to a cut-off of 30%. Although the graded association 
was not completely observed for both groups, these findings strongly suggest that 
even small temporary deteriorations in renal function are already an independent 
predictor for developing long-term CKD. Importantly, in additional sensitivity 
analyses using the RIFLE-criteria for AKI, both temporary and persistent declines 
in renal function became even stronger predictors for developing long-term CKD; 
however, as the focus of the present study was on small changes of renal function 
in relation to outcome, the 10% definition was used for the study outcomes.   
       
This study supports the use of small changes in renal function in daily 
clinical practice, as both a temporary and persistent declines in renal function were 
independent predictors of developing CKD. These small changes in Scr are a 
reflection of the onset of AKI; therefore, early management of AKI should be 
 212 
initiated. Despite the seeming reversible nature of clinical AKI, more attention 
should be given to perioperative impairment in renal function. Episodes of AKI 
confer increased risk of CKD and cardiovascular disease; therefore, follow-up and 
risk factor should be monitored more closely. In addition, medical therapies that 
are known to prevent these outcomes could be applied earlier and more 
aggressively.  
 
 Potential limitations of the current study merit consideration. This study 
has the disadvantage of a retrospective design. As a consequence, data on long-
term Scr levels were not available for all patients in the source population, but for 
59% of the patients. To study the possibility of selection bias, we compared the 
source population and the study population regarding baseline characteristics and 
no significant differences were observed. Furthermore, patients with established 
CKD before surgery were excluded from the study population. As a consequence of 
the study design we were not able to study the influence of AKI on kidney disease 
progression in those patients with established CKD. During the follow-up period 
Scr levels were not measured at prespecified time-points. Multivariate analyses 
were adjusted for the time between surgery and the last Scr level recorded, and 
additional sensitivity analyses were performed; however, the presence of potential 
survival bias in patients with multiple Scr measurements during long-term follow-
up has to be acknowledged. There is a possibility of ascertainment bias as patients 
with increased risk for CKD were likely to have more frequent Scr measurements. 
In addition, informative censoring could not be completely ruled out regarding the 
influence of CKD and death on the occurrence of the endpoint; however, sensitivity 
analyses using a combined endpoint of CKD and death demonstrated that 
temporary and persistent renal function declines remained independent predictors 
of the primary endpoint. There are several definitions for AKI; however, none of 
them includes small changes in renal function. In addition we evaluated the 
presence of AKI only during the first 3 postoperative days and did not examine 
specific causes of AKI. Furthermore, Scr levels at day of hospital discharge were not 
available. In the literature there is a growing consensus to use the RIFLE criteria, 
but these do not include small changes in Scr levels; therefore, in this study, we 
used the cutoff value of 10% in CKD-EPI eGFR on the basis of previous studies and 
a meta-analyses.8,10 It has to be noted that, independent of what prediction 
equation is used to estimate GFR, the changes in GFR in the acute setting are 
always difficult to interpret and a limitation of this study. Finally, although a minor 
dosage-dependent relationship between the magnitude of exposure (e.g. higher 
cutoff values) and the risk of outcome was observed, these data should be viewed 
as hypothesis-generating for future studies. 
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CONCLUSION 
Temporary or persistent perioperative decline in renal function has a high 
incidence in the vascular surgery population. Temporary decline of renal function 
was an independent prognostic predictor for the development of CKD during long-
term follow-up. 
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ABSTRACT 
 
Background and Aims: Serum phosphorus levels have been associated with 
adverse long-term outcome in several populations; however, no prior studies 
evaluated short-term postoperative outcome. The present study evaluated the 
predictive value of phosphorus levels on 30-day outcome after vascular surgery. 
 
Methods: The study included patients scheduled for major vascular surgery (aortic 
aneurysm repair, lower extremity revascularization or carotid surgery), divided into 
4 quartiles based on the preoperative fasting phosphorus level. The endpoints of 
the analyses were all-cause and cardiovascular mortality during the first 30 
postoperative days and during long-term follow-up (median 3.6 years, interquartile 
range 1.8-8.0). 
 
Results: Prior to surgery, 1.798 patients were categorized into the following 
quartiles: <2.9 mg/dL (N=459), 2.9-3.4 mg/dL (N=456), 3.4-3.8 mg/dL (N=444) and 
>3.8 mg/dL (N=439), respectively. During the first 30 postoperative days, 81 (4.5%) 
patients died of which 66 (81%) to a cardiovascular cause. In multivariate analyses, 
an independent association was observed between phosphorus level >3.8 mg/dL 
and all-cause (OR 2.53, 95% CI: 1.2 to 5.4) or cardiovascular mortality (OR 2.37, 
95% CI: 1.1 to 5.7). Baseline serum phosphorus >3.8 mg/dL was also significantly 
associated with long-term all-cause mortality (HR 1.38, 95% CI: 1.1 to 1.7).  
 
Conclusions: Preoperative elevated serum phosphorus demonstrated an 
independent relationship with the occurrence of all-cause and cardiovascular 
mortality during the first 30 days after major vascular surgery. In addition, an 
elevated serum phosphorus was independently associated with long-term mortality. 
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INTRODUCTION 
 
Phosphorus is essential for multiple and diverse biological functions, including 
cellular signal transduction and energy exchange. Approximately 85% of 
phosphorus is located in bones and teeth. Serum phosphorus primarily occurs in 
the form of inorganic phosphate, which is maintained within the physiological 
range (2.5 to 4.5 mg/dL) by regulation of dietary intake, gastrointestinal 
absorption, renal excretion, and shifts between the intracellular and extracellular 
spaces.1-3 
 
There has been considerable interest in the relation between serum 
phosphorus levels and adverse cardiovascular outcomes.4 Several studies have 
examined the relationship between phosphorus levels and long-term survival in 
patients with normal renal function, chronic kidney disease (CKD) not requiring 
chronic dialysis and end-stage renal disease.5-7 However, none of these studies 
have examined the association between serum phosphorus levels and short-term 
outcome after a surgical procedure. Patients referred for major vascular surgery are 
at increased risk of developing perioperative complications due to altered 
hemodynamics, surgical stress and a hypercoagulable state. In addition, these 
patients are characterized by extended atherosclerosis of the vascular beds, which 
creates the perfect substrate for ischemic complications. The mechanisms 
explaining the association between serum phosphorus level and adverse outcome 
are unclear, but several potential factors have been postulated, of which vascular 
calcification appears to be the most important.8,9 As the combination of generalized 
atherosclerosis and vascular calcification provides a significant increased risk of 
perioperative complications10, we hypothesized that higher preoperative serum 
phosphorus levels would be associated with increased mortality during the first 30 
postoperative days. 
 
 
METHODS 
 
Study design and participants 
This single center retrospective study comprised a source population of 2.933 
consecutive patients with peripheral arterial disease (PAD) referred for elective 
major vascular surgery. All patients underwent a major vascular surgery procedure 
during the time period 1990 to 2008. Fasting serum phosphorus levels were 
obtained prior to surgery in 1.798 (61%) patients, and these patients comprised the 
final study population. Baseline characteristics between the source population and 
the final study population were compared to rule out the possibility of selection 
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bias. No significant differences with respect to all baseline characteristics, cardiac 
risk factors and medication use at discharge between the two populations were 
observed. The study complies with the Declaration of Helsinki and enrolment was 
performed after approval of the hospital’s ethics committee, and after informed 
consent of all patients (or their guardians). 
 
Measurement of serum phosphorus and kidney function 
Fasting blood samples were obtained at baseline, including serum phosphorus and 
serum creatinine levels. We elected to evaluate quartiles of baseline serum 
phosphorus as our primary predictor variable (<2.9, 2.9-3.4, 3.4-3.8, >3.8 mg/dL). 
Estimated glomerular filtration rate (eGFR) was calculated by using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR = 141 x min (Scr/к, 
1)ª x max (Scr/к, 1)-1.209 x 0.993age x 1.018 [if female] x 1.159 [if black].11 Scr is 
serum creatinine level (micromoll per liter), к is 0.7 for females and 0.9 for males, a 
is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/к or 
1, and max indicates the maximum of Scr/к or 1. The CKD-EPI equation was 
chosen over the widely used Modification of Diet in Renal Diseases (MDRD) 
equation due to the reported improved performance at higher GFR values.12,13 In 
sensitivity analyses, the models were also adjusted for the four variable abbreviated 
MDRD study equation as an alternative estimate of kidney function. Furthermore, 
patients with eGFR <30 ml/min/1.73m2 were excluded for sensitivity analyses in 
patients without CKD. This sensitivity analyses was performed to exclude those 
with more severe CKD, to show that the association was not driven by those 
patients with more severe kidney disease.  
 
Follow-up and endpoints 
For the purpose of this analysis the main endpoint was all-cause mortality during 
the first 30 postoperative days. All-cause death during the long-term follow-up was 
also examined (median 3.6 years, IQR 1.8-8.0).  Survival status was assessed by 
reviewing the municipal civil registries. Cause of death was ascertained by 
examining death certificates, and otherwise by reviewing medical records. Cause of 
death was further classified as either cardiovascular or noncardiovascular death. 
Cardiovascular death was defined as any death with a cerebro-cardiovascular 
complication as the primary or secondary cause and included death following 
myocardial infarction, serious cardiac arrhythmias (defined as the presence of a 
sustained cardiac rhythm disturbance that required urgent medical intervention), 
congestive heart failure, stroke (cerebrovascular event or trainsient ischemic 
attack), and surgery related bleeding (only considered a 30-day postoperative cause 
of death). Sudden unexpected death was classified as a cardiovascular death.     
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Statistical analyses 
Summary statistics (mean and standard devation [SD] for continuous variables and 
percentages for categorical variables) were performed for all covariates. Chi-squared 
tests were used to compare categorical variables across phosphorus groups. To test 
differences in continuous factors we used 1-way ANOVA. Logistic regression 
analysis was used to determine the association between serum phosphorus level 
(lowest quartile as reference) and short-term mortality (30 days). Cumulative 
survival was determined by the Kaplan-Meier method and compared using the log-
rank test. We used unadjusted and adjusted Cox regression models to examine the 
association between serum phosphorus levels and long-term mortality. The 
covariates included in the adjusted models were chosen by running a univariate 
Cox regression model for each covariate by itself. The covariates that were 
significant at the p < 0.2 level, or were deemed clinically meaningful, were selected 
for inclusion in the final adjusted model for the relation between phosphorus and 
death. Covariates considered for inclusion in the adjusted models included: age, 
gender, diabetes mellitus, dyslipidemia, cerebrovascular disease, ischemic heart 
disease, heart failure, chronic obstructive pulmonary disease, smoking, systolic 
blood pressure, body mass index, and CKD-EPI GFR. Two sensitivity analyses were 
run on the final adjusted models: first by replacing the CKD-EPI GFR by the MDRD 
prediction equation and second by excluding a subset of the population with and 
eGFR <30 ml/min/1.73m2. Statistical analyses were performed using SPSS 
software (SPSS version 15.0; SPSS, Inc., Chicago, Illinois). A p-value < 0.05 (2-
sided) was considered statistically significant. 
 
 
RESULTS 
 
Description of the study population 
Baseline characteristics of the final study population by phosphorus level are 
described in Table 1. Patients in the highest phosphorus quartile were younger and 
more often female (p < 0.01). Serum phosphorus level above the normal range (>4.5 
mg/dL) was detected in 88 (4.9%) patients. Aortic abdominal aneurysm repair 
occurred in 816 (45%) patients, while lower extremity revascularization and carotid 
surgery were performed in 574 (32%) and 408 (23%) patients, respectively. 
Estimated CKD-EPI GFR was lowest in subjects in the higher quartiles of 
phosphorus, and these patients were also characterized by an increased prevalence 
of chronic heart failure.  
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Table 1 Baseline characteristics of the study population 
 Serum phosphorus quartiles (mg/dL)  
 
<2.9 
[N=459] 
2.9-3.4 
[N=456] 
3.4-3.8 
[N=444] 
>3.8 
[N=439] 
P- 
value 
Demographics  
Age (year), mean ± SD 68 ± 9 68 ± 10 67 ± 11 65 ± 11 <0.01 
Male (%) 396 (86) 370 (81) 307 (69) 272 (62) <0.01 
CVA/TIA 161 (35) 157 (34) 166 (37) 118 (27) <0.01 
Ischemic heart disease 205 (45) 208 (46) 209 (47) 201 (46) 0.91 
Type of surgery   
Abdominal aortic aneurysm 226 (49) 216 (47) 185 (42) 189 (43) 0.08 
Lower extremity revascularization 125 (27) 133 (29) 140 (32) 176 (40) <0.01 
Carotid surgery 108 (24) 107 (24) 119 (27) 74 (17) <0.01 
Cardiovascular risk factors   
Current smoker 164 (36) 182 (40) 174 (39) 165 (38) 0.57 
Diabetes mellitus 75 (16) 75 (16) 89 (20) 89 (20) 0.23 
Hypercholesterolaemia 120 (26) 148 (33) 137 (31) 148 (34) 0.07 
Chronic heart failure 23 (5) 32 (7) 45 (10) 42 (10) 0.02 
COPD 95 (21) 87 (19) 92 (21) 89 (20) 0.92 
Measurements   
SBP (mmHg) 149 ± 25 145 ± 23 150 ± 69 144 ± 63 0.29 
DBP (mmHg) 84 ± 13 82 ± 12 83 ± 13 79 ± 13 0.13 
BMI 25 ± 3.6 25 ± 3.8 26 ± 4.0 25 ± 4.1 0.04 
CKD-EPI GFR ml/min/1.73 m2 70 ± 19 71 ± 21 72 ± 21 65 ± 29 <0.01 
Phosphorus (mg/dL) 2.6 ± 0.3 3.2 ± 0.1 3.6 ± 0.1 4.4 ± 0.9 <0.01 
Abbreviations: CVA/TIA; cerebrovascular accident / transient ischemic attack, COPD; chronic obstructive 
pulmonary disease, SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI; body mass index, CKD-
EPI GFR; chronic kidney disease-epidemiology collaboration estimated glomerular filtration rate 
 
Short-term outcome  
During the first 30 days after surgery, 81 (4.5%) patients died of which 66 (81%) 
secondary to a cardiovascular cause. Using multivariate logistic regression 
analyses, patients within the highest phosphorus quartile showed a significant 
association with the risk of all-cause mortality during short-term follow-up (Table 
2a). The presence of a baseline phosphorus level >3.8 mg/dL was associated with a 
2.5 fold increased risk of all-cause mortality (OR 2.53, 95% CI: 1.2 to 5.4). This 
association was demonstrated for the occurrence of 30 day cardiovascular mortality 
as well, as patients within the highest quartile of serum phosphorus had a 2.4 fold 
increased cardiovascular mortality risk (OR 2.37, 95% CI: 1.1 to 5.7) (Table 2b).      
 
Long-term outcome 
After a median follow-up period of 3.6 (IQR 1.8-8.0) years, the mortality endpoint 
was reached in 813 (45%) patients, of which 509 (63%) died secondary to a 
cardiovascular cause and 304 (37%) died of non-cardiovascular causes. 
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Table 2a 30 days all-cause mortality 
All-cause Sensitivity 1 
 
OR 95% CI OR 95% CI 
Serum phosphorus quartiles (N=1.798} 
 < 2.9 (N=459) Ref.  Ref.  
 2.9-3.4 (N=456) 0.98 0.4-2.3 0.99 0.4-2.3 
 3.4-3.8 (N=444) 1.68 0.8-3.7 1.68 0.8-3.7 
 > 3.8 (N=439) 2.53 1.2-5.4 2.60 1.2-5.5 
Multivariate analyses with adjustment for: Age, gender, ischemic heart disease, cerebrovascular disease, 
current smoking, baseline serum creatinine, dyslipidemia, diabetes mellitus, heart failure, COPD, systolic 
blood pressure and body mass index. Sensitivity 1: GFR estimated by CKD-EPI prediction equation replaced 
by GFR estimated by the four variable abbreviated MDRD formula 
 
Table 2b 30 days cardiovascular mortality 
Cardiovascular Sensitivity 1 
 
OR 95% CI OR 95% CI 
Serum phosphorus quartiles (N=1.798} 
 < 2.9 (N=459) Ref.  Ref.  
 2.9-3.4 (N=456) 1.23 0.5-3.2 1.23 0.5-3.2 
 3.4-3.8 (N=444) 1.78 0.7-4.4 1.78 0.7-4.4 
 > 3.8 (N=439) 2.37 1.1-5.7 2.45 1.0-5.9 
Multivariate analyses with adjustment for: Age, gender, ischemic heart disease, cerebrovascular disease, 
current smoking, baseline serum creatinine, dyslipidemia, diabetes mellitus, heart failure, COPD, systolic 
blood pressure and body mass index. Sensitivity 1: GFR estimated by CKD-EPI prediction equation replaced 
by GFR estimated by the four variable abbreviated MDRD formula 
 
Kaplan-Meier estimates for long-term all-cause mortality stratified by phosphorus 
level showed that patients within the highest quartile had lower survival compared 
to patients within the lowest quartile (Figure 1). Log-rank test compared cumulative 
survival between the groups and showed a significant difference in survival 
between the highest and lowest quartile (p = 0.01). Using multivariate Cox 
regression analyses, a relationship between the highest phosphorus quartile and 
the risk of all-cause mortality was detected (HR 1.38, 95% CI: 1.1-1.7) (Table 3). 
During long-term follow-up, no association was observed between the phosphorus 
quartiles and cardiovascular mortality risk.   
 
Sensitivity analyses 
After replacing eGFR assessed by the CKD-EPI prediction equation with the MDRD 
formula (Table 2a and 2b, sensitivity 1) in the multivariate regression model, the 
predictive values of the highest quartiles regarding the occurrence of short-term all-
cause or cardiovascular mortality remained consistent (Table 2a and 2b). In 
addition, risk estimate of long-term all-cause mortality remained the same for the 
highest quartile (HR 1.40, 95% CI: 1.1 to 1.7) and the risk estimate for long-term 
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cardiovascular mortality for the highest quartile was not significant (HR 1.18, 95% 
CI: 0.90 to 1.56). In a second sensitivity analyses, patients with a CKD-EPI GFR 
<30 ml/min/1.73m2 were excluded (N=124 [7%]) to confirm that our main results 
were not driven by the patients with severe CKD. Repeating multivariate regression 
analyses on short-term all-cause mortality, demonstrated a consistent predictive 
value for the highest phosphorus quartile (OR 2.52, 95% CI: 1.2 to 5.5). Similar 
results were observed for the association between the highest phosphorus quartile 
and short-term cardiovascular mortality (OR 2.43, 95% CI: 1.0 to 6.0). 
 
Figure 1. Kaplan-Meier estimates of cumulative survival according the four groups of preoperative 
phosphorus level  
 
Table 3 Long-term outcome 
All-cause Cardiovascular 
 
HR 95% CI HR 95% CI 
Serum phosphorus quartiles (N=1.798} 
 < 2.9 (N=459) Ref.  Ref.  
 2.9-3.4 (N=456) 1.05 0.9-1.3 0.98 0.8-1.3 
 3.4-3.8 (N=444) 1.09 0.9-1.4 0.95 0.7-1.2 
 > 3.8 (N=439) 1.38 1.1-1.7 1.16 0.9-1.5 
Multivariate analyses with adjustment for: Age, gender, ischemic heart disease, cerebrovascular disease, 
current smoking, baseline eGFR, dyslipidemia, diabetes mellitus, heart failure, COPD, systolic blood pressure 
and body mass index 
 
 
DISCUSSION 
 
In the present study we observed an independent association between baseline 
fasting serum phosphorus level >3.8 mg/dL and the risk of all-cause and 
cardiovascular mortality during the first 30 days after major vascular surgery. 
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Furthermore, preoperative phosphorus >3.8 mg/dL was an independent predictor 
of long-term all-cause mortality in patients undergoing a major peripheral vascular 
surgery. 
 
Vascular surgery patients are characterized by a diversity of atherosclerotic 
risk factors, including smoking, hypertension, diabetes mellitus, and dyslipidemia.7 
Importantly, previous studies have demonstrated that these risk factors are often 
associated with higher serum phosphorus levels.6,7 Although the risk factors for 
hyperphosphatemia have been described in several studies, little is known about 
the potential mechanism for the association between serum phosphorus levels and 
adverse outcomes. Phosphorus excess may influence mortality by increasing 
circulation parathyroid hormone levels or decreasing 1,25 dihydroxyvitamin D 
levels by increasing secretion of fibroblast growth factor-23.14,15 Alternatively, the 
increased risk of death associated with elevated serum phosphorus in population 
based studies could be secondary to vascular calcification16-18 Foley et al. have 
demonstrated in healthy young adults that higher serum phosphorus levels, even 
within the normal range, were independently associated with the development of  
coronary artery calcification 15 years later.9 Vascular surgery patients are 
characterized by extended atherosclerosis in multiple vascular territories, and 
abnormalities in phosphorus homeostasis have been shown to be also related to 
the development of vascular calcification in the general population.9 Although the 
present study results need to be confirmed in future prospective studies, our study 
results indicate that elevated pre-operative serum phosphorus level could have 
incremental predictive value towards short- and long-term prognosis in vascular 
surgery patients.  
 
Recently, several studies examined the presence of the relationship 
between phosphorus levels and (cardiovascular) outcome in individuals with 
normal kidney function.5-7 However, no prior studies investigated the predictive 
value of preoperative phosphorus levels in vascular surgery patients towards the 
occurrence of short-term mortality. The present study demonstrated that baseline 
serum phosphorus level >3.8 mg/dL has an independent relation with the risk of 
death during the first 30 postoperative days. Although patients with CKD or end-
stage renal disease are at increased risk for developing perioperative complications, 
hyperphosphatemia is mainly seen as a marker of adverse long-term prognosis. In 
patients with CKD and end-stage renal disease, phosphorus excess has been 
independently linked with coronary artery and aorta calcification, as well as 
cardiovascular and all-cause mortality during long-term follow-up. As the present 
study demonstrated an independent association between elevated phosphorus and 
short-term outcome, it could be argued that this association is due to the inclusion 
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of patients with a severe decline in kidney function, as these patients are at high 
risk for developing perioperative complications. In addition, higher serum 
phosphorus levels might indicate impaired kidney function, even after adjustment 
for estimated GFR, and that the severity of renal disease rather than phosphorus 
levels per se might account for the association between elevated phosphorus and 
adverse clinical outcome. Therefore, we performed additional sensitivity analyses, 
excluding patients with severe CKD (CKD-EPI GFR <30 ml/min/1.73m2) which 
showed that a baseline phosphorus level >3.8 mg/dL was still independently 
associated with adverse short-term outcome. During the long-term follow-up, only 
patients in the highest preoperative phosphorus quartile had an increased risk of 
all-cause mortality. These results are in line with Tonelli et al. who described an 
increase in all-cause mortality in patients with elevated serum phosphorus without 
a decline in renal function, which could be related to the presence of generalized 
atherosclerotic disease in these patients.7  
 
In clinical practice, phosphorus is not routinely measured prior to vascular 
surgery. Risk factor stratification includes measurement of serum creatinine, but 
only when indicated in patients with established CKD, additional serum 
phosphorus and calcium levels are determined. The present study emphasizes the 
use of serum phosphorus measurement prior to vascular surgery as a predictor of 
perioperative mortality. Importantly, both in patients with or without a decline in 
renal function, serum phosphorus >3.8 mg/dL was independently associated with 
all-cause and cardiovascular mortality during short-term follow-up. Routine 
measurement of serum phosphorus in patients scheduled for vascular surgery 
provides a simple and effective way of additional risk factor analyses in patients at 
high-risk for perioperative events. 
 
Strengths of our study include the large number of patients and the ability 
to adjust for multiple factors that may affect phosphorus levels and mortality rates. 
However, our study also has potential limitations that should be considered. First, 
this study has the disadvantage of a retrospective design. As a consequence, data 
on preoperative phosphorus levels were not available for all patients in the source 
population, but for 61% of the patients. To study the possibility of selection bias we 
compared the source population and the study population regarding baseline 
characteristics and no significant differences were observed. Second, because this 
study was an observational analysis, we cannot rule out the possibility of residual 
confounding. However, we adjusted for multiple confounders, including 
characteristics associated with serum phosphorus levels in this cohort. Third, the 
present study included vascular surgery patients, which limits the generalizability 
of the results in other surgical populations. Fourth, we cannot exclude the 
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possibility that our findings were influenced by dietary intake of phosphorus and 
thus that dietary habits might confound the association between phosphorus levels 
and mortality rates. Finally, in the present study 25-hydroxyvitamin D, 1,25-
dihydroxyvitamin D, or intact parathyroid hormone levels were not measured.  
 
In conclusion, we found an independent relation between serum 
phosphorus level >3.8 mg/dL and the risk of all-cause and cardiovascular death 
during the first 30 postoperative days after vascular surgery. Furthermore, 
phosphorus >3.8 mg/dL was independently associated with all-cause mortality 
during long-term follow-up. Based on the ready availability and low cost of serum 
phosphorus assays, these findings could have a potential clinical use, however, the 
results of this study should be viewed as hypothesis generating. Additional 
prospective studies are required to determine the explanation for this association 
and to confirm that this relationship is present in other surgical populations. 
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INTRODUCTION 
 
Abdominal aortic aneurysms (AAA) have a prevalence between 1.3 – 8.9% in men 
and 1.0 – 2.2% in women aged above 55 years.1,2 Furthermore, AAA cause 1 – 3% 
of all deaths among men aged 65-85 years in developed countries.2,3 As the 
disorder is invariably associated with severe atherosclerotic damage of the arterial 
wall, it has traditionally been regarded as a direct consequence of generalized 
atherosclerotic disease.4 In patients with occlusive aortic disease, dyslipidemia is a 
well established risk factor. However, in patients with aneursymatic aortic disease, 
the association between dyslipidemia and the development of AAA is less clear. 
Large clinical trials in patients with cardiac and peripheral arterial disease have 
shown the strong relation between dyslipidemia, statin therapy and the risk of 
cardiovascular disease.5-9 Importantly, the effects of statin therapy were still 
present irrespective of the decrease in serum cholesterol levels. These findings 
resulted in the discussion of potential non-lipid lowering effects of statin therapy. 
These “pleiotropic effects” compose a diversity of cellular events which have an 
effect on several components of the arterial wall, including: (i) endothelial cells, (ii) 
smooth muscle cells, (iii) platelets, (iv) monocytes/macrophages, and (v) the process 
of inflammation.10,11 In the general population the role of dyslipidemia as an 
independent risk factor for AAA is debated. However, as patients with AAA 
frequently have concomitant arterial disease, statin therapy is often recommended. 
As a result, the non-lipid lowering effects of statins on aneurysm expansion rate 
are hardly studied, and most evidence comes from experimental and animal 
studies. In the current review article we provide an overview of all available 
literature on the effects of dyslipidemia, statin therapy and the risk of AAA 
expansion and rupture. In the first part we summarize all population-based studies 
that investigated the relation between hypercholesterolemia and the development of 
AAA. In the second part, the available literature regarding the effects of statins on 
aneurysm growth, expansion rate and the risk of rupture is summarized, including 
in vitro, animal and clinical human studies.  
 
 
ETIOLOGY 
 
Atherosclerosis is the underlying disorder in the majority of patients with 
cardiovascular disease. Although, AAA has traditionally been regarded as a direct 
consequence of atherosclerosis, insights regarding the pathogenic processes in 
aortic diseases are changing. Aortic disease includes (i) occlusive disease, (ii) 
aneurysmatic disease, and (iii) combined occlusive and aneursymatic disease. 
Aortic occlusive disease is a direct consequence of atherosclerotic plaque formation 
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with a subsequent damaging of the vessel wall and narrowing of the arterial lumen. 
In contrast, aneurysmatic disease is the result of inflammatory processes in the 
arterial wall, leading to elastin and collagen degradation and eventually 
aneurysmatic wall dilatation. As shown in Figure 1a, aneurysmtic disease can have 
a specific cause including trauma, acute infection (brucellosis, salmonellosis), 
chronic infection (tuberculosis), inflammatory diseases (Behçet and Takayasu 
disease), and (inherited) connective tissue disorders (Ehlers-Danlos type IV, Marfan 
Syndrome).12,13  
 
Figure 1a. Specific causes of abdominal aortic aneurysm  
 
However, most AAA are called non-specific, as no direct pathogenic mechanism can 
be identified (Figure 1b). In these patients connective tissue alterations in the 
arterial wall are a result of endothelial injury with subsequent atherosclerotic 
plaque formation and inflammation.  
 
Figure 1b. Schematic representation of the risk factors and pathogenic mechanisms and the interactions in 
the development of non-specific Aortic Aneurysms 
 
Hypercholesterolemia has an important role in this multifactorial process and the 
pathogenic aspects will be discussed in the next paragraph. 
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PATHOPHYSIOLOGY 
 
Atherosclerosis and hypercholesterolemia 
The development of atherosclerosis in patients with cardiovascular disease is a 
multifactorial process in which a clear association between elevated serum 
cholesterol levels and atherosclerotic disease is present.8 Additionally, large clinical 
trials have demonstrated that statins decrease the incidence of coronary heart 
disease in patients with hypercholesterolemia and atherosclerosis.6,9 As serum 
cholesterol levels are strongly associated with coronary atherosclerotic disease, it 
has been generally assumed that cholesterol reduction by statins is the 
predominant, if not the only, mechanism underlying their beneficial effects in 
cardiovascular diseases. However, subgroup analyses of large clinical trials like the 
West of Scotland Coronary Prevention (WOSCOP) and the Cholesterol and 
Recurrent Events (CARE) studies, indicates that despite comparable serum 
cholesterol levels among statin-treated and placebo groups, individuals treated with 
statins have a significantly lower risk of coronary heart disease compared to age-
matched placebo-controlled patients.7,9 These findings suggest that statins have 
beneficial effects beyond lowering of serum cholesterol levels.  
 
In addition, angiographic trials have demonstrated clinical improvements 
with statins that far exceed changes in the size of atherosclerotic lesions.14,15 
Therefore, it is believed that some other actions of statins, especially improvement 
of endothelial function, may have contributed to these additional benefits.16 These 
additional beneficial effects of statins are called pleiotropic effects.16 
 
Atherosclerosis and pleiotropic effects of statins 
The 3-hydroxy-3-methylglutaryl coenzyme A inhibitors or statins inhibit the 
synthesis of 1-mevalonic acid; thereby preventing the synthesis of other important 
isoprenoid intermediates of the cholesterol biosynthetic pathway was well.17 These 
intermediates serve as important lipid attachments for the posttranslational 
modification of a variety of intracellular signalling proteins, especially Ras and Rho 
proteins. Ras and Rho proteins are small Guanosine Triphosphate (GTP)-binding 
proteins that are crucial in a variety of cellular events, including cytoskeleton 
organization, membrane trafficking, secretion, transcriptional regulation, and 
growth control and development.10,11 These cellular events have effects on several 
components of the arterial wall, including endothelial cells, smooth muscle cells 
(SMC), platelets, monocytes/macorphages and the process of inflammation.10,11 As 
these are important aspects of aneurismal degeneration, it has been postulated 
that statin treatment might also have an impact on the development and 
progression of AAA.  
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Statins and endothelial function 
The vascular endothelium serves as an important autocrine and paracrine organ 
that has a regulatory function for the vascular wall contractile state and cellular 
composition. Endothelial dysfunction is one of the earliest manifestations of 
atherosclerosis, that occurs without the presence of angiographic evidence of 
disease.18 The most important effect of endothelial dysfunction is the impaired 
synthesis, release and activity of endothelium-derived Nitric Oxide (NO). 
Endothelium-derived NO mediates vascular relaxation, platelet aggregation, 
vascular smooth muscle cell proliferation, and endothelium-leukocyte interactions, 
thereby inhibiting the atherosclerotic process.19,20 Endothelium-dependent 
vasodilatation is improved by acute plasma LDL lowering, suggesting that statins 
could restore endothelial function, at least in part by lowering serum cholesterol 
levels.  
 
Statins increase bioavailability of NO by stimulating and upregulating 
endothelial NO-synthase (eNOS).21 Furthermore, statins exert many additional 
favourable effects on the endothelium, like increased expression of tissue-type 
plasminogen activator and inhibit the expression of endothelin-1, a potent 
vasoconstrictor.22 These effects of statins may attenuate endothelial dysfunction in 
the presence of atherosclerotic risk factors. The antioxidant effects of statins may 
be another mechanism by which statins may improve endothelial function. Statins 
enhance endothelium-dependent relaxation by inhibiting the production of reactive 
oxygen species (ROS).23  
 
Statins and smooth muscle cell proliferation 
Smooth muscle cell (SMC) proliferation is a central event in the pathogenesis of 
vascular lesions. It is suggested that statins inhibit SMC proliferation by arresting 
the cell cycle.24 Studies showed that inhibition of isoprenoid syntheses, but not 
cholesterol syntheses, by statins decreased platelet-derived growth factor-induced 
DNA synthesis in SMCs.24,25 Furthermore, it was indicated that inhibition of Rho 
proteins by statins is the predominant mechanism by which statins inhibit SMC 
proliferation.25  
 
Statins and platelets functions 
Hypercholesterolemia is associated with increased platelet reactivity, most 
presumably to increases in the cholesterol/phospholipids ratio in platelets and 
increased thromboxane A2 biosynthesis.26 As statins have been shown to inhibit 
platelet function, this is potentially derived by a reduction in thromboxane A2 
production and modifications in the cholesterol content of platelet membranes.27 
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Statins and plaque stability 
Atherosclerotic lesions contain a highly thrombogenic lipid core that is separated 
from the blood stream by a fibrous collagen cap. Plaque rupture and ensuing 
thrombosis results from fissuring, erosion, and ulceration of the fibrous cap.28 In 
AAA, most patients have an associated thrombus as well. Due to a maintained 
blood flow, there is a persistent remodelling of the thrombus components. An 
increasing thickness of the thrombus leads to local hypoxia at the inner layer of the 
media, resulting in increased medial neovascularization and inflammatory cells. 
The collagen layer in the fibrous cap provides the strength and the stability of the 
plaque. However, as macrophages are capable of degrading the collagen-containing 
fibrous cap, they play an important role in the development and subsequent 
instability of atherosclerotic plaques.29 Activated macrophages release proteolytic 
enzymes, such as matrix metalloproteinases (MMPs), which weaken the fibrous 
cap, leading to plaque instability and rupture with thrombosis. The main action of 
statins on contributing to plaque stability seems not to be the lipid lowering effects, 
but rather the inhibiting effects on macrophage accumulation and subsequent 
reduction in MMP secretion.30  
 
Statins and vascular inflammation      
The presence of monocytes or macrophages and T-lymphocytes in the 
atherosclerotic plaques characterizes the complex inflammatory processes in 
atherosclerosis. Endothelial function, SMC proliferation, collagen degradation, and 
thrombosis are all modified by the inflammatory cytokines that are released by 
macrophages and T-lymphocytes.31 A recent study suggested that statins possess 
anti-inflammatory properties by their ability to reduce the number of inflammatory 
cells in atherosclerotic plaques.27 An important clinical marker of low-grade 
systemic inflammation is high-sensitive C-reactive protein (hs-CRP), which is an 
acute-phase reactant produced by the liver in response to pro-inflammatory 
cytokines, such as Interleuking-6.32 Elevated hs-CRP levels are present in patients 
with coronary artery disease, coronary ischemia, and myocardial infarction and 
have been shown to be associated with an increased risk of coronary artery disease 
in apparently healthy men and women.33 Furthermore, the CARE trial showed that 
statins significantly decreased plasma hs-CRP levels over a 5-year period in 
patients who did not experience recurrent coronary events.34 The JUPITER trial 
study group investigated the effect of statin therapy on lowering LDL-cholesterol 
and hs-CRP.35 Treatment with rosuvastatin in initially healthy men and women 
resulted in a significant decrease in both LDL-cholesterol and hs-CRP. 
Furthermore, these effects resulted in a significant decrease in the risk of 
cardiovascular events during a 5-year follow-up period. These promising results 
 247 
need to be further studied in patients with aneurysmatic disease, before 
implementing them into the medical treatment of AAA.  
 
 
RISK FACTORS 
 
Risk factor patterns for the development of abdominal aortic aneurysms 
Risk factor patterns for the development of an AAA are well established and include 
(i) increasing age, (ii) male gender, (iii) genetic predisposition, (iv) diabetes mellitus, 
(v) hypertension, (vi) tobacco smoking, and (vii) dyslipidemia.36-38  
 
Age and male gender have been identified as non-modifiable risk factors for AAA in 
epidemiological screening studies.1,37 In the ADAM Program, a prevalence of 4.2% 
of AAA was observed in patients with a mean age of 66 years. A strong association 
between male gender, increasing age and the development of AAA was found. On 
the contrary, female gender showed a negative association with AAA.1 Familial 
screening studies for the detection of AAA have drawn attention to a possible 
genetic background of the disorder. One multinational study, including 653 
affected members, observed an autosomal recessive inheritance mode in 72% of the 
families and autosomal dominant in 25%.39 Ongoing multi-center studies are 
generating data, as some small previous studies have identified several candidate 
genes, without establishing a genetic profile.40 Diabetes mellitus (DM) is an 
established risk factor for the atherosclerotic process.41 However, several large 
registries observed a negative association between diabetes and the development of 
AAA.37,42 The effect of diabetes on the vessel wall mainly includes increasing 
stiffness, especially in the medial layers of the peripheral arteries. Although it was 
previously proposed that increasing stiffness could stabilize the aorta and resist 
aneurismatic dilatation, others found increased aortic wall stiffness in AAA as 
well.43,44 This discrepancy could possibly be explained by a difference in AAA wall 
constitution between diabetic and non-diabetic individuals. 
 
Hypertension results in an increased shear stress on the arterial wall with 
a subsequent production of radical oxygen species by smooth muscle cells.45 These 
effects have a leading role in the atherosclerotic process and could play an 
important role in the pathogenesis of AAA as well. Hypertension is suspected to 
have a detrimental effect on AAA development, growth rate and risk of rupture. The 
ADAM Program observed an odds ratio of 1.23 (95% CI: 1.14 to 1.32) for the 
presence of hypertension and the risk of AAA development.1 The REACH registry 
emphasized the use of blood pressure lowering therapy to decrease growth rate and 
rupture risk, as they showed an increased mortality in patients with AAA and 
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current high blood pressure, compared to AAA patients with normalized blood 
pressure.42 More recent studies indicated that hypertension is a moderate predictor 
for AAA development, but an important risk factor for AAA expansion and rupture.3 
Smoking leads to endothelial dysfunction, with a subsequent inflammatory process 
and plaque formation. Additionally, vascular disease is promoted as smoking also 
influences (i) hemodynamic stress, (ii) oxidant injury, (iii) disturbed lipid profiles, 
(iv) enhanced thrombosis, and (v) increased blood velocity. Several large studies 
and registries have identified tobacco smoking as the most important variable 
associated with an increased risk of AAA development.1,13,42,43   
 
High levels of serum cholesterol, LDL-cholesterol and low HDL-cholesterol 
have an established role in the pathogenesis of atherosclerosis. However, in AAA 
patients there are conflicting results about the presence of dyslipidemia as a risk 
factor for AAA development, expansion rate and risk of rupture. In a small case-
control study, Hobbs et al. demonstrated that patients, who developed a small AAA, 
had significantly higher LDL cholesterol levels (OR 1.30, 95% CI: 1.02 to 1.65), 
compared to patients that did not developed AAA.46 In contrast, Blanchard et al. 
observed no differences in serum total cholesterol, LDL cholesterol or triglycerides 
between AAA patients and matched controls (OR 0.84, 95% CI: 0.56 to 1.25).47 
 
Figure 2. Predictive value of high serum cholesterol for the development of new abdominal aortic aneurysm 
in population-based studies 
 
In addition to these case-control studies, several large population-based 
studies have been performed during the last two decades. (Table 1 and Figure 
2)2,4,37,48-53 All included studies investigated the incidence of AAA in several cohorts 
of patients with varying age and distribution of gender. The incidence of newly 
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developed AAA ranged between 0.4 and 14.4%, depending on the study population. 
Reed et al. were the first who described a large cohort of Japanese men (7.862 
individuals), in which they observed an incidence of 1.9% of new AAAs.4 High total 
serum cholesterol was an independent risk factor for the development of an AAA in 
this cohort (OR 2.32, 95% CI: 1.62 to 7.04). The majority of the population-based 
studies summarized in Table 1 found high serum total cholesterol to be a predictor 
for the development of AAA. (Figure 2) Additionally, three studies observed that 
high serum HDL cholesterol has a protective effect on the development of new 
AAAs.2,48,49 Elevated triglycerides were measured in 4 studies, but only 1 of these 
observed a positive association between the presence of high triglycerides and the 
development of AAA (OR 1.9, 95% CI: 1.2 to 3.1).2,4,51,52 Noteworthy, this study had 
the smallest study population of all included population-based studies.52 One 
study observed no association between the presence of dsylipidemia and AAA 
development at all.54  
 
Table 1  
Year Patients Age AAA Odds Ratios [95%CI] 
 
 [N] [yr] [%] Total Chol High HDL High TGL 
Reed et al. 1992 7.862 >45 1.9 
2.3 
[1.6-7.0] 
n.a. 1.1 
[0.9-1.4] 
Pleumeekers et al. 1995 5.419 >55 2.1 
6.6 vs 6.3 
P=0.04 
n.a. n.a. 
Simoni et al. 1995 1.601 >65 4.3 
1.2 
[0.7-2.1] 
n.a. n.a. 
Alcorn et al. 1996 4.741 >65 9.5 
n.a. 0.5 
[0.4-0.6] 
n.a. 
Lederle et al. 1997 73.451 >50 4.6 
1.3 
[1.2-1.5] 
n.a. n.a. 
Singh et al. 2001 6.386 >50 5.3 
1.2 
[1.0-1.4] 
0.6 
[0.5-0.8] 
0.96 
[0.8-1.1] 
Tornwall et al. 2001 29.133 >50 0.6 
1.2 
[0.7-2.1] 
0.4 
[0.3-0.6] 
n.a. 
Rodin et al. 2003 19.274 >40 2.2 
1.4 
[1.2-1.4] 
n.a. n.a. 
Lindblad et al 2005 33.426 >40 0.4 
1.5 
[1.1-2.0] 
n.a. 1.3 
[0.9-1.8] 
Wanhainen et al. 2005 504 >60 14.4 
1.9 
[1.3-2.8] 
n.a. 1.9 
[1.2-3.1] 
Iribarren et al. 2007 104.813 >18 0.6 
1.8 
[1.4-2.4] 
n.a. n.a. 
Description of the included population-based studies demonstrating the relation between 
hypercholesterolemia and the risk of AAA development. AAA; abdominal aortic aneurysm, n.a.; not available 
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Statins and aneurysm expansion rate 
Abdominal aortic aneurysm is a vascular inflammatory degenerative disease. The 
aneurysmatic wall is characterized by the presence of inflammatory cells that 
produce MMPs that probably contribute to elastolysis and remodeling of the 
aneurysm. In human aneurysmatic aortic wall specimens, MMP-9 has been 
demonstrated to be most abundant and plasma MMP-9 levels are elevated in 
patients with AAA.55 Several of the studies described above, have observed an 
association between the presence of AAA and total cholesterol. However, there is no 
clear relationship between total cholesterol and AAA expansion rate. Despite this 
absence of an association between cholesterol and growth rate, there is evidence 
from a number of studies to suggest that statins may influence aneurysm growth 
rate, presumably by pleiotropic effects. (Table 2) Several studies have been 
performed to identify risk factors that were associated with aneurysmal growth on 
the level of the human aorta itself using cell cultures obtained by aortic wall 
biopsies (Table 2). Important aspects in these studies were inflammation markers 
such as Interleukin-6, and specific MMPs such as MMP-9,56,57 as these induce 
collagen and elastin degradation of the aortic wall.58 Importantly, drugs with anti-
inflammatory action such as prostaglandin synthetase inhibitors reduce the 
inflammatory response and are associated, in a case-control study with human 
subjects, with a reduced aneurysm growth rate.59 Statins are known to be highly 
effective drugs for reducing LDL-cholesterol levels. Additionally, recent studies 
suggested the influence of the pleiotropic effects of statins on the inflammatory 
status of the aneurysmatic aortic wall.60 Statins may alter the inflammatory status, 
e.g. a reduction of Interleukin-6 release, and may modulate the release of several 
substances in the arterial wall, of which MMPs are most important.   
 
In vitro studies 
Several in vitro studies have been performed in animal and human arterial wall 
tissues to demonstrate the ability of statins to suppress the expression of various 
inflammatory molecules, including MMPs (Table 2).30,61-68 Ejiri et al. demonstrated 
that human thoracical aneurysmatic tissue had increased levels of ROS.69 In 
patients with aneurysmatic aortic wall dilatation, elevated MMP-9 levels especially 
presented the inflammatory activity. Therefore, most in vitro studies are directed at 
influencing the production and release of MMPs in the arterial wall and serum. 
Table 2 summarizes all in vitro studies performed to study the influence of statins 
on MMP levels. Cerivastatin, an intravenous statin, was used in two studies and 
was associated with a suppression of MMP-9 levels and macrophages in the arterial 
wall. 
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In vivo studies 
In vivo studies have been performed in animals with elastase induced aneurysmatic 
disease, but also in human patients with AAA. Steinmetz et al. investigated the 
influence of simvastatin on elastase-induced AAA development in normal and 
hypercholesterolemic mice.70 They demonstrated that simvastatin suppresses 
experimental AAA development and diameter in both normal and 
hypercholesterolemic mice. The mechanisms of these effects were independent of 
lipid-lowering and include preservation of medial elastin and smooth muscle cells, 
as well as altered aortic wall expression of MMPs and their inhibitors.  
 
Table 2  
In vitro studies 
 Year Statin type Cell culture 
Effect on MMP-9 
activity 
 Bellosta et al. 1998 Fluvastatin 
Mouse macrophages 
Human macrophages 
Dose-dependent ↓ 40% 
Dose-dependent ↓ 45% 
 Ganne et al. 2000 Cerivastatin Human monocytes Dose-dependent ↓ 
 Wang et al. 2000 Lovastatin Human fibroblasts Dose-dependent ↓ 60% 
 Crisby et al. 2001 Pravastatin Human macrophages No ↓ 
 Aikawa et al. 2001 Cerivastatin Rabbit macrophages ↓ 40% 
 Wong et al. 2001 Simvastatin Human monocytes Dose-dependent ↓ 50% 
 Nagashima et al. 2002 Cerivastatin Human macrophages Dose-dependent ↓ 50% 
 Luan et al. 2003 
Cerivastatin 
Simvastatin 
Lovastatin 
Rabbit macrophages 
Dose-dependent ↓ 34% 
Dose-dependent ↓ 32% 
Dose-dependent ↓ 31% 
Animal studies 
 Year Statin type Subjects Outcome vs controls 
 Steinmetz et al. 2005 Simvastatin 
Normal mice [n=35] 
 
Hypercholesterol mice 
[n=53] 
AAA development ↓ 33% 
Aortic diameter ↓ 21% 
AAA development ↓ 30% 
Aortic diameter ↓ 26% 
 Kalyanasundarm  2006 Simvastatin 
Statin rats [n=17] 
Placebo rats [n=17] 
Mean AAA diameter 3.4 
vs 4.3, p<0.001 
Human studies 
 Schouten et al. 2006 
Simvastatin 
Fluvastatin 
59 statin users 
91 controls 
Mean AAA grow rate: 
statin -1.16 [-0.3 to -2.0] 
 Sukhija et al. 2006 
Atorvastatin 
Simvastatin 
75 statin users 
 
55 controls 
Statin users: no change 
in AAA diameter 
No statin: significant 
increase in AAA diameter 
 Evans et al. 2007 Simvastatin 
10 statin 
11 placebo 
Statin user: 40 ↓ in MMP-
9 activity 
 
Schlosser et al. 
(SMART study) 
2008 n.a. 
63 statin 
84 controls 
Mean AAA grow rate: 
Statin -1.2 [-2.3 to -0.1] 
 Mosorin et al. 2008 n.a. 
34 statin 
87 controls 
 
Statin: 1.9±1.8 mm/yr 
Control: 2.6±2.4 mm/yr 
P=0.27 
MMP-9; matrix metalloproteinase-9, AAA; abdominal aortic aneurysm, n.a.; not available 
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Kalyanasundaram et al. confirmed these results by demonstrating that simvastatin 
suppressed aneurysm expansion and reduced protein levels of MMP-9.71 Gene 
array analysis of this study provided evidence that several mediators of 
inflammation, matrix remodeling, and oxidative stress are down regulated by 
simvastatin treatment.      
 
Schouten et al. were the first who performed a retrospective clinical study 
in human subjects with AAA to investigate the effect of statins on aneurysmatic 
growth rate.72 In a population of 150 patients with known AAA who did not require 
surgical intervention, 40% of the patients used statins during a median follow-up 
period of 3.1 years. The overall aneurysm growth rate in the total study population 
was 2.59 ± 2.8 mm/year. Patients treated with statins during the follow-up period 
had a 1.16 mm/year lower growth rate compared to patients without statin therapy 
(95% CI 0.33 to 1.99). They concluded that statins appear to be associated with 
attenuation of AAA growth rate, irrespective of other known factors influencing 
aneurysm growth.72 Sukhija et al. also performed a clinical study on the influence 
of statins on aneurysm growth rate.73 They demonstrated that patients with statin 
therapy had no change in aortic wall diameters during 24 months of follow-up, 
while patients without statins had a significant increase in aneurysms size 
compared to baseline. Mosorin et al. observed no influence of statin therapy on AAA 
growth rate in a retrospective cohort study including 131 patients.74 Statin users 
had a lower AAA growth rate compared to control patients, however, this was not 
statistically significant (1.9 ± 1.8 mm/yr vs 2.6 ± 2.4 mm/yr, p = 0.27).   
 
Although these associative data are intriguing, there are potential biases in 
these uncontrolled retrospective observational studies. The Second Manifestations 
of ARTerial disease (SMART) study group prospectively studied the influence of 
statin therapy on aneurysm growth rate in 147 patients with known AAA.75 Statin 
users had a significantly decreased (-1.2 mm/yr, 95% CI: –2.34 to –0.06) aneurysm 
growth rate compared to patients without statin therapy. This study demonstrated 
that lipid-lowering drug treatment was independently associated with lower AAA 
growth rates. In addition, the risk of rupture in these patients was low, which 
pleads for watchful waiting.  
 
Due to the high prevalence of concomitant cardiovascular and peripheral 
arterial disease in AAA patients, current guidelines recommend statin therapy in 
those patients.76 Consequently, high prevalence of statin use among AAA patients 
will make it challenging to design trials to assess the specific role of statin therapy 
as an inhibitor of aneurysm expansion. At the present time the American College of 
Cardiology/American Heart Association guidelines provide a level B (small 
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randomized trials) and C evidence (case-series studies) to suggest that statins may 
inhibit aneurysm expansion.76    
 
 
CONCLUSION 
 
Analyses of large clinical trials have demonstrated that statin therapy has more 
effects than just lowering serum cholesterol levels. These additional benefits are 
called non-lipid lowering or pleiotropic effects and include a diversity of cellular 
events in the arterial wall. Hypercholesterolemia has been identified in the general 
population as an independent risk factor for the development of AAA. In vitro 
studies have clearly demonstrated the additional beneficial effects of statin therapy 
on the aneurysmatic arterial wall. Several clinical studies have reported beneficial 
effects of statin therapy in decreasing aneurysm growth rate and the subsequent 
risk of rupture. However, as these are small non-randomized trials, further large 
randomized controlled trials are required to establish the role of statin therapy as a 
preventive medical treatment possibility for AAA expansion and rupture.   
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ABSTRACT 
 
Background: Prophylactic coronary revascularization in vascular surgery patients 
with extensive coronary artery disease was not associated with an improved 
immediate postoperative outcome. However, the potential long-term benefit was 
unknown. This study was performed to assess the long-term benefit of prophylactic 
coronary revascularization in these patients.  
 
Methods: Of 1.880 patients scheduled for major vascular surgery, 430 had >3 risk 
factors (>70 yrs, angina pectoris, myocardial infarction, heart failure, stroke, 
diabetes mellitus, and renal failure). All underwent cardiac testing using 
dobutamine echocardiography or nuclear stress imaging. Patients with extensive 
stress-induced ischemia (≥5 segments or ≥3 walls) were randomly assigned to 
additional revascularization.  
 
Results: In total, 101 patients showed extensive ischemia and were assigned to 
revascularization (N=49) or no-revascularization (N=52). After 2.8 years, the overall 
survival was 64% for patients randomly assigned to no preoperative coronary 
revascularization versus 61% for patients assigned to preoperative coronary 
revascularization (HR 1.18, 95% CI: 0.63 to 2.19, p = 0.61). Rates for survival free 
of all-cause death, nonfatal myocardial infarction, and coronary revascularization 
were similar in both groups at 49 and 42% for patients allocated to medical 
treatment or coronary revascularization, respectively (HR 1.51, 95% CI: 0.89 to 
2.57, p = 0.13). Only two patients assigned to medical treatment required coronary 
revascularization during follow-up. Also, in patients who survived the first 30 days 
after surgery there was no apparent benefit of revascularization on cardiac events 
(HR 1.35, 95% CI: 0.72 to 2.52, p = 0.36).  
 
Conclusions: Preoperative coronary revascularization in high-risk patients 
undergoing major vascular surgery was not associated with an improved 
postoperative or long-term outcome compared with the best medical treatment. 
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INTRODUCTION 
 
According to the guidelines of the American College of Cardiology /American Heart 
Association, it is recommended to perform coronary angiography in patients with 
high-risk noninvasive test results. Subsequently, myocardial revascularization 
should be performed in patients with prognostic high-risk anatomy in whom long-
term outcome is likely to be improved.1 However in both the Coronary Artery 
Revascularization Prophylaxis (CARP) trial and Dutch Echocardiographic Cardiac 
Risk Evaluation Applying Stress Echocardiography (DECREASE) V trial, 
prophylactic preoperative coronary revascularization was not associated with 
improved immediate postoperative outcome.2,3 As recently shown, early surgery 
after coronary stent placement might lead to an increase in adverse cardiac events 
caused by in-stent thrombosis or bleeding complications.4 This might explain the 
lack of perioperative benefit. However, it was expected that at least long term 
outcome, such as after the potentially hazardous perioperative period, should be 
improved in these patients. Therefore, we analyzed the long-term outcome of the 
randomized DECREASE V trial to assess whether there was a long-term benefit of 
prophylactic coronary revascularization in high-risk patients undergoing major 
vascular surgery.  
 
 
METHODS 
 
The study design and the perioperative results of the original DECREASE V trial 
have been published previously.2 In brief, patients were considered eligible for the 
study if they were scheduled for elective open abdominal aortic or infrainguinal 
arterial reconstruction. Patients were screened for the prevalence of cardiac risk 
factors including age >70 years, angina pectoris, previous myocardial infarction, 
compensated congestive heart failure or history of congestive heart failure, drug 
therapy for diabetes mellitus, renal dysfunction (serum creatinine >160 µmol/L), 
and prior stroke or transient ischemic attack. All patients with ≥3 risk factors 
underwent cardiac stress testing prior to surgery. Those who experienced extensive 
stress-induced ischemia were enrolled in the DECREASE V trial. All patients 
provided informed consent, and the Erasmus MC (Rotterdam, The Netherlands) 
medical ethics committee and local research ethics committees approved the study. 
Out of 1.880 screened patients, 101 (5.3%) were considered eligible, had ≥3 risk 
factors, had extensive stress induced myocardial ischemia and were subsequently 
randomized. A total of 49 patients were allocated to best medical treatment and 
preoperative coronary revascularization and 52 patients to best medical treatment 
only.  
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Cardiac stress testing was performed using dobutamine echocardiography 
or dobutamine or dipyridamole perfusion scintigraphy, as previously described.5,6 
Test results were scored according to the extent of stress-induced ischemia using a 
17-segment model for dobutamine echocardiography and a 6-wall model for stress 
perfusion scintigraphy. Limited ischemia was defined by the presence of 1 to 4 
ischemic segments or 1 to 2 ischemic walls, whereas extensive ischemia was 
defined as ≥5 ischemic segments or ≥3 ischemic walls. 
 
All patients were monitored for cardiac events after screening. The 12-lead 
electrocardiogram and serum troponin-T level were systematically assessed 1, 3, 7, 
and 30 days after surgery. Outpatient follow-up was performed at 30 days if a 
patient had been discharged from the hospital. At the outpatient clinic, all patients 
were screened at 3-month intervals for cardiac events using clinical history and 12-
lead electrocardiogram and additional tests were performed when indicated by the 
treating physicians. For this report, outcomes were long-term all-cause death and a 
combined end-point of all-cause death, nonfatal myocardial infarction, and 
coronary revascularization during follow-up. 
 
Myocardial infarction was defined as the presence of two of the three 
criteria of (i) characteristic ischemic symptoms lasting >20 minutes; (ii) 
electrocardiographic changes, including acute ST elevation followed by the 
appearance of Q waves or loss of R waves; new left bundle branch block or new 
persistent T-wave inversion for ≥24 hours; or new ST segment depression that 
persisted >24 hours; and (iii) a positive troponin-T (i.e. >0.10 ng/ml) or peak 
creatinine kinase-MB >8% of increased total creatinine kinase with characteristic 
increase and decrease.  
 
Continuous data were presented as median and corresponding 25th and 
75th percentiles, whereas dichotomous data are presented as percentages. 
Differences in clinical and surgical characteristics between patients allocated to 
revascularization or no revascularization were evaluated by Wilcoxon's 
nonparametric tests, χ2 or Fisher's exact tests, as appropriate. The incidence of 
outcome events over time was examined by the Kaplan-Meier method. Multivariate 
(Cox) regression was used to compare differences in overall survival and cardiac 
event free survival between the allocated treatment strategies, adjusted for baseline 
clinical risk factors. Patients who had an event prior to surgery but after screening 
were included in the analyses as the day of screening was considered to be 
baseline. Analyses were performed according to the intention-to-treat principle. All 
statistical tests were 2 sided and a p < 0.05 was considered significant. 
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RESULTS 
 
Baseline variables in patients who underwent preoperative coronary 
revascularization (N=49) or best medical treatment only (N=52) are shown in Table 
1. In patients allocated to coronary revascularization, 32 underwent a 
percutaneous coronary intervention (PCI), with a bare-metal stent in two and drug-
eluting stent in 30. Patients continued with dual-antiplatelet therapy during 
surgery. After surgery, patients with bare-metal stents stopped dual-antiplatelet 
therapy after three months and continued with aspirin afterward. Patients with 
drug-eluting stent continued dual-antiplatelet therapy during follow-up. A bypass 
procedure was performed in 17 patients. The impact of drug-eluting stents versus 
bare-metal stents could not be assessed because of the number of patients 
included in the study.  
 
Table 1 Baseline characteristics 
 Revascularization  
 Yes (N=49) No (N=52) p-value 
Age (yrs) 71 (64,7) 70 (63,8)  
Men 42 (86%) 47 (90%) 0.55 
Diabetes Mellitus 18 (37%) 15 (29%) 0.53 
Current angina pectoris 25 (51%) 22 (42%) 0.43 
Previous myocardial infarction 49 (100%) 50 (96%) 0.50 
Previous heart failure 23 (47%) 24 (46%) 1.0 
Previous cerebrovascular accident 20 (41%) 13 (25%) 0.14 
Previous renal failure 9 (18%) 11 (21%) 0.81 
Medication    
 Aspirin 37 (76%) 30 (58%) 0.09 
 ß-blocker 34 (70%) 36 (69%) 1.0 
 ACE - inhibitor 28 (57%) 22 (42%) 0.17 
 Statin 34 (69%) 30 (58%) 0.30 
Coronary artery narrowed >50%    
 Right coronary 39 (80%) –  
 Left artery descending 46 (94%) –  
 Left circumflex 37 (76%) –  
No. of narrowed arteries    
 1 0 –  
 2 12 (24%) –  
 3 33 (67%) –  
 Left main 4 (8%) –  
 
The 30-day outcome of the study population has been described in detail 
previously.2 Two patients died prior to vascular surgery because of a ruptured 
aneurysm after successful bypass surgery and 1 patient experienced myocardial 
infarction after unsuccessful coronary revascularization. Revascularization did not 
improve 30-day outcome after vascular surgery. The incidence of all-cause death or 
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non-fatal myocardial infarction for patients with preoperative revascularization or 
medical treatment only was 43 vs. 33% respectively (hazard ratio [HR] 1.4, 95% 
confidence interval [CI]: 0.7 to 2.8 p = 0.30).  
 
During a median follow-up of 2.8 years (interquartile range 0.9 to 4.2 
years) 42 of 101 patients died. After 2.8 years, the overall survival rate was 64% for 
patients randomly assigned to no preoperative coronary revascularization versus 
61% for patients assigned to preoperative coronary revascularization (HR 1.18, 95% 
CI: 0.63 to 2.19, p = 0.61; Figure 1). As shown in Figure 2, the incidence of all-
cause death, nonfatal myocardial infarction, and coronary revascularization was 
similar in both groups. Event-free survival after 2.8 years were 49% and 42% for 
patients allocated to medical treatment or coronary revascularization, respectively 
(HR 1.51, 95% CI: 0.89 to 2.57, p = 0.14). In the no-revascularization group, two 
patients (4%) underwent coronary revascularization during follow-up; one patient 
underwent coronary artery bypass surgery 12 months after vascular surgery 
because of unstable angina pectoris, and one patient underwent PCI using drug-
eluting stents 27 months after vascular surgery because of progressive angina 
pectoris symptoms.  
 
Figure 1. Overall survival   Figure 2. Cardiac event-free survival  
 
 
It might be argued that preoperative coronary revascularization, in 
particular, stent placement, might lead to an increased 30-day risk for in-stent 
thrombosis or bleeding after discontinuation or continuation of antiplatelet 
therapy.4 Therefore, we performed a separate analysis including only patients who 
survived ≥30 days after surgery (N=36 and N=46 for revascularization and medical 
treatment only, respectively). As shown in Figures 3 and 4, in these survivors, no 
apparent benefit of revascularization was observed. Of patients who underwent 
revascularization, 47% had an event within a median of 2.8 years of follow-up 
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versus 44% in those who did not undergo preoperative coronary revascularization 
(HR 1.35, 95% CI: 0.72 to 2.52, p = 0.36). In addition, all-cause mortality did not 
differ between groups (HR 0.79, 95% CI: 0.35 to 1.78, p = 0.57).  
 
Figure 3. Overall survival >30 days  Figure 4. Event-free survival >30 days 
 
 
There was no difference in long-term event free survival between patients 
who underwent preoperative PCI or coronary artery bypass grafting (HR 0.91, 95% 
CI: 0.44 to 1.88, p = 0.80). After a median of 2.8 years, event-free survival was 41% 
versus 44% for PCI and coronary artery bypass grafting, respectively. In addition, 
for the endpoint of all-cause death, no significant difference was observed (HR 0.81, 
95% CI: 0.33 to 1.96, p = 0.64). However, patients with an incomplete 
revascularization procedure had the worst outcome; six of seven (86%) patients 
died within two years after the attempted revascularization compared with 13 of 42 
(31%) with complete revascularization (HR 4.07, 95% CI: 1.53 to 10.82, p = 0.005, 
Figure 5).   
 
Figure 5. Cardiac event-free survival after successful or not successful preoperative revascularization 
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DISCUSSION 
 
The DECREASE-V study did not show a long-term benefit of prophylactic 
preoperative coronary revascularization in stable patients with multiple cardiac risk 
factors and extensive stress-induced myocardial ischemia scheduled for major 
vascular surgery.  
 
The current findings were in line with results of large randomized trials in 
the nonsurgical population. Patients with stable multivessel coronary artery 
disease did not have better survival after coronary stent placement or bypass 
grafting compared with medical treatment only. The recent published Medicine, 
Angioplasty, or Surgery Study (MASS II) was the first randomized controlled clinical 
trial to report 5-year outcomes of nonsurgical patients with stable multivessel 
coronary artery disease treated with either bare-metal stent placement, coronary 
artery bypass grafting, or best medical treatment only.7 That study showed that 
optimal medical therapy in patients with stable multivessel coronary artery disease 
resulted in similar long-term outcomes in terms of cardiac-related death or all-
cause mortality. The investigators concluded that “patients with mild to moderate 
angina can be safely managed medically, whereas PCI or [coronary artery bypass 
grafting] CABG is appropriate if symptoms are not adequately controlled by 
medication or other high-risk features are apparent.”7 The Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial also 
found no additional benefit of coronary revascularization in addition to optimal 
medical therapy in 2.287 patients with objective evidence of myocardial ischemia 
and significant coronary artery disease.8 During a median follow-up of 4.6 years, 
cumulative event rate of all-cause death and myocardial infarction were 19.0 in the 
PCI group and 18.5% in the medical-therapy group. As discussed by the COURAGE 
trialists, these findings may be explained by differences in atherosclerotic plaque 
morphologic characteristics and vascular remodeling associated with acute 
coronary syndromes compared with stable coronary artery disease. Medical 
treatment in both MASS II and COURAGE included rigorous statin and aspirin 
therapy. This might have prevented vulnerable plaques, which are usually difficult 
to detect and impossible to treat using coronary angioplasty or bypass, to rupture 
and cause acute coronary syndromes. It is important to realize that vulnerable 
coronary lesions are not necessarily severely stenotic, and severely stenotic lesions 
are not necessarily unstable. Focal management of severely stenotic coronary 
lesions using PCI in both MASS II and COURAGE did not reduce the rate of death 
and myocardial infarction, presumably because the treated, severely stenotic 
lesions were not likely to trigger an acute coronary event.8  
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Remarkably, in MASS II and COURAGE, annual mortality rates were 
approximately 1 to 2% whereas in CARP and DECREASE V the annual mortality 
rates in patients who survived surgery were 6.8 and 8.2%, respectively. Baseline 
angiographic cardiac status in MASS II and COURAGE was not significantly better 
or worse than in CARP and DECREASE V: 3-vessel disease was present in 58 and 
31% versus 33 and 75%, respectively. In line with these findings, it was recently 
shown that patients with so-called “polyvascular” disease, i.e. multiple vascular 
beds affected, have a significant worse outcome compared to patients with coronary 
artery disease only.9 In Reduction of Atherothrombosis for Continued Health 
(REACH), event rates (cardiovascular death, MI, stroke, or hospitalization for a 
cardiovascular event) increased with the number of symptomatic vascular beds: 
5.3% of patients with risk factors only to 12.6% with one, 21.1 with two, and 26.3% 
with three disease locations.9 Because all patients in DECREASE V and CARP had 
proven coronary artery disease and were planned for noncardiac vascular surgery, 
these patients can be considered to have polyvascular disease. This indicated that 
patients scheduled for vascular surgery with extensive coronary artery disease 
should be considered to be a different population than patients without peripheral 
arterial disease, but with coronary artery disease only. However, also in this patient 
population with stable severe coronary artery disease, optimal medical therapy 
seems to be equal to coronary revascularization in addition to best medical 
treatment. 
 
The findings of both CARP and DECREASE V support the current 
guidelines of the American College of Cardiology/American Heart Association for 
perioperative management in high-risk patients to reserve revascularization for 
cardiac unstable patients. Considering the high long-term mortality and cardiac 
event rates, these patients should be regularly screened for the presence of 
ischemic symptoms, and aggressive anti-ischemic medical therapy must be used.  
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ABSTRACT 
 
Background: The current guidelines have recommended postponing noncardiac 
surgery (NCS) for ≥6 weeks after bare metal stent (BMS) placement and 1 year after 
drug-eluting stent (DES) placement. However, much debate has ensued about 
these intervals. The aim of the present study was to assess the influence of 
different intervals between stenting and NCS and the use of dual antiplatelet 
therapy on the occurrence of perioperative major adverse cardiac events (MACEs).  
 
Methods: We identified 550 patients (376 with a DES and 174 with a BMS) by 
cross-matching the Erasmus Medical Center percutaneous coronary intervention 
(PCI) database with the NCS database. The following intervals between PCI-BMS 
(<30 days, <3 months, >3 months) or PCI-DES (<30 days, <3 months, 3-6 months, 
6-12 months and >12 months) and NCS were studied. MACEs included death, 
myocardial infarction and repeated revascularization.  
 
Results: In the PCI-BMS group, the rates of MACEs during the intervals of <30, 30 
days–3 months, and >3 months was 50, 14, and 4%, respectively (overall p < 
0.001). In the PCI-DES group, the rate of MACE changed significantly with the 
interval after PCI (35, 13, 15, 6, and 9% for patients undergoing NCS <30 days, 30 
days to 3 months, 3 to 6 months, 6 to 12 months, and >12 months after PCI-DES 
respectively, overall p < 0.001). Of the patients who experienced a MACE, 45 and 
55% were receiving single and dual antiplatelet therapy at NCS, respectively (p = 
0.92). The risk of severe bleeding in patients with single and dual therapy at NCS 
was 4 and 21%, respectively (p < 0.001). 
 
Conclusions: We found an inverse relation between the interval from PCI to NCS 
and perioperative MACEs. Continuation of dual antiplatelet therapy until NCS did 
not provide complete protection against MACEs. 
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INTRODUCTION 
 
Approximately 5% of patients who undergo coronary stenting require some form of 
noncardiac surgery (NCS) within one year.1 Surgery increases the risk of 
thrombosis owing to a perioperative stress response; including sympathetic 
activation promoting reduced fibrinolytic activity, platelet activation, and 
hypercoagulability. In addition, dual antiplatelet therapy is often interrupted 
because of the fear of excessive perioperative bleeding complications. The 
prevention of cardiac complications versus the risk of severe bleeding creates a 
double-edged sword on the timing of surgery and the antiplatelet regimen. The 
current guidelines from the American College of Cardiology/American Heart 
Association (ACC/AHA) have recommend delaying NCS for ≥6 weeks after PCI with 
a bare metal stent (BMS) and ≥1 year after PCI with a drug-eluting stent (DES).2,3 
However, in a recent large study including patients with DES placement these 
recommendations could not be confirmed.4 Therefore, the aim of the present study 
was to assess the relation among the interval to NCS after PCI, medical therapy 
and the occurrence of perioperative major adverse cardiovascular events (MACEs).     
 
 
METHODS 
 
The present study included 1.000 patients who had undergone cardiac surgery or 
NCS after successful PCI because of severe ischemia between January 2000 and 
December 2007. The final study population included 550 patients who had 
undergone NCS. The patients were identified by cross matching the Erasmus 
Medical Centre PCI database with the NCS database (including 78.000 procedures). 
The PCI database is a prospectively maintained registry of 13.000 procedures 
performed from January 2000 to December 2007.5  
 
All patients underwent PCI using either a BMS (2000 to March 2002) or 
DES (april 2002 to 2007; sirolimus or paclitaxel). The patient characteristics were 
prospectively collected directly after the PCI procedure and included the PCI-
indication, number of affected and stented coronary arteries, left ventricular 
ejection fraction, and medication use during and after PCI. Patients with a BMS 
were prescribed lifelong aspirin and clopidogrel (loading dose 300mg, followed by 
75mg daily) for ≥30 days. Patients with a DES usually were prescribed lifelong 
aspirin and clopidogrel for ≥3 months (sirolimus) to 6 months (paclitaxel), or longer, 
at the discretion of the treating physician. The treating physician determined the 
type of used stent at the PCI procedure.        
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All data on the surgical procedure were retrospectively collected by 
screening the medical charts. The type of surgery was classified and categorized 
according to the surgical risk, determined using the ACC/AHA classification.6 In 
addition, cardiac history and cardiac risk factors were assessed at stenting and 
surgery. Medication use was assessed during the initial PCI procedures and was 
updated at the point of surgery. The use of proton pump inhibitors concomitantly 
with clopidogrel was also noted. No standard protocol for perioperative antiplatelet 
therapy was used in the present study population, becuse this was an 
observational study and the surgical procedures included all types of NCS. 
Consequently, some patients received aspirin and/or clopidogrel throughout the 
surgical procedure, but for other patients, aspirin and/or clopidogrel were 
discontinued five to ten days before surgery. All medical records were reviewed to 
categorize the maintenance of antiplatelet therapy (i.e. no therapy, aspirin, 
clopidogrel or dual antiplatelet therapy) in the period before NCS as discontinued 
>30 days, discontinued 7 to 30 days, or continued to within <7 days before NCS. 
 
The perioperative complications were defined as the occurrence of MACEs 
(i.e. death, myocardial infarction [either ST-elevation or non-ST-elevation 
myocardial infarction], stent thrombosis, repeated revascularization) within 30 days 
after NCS. Perioperative myocardial infarction was defined according to the 
European Society of Cardiology/ACC criteria.7 Bleeding complications were 
categorized as life-threatening or moderate bleedings, during the first 30 
postoperative days. Life-threatening bleeding was defined as fatal bleeding, 
intracranial bleeding, or bleeding requiring surgical intervention or transfusion of 
≥4 U of blood or blood products. Moderate bleeding was defined as bleeding 
requiring transfusion of 1 to 3 U of blood or blood products.8 
 
Statistical analyses were performed using the Statistical Package for Social 
Sciences, version 15.0 (SPSS, Chicago, Illinois). Continuous data were compared 
using Student’s t test and are expressed as mean ± SD. Categorical data are 
presented as percentages, and differences between proportions were compared 
using the χ2 test. To assess whether the risk of the occurrence of MACEs after NCS 
was associated with the interval from PCI to NCS, the interval from PCI to NCS was 
assessed as a categorical variable. Determined by the current guidelines and 
recommendations, the intervals used for patients with a BMS were <30days, <3 
months, and >3 months and for a DES were <30 days, 30 days to 3 months, 3 to 6 
months, 6 to 12 months, and >12 months.3,4,9 Logistic regression analyses were 
used to calculate the association between the intervals from PCI to NCS and 
MACEs. Logistic regression analyses were also used to determine possible 
associations between the presence of cardiac risk factors and the development of 
 273 
MACEs. Adjustments were made for age, gender, and all baseline cardiac risk 
factors (history of myocardial infarction, PCI/coronary artery bypass grafting, 
congestive heart failure, renal dysfunction, smoking, hypertension, diabetes 
mellitus, hypercholesterolemia, positive family history of cardiovascular (CV) 
disease), vessel/stent-diameter, lesion length and use of proton pump inhibitors 
during clopidogrel treatment. In all analyses, two-tailed tests were performed, and 
statistical significance was inferred at p < 0.05.   
 
 
RESULTS 
 
A total of 1.000 PCI procedures with stent placement followed by a surgical 
procedure were identified. NCS was performed in 550 patients either after PCI-BMS 
(N=174) or PCI-DES (N=376). No difference was found in the cardiac history or type 
of indication for PCI between the patients undergoing PCI-BMS and PCI-DES (Table 
1). Most patients underwent intermediate to high-risk surgery; a trend was found 
for more emergency surgical procedures in patients with a DES (p = 0.054; Table 
2).   
 
The median interval between PCI–BMS and NCS was 3.6 years 
(interquartile range 1.8 to 5.4). Of the patients who underwent NCS after PCI-BMS, 
8 (5%) patients had NCS within 30 days, 7 (4%) between 30 days and 3 months, 
and 159 (91%) after 3 months. During the first 30 days after NCS, 11 patients (6%) 
with PCI-BMS experienced a MACE (10 cardiovascular death and 1 myocardial 
infarction). An inverse relation was found between the rate of postoperative MACEs 
and the interval to NCS after PCI-BMS. The rate of MACEs for intervals of <30, 30 
days to 3 months, and >3 months was 50, 14, and 4%, respectively (overall 
p<0.001; Figure 1 and Table 3). When NCS was postponed for ≥3 months after PCI 
with a BMS, the lowest risk of perioperative MACE was observed (Figure 1). 
  
Dual antiplatelet therapy was used in 100 and 75% of the patients who 
underwent NCS within 30 days or 30 days to 3 months after PCI-BMS, respectively. 
Overall, at NCS, 157 (91%) and 16 (9%) patients were receiving single and dual 
antiplatelet therapy, respectively. Of the patients who experienced a MACE, 5 (46%) 
and 6 (55%) had been receiving single or dual antiplatelet therapy at NCS (p = 
0.92). All patients who underwent NCS within 30 days after PCI-BMS and 
experienced a MACE were receiving dual antiplatelet therapy until NCS. Patients 
with concomitant use of proton pump inhibitors and clopidogrel at NCS seemed to 
have greater rates of MACE than patients without proton pump inhibitor use (46 vs 
20%); however, this was not statistically significance (p = 0.33). Of the patients 
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undergoing PCI-BMS, 81% had a large stent/vessel diameter (>3.0 mm) or a short 
lesion length (<25 mm). No association was found between the stent/vessel 
diameter or lesion length and the risk of MACEs in these patients. 
 
Table 1 Baseline characteristics 
 
Total 
[N=550] 
BMS 
[N=174 
DES 
[N=376] 
P- 
value 
Demographics 
Age (yrs), mean ± SD 62.6 61.2 63.3 0.04 
Male  74.9% 75.3% 74.7% 0.89 
Medical history 
Myocardial infarction  179 (33%) 56 (32%) 123 (33%) 0.77 
CABG 66 (12%) 23 (13%) 43 (12%) 0.61 
PCI 161 (30%) 52 (30%) 109 (30%) 0.95 
Risk factors 
Smoking     
 Current 253 (46%) 65 (37%) 188 (50%) <0.001 
 History 86 (16%) 10 (6%) 76 (20%) <0.001 
Hypertension 118 (22%) 39 (22%) 79 (21%) 0.71 
Diabetes Mellitus 119 (22%) 26 (15%) 93 (25%) 0.01 
Dyslipidemia 296 (54%) 81 (47%) 215 (57%) 0.02 
Renal failure 47 (9%) 7 (4%) 40 (11%) 0.01 
LVEF <50% 236 (44%) 170 (46%) 66 (38%) 0.07 
PCI indication: 0.31 
 Stable-Angina pectoris 245 (45%) 175 (47%) 70 (40%)  
 Instable-Angian pectors 174 (32%) 112 (30%) 62 (36%)  
 Acute myocardial infarction 131 (24%) 89 (24%) 42 (24%)  
Discharge medication 
Aspirin 503 (92%) 160 (92%) 343 (91%) 0.78 
Statin 318 (58%) 90 (52%) 228 (61%) 0.05 
ß-blocking agents 502 (91%) 158 (91%) 344 (92%) 0.79 
ACE-inhibitors 149 (27%) 40 (23%) 109 (29%) 0.14 
Diuretics 48 (9%) 10 (6%) 38 (10%) 0.09 
Calcium antagonists 182 (33%) 84 (48%) 98 (26%) <0.001 
Nitrates 56 (10%) 13 (8%) 43 (11%) 0.15 
Ticloxpidines 477 (87%) 151 (87%) 326 (87%) 0.98 
Clopidogrel use (mo)    <0.001 
 Median 3 2 6  
 Interquartile range 1-6 1-3 1-6  
Abbreviations: CABG; Coronary Artery Bypass Grafting, PCI; Percutaneous Coronary Intervention, LVEF; Left 
Ventricular Ejection Fraction, ACE: Angiotensin Converting Enzyme  
 
The median time between PCI–DES and NCS was 1.4 years (interquartile range 0.5 
to 2.6). NCS after PCI-DES was performed within 30 days, at 30 days to 3 months, 
3 to 6 months, 6 to 12 months, and >12 months in 45 (12%), 25 (6%), 27 (7%), 47 
(13%) and 232 (62%) patients, respectively. A total of 48 patients (13%) experienced 
a MACE within the first 30 postoperative days (36 [82%] cardiovascular death, 4 
[9%] noncardiovascular death, 2 [5%] myocardial infarction, 6 [14%] stent 
 275 
thrombosis). The MACE rate changed significantly with the interval after PCI-DES 
(35, 13, 15, 6, and 9% for patients undergoing NCS <30 days, 30 days to 3 months, 
3 to 6 months, 6 to 12 months, and >12 months after PCI-DES respectively; overall 
p < 0.001; Figure 1 and Table 3). In line with the ACC/AHA guidelines, NCS within 
one year after PCI-DES was associated with an increased rate of MACEs (18 vs 
10%, p = 0.015).  
 
Table 2 Surgical Group catergorized according to ACC/AHA classification 
 BMS (N=174) DES (N=376) 
High risk   
 Vascular System 23 (13%) 41 (11%) 
 Emergency 4 (2%) 40 (11%) 
Intermediate risk   
 Nose, mouth, pharynx 13 (8%) 15 (4%) 
 Eye 29 (17%) 42 (11%) 
 Digestive System 16 (9%) 48 (13%) 
 Musculoskeletal System 20 (12%) 39 (10%) 
 Respiratory System 4 (2%) 11 (3%) 
 Nervous System 6 (3%) 23 (6%) 
 Endocrine System - 2 (1%) 
 Oncology 1 (1%) 1 (1%) 
Low risk   
 Urinary System 28 (16%) 49 (13%) 
 Cosmetic surgery 9 (5%) 18 (5%) 
 Dermatologic 9 (5%) 17 (5%) 
 Miscellaneous 12 (7%) 30 (8%) 
 
Table 3 30-day MACEs 
PCI to NCS interval N p-value 
BMS (N=174)   
 0 – 30 d (N=8) 4  (50%) <0.001 
 31– 90 d (N=7) 1  (14%)  
 > 91 d (N=159) 6  (4%)  
 < 30 d (N=8) 4  (50%) <0.001 
 ≥ 30 d (N=166) 7  (4%)  
 < 3 mo  (N=15) 5  (33%) <0.001 
 ≥ 3 mo  (N=159) 6  (4%)  
DES (N=376) 
 < 30 d (N=46) 16 (35%) <0.001 
 30 d – 3 mo (N=24) 3  (13%)  
 3 – 6 mo (N=27) 4  (15%)  
 6 – 12 mo (N=47) 3  (6%)  
 > 12 mo (N=232) 22 (9%)  
 < 1yr (N=144) 26 (18%) 0.015 
 ≥ 1yr (N=232) 22 (9%)  
Thirty-day major adverse cardiovascular events (MACEs), stratified by interval between percutaneous 
coronary intervention (PCI) and noncardiac surgery (NCS)  
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On multivariate analysis, patients undergoing NCS within one year after PCI-DES, 
had an increased risk of perioperative MACEs (hazard ratio 2.0, 95% confidence 
interval 1.1 to 3.5) compared to patients undergoing NCS >1 year after PCI-DES. 
 
Figure 1. (A) Perioperative MACE and antiplatelet regimen in PCI-BMS. (B) Perioperative MACE and 
antiplatelet regimen in PCI-DES. Risk of perioperative MACEs during prespecified intervals between PCI and 
NCS. Antiplatelet regimens (single or dual antiplatelet therapy) subdivided according to occurrence of 
perioperative MACEs  
 
 
Dual antiplatelet therapy was used in 100 and 80% of the patients during 
the first 3 and 6 months after PCI-DES, respectively. Overall, dual antiplatelet 
therapy was continued until NCS in 112 (30%) patients, and 264 (70%) patients 
received single antiplatelet therapy. Of the patients who experienced a perioperative 
MACE, 56 and 44% had received dual or single antiplatelet therapy, respectively (p 
= 0.72). Because all patients were receiving dual antiplatelet therapy during the 
first 3 to 6 months after PCI-DES, the risk of perioperative MACE was only related 
to the interval to NCS after PCI. No relation was found between the concomitant 
use of clopidogrel and proton pump inhibitors and the risk of perioperative MACEs 
(28 vs 21% p = 0.38), compared to patients without proton pump inhibitor use. 
Patients in the PCI-DES group more often had a small stent-vessel diameter, but 
an increased lesion length, compared to those in the PCI-BMS group (84 vs 16% 
and 78 vs 22%, p < 0.001), respectively. No association was found between the 
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stent/vessel diameter or lesion length and the risk of perioperative MACEs (12 vs 
15%, p = 0.4, and 11 vs 15%, p = 0.2), respectively. 
 
Moderate and severe bleeding after surgery occurred in 56 (10%) and 42 
(8%) patients, respectively. A strong association was found between the use of 
single or dual antiplatelet therapy at NCS and the risk of moderate, severe or any 
bleeding (p < 0.001; Figure 2). The risk of severe bleeding in patients receiving 
single or dual therapy at NCS was 4 and 21%, respectively (p < 0.001). Additionally, 
the risk of bleeding was associated with interval from PCI to NCS.      
 
Figure 2. Bleeding risk according to antiplatelet regimen (single or dual antiplatelet therapy) 
 
 
DISCUSSION 
 
The results of the present study revealed an inverse relation between the interval 
from PCI to NCS and the occurrence of MACEs within 30 days after NCS in patients 
with PCI-BMS or PCI-DES. Irrespective of dual antiplatelet therapy continuation 
until NCS, early surgery after stenting was associated with an increased risk of 
MACEs. In addition, dual antiplatelet therapy at NCS increased the bleeding risk. 
Therefore, elective NCS should preferably be postponed for 90 days after PCI-BMS; 
however, if more urgent surgery is needed, a minimum interval of 30 days should 
be recommended. After PCI-DES, NCS should be delayed for ≥1 year.      
 
In response to several small studies that reported cases of late stent 
thrombosis,10,11 the first European Society of Cardiology guidelines recommended 
dual antiplatelet therapy for a minimum of three to four weeks after PCI-BMS. The 
most recent scientific advisory of the ACC/AHA on the discontinuation of dual 
antiplatelet therapy for patients with coronary stents proposed an interval of 6 
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weeks after PCI-BMS.2,3 In the present study, the strongest decrease in the risk of 
perioperative MACEs in patients undergoing NCS after PCI-BMS was reached when 
NCS was postponed for a minimum of 30 days from PCI. In contrast, only a small 
additional effect was realized if NCS was postponed until six weeks after PCI 
compared to 30 days. Previous studies of patients undergoing NCS after PCI-BMS 
reported high rates of MACEs when NCS was performed within two weeks after 
PCI,12,13 and others have recommended a delay of ≥6 weeks.14,15 Recent studies 
have shown the greatest risk of ischaemic events when NCS was performed within 
30 days of PCI, and the lowest after 90 days.9 In line with these studies, our study 
found the same high risk of perioperative MACE with NCS within 30 days of PCI-
BMS. However, the number of events in the present study was greater (10.7 vs 
5.4%), possibly because of the intensive and close follow-up of our patient 
population. As mentioned by Nutall et al.9 they used no protocol for the detection of 
perioperative MACE. 
 
The occurrence of stent thrombosis is a multifactorial process that includes 
device-related factors (e.g. surface coating, stent diameter, stent length) and 
patient- or lesion-specific factors (e.g. interval from PCI to NCS, stent/vessel 
diameter, antiplatelet therapy, proton pump inhibitor use and left ventricular 
ejection fraction).16 In the present study, only the interval from PCI to NCS was 
independently associated with an increased risk of perioperative MACEs after NCS. 
The continuation of dual antiplatelet therapy until NCS in PCI-BMS patients was 
not associated with lower rates of MACEs in the perioperative phase but was, 
however, associated with an increased risk of bleeding complications. Nuttall et al.9 
found no association between the different intervals after PCI-BMS and the 
frequency of bleeding events. After an interval of ≥30 days, they found a bleeding 
event rate of 4.6%, in line with our rate of 4%. 
 
A significant association between the interval from PCI-DES to NCS and the 
risk of perioperative MACEs was detected, confirming the ACC/AHA advisory to 
postpone elective NCS for ≥1 year after PCI.3 Although stabilization for the 
occurrence of MACEs was detected at a 6-month interval between PCI and NCS, 
other studies have shown catastrophic effects of early discontinuation.17 The value 
of at least a 1-year continuation of dual antiplatelet therapy after DES placement 
was also shown.18 In addition, more recent studies have shown that even if 
clopidogrel is stopped after the previous recommended three to six months, those 
who continue dual antiplatelet therapy have better survival and less late in-stent 
thrombosis than those with single or no antiplatelet therapy.18,19 Rabbits et al.4 
performed the largest trial in patients with PCI-DES before NCS, and observed a 
nonsignificant trend-wise decrease in the rate of MACEs with an increasing interval 
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after PCI.4 From these cited studies, prolonged dual antiplatelet therapy for ≥1 year 
is supported for patients with PCI-DES. Although our study demonstrated 
stabilization for the risk of MACEs after an interval of six months after PCI, an 
overall reduction in the incidence of MACEs was seen when NCS was performed ≥1 
year after PCI-DES.  
 
The continuation of dual antiplatelet therapy until surgery was not 
associated with a reduced risk of perioperative MACEs, compared to the 
discontinuation of dual antiplatelet therapy. In patients who underwent NCS within 
three months after PCI-DES, continuation of dual antiplatelet therapy was not 
sufficiently protective to prevent perioperative MACEs. Although this finding 
surprised us, Rabbitts et al.4 detected the same association. They even found that 
use of thienopyridine <7 days from NCS was associated with an increased rate of 
MACEs, compared to the use of single antiplatelet therapy. In contrast, other 
studies showed the adverse effects of stopping dual antiplatelet too early.12,19,20 In 
our study, all patients who developed a MACE during dual antiplatelet therapy had 
undergone surgery within three months after PCI. A possible explanation for the 
occurrence of MACEs in this specific subset of patients is minimal early re-
endothelization of the coronary arteries at the stent-location. The combination of 
aspirin and thienopyridines during the hypercoagulable state during NCS seemed 
insufficient to reduce the risk of in-stent thrombosis during this vulnerable period. 
 
Although the overall bleeding risk was in line with that reported by 
previous studies4, an increased rate of severe bleeding episodes occurred in the 
PCI-DES patients that was related to (1) the use of dual antiplatelet therapy at 
NCS, (2) high-risk NCS, and (3) NCS within 30 days after PCI.  Harder et al.21 
concluded that monotherapy with aspirin or clopidogrel usually does not need to be 
discontinued during surgery, which was confirmed in a meta-analysis by Burger et 
al.21 However, an increased risk of severe bleeding was shown by the Clopidogrel in 
Unstable angina to prevent Recurrent ischemic Events (CURE) trial for patients 
receiving dual antiplatelet therapy.22 Although the use of dual antiplatelet therapy 
has the disadvantage of an increased bleeding risk, the long-term survival effects of 
thienopyridines seem to outweigh these short-term negative effects.  
 
The potential limitations of the present study merit consideration. First, a 
referral bias was possible, because we did not include patients who underwent NCS 
elsewhere. Second, although the present sample size represented a very small part 
of both databases, a minor susceptibility to chance remained. Third, a selection 
bias for the occurrence of MACEs during dual antiplatelet therapy was possible, 
because these patients were more prone to undergo nonelective NCS early after 
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PCI. Although no independent events’ committee adjudicated clinical events, this 
was performed by 2 of us. Finally, we were unable to determine whether PCI was 
performed specifically for the subsequent surgery; however, almost 80% of PCI 
procedures were performed in a stable cardiac setting.      
 
 In conclusion, after PCI-BMS, NCS should preferably be postponed 90 
days; however, if more urgent surgery is needed, a minimum interval of 30 days 
should be recommended. In patients with PCI-DES, elective NCS should be 
postponed for ≥1 year after PCI. 
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ABSTRACT 
 
Background and Aims: Abdominal aortic aneurysms (AAA) are often diagnosed at 
time of (impending) rupture leading to a dramatic increase of morbidity and 
mortality. A simple screening device might be the key solution for widespread AAA 
screening. This study evaluated the diagnostic accuracy of a new portable 
ultrasound scanner (Aortascan BVI 9600) developed for automatic AAA detection. 
 
Methods: A total of 150 patients with presumed aneurysmatic peripheral 
atherosclerotic disease were included in the study. Patients were first scanned with 
conventional ultrasound (US), serving as reference technique. An infra-renal 
abdominal aorta diameter of ≥30 mm was defined as an AAA. Hereafter, the aorta 
was scanned using the Aortascan BVI 9600. Statistical analyses were performed 
using SPSS version 15.0 statistical software. 
 
Results: Abdominal aortic aneurysms were detected with conventional US in 78 
(52%) patients, compared with 74 (49%) AAAs detected with Aortascan BVI 9600. 
The Aortascan BVI 9600 demonstrated a sensitivity, specificity, positive and 
negative predictive value of 90, 94, 95 and 89%, respectively, in the detection of 
AAA’s. 
 
Conclusions: The Aortascan BVI 9600 automatically detects the aortic diameter 
with a 90% sensitivity without the need for a trained operator. Because of these 
unique capabilities, it can be used for AAA screening outside the hospital. 
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INTRODUCTION 
 
The prevalence of abdominal aortic aneurysm (AAA), in patients aged above 55 
years, ranges from 4.1 to 14.2% in men and 0.35 to 6.2% in women.1 The incidence 
of AAA is known to increase, due to an increased life expectancy.2 Effective 
screening programs for detecting AAA are currently not available. Therefore AAA’s 
are often diagnosed at time of (impending) rupture which leads to a dramatic 
increase of morbidity and mortality.3 Abdominal ultrasound (US) and computerized 
tomography (CT) are the most frequently used non-invasive imaging tests to detect 
or exclude the presence of an AAA. These imaging techniques are expensive and 
require trained staff.  In case of CT, the patient is exposed to a fair amount of 
radiation. Hence these techniques are not ideal for screening purposes. A simple 
screening device, which is less expensive and offers the possibility for use outside 
the hospital, might be the key solution for widespread AAA screening. In 2006, a 
pilot study conducted by Vidakovic et al.4 demonstrated the diagnostic potential of 
an automatic bladder volume scanner (BVI 6400, Verathon Medical, Bothell, USA) 
to detect AAA. The current study evaluated the diagnostic accuracy of a new 
portable ultrasound scanner [Aortascan BVI 9600 (BVI 9600), Verathon Medical] 
developed for automatic AAA detection.  
 
 
METHODS 
 
Study population 
The study population consisted of 150 consecutive patients referred to the 
outpatient clinic of the Department of Vascular Surgery of the Erasmus Medical 
Center (Rotterdam, The Netherlands) for presumed aneurysmatic peripheral 
atherosclerotic disease. Patient enrolment was performed from January until 
December 2008, after approval of the hospital’s Ethics Committee. All patients gave 
informed consent at time of inclusion. Patients with abdominal aortic stents or a 
previous open aortic reconstruction were excluded from the study. 
 
Baseline characteristics 
A detailed history was obtained from every patient and the following characteristics 
were recorded; age, gender, body mass index, heart failure (defined as the presence 
of heart failure symptoms according the New York Heart Association classification 
or previous hospital admission for decompensated heart failure), ischemic heart 
disease (defined as history of angina pectoris, coronary revascularization or 
myocardial infarction), cerebrovascular disease (defined as a history of ischemic or 
hemorrhagic stroke), lower extremity arterial disease (defined as ankle brachial 
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index <0.9), renal dysfunction (defined as creatinin clearance >2.0 mg/dL), diabetes 
mellitus (fasting blood glucose ≥7.0 mmol/L or requirement for insulin and/or anti-
diabetic medication), hypertension (blood pressure was measured during 
preoperative evaluation at the outpatient clinic and hypertension was defined as 
systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg in non-
diabetics, systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg 
in diabetics or the use of antihypertensive medication), hypercholesterolemia (low-
density lipoprotein cholesterol >3.5 mmol/L and the requirement of lipid-lowering 
medication), chronic obstructive pulmonary disease (according to the Global 
Initiative on Obstructive Lung Diseases classification) and smoking status. 
 
Measurement of the abdominal aortic diameter 
All patients were first scanned with conventional US and measurements obtained 
with conventional US served as the reference value. An infra-renal abdominal aorta 
diameter (either anterior-posterior or transverse) of ≥30 mm was defined as an 
AAA.5 Hereafter, the aorta was scanned using the Aortascan BVI 9600 (Figure 1 
and 2). The examinations were performed and reviewed by 2 physicians, both 
skilled and experienced in abdominal US. The interobserver variability between the 
two echocardiographists was up to 95% for the measured aortic diameter. 
 
Conventional abdominal ultrasound  
A handheld US device (SonoSite Titan, SonoSite Inc., Bothell, Washington) with a 
C11/8-5MHz broadband slightly curved array transducer was used for US 
evaluation of the abdominal aorta. Both anterior-posterior and transverse 
diameters at the largest portion of the abdominal aorta were measured. The aortic 
diameters were obtained using on-screen callipers from the outer edge to edge of 
the aortic wall, including intraluminal thrombus if present. The maximal obtained 
diameter, measured in the xiphoid to umbilical traject, was used for analysis.  
 
 Figure 1. The Aortascan BVI 9600  Figure 2. Screenplay Aortascan BVI 9600 
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The 3D dimensional scan is obtained as a set of 12 mechanically rotated two 
dimensional scans, 15 degrees apart. Each planar scan is obtained by 
mechanically sweeping a single element transducer through a 120º arc. The 
transducer is used for transmission and reception of ultrasonic waves at 3.7 MHz. 
Echoes originating from a depth up to 20 cm were included for analysis. Dedicated 
detection software uses the data obtained from the 3D scan to create a 3D 
geometry of the abdominal aorta. From this 3D geometry, the maximum diameter is 
deduced and displayed as result for the user. The user is also provided with a B-
mode image representing the cross-sectional scan plane. Electronic callipers are 
provided to manually redefine the maximum diameter when necessary. Each 
Aortascan BVI 9600 assessment consisted of four consecutive scans, located at the 
midline of the abdomen, starting ~2.5 cm below the xiphoid. Scanning locations are 
shown in Figure 3. Abdominal aortic diameter measurements <30 mm were 
displayed solely as being <3.0 cm. An estimated diameter in mm was provided by 
the Aortascan, when the abdominal aorta diameter was assumed to be >30 mm. 
The maximal abdominal aorta diameter was used for the hypothesis on the 
presence of AAA. 
 
Figure 3. Scanning locations of the Aortascan BVI 9600 
 
Statistics 
Dichotomous data are described as numbers and percentages. The continuous 
variables age and BMI are described as mean ± standard deviation (SD). Differences 
in baseline characteristics between patients with abdominal aorta diameter <30 or 
>30 mm, detected with conventional US, were evaluated using χ2 tests for 
categorical data. Continuous data were compared using one-way ANOVA. For all 
tests, a p-value less than 0.05 (two sided) was considered significant. All analyses 
were performed using SPSS version 15.0 statistical software (SPSS, Inc., Chicago, 
IL, USA). 
 304 
RESULTS 
 
A total of 150 patients with presumed aneurysmatic peripheral atherosclerotic 
disease were included in the study. Abdominal aortic aneurysms were detected 
with conventional US in 78 (52%) patients, compared with 74 (49%) presumed 
AAA’s detected with Aortascan BVI 9600. Mean abdominal aortic size was 39 mm, 
measured with conventional US. Patients with aneurysmatic disease were older (70 
vs. 65 years), more likely to be male (89 vs 59%, p < 0.01) and more often a BMI 
>25 compared with patients with normal abdominal aortic size. Other factors 
associated with an AAA were heart failure, renal dysfunction, and smoking. 
Baseline characteristics are shown in Table 1.  
 
Table 1 Baseline characteristics of the study population 
Conventional ultrasound 
 No AAA 
[N=72] 
AAA 
[N=78] 
p-value 
 
Demographics    
  Age (± SD) 65 (10) 70 (10) 0.022 
  Male (%)    43 (59) 72 (89) <0.01 
  Body mass index (± SD) 25 (3) 27 (4) 0.008 
Medical history (%)    
  Clinical heart failure  4 (6) 16 (20) 0.009 
  Ischemic heart disease   20 (27) 33 (41) 0.082 
  Cerebrovascular disease 27 (37) 19 (24) <0.01 
  Lower extremity arterial disease 42 (58) 27 (33) 0.003 
  Renal dysfunction 4 (6) 18 (23) 0.003 
  Diabetes mellitus 20 (25) 13 (18) 0.300 
  Hypertension 44 (61) 53 (66) 0.510 
  Hypercholesterolemia  37 (51) 45 (56) 0.548 
  Chronic Obstructive Pulmonary Disease 11 (15) 13 (16) 0.870 
  Smoking, current 28 (39) 20 (25) 0.066 
Abdominal aortic aneurysm (AAA), standard deviation (SD), ultrasound (US) 
 
In total, 70 (90%) AAA patients measured with conventional US were 
detected with the Aortascan BVI 9600 as well. Furthermore, 68 (95%) patients with 
normal abdominal aorta observed with conventional US had a normal abdominal 
aorta, measured with the Aortascan BVI 9600 as well. False-positive 
measurements, i.e. a presumed AAA detected with the Aortascan BVI 9600, which 
was not present with conventional US was observed in four patients (5%). False-
negative measurements, i.e. an AAA detected with conventional US and missed 
with the Aortascan BVI 9600 was present in eight (10%) patients. We have found 
sensitivity, specificity, positive-predictive value and negative-predictive values of 
90, 94, 95 and 89%, respectively (Table 2).  
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Table 2 Conventional ultrasound vs. aortascan BVI 9600 
 Aortascan BVI 9600 
Conventional ultrasound AAA yes AAA no p-value 
AAA yes 70  (95) 8  (10) <0.01 Sensitivitya: 90 
AAA no 4  (5) 68  (90) <0.01 Specificitya: 94 
aAortascan BVI 9600. Abdominal aortic aneurysm (AAA) 
 
Furthermore, the correlation, in measured AAA diameter, between conventional US 
and the Aortascan BVI 9600 is demonstrated in Figure 4. 
 
Figure 4. Correlation between conventional ultrasound and Aortascan BVI 9600 (abdominal aorta size 
<30mm are not included because not measured with Aortascan BVI 9600), Ultrasound (US) 
 
 
 
DISCUSSION 
 
The current study provides early results on the detection of AAA with the Aortascan 
BVI 9600, compared with conventional US. The main finding of this study was that 
the Aortascan BVI 9600 detects abdominal aortic aneurysms with a sensitivity and 
specificity of 90 and 94%, respectively. In addition to this, the positive- and 
negative- predictive values were 95 and 89%, respectively.  
 
The development of aortic aneurysmatic disease is associated with 
alterations of connective tissue in the aortic wall, in which the process of 
atherosclerosis is regarded an important factor.6 The formation of an AAA is 
initiated when vascular endothelium is injured and AAA progression is influenced 
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by factors such as (i) infection and complement activation, (ii) shear stress forces, 
(iii) increased oxidative stress and cytokine release leading to endothelial activation 
and dysfunction.7,8 The prevalence and incidence of AAA has been widely 
investigated and a population-based study including 6.386 patients showed a 
prevalence of AAA in 263 (8.9%) men and 74 (2.2%) women.9 Approximately 6% of 
men have an aortic diameter of more than 2.9 cm by the age of 65 years.10  A meta-
analysis performed by Cornuz et al. in 2004 included around 110.000 patients 
screened for AAA and concomitant risk factors.  
 
The prevalence of AAA in Europe and America ranged from 4.1 to 14.2% in 
men and from 0.35 to 6.2% in women with all patients aged above 55 years.1 In 
patients with symptomatic atherosclerotic disease, the prevalence of aneurysmatic 
disease is much higher, as data of our own population showed prevalence up to 
25%. Therefore, the use of a quick and efficient AAA screening tool in this high-risk 
population, could add significantly to complete the patients risk profile. Patients 
with ruptured AAA have a worse prognosis, as up to 55% of the patients that reach 
the hospital alive will still die in the first 30 postoperative days.11,12 Therefore, 
screening of patients at increased risk for developing AAA and subsequent elective 
surgical interventions may improve outcome. As noted by Hailey et al.,13 the non-
availability of an echo-system and/or operator at the point-of-care may lead to a 
delay in diagnosis and patient management. Although the first portable echo 
devices were developed in the 1970s,14,15 portable echo has become commercially 
available since 1996.16 In 2003, for instance, portable cardiac US (or echo-
stethoscope) broadened the application of echocardiography to the patient’s 
bedside.17 The use of portable US for AAA detection was first described by 
Vidakovic et al.,4 using the automatic BVI 6400 system. 
 
Ultrasonography provides the possibility to diagnose or rule-out AAA 
rapidly and accurately.18,19 However, finding the correct cross-sectional scan plane 
with the maximum aortic diameter remains the most difficult part in AAA 
screening. Small errors in the angle of cross-section causes direct errors in the 
found diameter and may lead to wrong diagnosis. Therefore, only well-trained 
echocardiographists should perform conventional US for the detection of AAA. 
Hence Vidakovic et al.4 proposed to use the automatic BVI 6400 system for AAA 
screening because of (i) potential widespread availability, (ii) low costs (~10.000 €) 
compared with expensive conventional US equipment and (iii) steep learning curve 
compared with more intensive training required for conventional US. They 
concluded that the BVI 6400 is simpler for use, requires a less intensive training 
period and therefore can be used by a nurse or a technician. Furthermore, the BVI 
6400 is roughly four times less expensive compared with conventional US. In the 
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pilot study conducted by Vidakovic et al., volume measurements of the infrarenal 
abdominal aorta were performed with the BVI 6400 and compared with 
conventional US. On the basis of the technical characteristics of the BVI 6400, they 
estimated that a volume of 14 mL measured with the BVI 6400 corresponded with 
an abdominal aortic diameter of 30 mm, which is considered an AAA. Using the 
cut-off value of >14 mL for the presence of AAA, they demonstrated a sensitivity of 
94% and specificity of 82% of the BVI 6400 in the detection of AAA. Furthermore, 
positive- and negative-predictive values for the BVI 6400 to detect AAAs were 88 
and 92%, respectively. However, although these data look promising, the use of 
volume measurements, which have to be recalculated, remains questionable.  
 
In our study, the Aortascan BVI 9600 directly measured the maximum 
abdominal aortic diameter and therefore, we did not have to estimate a volume cut-
off value corresponding with the abdominal aortic diameter in mm. Consequently, 
results obtained from the Aortascan BVI 9600 can be directly compared with 
conventional US. With the use of these new types of measurements, we found a 
sensitivity of 90% and an increased specificity of 94% compared with the BVI 6400. 
Furthermore we found a negative-predictive value of 89% and an increased 
positive-predictive value of 95% compared with the BVI 6400. The Aortascan BVI 
9600 provides a scan depth of 20 cm, which was sufficient for the patient 
population. Hence, no false negatives occurred due to a limited field of view. 
However, although the Aortascan BVI 9600 seems to detect AAA with a sufficient 
accuracy, the use of the system should not be extended as a replacement for 
conventional US. Patients with AAA detected by the Aortascan BVI 9600 should be 
referred to a radiologist to perform a conventional abdominal US. 
 
Although we have used conventional US as the reference technique, we are 
aware that the sensitivity and specificity of conventional US is not 100%. This is 
mainly due to the difficulty of finding the right cross-sectional plane and location of 
the aorta, even for experienced operators. The 3D acquisition of the Aortascan BVI 
9600 is likely to overcome the problems associated with two dimensional US. This 
was demonstrated in a patient with a curved aortic shape (including an AAA) not 
located at the midline of the abdomen. The measurement with conventional US 
initially produced a false-negative result, where the Aortascan BVI 9600 did detect 
an AAA. The presence of a true AAA was confirmed with a second conventional US 
measurement. This case underlines the need for future studies, evaluating the 
accuracy of the Aortascan BVI 9600, using angio-CT as the reference technique.  
 
In conclusion, the Aortascan BVI 9600 automatically detects and 
calculates the aortic diameter with a 90% sensitivity without the need for a trained 
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operator. Because of these unique capabilities, it can be used for AAA screening 
outside the hospital and allows for AAA detection in patients who would not have 
been examined otherwise. However, final diagnosis and subsequent treatment 
requires additional medical examination. 
 
 
REFERENCES 
 
1. Cornuz J, Sidoti Pinto C, Tevaearai H, et al. Risk factors for asymptomatic abdominal aortic 
aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J 
Public Health. 2004;14(4):343-349. 
2. Barba A, Estallo L, Rodriguez L, et al. Detection of abdominal aortic aneurysm in patients with 
peripheral artery disease. Eur J Vasc Endovasc Surg. 2005;30(5):504-508. 
3. Daly KJ, Torella F, Ashleigh R, et al. Screening, diagnosis and advances in aortic aneurysm 
surgery. Gerontology. 2004;50(6):349-359. 
4. Vidakovic R, Schouten O, Feringa HH, et al. Abdominal aortic aneurysm screening using non-
imaging hand-held ultrasound volume scanner--a pilot study. Eur J Vasc Endovasc Surg. 
2006;32(6):615-619. 
5. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of 
patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal 
aortic): executive summary a collaborative report from the American Association for Vascular 
Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, 
Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the 
ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the 
Management of Patients With Peripheral Arterial Disease) endorsed by the American Association 
of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; 
Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease 
Foundation. J Am Coll Cardiol. 2006;47(6):1239-1312. 
6. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-126. 
7. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging 
pathophysiological paradigm in aortic aneurysm. Circulation. 1997;96(7):2115-2117. 
8. Van Kuijk JP, Flu WJ, Dunckelgrun M, et al. Coronary artery disease in patients with abdominal 
aortic aneurysm: a review article. J Cardiovasc Surg (Torino). 2009;50(1):93-107. 
9. Singh K, Bonaa KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic 
aneurysms in a population-based study : The Tromso Study. Am J Epidemiol. 2001;154(3):236-
244. 
10. Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med. 
2003;348(19):1895-1901. 
11. Akkersdijk GJ, van der Graaf Y, van Bockel JH, et al. Mortality rates associated with operative 
treatment of infrarenal abdominal aortic aneurysm in The Netherlands. Br J Surg. 
1994;81(5):706-709. 
12. Dardik A, Burleyson GP, Bowman H, et al. Surgical repair of ruptured abdominal aortic 
aneurysms in the state of Maryland: factors influencing outcome among 527 recent cases. J 
Vasc Surg. 1998;28(3):413-420; discussion 420-411. 
13. Hailey D, Topfer LA. Hand-carried ultrasound units for point-of-care cardiac examinations. 
Issues Emerg Health Technol. 2002(41):1-4. 
14. Ligtvoet C, Rijsterborgh H, Kappen L, et al. Real time ultrasonic imaging with a hand-held 
scanner. Part I--technical description. Ultrasound Med Biol. 1978;4(2):91-92. 
 309 
15. Roelandt J, Wladimiroff JW, Baars AM, et al. Ultrasonic real time imaging with a hand-held-
scanner. Part II--initial clinical experience. Ultrasound Med Biol. 1978;4(2):93-97. 
16. Bom N, van der Steen AF, de Jong N, et al. Early, recent and future applications of 
echocardiography. Clin Physiol Funct Imaging. 2004;24:141-146. 
17. Vourvouri EC, Koroleva LY, Ten Cate FJ, et al. Clinical utility and cost effectiveness of a personal 
ultrasound imager for cardiac evaluation during consultation rounds in patients with suspected 
cardiac disease. Heart. 2003;89(7):727-730. 
18. Giaconi S, Lattanzi F, Orsini E, et al. Feasibility and accuracy of a rapid evaluation of the 
abdominal aorta during routine transthoracic echocardiography. Ital Heart J Suppl. 
2003;4(4):332-336. 
19. Kuhn M, Bonnin RL, Davey MJ, et al. Emergency department ultrasound scanning for 
abdominal aortic aneurysm: accessible, accurate, and advantageous. Ann Emerg Med. 
2000;36(3):219-223. 
 
 
 
 310 
 311 
Chapter 23 
 
 
 
 
 
 
Remote ischemic preconditioning in 
vascular surgery patients:  
the additional value to medical 
treatment  
 
 
Jan-Peter van Kuijk 
Willem-Jan Flu 
Hence J.M. Verhagen 
Jeroen J. Bax 
Don Poldermans  
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Endovascular Therapy 2009;16(6):690-693 
 312 
PERIOPERATIVE CARDIAC DAMAGE 
 
Annually, more than 230 million major surgeries are performed worldwide, and this 
number continuous to grow.1 Postoperative myocardial infarction and mortality are 
estimated to occur in 1% (2.300.000 patients) and 0.3% (690.000 patients), 
respectively.1 The incidence of asymptomatic perioperative cardiac damage is 
estimated to be as high as 20% in patients undergoing high-risk surgery, such as 
vascular surgery.2,3 Perioperative cardiac complications remain a significant 
problem, despite improved medical treatment and less invasive surgical techniques 
such as endovascular aneurysm repair (EVAR).  
 
Since the early 1990s when EVAR was introduced to the worldwide 
vascular community, the use of the technique increased has increased steadily; in 
2003, it accounted for over 40% of elective repairs of abdominal aortic aneurysms 
(AAA).4 Several randomized trials have shown a perioperative survival benefit of 
EVAR compared to open repair, with fewer perioperative complications and a 
shorter recovery time.5,6 In a recent population-based study, Schermerhorn and 
colleagues demonstrated that perioperative mortality rates were significantly lower 
in patients undergoing endovascular compared to open repair.7  
 
However, renal and myocardial injuries still occur after elective EVAR in 
5.5 and 7.0% of the patients, respectively.7 These perioperative complications are 
the result of a multifactorial process in which hemodynamic instability with 
hypoperfusion plays a pivotal role. Vascular surgery patients are susceptible to 
ischemia-reperfusion injury, as this is an integral part of most vascular 
procedures. Renal injury may result from either (i) a low-flow state in the renal 
vasculature due to systemic hemodynamic instability, (ii) a no-flow state arising 
from direct interference with renal blood flow due to suprarenal or juxtarenal 
clamping, or (iii) to toxic metabolites that are released into the systemic circulation 
at the time of reperfusion of the lower limbs.8 Perioperative cardiac events can be 
characterized by two distinct mechanisms, described as either type 1 and type 2 
myocardial infarction.9 Type 1 is defined as an acute coronary syndrome that 
occurs when a plaque ruptures, leading to thrombus formation and subsequent 
acute coronary thrombosis, ischemia and infarction. This type is elucidated by the 
perioperative stress response that includes a cathecholamine surge with associated 
hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation 
and consequent hypercoagulability.10 Type 2 arises from a low-flow state across a 
hemodynamically significant coronary artery stenosis, resulting in a sustained 
myocardial supply-demand imbalance.10 Importantly, ischemia-reperfusion injury 
remains the final common pathway that leads to end-organ damage regardless of 
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the mechanism that led to ischemia in the first place.11 Therefore, in addition to 
medical treatment, innovative strategies such as “ischemic preconditioning” (IPC) 
are increasingly investigated.   
 
 
REMOTE ISCHEMIC PRECONDITIONING 
 
Murry and colleagues were the first who used the term IPC in a study that 
demonstrated the ability to “condition” the heart to tolerate the effects of acute 
ischemia-reperfusion injury.12 Several studies in human organs including the 
heart, kidney, liver and brain have demonstrated a powerful cardioprotective effect 
of IPC.13,14 The mechanistic pathways underlying these endogeneous 
cardioprotective effects are complex in nature and have conventionally been divided 
into trigger factors, mediators and effectors, which include cell surface receptors 
(adenosine, bradykinin and opioids), signaling kinases and mitochondrial 
components.15  
 
Intriguingly, some studies have reported that similar levels of 
cardioprotection can be achieved by applying brief episodes of non-lethal ischemia 
and reperfusion to an organ or tissue remote from the heart or kidneys, thereby 
obviating the need to “condition” the heart directly. This approach has been called 
remote ischemic preconditioning (RIPC) or ischemic preconditioning at a distance. 
In 1997, Birnbauam and colleagues presented the first animal study suggesting 
that transient ischemic limb ischemia could remotely pre-condition the ischemic 
heart.16 Subsequent studies demonstrated that transient limb ischemia in humans 
protected against endothelial ischemic-reperfusion injury of an opposite limb and 
reduced ischemic myocardial damage during cardiac surgery.17,18 Remote ischemic 
preconditioning in the setting of open AAA repair has been performed in one large 
clinical trial conducted by Ali and colleagues.19 Postoperative myocardial injury 
(serum troponin ≥1.5 ng/mL) was significantly less frequent in patients who 
underwent RIPC prior to surgery. In addition, length of stay on the critical care unit 
was significantly shorter in the RIPC patients. Although the trial was relatively 
small, the results suggest that RIPC could have a role in strategies aimed at 
lowering the complication burden of major vascular surgery. 
 
In this issue of Journal of Endovascular Therapy, Walsh and colleagues 
extend the concept of RIPC by reporting the results of a randomized clinical trial 
designed to determine the ability of RIPC in reducing renal and cardiac damage 
after EVAR. Forty AAA patients were randomized to preconditioning using 
sequential lower limb ischemia induction (N=18) or a control group (N=22). Primary 
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outcome was renal injury, measured by urinary levels of retinol binding protein 
(RBP) and urinary albumin:creatinin ratio (ACR). A significantly lower increase of 
RBP in the preconditioned group was detected. A secondary outcome was the 
occurrence of cardiac events; however, no difference was detected between the two 
groups in cardiac outcome. The results of this study performed in patients 
scheduled for elective EVAR seems promising with regard to the prevention of renal 
injury; however, several remarks can be made.  
 
First, the study was designed and powered to assess the impact of RIPC on 
renal injury following EVAR. However, the only significant parameter for renal 
injury between the two groups was a significant increase of urinary RBP in the 
control group, while no differences in serum creatinin and estimated Glomerular 
Filtration Rate (eGFR) were observed between the two arms. Urinary RBP is a 
highly sensitive marker of renal tubular injury; however, in daily clinical practice, 
changes in serum creatinin are most often used.  Notably, eGFR has been 
demonstrated to be a reliable marker for renal injury, and even minor temporary 
changes in eGFR after vascular surgery have been associated with adverse 
cardiovascular outcome.20  
 
Second, no evidence of a cardioprotective effect of RIPC was detected, as 
there were no significant differences in either serum troponin elevations or major 
adverse cardiac events between the two arms of the trial. Troponin elevations after 
both open and endovascular repair of abdominal aortic aneurysm, have been 
associated with short- and long-term adverse cardiovascular outcome.6,21  
 
Finally, preoperative statin use was significantly higher in patients who 
received RIPC. Statins are an important part of the medical treatment strategies for 
the prevention of renal injury and cardiac events after vascular surgery.22 
Therefore, patients with RIPC received more often optimal medical treatment in 
addition to RIPC, which could have influenced the occurrence of troponin 
elevations postoperatively.       
      
 
MANAGEMENT OF PATIENTS WITH ASYMPTOMATIC CARDIAC DAMAGE 
 
The need for cardiovascular prevention and treatment has emerged from the strong 
association between high-risk patients, perioperative ischemia characterized by 
troponin release, and its influence on short- and long-term outcome.6,21 The 
unpredictable progression of an unstable coronary plaque during surgical stress is 
the most important target for systemic therapy. Medical treatment (including 
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perioperative β-blockade, statins and aspirin) has been established for 
perioperative as well as long-term risk reduction. The recent European Society of 
Cardiology (ESC) guidelines for preoperative cardiac risk assessment and 
perioperative cardiac management in non-cardiac surgery provide a Class I 
recommendation for ß-blockade in patients with known ischemic heart disease or 
myocardial ischemia on pre-operative stress testing and in patients scheduled for 
high-risk surgery.23 In our center, all patients scheduled for major vascular surgery 
are prescribed a low dose β-blocker (e.g. bisoprolol 2.5mg) initiated as early as 
possible, preferably 30 days prior to surgery. Furthermore, we promote the idea of 
prolonged treatment after surgery. As recommended, high-risk patients should 
receive statins in the perioperative period as well, ideally between 30 days and at 
least 1 week before surgery.23,24  
 
Although these strategies have been demonstrated to improve outcome 
after surgery, each drug addresses a single etiologic mechanism. Therefore, other 
perioperative protective strategies such as RIPC, with the possible capability to 
protect multiple at-risk tissues simultaneously, could have an additional value. 
Although in patients undergoing major vascular surgery 2 randomized controlled 
trials have been performed, both had a relatively small sample size.  
 
 
CONCLUSION 
 
In conclusion, the occurrence of perioperative myocardial damage after vascular 
surgery is strongly associated with an increased risk for short- and long-term 
adverse cardiac outcome. Medical pre- and perioperative treatment strategies 
including ß-blockade, statins and aspirin have recently been recommended by the 
ESC, and remain the most important strategy for the prevention of postoperative 
cardiac complications.23 Remote ischemic preconditioning has shown promising 
results in cardiac and vascular surgery patients; however, the clinical applicability 
should be further studied in large multi-centered randomized trials.       
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ABSTRACT 
 
Background: Major vascular surgery patients are at high-risk for developing 
asymptomatic perioperative myocardial ischemia reflected by a postoperative 
troponin release without the presence of chest pain or electrocardiographic 
abnormalities. Long-term prognosis is severely compromised and characterized by 
an increased risk of long-term mortality and cardiovascular events. Current 
guidelines on perioperative care recommend single antiplatelet therapy with aspirin 
as prophylaxis for cardiovascular events. However, as perioperative surgical stress 
results in a prolonged hypercoagulable state, the postoperative addition of 
clopidogrel to aspirin within seven days after perioperative asymptomatic cardiac 
ischemia could provide improved effective prevention for cardiovascular events.    
 
Study design: DECREASE-VII is a phase III, randomized, double-blind, placebo-
controlled, multicenter clinical trial designed to evaluate the efficacy and safety of 
early postoperative dual antiplatelet therapy (aspirin and clopidogrel) for the 
prevention of cardiovascular events after major vascular surgery. Eligible patients 
undergoing a major vascular surgery (abdominal aorta or lower extremity vascular 
surgery) who developed perioperative asymptomatic troponin release are 
randomized 1:1 to clopidogrel or placebo (300mg loading dose, followed by 75mg 
daily) in addition of standard medical treatment with aspirin. The primary efficacy 
endpoint is the composite of cardiovascular death, stroke, or severe ischemia of the 
coronary or peripheral arterial circulation leading to an intervention. The 
evaluation of long-term safety includes bleeding defined by TIMI criteria. 
Recruitment began early 2010. The trial will continue until 750 patients are 
included and followed for at least 12 months. 
 
Summary: DECREASE-VII is evaluating whether early postoperative dual 
antiplatelet therapy for patients developing asymptomatic cardiac ischemia after 
vascular surgery reduces cardiovascular events with a favourable safety profile. 
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INTRODUCTION 
 
The atherosclerotic process is often not limited to a single arterial location, giving it 
the character of a systemic and generalized disease. In 1984, Hertzer and 
colleagues demonstrated that only 6% of the patients undergoing vascular surgery 
for abdominal aortic aneurysms had a healthy coronary tree.1 In the vast majority 
of the patients, the atherosclerotic process remains asymptomatic, until an 
accelerated progression is precipitated by a stressing factor such as a major 
surgical intervention. Worldwide more than 230 million surgeries are performed 
annually, and this number continues to grow.2 The estimated post-operative 
myocardial infarction (MI) rate is 1% (approximately 2.300.000 patients).3 
According to the current guidelines, MI is characterized by the presence of 2 of the 
following 3 criteria: 1) presence of chest pain, 2) electrocardiographic (ECG) criteria, 
and 3) cardiac enzymes including creatine kinase (MB) and cardiac troponins.4 
However, in the perioperative period symptoms of cardiac complications might be 
masked by residual anaesthetic effects and postoperative pain. Consequently, as 
most cardiac events are asymptomatic or masked by other postoperative symptoms 
and ECG changes are often transient, cardiac ischemia might not be detected until 
it develops into an MI. It is estimated that up to 25% of patients undergoing high-
risk surgery, such as vascular surgery, developed perioperative troponin release, of 
which more than 75% remain asymptomatic.5,6 Importantly, the occurrence of 
asymptomatic troponin T release in vascular surgery patients has been associated 
with a more than 2-fold increased risk for short- and long-term mortality.6,7  
 
The strong association between high-risk patients, perioperative ischemia 
characterized by asymptomatic troponin release, and its influence on short- and 
long-term outcome has emerged the need for prevention and treatment. The most 
recent guidelines on perioperative cardiac management in non-cardiac surgery 
patients, recommended medical therapy including beta-blockers, statins and 
aspirin.8 Of note, perioperative stress results in a prolonged hypercoagulable state, 
which creates in combination with the presence of atherosclerotic plaques the 
perfect milieu for the development of perioperative cardiac ischemia. Although 
aspirin reduces the risk of plaque rupture and subsequent cardiovascular events, 
there remains a substantial risk for such events during the post-operative period 
and long term follow-up. The thienopyridine derivate clopidogrel is an antiplatelet 
agent that inhibits platelet aggregation induced by adenosine diphosphate. These 
distinct platelet-inhibiting mechanisms and separate target pathways for reducing 
platelet aggregation have made clopidogrel a more potent platelet-inhibiting agent 
when compared to aspirin. In the last decade, data from large randomized 
controlled trials of patients with acute coronary syndromes or those undergoing 
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percutaneous coronary intervention have demonstrated a significant reduction in 
cardiovascular endpoints with dual aspirin-thienopyridine therapy compared with 
aspirin alone.9,10 More recent, a meta-analysis by Bowry et al. demonstrated the 
efficacy of combining clopidogrel and aspirin (dual antiplatelet therapy) compared 
to aspirin alone in patients with acute coronary syndromes, for the prevention of 
long-term cardiac complications.11   
 
The most important complication of platelet inhibiting agents is the 
increased risk of bleeding. The combined use of aspirin and clopidogrel has been 
associated with an increased risk of minor bleeding. However, in large randomized 
controlled trials in patients with acute coronary syndromes, dual antiplatelet 
therapy was not associated with a significant increased risk of major bleeding 
compared with aspirin alone.10,12 Most bleeding events are gastro-intestinal in 
origin as dual antiplatelet therapy has been associated with impaired healing of 
asymptomatic gastric ulcers.13 To reduced these risks, recommendations from an 
expert consensus document supported the use of a gastroprotective agent, 
preferably proton pump inhibitors (PPIs), for the prophylaxis of dual antiplatelet-
associated gastrointestinal injury.13 However, several studies have demonstrated 
an increased risk of death in patients receiving both clopidogrel and PPIs.14,15 
Therefore the Food and Drug Administration has issued a warning on the co-
administration of PPIs and clopidogrel, advising that the drugs should not be co-
administered.   
 
No prior studies investigated the use of dual antiplatelet therapy in high-
risk patients developing asymptomatic cardiac ischemia immediately during the 
postoperative period. In the present study we aimed to assess the efficacy and 
safety of starting dual antiplatelet therapy within 7 days after vascular surgery, for 
the prevention of adverse long term cardiac events. Therefore, a large multicenter, 
prospective, randomized controlled trial has been set up: the Dutch 
Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-VII (DECREASE-
VII) study.  
 
 
METHODS 
 
Sources of funding 
JP van Kuijk, WJ Flu and SE Hoeks are supported by an unrestricted grant from 
the “lijf en leven” Foundation, Rotterdam the Netherlands. MT Voute is supported 
by an unrestricted grant from the Netherlands Heart Foundation (NHF 
#2009B020). All the authors of the manuscript are solely responsible for the design 
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and conduct of this study, all study analyses, the drafting and editing of the paper 
and its final contents. 
 
Study objective 
The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-VII 
(DECREASE-VII) study (trial identifier NTR1436) is an investigator-initiated, 
national, multi-center, randomized, double-blind, placebo-controlled study. The 
primary objective is to assess the efficacy of clopidogrel in addition of standard 
medical treatment, compared to placebo, in preventing the primary endpoint. The 
secondary objective is to assess the safety of clopidogrel, compared to placebo, in 
addition of standard perioperative treatment with low molecular weight heparin 
and aspirin (100mg daily), on the occurrence of bleeding complications. The tertiary 
objective is to identify preoperative risk factors and novel biomarkers for the 
occurrence of the primary and secondary endpoint. 
 
Table 1 Principal inclusion and exclusion criteria 
INCLUSION CRITERIA  
Major vascular surgery 
Abdominal Aortic Aneurysm repair, Aortic stenosis 
repair, lower extremity vascular surgery 
Age ≥ 18 years  
Asymptomatic Troponin T release 
Elevated troponin T level at day 1, 3, or 7 after surgery, 
in the absence of chest pain complaints or 
electrocardiogram abnormalities 
EXCLUSION CRITERIA  
Active bleeding  
Untreated left main disease  
Active cardiac conditions 
Unstable angina pectoris, active chronic heart failure, 
serious cardiac arrhythmias, symptomatic valvular 
disease, in the recent <6 months 
Preoperative elevated troponin T  
Inability to take clopidogrel orally   
Clear indication for long-term clopidogrel use  
Previous allergy or intolerance to clopidogrel  
Renal failure requiring dialysis  
Significant liver disease ALAT, ASAT > 3 times Upper-Limit-of-Normal 
Cancer  With an expected life expectancy <6 months 
Anticipated non-adherence to clopidogrel  
Excessive alcohol abuse  
Pregnancy or planning to become pregnant  
Failure to provide informed consent  
 
Study population 
The trial will enroll male and female patients who are 1) ≥18 years of age, 2) 
scheduled for elective major vascular surgery, and 3) develop asymptomatic 
postoperative troponin T release within 7 days after surgery. Major vascular 
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surgery is defined as 1) abdominal aortic aneurysm (AAA) repair, 2) abdominal 
aorta stenosis repair (Leriche syndrome), and 3) lower extremity vascular surgery. 
Asymptomatic troponin T release is an elevated troponin T measurement without 
the presence of ECG changes and/or presence of chest pain. Key exclusion criteria 
for this trial includes pre-operative active bleeding, untreated left main disease, 
active cardiac conditions, preoperative troponin T elevation, and inability to take 
oral medication. A complete listening of the entry criteria is provided in Table 1.  
 
Figure 1. Flow-chart of DECREASE-VII trial 
 
 
Study procedures 
During a period of 4 years, all patients planned for elective surgery at the 
participating centers, will be screened for eligibility in the study. Those patients 
that fulfill all inclusion and exclusion criteria will be asked to participate in the 
study. Patients are pre-operatively asked for informed consent, with the knowledge 
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that definite inclusion into the study will only be accorded if they develop 
asymptomatic troponin T release during the perioperative period. Those patients 
that do not develop asymptomatic postoperative troponin T release will not be 
randomized and not be included in this study. However these patients will be 
followed according to the standard protocol after major vascular surgery, i.e. 
regular outpatient clinic controls. Data of these patients will be used for the tertiary 
objectives of this study. Prior to surgery, pre-operative work-up will be done in all 
patients, according the current ACC/AHA guidelines16 which includes : 1) Age >70 
years, 2) history of or current angina pectoris, 3) history of MI, 4) history of 
CVA/TIA, 5) history of or current congestive heart failure, 6) diabetes mellitus, 
insulin dependent or non-insulin dependent, 7) renal dysfunction (serum 
creatinine > 160 mmol/l), 8) history of or current treatment for hypertension, and 
9) chronic obstructive pulmonary disease. In addition, standard laboratory 
measurements (fasting glucose in non-diabetic patients, N-terminal-pro-Brain 
Natriuretic Peptide, troponin T, lipid spectrum and high-sensitive C-reactive 
protein) will be performed during routine outpatient clinic follow-up. Furthermore 
an electrocardiogram (ECG) will be performed in all patients. Additional stress 
testing, using stress-echocardiography or myocardial perfusion scintigraphy, will 
also be performed in patients with ≥3 cardiac risk factors (MI, stroke, angina 
pectoris, chronic heart failure, renal failure, age > 70 years). Preoperative stress 
test results will guide perioperative management. Patients with evidence of left 
main disease during additional stress testing will undergo coronary angiography 
and prophylactic coronary revascularization if needed. Prior to surgery all patients 
without contraindication will receive at least the following medication: 1) beta-
blocker therapy (bisoprolol, with dose titration to a target heart rate of 60-70 beats 
per minute), 2) statin therapy (fluvastatin XL 80mg daily), 3) aspirin therapy 
(100mg daily), and 4) low molecular weight heparin (dose adjusted according 
manufacturers’ recommendations and ESC guidelines8).   
 
To assess the occurrence of troponin release, serial troponin T 
measurements and ECG recording will be performed on day 1, 3, 7 after surgery. 
Patients that do develop asymptomatic troponin T release at 1 or more time-points 
will be randomly assigned in a 1:1 ratio to double-blind treatment with either 
clopidogrel 75 mg once daily (with an initial dose of 300mg) plus aspirin (100mg 
daily) or placebo 75mg once daily (with an initial dose of 300mg) plus aspirin 
(100mg daily) during a treatment period of 12 months. Randomization of study 
treatment is performed via a central computerized telephone system. The presence 
of known cardiac risk modifiers for long-term outcome in vascular surgery patients 
with troponin T release (e.g. heart failure, renal dysfunction) will not be used for 
risk stratification before randomization. After randomization, all patients will be 
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treated according the current European Society of Cardiology guidelines on 
perioperative care, and must include at least a follow-up visit at 30 days, 3 months, 
6 months and 12 months after surgery.8 During these visits the occurrence of 
cardiovascular events are reported and verified with the treating specialist, in 
addition, standard laboratory measurement (fasting glucose, N-terminal-pro-Brain 
Natriuretic Peptide, troponin T, lipid spectrum and high-sensitive C-reactive 
protein) will be performed. In addition, after 18 and 24 months patients are 
followed by written or telephonic consultation.  
 
Table 2 Definitions of study endpoints 
EFFICACY ENDPOINTS 
Cardiovascular death 
Any death with a cardiovascular cause, including those 
deaths following a cardiac procedure, cardiac arrest, 
myocardial infarction, pulmonary embolus, stroke, 
haemorrhage, or deaths due to unknown causes. Only 
deaths due to a documented non-cardiovascular cause will 
be classified as non-cardiovascular. 
Non-fatal myocardial infarction 
Requires 2 of the following: 
 Characteristic ischemic symptoms (ie. Chest pain, shortness 
of breath, etc) lasting longer than 20 minutes; 
 ECG changes including ST-elevation followed by appearance 
of Q-waves or loss of R-waves, or new left bundle branch 
block, or new persistent T-wave inversion for at least 24 
hours, or new ST-segment depression which persists for at 
least 24 hours; 
 A positive troponin, ie > 0.10 ng/ml, or peak CK-MB ≥ 8% of 
an elevated total CK with characteristic rise and fall 
Stroke / Trainsient ischemic attack 
Stroke: new focal neurological deficit thought to be vascular 
in origin lasting greater than 24 hours. Confirmation with 
CT-scan/MRI is recommended but not mandatory. Strokes 
will be further classified as ischemic, hemorrhagic or 
uncertain. 
TIA: new onset focal neurological deficit that resolves within 
24 hours. 
Severe coronary ischemia leading to 
intervention 
Unstable angina with ECG changes requiring hospitalization 
which leads to coronary revascularization, using either 
percutaneous transluminal coronary angiography or 
coronary artery bypass grafting.   
Severe limb ischemia leading to 
intervention 
Severe ischemia of the lower extremity which is deemed to 
threaten the viability of the limb, and is associated with 
continuing ischemic pain, and neurological deficit, or 
inadequate skin capillary circulation, or inaudiable arterial 
flow signals by Doppler of the pedal arteries and which leads 
to hospitalization for an intervention such as thrombolytic 
therapy, angioplasty, bypass surgery, or amputation. 
SAFETY ENDPOINTS 
Life-threatening bleeding  
Fatal or intra-cranial bleeding requiring surgical intervention 
or transfusion of at least 4 units of blood or plasma 
expanders 
Moderate bleeding Bleeding which requires ≤ 3 units of blood or blood products 
Minor bleeding 
All other bleeding not requiring transfusion (leading to the 
temporary or permanent cessation of the study medication 
and/or aspirin). 
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Study endpoints 
The primary efficacy objective is to determine the impact of clopidogrel on the 
incidence of long-term (12 months) cardiovascular death, myocardial infarction, 
stroke, or severe ischemia of the coronary or peripheral arterial circulation leading 
to an intervention. Detailed criteria for each type of primary end point event are 
described in Table 2. The major secondary safety objective is to determine the 
impact of clopidogrel on the occurrence of bleeding complications, defined as life-
threatening bleeding, moderate and minor bleeding, according the Thrombolysis in 
Myocardial Infarction (TIMI) criteria.17 Transfusions and the clinical site of bleeding 
will be recorded and reported. If a patient has to undergo an elective procedure 
with an increased bleeding risk due to the dual antiplatelet therapy, the 
continuation of dual or single antiplatelet therapy will be at the discretion of the 
treating physician or surgeon. If the treating physician decided to discontinue one 
or both antiplatelet drugs, it is recommended to stop aspirin at least 5-7 days and 
clopidogrel at least 7-9 days prior to the procedure or surgery.8,18  
 
Statistical considerations 
We anticipate an incidence of 30% of the primary outcome in the control group. 
These results are based on several reports in literature and our experience 
including approximately 2000 patients undergoing major vascular surgery.7, 19-21 
Clopidogrel treatment is expected to be associated with a 30% relative risk 
reduction. Based on these assumptions, we propose a sample size of at least 750 
patients, with 375 patients in each group. The study will then have 80% power to 
detect the anticipated 30% risk reduction associated with clopidogrel therapy, with 
an α = 0.05 (two-sided). The proposed study will be a multi-centre trial, including 
approximately 7 hospitals, to obtain the sample size of 750 patients within 3 years. 
They will be followed and analysed in the group to which they are allocated, 
regardless of whether or not they receive the assigned treatment or fulfil the 
eligibility criteria. Time-to-the-first occurrence of one of the components of the 
primary efficacy endpoint will be presented using the Kaplan-Meier curves. The rate 
of occurrence of the primary endpoint will be compared using the log-rank 
statistics. Employing the Cox proportional hazards model, the hazard ratio and its 
associated 95% confidence interval will derive treatment effect. Univariate and 
multivariate analyses will be conducted.  
 
Safety outcomes will be compared using the log-rank statistic. An 
independent Data and Safety Monitoring Board (DSMB) will be established to 
monitor the progress of all aspects of the study and to ensure that the study meets 
the highest standards of ethics and patient safety. Stopping rules for futility 
endpoints are based on the estimate employed to reach the appropriate sample 
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size. One formal interim analysis is planned after the first 375 patients have been 
followed for 12 months. For efficacy, the combined endpoint of CV death, MI or 
stroke will be monitored. A modified Haybittle-Peto rule of 4 standard deviations in 
the first half of the study (before 50% of patients’ 1-year data are available) will be 
used. The boundary will have to be exceeded at the 12-months time point. Safety 
data will be monitored every 6 months or more frequently if requested by the 
DSMB. Given the extensive previous experience with clopidogrel the main potential 
for adverse events is related to life-threatening bleeding. Data on bleeding risk in 
patients with dual antiplatelet therapy can be generated from large randomized 
trials comparing dual versus single antiplatelet therapy in patients with ACS or 
undergoing PCI. Bowry et al. performed a meta-analyses and demonstrated that 
long-term (>1 month) dual antiplatelet therapy had a 1.8 times increased risk of 
major bleeding (HR 1.80, 95% CI 1.41 to 2.30).11 Based on these data we generated 
safety boundaries for the DSMB. A 2 standard deviation excess of life-threatening 
bleeding with the active agent (clopidogrel) constitutes ground for the DSMB to 
recommend study termination. The recommendation of the DSMB to stop the trial 
would be based on the pattern of the treatment effect of clopidogrel across all 
endpoints, and include an assessment of the overall benefit/risk ratio.  
 
 
DISCUSSION 
 
The DECREASE-VII trial was designed to test the hypothesis that early 
postoperative dual antiplatelet therapy for vascular surgery patients with 
asymptomatic perioperative troponin release will have a reduced incidence of 
cardiovascular events during long-term follow-up. This issue is of significant 
importance since asymptomatic troponin release after vascular surgery has a high 
incidence and is invariably associated with a poor prognosis during long-term 
follow-up. Currently medical treatment strategies for patients undergoing vascular 
surgery, with preoperative stress-inducible myocardial ischemia and to treat 
angina, symptomatic arrhythmias, heart failure and hypertension, include 
continuation of beta-blockade in patients already on beta-blocker therapy and 
initiation with up-titration of beta-blockers in beta-blocker naïve patients.8 In 
addition, high-risk patients should also receive statins and aspirin in the 
perioperative period. Although aspirin has been demonstrated to effectively reduce 
the risk of plaque rupture and subsequent cardiovascular events in high-risk 
patients, there is a remaining substantial risk for such cardiac events during 
follow-up.21 Extended antiplatelet therapy to reduce the adverse effects of the 
prolonged hypercoagulable perioperative state could effectively reduce this 
remaining risk.  
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Prophylactic coronary revascularization in cardiac stable patients with 
extensive stress-induced ischemia during preoperative testing is a subject of 
considerable debate. Both the Coronary Artery Revascularization Prophylaxis 
(CARP) trial and the DECREASE-V-pilot study showed no benefit of prophylactic 
coronary revascularization compared with optimal medical therapy, with the 
possible exception of left main disease.22,23 Therefore the current recommendations 
for preoperative revascularization for patients undergoing surgery is similar to the 
general non-surgical population.8 
 
Currently, asymptomatic cardiac ischemia detected by troponin 
measurements without ECG changes and/or presence of chest pain is not treated, 
although long-term outcome hereafter is severely compromised. According the ESC 
guidelines on the management of acute coronary syndromes in symptomatic 
patients presenting without persistent ST-segment elevation (NSTEMI), 
intermediate to high-risk patients have an increased risk for rapid progression to 
MI or death after non-ST-elevation myocardial infarction.24 Therefore, early (<72hr) 
coronary angiography followed by revascularization (PCI or CABG) in these patients 
is recommended (Class I-A).24 Prior to these intervention, antiplatelet and 
anticoagulant therapy should be initiated and include: aspirin, clopidogrel and 
unfractionated heparin, respectively. If a PCI has to be performed, additional 
treatment with glycoprotein IIb/IIIa should be initiated.  
 
Surgery patients, and especially those after major vascular surgery, are at 
increased risk for bleeding complications immediately after surgery. In addition, if 
bleeding complications occur, local hemostasis is difficult to obtain, due to the site 
of surgery. Early postoperative revascularization, including medical treatment with 
dual antiplatelet therapy and heparin, for patients developing symptomatic 
troponin release is associated with an increased bleeding risk. However, based on 
several large randomized controlled trials it is recommended to use dual 
antiplatelet therapy in patients with ACS, even before the coronary anatomy is 
defined. Although the bleeding risk is increased, the risk:benefit ratio favors this 
strategy, mainly because only a minority of the patients (5-12%) with ACS will 
undergo cardiac surgery. Previous studies have demonstrated that of the patients 
with postoperative troponin T release, up to 25% had angina pectoris and/or ECG 
changes as well.25 Of these patients, the majority (85%) had NSTEMI, while the 
remaining 15% had a STEMI and were referred for cardiac catheterization. Of the 
patients with a NSTEMI, only 15% was finally referred for cardiac catheterization. 
The addition of clopidogrel in addition of aspirin therapy in asymptomatic patients 
could effectively reduce the risk of early and long-term cardiac complications. The 
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addition of clopidogrel to aspirin (dual antiplatelet therapy) has a proven efficacy 
for the prevention of cardiac complications in symptomatic patients with acute 
coronary syndromes.11 Although dual antiplatelet therapy is associated with an 
increased risk of bleeding complications, in patients with acute coronary 
syndromes there was a net benefit of dual antiplatelet therapy. Recent studies have 
reported the efficacy and safety of direct thrombin inhibitors. These drugs were 
demonstrated to have consistent positive outcomes in symptomatic patients with 
(un)stable angina, NSTEMI and STEMI.26,27  Either with or without the addition of a 
glycoprotein IIb/IIIa inhibitor, direct thrombin inhibitors prevented ischemic 
complications with an associated lower risk of bleeding. However, in the present 
study with high-risk subjects we decided to use clopidogrel as this agent has a 
proven efficacy in a diversity of other populations with an acceptable safety profile.   
 
Therefore, early detection of asymptomatic perioperative ischemia with 
subsequent extended antiplatelet therapy to prevent cardiovascular complications 
may have a major beneficial effect on long-term cardiovascular events. It is 
estimated that the additional costs of clopdiogrel will outweigh the costs associated 
with cardiac complications requiring hospitalization. Initial recruitment of patients 
at the Erasmus Medical Center and the participating hospitals began in (please add 
month) 2010. The end of patient recruitment and the results of this trial are 
expected in the summer of 2014. Further information on the DECREASE-VII trial 
can be obtained by www.erasmusmc.nl or by calling +31 10 7034613. 
 
Summary 
DECREASE-VII is a phase III, randomized, double-blind, placebo-controlled, 
multicenter, clinical trial designed to study the efficacy and safety of early 
postoperative clopidogrel treatment for the prevention of long-term cardiovascular 
events in patients who develop asymptomatic troponin T release after major 
vascular surgery. The trial will provide valuable information regarding the effects of 
this new indication of clopidogrel that has been proven to reduce ischemic 
complications in patients with acute coronary syndromes. 
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SUMMARY AND CONCLUSIONS 
 
The process of atherosclerosis is a multifactorial syndrome which is very often not 
limited to a single arterial location. These aspects give it the character of a systemic 
and generalized disease. This thesis demonstrated a high prevalence of 
symptomatic and asymptomatic atherosclerotic disease in patients scheduled for 
vascular surgery. The presence of multiple affected vascular territories, called 
polyvascular disease, was invariably associated with a severely compromised long-
term prognosis after surgery.  
 
In the second and third part of this thesis two other important 
manifestations of atherosclerotic disease, namely insulin resistance and chronic 
kidney disease (CKD), are discussed. The prevalence and prognostic implications of 
these common co-morbidities in vascular surgery patients are reported.  
 
In the last part the early results of a new screening tool for early detection 
of abdominal aortic aneurysm and a sophisticated treatment modality are 
presented. Finally, a randomized controlled trial for the treatment of asymptomatic 
perioperative troponin T release after vascular surgery was developed and is 
described in this thesis.  
 
Part I: Prevalence and prognosis  
Abdominal aortic aneurysms (AAA) and coronary artery disease (CAD) have 
traditionally been regarded as two separate vessel disorders with the 
atherosclerotic process as the common background. In Chapter 2, a detailed 
description of the pathophysiological processes, risk factors and prevalence of CAD 
in patients with AAA is given. Risk factor analysis identified age and gender as the 
most influencing factors for AAA development. Prognosis is strongly influenced by 
modifiable risk factors such as (a)symptomatic atherosclerosis in other arterial 
beds. Therefore early life style intervention and medical treatment is recommended 
to reduce the risk of cardiovascular complications. 
 
 Chapters 3 and 4 focus on the presence of asymptomatic vascular disease 
in symptomatic patients scheduled for vascular surgery. In chapter 3 a high 
prevalence of asymptomatic PAD, measured by a reduced ankle-brachial index, was 
demonstrated in subjects free of cardiovascular disease. The presence of an 
asymptomatic reduced ankle-brachial index had an additional value for long-term 
cardiac risk estimation. In chapter 4 the same association was observed for an 
increased common carotid intima-media thickness in patients free of 
cerebrovascular disease. The presence of an intima-media thickness ≥1.25 mm was 
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independently associated with 30-day cardiovascular events and long-term 
cardiovascular mortality.  
 
 Long-term prognosis of patients with atherosclerotic disease is diminished 
due to the occurrence of cardiovascular complications. In Chapter 5 we studied a 
cohort of almost 3000 patients having elective vascular surgery for the presence of 
polyvascular disease. The prevalence and number of affected vascular beds before 
surgery were evaluated, and the prognostic implications of polyvascular disease on 
short –and long-term mortality were determined. Polyvascular disease was present 
in 54% of the patients, and the number of affected vascular beds correlated with 
the risk of cardiac complications during short –and long term follow-up. Patients 
with 3 affected vascular beds had the worst prognosis, as during a follow-up period 
of 10 years only 25% of the patients survived. In Chapter 6, the association 
between the obesity paradox and polyvascular disease was evaluated in the same 
cohort of patients. We demonstrated that patients with underweight had a reduced 
survival compared to patients with normal weight. In contrast, overweight patients 
had an increased survival. However, no direct interaction was observed between the 
obesity paradox and polyvascular disease. 
 
 During the period between 2002 and 2008, 1.005 patients scheduled for 
vascular surgery were preoperatively evaluated using echocardiography, as 
described in Chapter 7. Left ventricular dysfunction was observed in 506 (50%) 
patients, of which 80% had no clinical symptoms of heart failure. In patients 
undergoing open vascular surgery, asymptomatic left ventricular dysfunction was 
predictive for 30-day and long-term cardiovascular outcome. These results suggest 
the use of routine screening for asymptomatic left ventricular dysfunction in 
patients scheduled for open vascular surgery. 
 
 Myocardial ischemia during the perioperative period is an important 
predictor of morbidity and mortality after vascular surgery. Chapters 8 and 9 
emphasize the need of routine troponin T measurements for the detection of 
perioperative myocardial ischemia. Up to 20% of the patients undergoing vascular 
surgery will develop troponin T release, of which 90% remain asymptomatic. 
Importantly, even these asymptomatic troponin T releases are invariably associated 
with a risk of early or late myocardial complications. In chapter 8 we discussed the 
results of a randomized controlled trial comparing open versus endovascular AAA 
repair. We hypothesized that the lack of a survival benefit after 2 years of follow-up 
could be due to perioperative asymptomatic cardiac ischemia. 
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Part II: Diabetes mellitus 
Patients with peripheral arterial disease (PAD) have a high prevalence of insulin 
resistance disorders due to generalized atherosclerotic disease. The majority of 
these patients are in a pre-diabetic phase, characterized by elevated glucose levels 
without the presence of symptoms. Importantly, elevated glucose levels are usually 
present for 7 to 10 years before the diagnosis of diabetes mellitus (DM) is made. In 
Chapter 11 the results of a screening study for glucose regulation disorders in 404 
consecutive patients without known DM are described. Impaired glucose tolerance 
and DM were detected using fasting plasma glucose in 26 (25%) and 12(28%) 
patients, compared to 78 (75%) and 31(72%) by using oral glucose tolerance 
testing. Importantly, patients with newly detected glucose regulation disorders had 
an increased risk of developing cardiovascular events and mortality during follow-
up. Treatment of glucose regulation disorders during the perioperative phase has 
extensively been studied in intensive care unit patients. In Chapter 10 these 
results are systematically reviewed and translated to the vascular surgery 
population. We recommended a moderate tight glucose control regimen as the most 
safest and efficient approach for vascular surgery patients. 
 
 Metabolic syndrome was primarily developed as a multiplex risk factor for 
the development of cardiovascular disease in patients free of cardiac history. In 
Chapter 12 we compared the prevalence and prognostic implications of metabolic 
syndrome in high-risk vascular surgery patients with either occlusive or 
aneurysmatic disease. We observed a high prevalence of metabolic syndrome in 
both groups. In addition, the syndrome was an independent predictor of long-term 
cardiovascular events. Importantly, we demonstrated that if only the single 
components of metabolic syndrome were used as predictors of cardiac 
complications, the risk of future events would be under-estimated.   
 
 Diabetes mellitus and left ventricular dysfunction are often co-existent and 
invariably associated with increased mortality. However, as data on long-term 
prognosis of “isolated” diastolic left ventricular dysfunction are lacking, we 
evaluated the prognostic implications in vascular surgery patients with or without 
DM. In Chapter 13 it was demonstrated that diabetic patients with PAD have an 
increased prevalence of isolated and combined left ventricular dysfunction. The 
presence or absence of DM did not influence the prognostic implications of left 
ventricular dysfunction on long-term outcome.  
 
 
 
 
 338 
Part III: Renal disease 
As a result of the systemic character of atherosclerotic disease, the process involves 
the renal vasculature as well. Importantly, polyvascular disease and chronic kidney 
disease have both separately been associated with an adverse cardiovascular 
outcome. In Chapter 14 we assessed the prevalence of polyvascular disease in 
vascular patients with preoperative established CKD and observed that one-vessel 
disease was present in 54% of the patients with normal kidney function, while 62% 
of the patients with CKD (GFR<60() had polyvascular disease. Importantly, CKD 
patients with polyvascular disease had an increased risk for all-cause and 
cardiovascular mortality compared to patient without polyvascular disease. 
 
 The presence of subclinical atherosclerosis in the renal vasculature is 
reflected by the increased risk of acute kidney injury (AKI) after major vascular 
surgery. Although several studies investigated the predictive value of AKI for long-
term cardiovascular disease and mortality, data regarding the relationship between 
temporary decline in renal function during the perioperative period with incident 
CKD are lacking. In Chapter 15 we describe our results of a study that assessed 
the prognostic value of temporary renal function decline on the development of 
long-term CKD. We observed that vascular surgery patients have a high incidence 
of temporary (22%) or persistent (21%) renal function declines, both of which were 
independent predictors for development of long-term CKD. In addition, in Chapter 
16 we evaluated the influence of preoperative left ventricular dysfunction and the 
risk of AKI. We observed that patients with left ventricular dysfunction have an 
increased risk of developing AKI after surgery, and that the occurrence of AKI in 
these patients has an incremental predictive value towards cardiovascular 
mortality during long-term follow-up. 
 
 Serum phosphorus levels are a marker of renal function and have been 
associated with adverse long-term outcome in several populations. In Chapter 17 
we were the first to demonstrate the role of serum phosphorus levels as an 
independent predictor of all-cause and cardiovascular mortality during the first 30 
days after vascular surgery. This study supported the use of routine phosphorus 
measurements before vascular surgery, thereby providing a simple and effective 
way of additional risk factor analyses in patients at high-risk for perioperative 
events. 
 
Part IV: Risk reduction strategies and future perspectives 
The management of polyvascular atherosclerotic disease consists of several 
treatment strategies, including life-style interventions, medical therapy and 
invasive procedures. According the European Society of Cardiology guidelines for 
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preoperative cardiac risk assessment, medical therapy in patients with PAD 
scheduled for vascular surgery included statins, ß-blockers and aspirin. In 
Chapter 18 the role of statins in the treatment of patients with AAA is described. A 
systematic review of the current available literature demonstrated that statins 
reveal important pleiotropic effects. These non-lipid lowering effects could reduce 
aneurysm expansion; however, randomized controlled trials are needed. Another 
important medical agent used in patients with PAD are ß-blockers, which have 
important cardioprotective characteristics. Factors that may influence the effect of 
ß-blocker therapy include (i) type, (ii) dose, and (iii) timing of ß-blocker initiation 
before surgery. In Chapter 21 we evaluated three different timing regimens of ß-
blocker initiation. Our results indicated that ß-blocker treatment initiated >1 week 
before surgery is associated with lower preoperative heart rate and improved 
outcome, compared with treatment initiated <1 week preoperatively.  
 
 In patients with extensive atherosclerosis in the coronary arteries, 
preoperative coronary angiography is recommended in patients with high-risk 
noninvasive test results. However, in two randomized controlled trials, prophylactic 
preoperative coronary revascularization was not associated with improved 
immediate postoperative outcome. Chapter 19 describes the long-term outcome 
data of one of these randomized trials, the DECREASE-V pilot study. This study 
demonstrated that preoperative coronary revascularization in high-risk patients 
undergoing major vascular surgery was not associated with an improved 
postoperative or long-term outcome compared with the best medical treatment. The 
lack of an (immediate) postoperative benefit might be explained by the fact that 
early surgery after coronary stent placement leads to an increase in adverse cardiac 
events caused by in-stent thrombosis or bleeding complications. Chapter 20 
demonstrates the results of our study to define the optimal timing interval between 
coronary artery stenting and noncardiac surgery. We found an inverse relationship 
between the interval from coronary artery stenting to noncardiac surgery and 
perioperative major adverse cardiovascular events. Continuation of dual 
antiplatelet therapy did not provide complete protection against cardiac 
complications. Based on these results, elective noncardiac surgery should be 
preferably postponed 90 days after placement of a bare metal stent and at least 1 
year after placement of a drug eluting stent. 
 
 Abdominal aortic aneurysm has an increasing prevalence with age. 
Currently, no effective screening programs for early detection of AAA in subjects at 
risk are available. In Chapter 22 the early results of a new screening tool for AAA 
are discussed. We observed a 90% sensitivity for the Aortascan BVI 9600 which 
automatically detects AAA. Based on these early results we recommended studies 
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for further validation of the screening tool in the primary care. In addition to new 
screening methods, Chapter 23 is an editorial comment on the use of a potential 
treatment method for improvement of postoperative outcome. Remote ischemic 
preconditioning is a technique in which brief episodes of non-lethal ischemia and 
reperfusion are applied to an organ remote from the heart, thereby obviating the 
need to “condition” the heart directly. Early results of this technique in addition 
has demonstrated promising results; however, the clinical applicability should be 
further studied in large randomized trials. 
 
 In conclusion, patients with atherosclerotic disease have a high prevalence 
of polyvascular disease. In this thesis it was demonstrated that patients with 
symptomatic atherosclerotic disease, have two or more affected other vascular 
territories in 54% of the patients. The presence of extended atherosclerotic disease 
increases the risk of insulin resistance, acute kidney injury, chronic kidney disease 
and perioperative ischemia. The latter is reflected by troponin T release during the 
early postoperative period. The majority of these troponin T releases remain 
asymptomatic until it progresses to myocardial infarction. Nowadays, no treatment 
options are recommended for patients with perioperative ischemia, although late 
outcome hereafter is severely compromised. Therefore, we developed the 
DECREASE-VII trial (Chapter 24) which will evaluate in a randomized controlled 
design the efficacy and safety of immediate postoperative dual antiplatelet therapy 
(asprin and clopidogrel) for the prevention of late cardiac events after asymptomatic 
troponin T release.        
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SAMENVATTING EN CONCLUSIES 
 
Atherosclerose is een multifactorieel syndroom hetgeen gekenmerkt wordt door een 
uitbreiding van de ziekte naar meerdere vaatgebieden. Deze aspecten geven 
atherosclerotisch vaatlijden het karakter van een systemische en gegeneraliseerde 
ziekte.  In dit proefschrift wordt aangetoond dat patiënten die een vaatchirurgische 
ingreep ondergaan een hoge prevalentie van symptomatisch en asymptomatisch 
atherosclerotisch vaatlijden hebben. De aanwezigheid van meerdere aangedane 
vaatbedden, ofwel polyvasculair vaatlijden, is direct geassocieerd met een tweemaal 
verhoogd sterfterisico gedurende de lange termijn follow-up na de vaatoperatie. 
 
 In het tweede en derde deel van dit proefschrift worden twee belangrijke 
manifestaties van atherosclerose besproken, namelijk insuline-resistentie / 
diabetes mellitus (DM) en chronische nierinsufficiëntie. Het proefschrift toont een 
hoge prevalentie aan van deze comorbiditeiten in vaatchirurgische patiënten. 
Daarnaast wordt de belangrijke rol van deze ziekten met betrekking tot de korte en 
lange termijn prognose na een vaatoperatie beschreven.  
 
 In het vierde deel van het proefschrift worden de eerste resultaten van een 
nieuw screeningsmethode voor vroegtijdige opsporing van aneurysmata van de 
abdominale aorta gepresenteerd. Daarnaast worden diverse medicamenteuze en 
meer invasieve behandelingsmethoden van atherosclerotisch vaatlijden besproken. 
Als laatste wordt een nieuw geïnitieerde studie beschreven die zich richt op de 
behandeling van asymptomatische hartschade, hetgeen vaak voorkomt bij 
patienten die een vaatchirurgische ingreep ondergaan.  
 
Deel I: Prevalentie en prognose  
Aneurysmata van de abdominal aorta (AAA) en coronaire hartziekten worden van 
oudsher beschouwd als twee afzonderlijke aandoeningen met als 
gemeenschappelijke achtergrond het atherosclerotisch proces. In Hoofdstuk 2 
wordt een gedetailleerde beschrijving van de pathofysiologische processen, de 
risicofactoren en de prevalentie van coronaire hartziekten bij patiënten met een 
AAA gegeven. Op basis van een risicoanalyse blijken de leeftijd en het geslacht de 
meest belangrijke risicofactoren te zijn voor het ontwikkelen van een AAA. 
Daarnaast wordt de prognose sterk beïnvloed door de aanwezigheid van 
(a)symptomatische atherosclerose in andere arteriële vaatbedden. Het wordt 
aanbevolen om vroegtijdig te starten met life-style interventies en medicamenteuze 
behandeling, om het risico op cardiale complicaties te verminderen. 
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De hoofdstukken 3 en 4 richten zich specifiek op de aanwezigheid van 
asymptomatische atherosclerose in patiënten met symptomatisch vaatlijden in een 
ander vaatbed. In Hoofdstuk 3 wordt een hoge prevalentie van asymptomatisch 
vaatlijden in de benen geobjectiveerd, middels meting van de enkel-arm-index, bij 
patiënten zonder aanwijzingen voor symptomatisch vaatlijden. Deze bevinding heeft 
een toegevoegde waarde voor de risico inschatting op cardiale complicaties. In 
Hoofdstuk 4 wordt dezelfde bevinding gedaan in patiënten met een verdikte 
intima-media breedte in de wand van de halsslagader. De aanwezigheid van een 
intima-media breedte ≥1,25mm is een onafhankelijke voorspeller voor het ontstaan 
van cardiovasculaire complicaties binnen 30 dagen na de operatie en tevens 
gedurende de lange termijn follow-up.       
  
Bij patiënten met atherosclerose is de lange termijn prognose verminderd 
door het optreden van cardiovasculaire complicaties. In Hoofdstuk 5 wordt een 
cohort van bijna 3000 patiënten bestudeerd naar het voorkomen van polyvasculair 
vaatlijden in deze groep. De prevalentie en het precieze aantal aangedane 
vaatbedden werden geobjectiveerd, waarna de prognostische gevolgen van de ziekte 
op korte en lange termijn overleving werden bepaald. Het blijkt dat polyvasculair 
vaatlijden aanwezig is in 54% van de patiënten, en dat het aantal aangedane 
vaatbedden direct gecorreleerd is aan het risico op cardiale complicaties gedurende 
de korte en lange termijn follow-up na een vaatoperatie. Patiënten met 3 aangedane 
vaatbedden hebben de slechtste prognose, aangezien na een follow-up periode van 
10 jaar nog slechts 25% van de patiënten in leven is. In Hoofstuk 6 wordt de 
invloed van de zogenoemde “obesitas paradox” op de aanwezigheid van 
polyvasculair vaatlijden beschreven. Het blijkt dat patiënten met ondergewicht een 
slechtere prognose hebben in vergelijking met patiënten met een normaal gewicht. 
Patiënten met overgewicht blijken echter een verbeterde prognose te hebben. De 
aanwezigheid van polyvascular vaatlijden in deze patiëntengroepen blijkt niet van 
invloed te zijn op de paradoxale overlevingsverschillen. 
 
 Gedurende de periode van 2002 tot en met 2008 werden 1005 patiënten 
preoperatief onderzocht middels echocardiografie, zoals beschreven wordt in 
Hoofdstuk 7. Een linker ventrikel dysfunctie wordt waargenomen in 506 (50%) 
patiënten, waarvan 80% geen klinische symptomen van hartfalen heeft. Bij 
patiënten die een open vaatoperatie ondergaan, blijkt de aanwezigheid van 
asymptomatische linker ventrikel dysfunctie een voorspeller te zijn van de uitkomst 
kort na en gedurende lange termijn na de operatie. Op basis van deze resultaten 
kan het routinematig gebruik van echocardiografie, bij patiënten die een open 
vaatoperatie ondergaan, worden aanbevolen.  
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Ischemie van het hart tijdens de perioperatieve periode is een belangrijke 
voorspeller van morbiditeit en mortaliteit na een vaatoperatie. De Hoofdstukken 8 
en 9 wijzen op de noodzaak van routinematige metingen van het troponine T voor 
de detectie van perioperatieve ischemie. Het blijkt dat 20% van de patiënten die een 
vaatoperatie ondergaat een troponine T stijging zal ontwikkelen, hetgeen in 90% 
asymptomatisch blijft. Belangrijk hierbij is dat zelfs asymptomatische troponine T 
stijgingen direct geassocieerd zijn met een verhoogd risico op cardiale complicaties. 
In hoofdstuk 8 worden de resultaten van een gerandomiseerde studie van 
commentaar voorzien. Deze studie toont aan dat er 2 jaar na behandeling van een 
AAA middels open of endovasculaire chirurgie geen verschil in overleving is. Een 
mogelijke verklaring hiervoor zou de hoge prevalentie van perioperatieve 
myocardiale schade tijdens beide behandelingen kunnen zijn.  
 
Deel II: Diabetes mellitus 
Patiënten met perifeer arterieel vaatlijden (PAD) hebben een hoge prevalentie van 
insuline resistentie als gevolg van gegeneraliseerde atherosclerose. De meerderheid 
van patiënten met PAD bevindt zich in een pre-diabetische fase, gekenmerkt door 
verhoogde glucosespiegels zonder de aanwezigheid van symptomen. Opvallend is 
dat verhoogde glucosespiegels aanwezig zijn gedurende 7 to 10 jaar voordat de 
diagnose DM wordt gesteld. 
 
In Hoofdstuk 11 worden de resultaten van twee screeningsmethodes voor 
het opsporen van glucose regulatie stoornissen besproken, in een cohort van 404 
opeenvolgende patiënten zonder bekende DM. Een gestoorde glucose tolerantie en 
DM wordt gedetecteerd op basis van nuchter plasma glucose bepaling in 25 en 28% 
van de patiënten. Bij gebruik van de orale glucose tolerantie test, wordt een 
gestoorde glucose tolerantie en DM gevonden in 75 en 72% van de patiënten. 
Belangrijk is dat patiënten met een nieuw ontdekte glucose regulatie stoornis of 
DM een verhoogd risico blijken te hebben op het ontwikkelen van cardiovasculaire 
complicaties. De behandeling van glucose regulatie stoornissen tijdens de 
perioperatieve fase is uitvoerig onderzocht bij intensive care patiënten. In 
Hoofdstuk 10 worden deze resultaten systematisch beoordeeld en toegepast op de 
vaatchirugische populatie. Op basis hiervan wordt een matig strenge glucose 
controle als de meest veilige en efficiënte strategie aanbevolen voor vaatpatiënten 
tijdens perioperatieve periode. 
       
Het metabool syndroom, ofwel insuline resistentie syndroom, werd in de 
eerste plaats ontwikkeld als een risicofactor voor de ontwikkeling van hart- en 
vaatziekten in de algemene populatie. In Hoofdstuk 12 vergelijken wij de 
prevalentie en prognostische implicatie van het metabool syndroom in hoog-risico 
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patiënten met occlusief of aneurysmatisch vaatlijden. In beide groepen wordt een 
hoge prevalentie van het metabool syndroom gevonden. Bovendien blijkt het 
metabool syndroom een voorspeller van cardiovasculaire complicaties in 
vaatchirurgische patiënten te zijn. De belangrijkste bevinding is dat indien alleen 
de afzonderlijke componenten van het syndroom worden beschouwd als voorspeller 
van cardiale complicaties, er een onderschatting van het risico plaats vindt. 
 
Diabetes mellitus en linker ventrikel dysfunctie komen vaak samen voor en 
beïnvloeden de prognose negatief. Aangezien gegevens met betrekking tot de lange 
termijn prognose van geïsoleerde diastolische linker ventrikel dysfunctie ontbraken, 
hebben wij de prognostische gevolgen hiervan bestudeerd in patiënten met of 
zonder DM. In Hoofdstuk 13 wordt aangetoond dat patiënten met PAD en DM een 
verhoogde prevalentie van geïsoleerde en gecombineerde linker ventrikel dysfunctie 
hebben. Het al dan niet aanwezig zijn van DM heeft geen toegevoegd risico op de 
prognostische implicaties van linker ventrikel dysfunctie.  
  
Deel III: Nierziekten  
Als gevolg van het systemische karakter van atherosclerose, zijn de nieren ook 
betrokken binnen het ziekteproces. Uit de literatuur blijkt dat polyvasculair 
vaatlijden en chronische nierinsufficiëntie beide afzonderlijk in verband zijn 
gebracht met een ongunstige prognose. In Hoofdstuk 14 wordt aangetoond dat 
46% van de patiënten zonder nierinsufficiëntie polyvasculair vaatlijden heeft. 
Patiënten met nierinsufficiëntie (eGFR <60) blijken echter in 62% van de gevallen 
polyvascular vaatlijden te hebben. De aanwezigheid van polyvascular vaatlijden in 
patiënten met nierinsufficiëntie is geassocieerd met een verhoogd sterfte risico.  
 
De aanwezigheid van subklinische atherosclerose in het renale vaatbed 
wordt weerspiegeld door het verhoogde risico op acute nierinsufficiëntie na een 
grote chirurgische ingreep. Hoewel diverse studies hebben aangetoond dat acute 
nierinsufficiëntie geassocieerd is met lange termijn sterfte aan cardiale oorzaken, 
ontbreken er studies betreffende het risico op lange termijn chronische 
nierinsufficiëntie. In Hoofstuk 15 worden de resultaten van onze studie 
beschreven waarin de prognostische waarde van tijdelijke nierfunctie verslechtering 
ten opzichte van het ontstaan van chronische nierinsufficiëntie wordt bepaald. Een 
tijdelijke of continue verslechtering wordt gevonden in respectievelijk 22 and 21% 
van de patiënten. Het blijkt dat zelfs een kortdurende tijdelijke verslechtering van 
de nierfunctie een verhoogd risico geeft op het ontstaan van chronische 
nierinsufficiëntie. Daarnaast blijkt uit Hoofdstuk 16 dat patiënten met een 
verminderde linker ventrikel functie een verhoogde kans hebben op acute 
nierinsufficiëntie. Wij hebben aangetoond dat het ontstaan van acute 
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nierinsufficiëntie in deze patiënten een additionele waarde heeft voor de risico-
inschatting op lange termijn complicaties. 
 
 Serum fosfaat is een marker van de nierfunctie en wordt in diverse 
populaties gebruikt als een voorspeller voor lange termijn complicaties. In 
hoofdstuk 17 beschrijven wij als eerste de rol van serum fosfaat als onafhankelijke 
voorspeller van cardiovasculaire mortaliteit gedurende de eerste 30 dagen na 
vaatchirurgie. De studie ondersteunt het gebruik van routinematig fosfaat 
bepalingen tijdens de preoperatieve evaluatie voorafgaande aan vaatchirurgie. 
 
Deel IV: Risicoreductie strategieën en toekomstperspectieven  
De behandeling van polyvasculair vaatlijden bestaat uit diverse aspecten, 
waaronder life-style interventies, medicamenteuze therapie en invasieve 
procedures. De Europose Vereniging voor de Cardiologie beveelt in haar richtlijnen 
betreffende preoperatieve cardiale risico-evaluatie, het gebruik van 
medicamenteuze therapie middels statines, ß-blokkers en aspirine aan. In 
hoofdstuk 18 wordt de rol van statines bij de behandeling van patiënten met een 
AAA beschreven. Een systematische beoordeling van de literatuur laat zien dat 
statines belangrijke zogenoemde “pleiotrope” effecten hebben. Deze niet-lipiden 
verlagende effecten kunnen de groei van AAAs verminderen, echter dit dient 
uitgebreider onderzocht te worden in gerandomiseerde klinische studies. Een 
andere belangrijke groep medicijnen in de behandeling van atherosclerotisch 
vaatlijden zijn ß-blokkers. Deze groep medicamenten heeft belangrijke 
cardioprotectieve effecten tijdens en na vaatchirurgische ingrepen. De effectiviteit 
wordt echter sterk beïnvloed door (i) type, (ii) dosering, en (iii) het tijdsinterval 
tussen therapie initiatie en de operatie. In hoofdstuk 21 worden drie verschillende 
tijdsintervallen bestudeerd. Het blijkt dat als ß-blokker therapie meer dan 1 week 
voor de operatie wordt gestart, er een belangrijke verlaging van de hartsslag 
optreedt en er een lagere kans op complicaties rond de operatie is. Bij patiënten 
met ß-blokker therapie korter dan 1 week voor de operatie worden deze effecten 
niet gevonden. 
 
Invasieve procedures middels coronair angiografie voor de behandeling van 
atherosclerose, wordt aanbevolen bij patiënten met uitgebreide atherosclerose van 
de kransslagaders. Echter, uit twee gerandomiseerde studies is gebleken dat 
profylactische coronair revascularisatie niet is geassocieerd met een verbeterde 
uitkomst direct na de operatie in deze patiënten. In hoofdstuk 19 worden de lange 
termijn resultaten na deze behandeling beschreven van één van deze studies, de 
DECREASE-V pilot studie. Deze studie toont aan dat preoperatieve coronair 
revascularisatie, bij patiënten met een hoog risico op cardiale complicaties, niet 
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geassocieerd is met een verbeterde lange termijn prognose, in vergelijking met 
optimale medicamenteuze behandeling. Het ontbreken van een (direct) 
postoperatief voordeel kan worden verklaard door het feit dat een snelle operatie na 
een coronair revascularisatie leidt tot een toename van cardiale complicaties ten 
gevolge van in-stent trombose of bloedingcomplicaties. Hoofdstuk 20 toont de 
resultaten van onze studie betreffende het optimale tijdsinterval tussen coronair 
stenting en niet-cardiale chirurgie. Wij vonden een omgekeerde relatie tussen het 
interval van stenting tot chirurgie met betrekking tot het ontwikkelen van 
belangrijke cardiovasculaire complicaties. Continueren van “dual antiplatelet” 
therapie gaf in onze studie geen volledige bescherming tegen cardiale complicaties 
tijdens chirurgie na coronair stenting. Gebaseerd op deze resultaten, dient niet-
cardiale chirurgie bij voorkeur 90 dagen uitgesteld te worden na gebruik van een 
“bare-metal stent” en tenminste 1 jaar na plaatsing van een “drug-eluting” stent. 
 
De prevalentie van AAA is geassocieerd met toenemende leeftijd. Momenteel 
zijn er geen effectieve screenings methoden voor vroegtijdige opsporing van AAA. In 
hoofdstuk 22 worden de eerste resultaten beschreven van een nieuw screenings 
apparaat voor de detectie van aneurysmata. De Aortascan BVI 9600 met 
automatische AAA detectie, heeft een sensitiviteit van 90% in deze eerste klinische 
studie. Uitgebreide validatie studies, bij voorkeur in de huisartsenpraktijk, zijn 
nodig voordat het apparaat daadwerkelijk toegepast kan worden als 
screeningsmethode. Naast nieuwe screenings methoden worden er ook nieuwe 
behandelmethoden voor patiënten met vaatlijden ontwikkeld. Hoofdstuk 23 is een 
commentaar op een studie waarin het gebruik van “remote ischemic 
preconditioning” als nieuwe therapie voor de preventie van cardiovasculaire 
complicaties wordt beschreven. Deze techniek betreft het veroorzaken van 
kortdurende periodes van niet-schadelijke ischemie en reperfusie aan 
lichaamsdelen op enige afstand van het hart, zoals de armen of benen. Hierdoor 
wordt het hart als het ware getraind op het doormaken van kortdurende episodes 
van ischemie tijdens een vaatoperatie.  
 
Concluderend kan worden vastgesteld dat patiënten met atherosclerose een 
hoge prevalentie van polyvasculair vaatlijden hebben. In dit proefschrift wordt 
aangetoond dat bij patiënten met symptomatisch atherosclerotisch vaatlijden, in 
54% van de patiënten tevens sprake is van vaatlijden in twee of meer andere 
vaatbedden. De aanwezigheid van gegeneraliseerde atherosclerose verhoogt het 
risico op insulineresistentie, acute nierinsufficiëntie, chronische nierinsufficiëntie 
en perioperatieve ischemie. Dit laatste komt voornamelijk tot uiting door een 
stijging van het troponine T tijdens de vroege postoperatieve periode. De 
meerderheid van deze troponine T stijgingen verlopen asymptomatisch totdat het 
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zich ontwikkelt tot een volledig myocard infarct. Momenteel wordt er geen 
behandeling van deze perioperatieve ischemie aanbevolen door internationale 
richtlijnen, ondanks dat de korte en lange termijn prognose hierdoor sterk negatief 
beïnvloed wordt. In hoofdstuk 24 wordt een nieuwe studie beschreven die wij 
hebben ontwikkeld voor de behandeling van deze patiëntengroep. Patiënten met 
postoperatieve troponine T stijging zullen dubbelblind gerandomiseerd worden voor 
een behandeling met clopidogrel of placebo om de effectiviteit en veiligheid van deze 
behandeling te testen met betrekking tot het voorkomen van cardiale complicaties 
na een vaatoperatie.  
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